







INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 413/14, 417/14, C07F 9/6558, C07D 413/12, 487/08, 451/02, A61K 31/42, 31/44 // (C07D 487/08, 209:00, 209:00)</p>	A2	<p>(11) International Publication Number: WO 99/64417</p> <p>(43) International Publication Date: 16 December 1999 (16.12.99)</p>
<p>(21) International Application Number: PCT/GB99/01753</p> <p>(22) International Filing Date: 3 June 1999 (03.06.99)</p> <p>(30) Priority Data: 9812021.5 5 June 1998 (05.06.98) GB 9820164.3 17 September 1998 (17.09.98) GB 9826066.4 28 November 1998 (28.11.98) GB</p> <p>(71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): GRAVESTOCK, Michael, Barry [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).</p> <p>(74) Agent: BRYANT, Tracey; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM</p> <div style="display: flex; justify-content: space-around; align-items: flex-start; margin-top: 20px;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(Q1)</p> </div> <div style="text-align: center; margin-top: 20px;">  <p>(Q2)</p> </div> <div style="text-align: center; margin-top: 20px;">  <p>(TC5)</p> </div> </div>		
<p>(57) Abstract</p> <p>Compounds of formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, X is -O- or -S-; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, formulae (Q1) and (Q2); R² and R³ are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5) wherein R_c is, for example, R¹³CO-, R¹³SO₂- or R¹³CS-; wherein R¹³ is, for example, optionally substituted (1-10C)alkyl or R¹⁴C(O)O(1-6C)alkyl wherein R¹⁴ is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CHEMICAL COMPOUNDS

The present invention relates to antibiotic compounds and in particular to antibiotic compounds containing a substituted oxazolidinone ring. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.

The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. In general, bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens. Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded primarily as effective against Gram-positive pathogens because of their particularly good activity against such pathogens.

Gram-positive pathogens, for example Staphylococci, Enterococci, Streptococci and mycobacteria, are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established. Examples of such strains are methicillin resistant staphylococcus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiply resistant Enterococcus faecium.

The major clinically effective antibiotic for treatment of such resistant Gram-positive pathogens is vancomycin. Vancomycin is a glycopeptide and is associated with nephrotoxicity and ototoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens.


Certain antibacterial compounds containing an oxazolidinone ring have been described in the art (for example, Walter A. Gregory et al in J.Med.Chem. 1990, 33, 2569-2578 and Chung-Ho Park et al in J.Med.Chem. 1992, 35, 1156-1165). Such antibacterial oxazolidinone compounds with a 5-methylacetamide sidechain may be subject to mammalian peptidase metabolism. Furthermore, bacterial resistance to known antibacterial agents may develop, for

- 2 -

example, by (i) the evolution of active binding sites in the bacteria rendering a previously active pharmacophore less effective or redundant, and/or (ii) the evolution of means to chemically deactivate a given pharmacophore. Therefore, there remains an ongoing need to find new antibacterial agents with a favourable pharmacological profile, in particular for
 5 compounds containing new pharmacophores.

We have discovered a class of antibiotic compounds containing a new class of substituted oxazolidinone ring which has useful activity against Gram-positive pathogens including MRSA and MRCNS and, in particular, against various strains exhibiting resistance to vancomycin and against *E. faecium* strains resistant to both aminoglycosides and clinically
 10 used β -lactams.



Accordingly the present invention provides a compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof,



wherein X is -O-, -S-, -SO- or -SO₂-;

HET is a C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S, which ring is optionally substituted on an available carbon atom by 1 or 2 substituents independently selected from (1-4C)alkyl, amino, (1-4C)alkylamino, (1-
 20 4C)alkoxy and halogen, and/or on an available nitrogen atom (provided that the ring is not thereby quaternised) by (1-4C)alkyl;

Q is selected from Q1 to Q9 :-




25

Q1

Q2

- 3 -




5

Q3


Q4

Q5


Q6



Q7



Q8



Q9

10

wherein R^2 and R^3 are independently hydrogen or fluoro;

wherein A_1 is carbon or nitrogen; B_1 is O or S (or, in Q9 only, NH); X_q is O, S or N- R^1

(wherein R^1 is hydrogen, (1-4C)alkyl or hydroxy-(1-4C)alkyl); and wherein

in Q7 each A_1 is independently selected from carbon or nitrogen, with a maximum of 2

15 nitrogen heteroatoms in the 6-membered ring, and Q7 is linked to T via any of the A_1 atoms (when A_1 is carbon), and linked in the 5-membered ring via the specified carbon atom, or via

A_1 when A_1 is carbon; Q8 is linked to T via either of the specified carbon atoms in the 5-

membered ring, and linked in the benzo-ring via either of the two specified carbon atoms on either side of the linking bond shown; and Q9 is linked via either of the two specified carbon

20 atoms on either side of the linking bond shown;

wherein T is selected from the groups in (TA) to (TD) below (wherein AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1 and CY2 are defined hereinbelow);

(TA) T is selected from the following groups :-

(TAa) AR1, AR1-(1-4C)alkyl-, AR2 (carbon linked), AR3;

25 (TAb) AR1-CH(OH), AR2-CH(OH)-, AR3-CH(OH)-;

(TAc) AR1-CO-, AR2-CO-, AR3-CO-, AR4-CO-;

(TAd) AR1-O-, AR2-O-, AR3-O-;

- 4 -

(TAe) $AR1-S(O)_q$ -, $AR2-S(O)_q$ -, $AR3-S(O)_q$ - (q is 0, 1 or 2);

(TAf) an optionally substituted N-linked (fully unsaturated) 5-membered heteroaryl ring system containing 1, 2 or 3 nitrogen atoms;

(TAg) a carbon linked tropol-3-one or tropol-4-one, optionally substituted in a position not
5 adjacent to the linking position; or

(TB) T is selected from the following groups :-

(TBa) halo or (1-4C)alkyl

{optionally substituted by one or more groups each independently selected from hydroxy, (1-
10 4C)alkoxy, (1-4C)alkanoyl, cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, -NR^vR^w, (1-
6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-
4C)alkylS(O)_q- (q is 0, 1 or 2), CY1, CY2 or AR1};

(TBb) -NR^v¹R^w¹ ;

(TBc) ethenyl, 2-(1-4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-
15 nitroethenyl, 2-nitro-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-
4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl;

(TBd) R¹⁰CO-, R¹⁰S(O)_q- (q is 0, 1 or 2) or R¹⁰CS-
wherein R¹⁰ is selected from the following groups :-

(TBda) CY1 or CY2;

20 (TBdb) hydrogen, (1-4C)alkoxycarbonyl, trifluoromethyl, -NR^vR^w, ethenyl, 2-(1-
4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-nitroethenyl, 2-nitro-2-
((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-
4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl or 2-(AR2)ethenyl; or

(TBdc) (1-4C)alkyl {optionally substituted as defined in (TBa) above, or by (1-
25 4C)alkylS(O)_pNH- or (1-4C)alkylS(O)_p-((1-4C)alkyl)N- (p is 1 or 2)};

wherein R^v is hydrogen or (1-4C)alkyl; R^w is hydrogen or (1-4C)alkyl; R^v¹ is hydrogen, (1-
4C)alkyl or (3-8C)cycloalkyl; R^w¹ is hydrogen, (1-4C)alkyl, (3-8C)cycloalkyl, (1-4C)alkyl-
CO- or (1-4C)alkylS(O)_q- (q is 1 or 2); or

30 (TC) T is selected from the following groups :-

(TCa) an optionally substituted, fully saturated 4-membered monocyclic ring containing 1

- 5 -

heteroatom selected from O, N and S (optionally oxidised), and linked via a ring nitrogen or sp^3 carbon atom;

(TCb) an optionally substituted 5-membered monocyclic ring containing 1 heteroatom selected from O, N and S (optionally oxidised), and linked via a ring nitrogen atom or a ring sp^3 or sp^2 carbon atom, which monocyclic ring is fully saturated other than (where appropriate) at a linking sp^2 carbon atom;

(TCc) an optionally substituted 6- or 7-membered monocyclic ring containing 1 or 2 heteroatoms independently selected from O, N and S (optionally oxidised), and linked via a ring nitrogen atom or a ring sp^3 or sp^2 carbon atom, which monocyclic ring is fully saturated other than (where appropriate) at a linking sp^2 carbon atom; or

(TD) T is selected from the following groups :-

(TDa) a bicyclic spiro-ring system containing 0, 1 or 2 ring nitrogen atoms as the only ring heteroatoms, the structure consisting of a 5- or 6-membered ring system (linked via a ring nitrogen atom or a ring sp^3 or sp^2 carbon atom) substituted (but not adjacent to the linking position) by a 3-, 4- or 5-membered spiro-carbon-linked ring; which bicyclic ring system is

- (i) fully saturated other than (where appropriate) at a linking sp^2 carbon atom;
- (ii) contains one -N(Rc)- group in the ring system (at least two carbon atoms away from the linking position when the link is via a nitrogen atom or an sp^2 carbon atom) or one -N(Rc)- group in an optional substituent (not adjacent to the linking position) and is
- (iii) optionally further substituted on an available ring carbon atom; or

(TDb) a 7-, 8- or 9-membered bicyclic ring system (linked via a ring nitrogen atom or a ring sp^3 or sp^2 carbon atom) containing 0, 1 or 2 ring nitrogen atoms (and optionally a further O or S ring heteroatom), the structure containing a bridge of 1, 2 or 3 carbon atoms; which bicyclic ring system is

- (i) fully saturated other than (where appropriate) at a linking sp^2 carbon atom;
- (ii) contains one O or S heteroatom, or one -N(Rc)- group in the ring (at least two carbon atoms away from the linking position when the link is via a nitrogen atom or an sp^2 carbon atom) or one -N(Rc)- group in an optional substituent (not adjacent to the linking position) and is
- (iii) optionally further substituted on an available ring carbon atom;

- 6 -

wherein R_c is selected from groups (R_{c1}) to (R_{c5}) :-

(R_{c1}) (1-6C)alkyl {optionally substituted by one or more (1-4C)alkanoyl groups (including geminal disubstitution) and/or optionally monosubstituted by cyano, (1-4C)alkoxy,

5 trifluoromethyl, (1-4C)alkoxycarbonyl, phenyl (optionally substituted as for AR defined hereinafter), (1-4C)alkylS(O)_q- (q is 0, 1 or 2); or, on any but the first carbon atom of the (1-6C)alkyl chain, optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy and fluoro, and/or optionally monosubstituted by oxo, -NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen
10 or (1-4C)alkyl], (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylS(O)_pNH- or (1-4C)alkylS(O)_p-((1-4C)alkyl)N- (p is 1 or 2));

(R_{c2}) R¹³CO-, R¹³SO₂- or R¹³CS-

wherein R¹³ is selected from (R_{c2a}) to (R_{c2e}) :-

(R_{c2a}) AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1, CY2;

15 **(R_{c2b})** hydrogen, (1-4C)alkoxycarbonyl, trifluoromethyl, -NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl], ethenyl, 2-(1-4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-nitroethenyl, 2-nitro-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, 2-(AR2a)ethenyl;

20 **(R_{c2c})** (1-10C)alkyl

{optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkanoyl, phosphoryl [-O-P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group
25 selected from phosphonate [phosphono, -P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinate [-P(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino,
30 di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-


- 7 -

4C)alkylS(O)_p-((1-4C)alkyl)N-, fluoro(1-4C)alkylS(O)_pNH-, fluoro(1-4C)alkylS(O)_p((1-4C)alkyl)N-, (1-4C)alkylS(O)_q-, CY1, CY2, AR1, AR2, AR3, AR1-O-, AR2-O-, AR3-O-, AR1-S(O)_q-, AR2-S(O)_q-, AR3-S(O)_q-, AR1-NH-, AR2-NH-, AR3-NH- (p is 1 or 2 and q is 0, 1 or 2), and also AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing
5 groups};

(Rc2d) R¹⁴C(O)O(1-6C)alkyl wherein R¹⁴ is AR1, AR2, (1-4C)alkylamino, benzyloxy-(1-4C)alkyl or (1-10C)alkyl {optionally substituted as defined for (Rc2c)};

(Rc2e) R¹⁵O- wherein R¹⁵ is benzyl, (1-6C)alkyl {optionally substituted as defined for (Rc2c)}, CY1, CY2 or AR2b;

10 **(Rc3)** hydrogen, cyano, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-4C)alkoxycarbonyl)ethenyl, 2-nitroethenyl, 2-nitro-2-((1-4C)alkyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, or of the formula **(Rc3a)**

**(Rc3a)**

15

wherein X⁰⁰ is -OR¹⁷, -SR¹⁷, -NHR¹⁷ and -N(R¹⁷)₂;

wherein R¹⁷ is hydrogen (when X⁰⁰ is -NHR¹⁷ and -N(R¹⁷)₂), and R¹⁷ is (1-4C)alkyl, phenyl or AR2 (when X⁰⁰ is -OR¹⁷, -SR¹⁷ and -NHR¹⁷); and R¹⁶ is cyano, nitro, (1-4C)alkylsulfonyl, (4-7C)cycloalkylsulfonyl, phenylsulfonyl, (1-4C)alkanoyl and (1-4C)alkoxycarbonyl;

20 **(Rc4)** trityl, AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b;

(Rc5) RdOC(Re)=CH(C=O)-, RfC(=O)C(=O)-, RgN=C(Rh)C(=O)- or

RiNHC(Rj)=CHC(=O)- wherein Rd is (1-6C)alkyl; Re is hydrogen or (1-6C)alkyl, or Rd and Re together form a (3-4C)alkylene chain; Rf is hydrogen, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxy(1-6C)alkyl, -NRvRw [wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen
25 or (1-4C)alkyl], (1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy, hydroxy(2-6C)alkoxy, (1-4C)alkylamino(2-6C)alkoxy, di-(1-4C)alkylamino(2-6C)alkoxy; Rg is (1-6C)alkyl, hydroxy or (1-6C)alkoxy; Rh is hydrogen or (1-6C)alkyl; Ri is hydrogen, (1-6C)alkyl, AR1, AR2, AR2a, AR2b and Rj is hydrogen or (1-6C)alkyl;

wherein

AR1 is an optionally substituted phenyl or optionally substituted naphthyl;

AR2 is an optionally substituted 5- or 6-membered, fully unsaturated (i.e with the maximum degree of unsaturation) monocyclic heteroaryl ring containing up to four heteroatoms

independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and

5 linked via a ring carbon atom, or a ring nitrogen atom if the ring is not thereby quaternised;

AR2a is a partially hydrogenated version of **AR2** (i.e. **AR2** systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom or linked via a ring nitrogen atom if the ring is not thereby quaternised;

AR2b is a fully hydrogenated version of **AR2** (i.e. **AR2** systems having no unsaturation),

10 linked via a ring carbon atom or linked via a ring nitrogen atom;

AR3 is an optionally substituted 8-, 9- or 10-membered, fully unsaturated (i.e with the maximum degree of unsaturation) bicyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom in either of the rings comprising the bicyclic system;

15 **AR3a** is a partially hydrogenated version of **AR3** (i.e. **AR3** systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen atom if the ring is not thereby quaternised, in either of the rings comprising the bicyclic system;

AR3b is a fully hydrogenated version of **AR3** (i.e. **AR3** systems having no unsaturation),

20 linked via a ring carbon atom, or linked via a ring nitrogen atom, in either of the rings comprising the bicyclic system;

AR4 is an optionally substituted 13- or 14-membered, fully unsaturated (i.e with the maximum degree of unsaturation) tricyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and

25 linked via a ring carbon atom in any of the rings comprising the tricyclic system;

AR4a is a partially hydrogenated version of **AR4** (i.e. **AR4** systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen atom if the ring is not thereby quaternised, in any of the rings comprising the tricyclic system;

CY1 is an optionally substituted cyclobutyl, cyclopentyl or cyclohexyl ring;


30 **CY2** is an optionally substituted cyclopentenyl or cyclohexenyl ring.

- 9 -

In this specification, where it is stated that a ring may be linked via an sp^2 carbon atom, which ring is fully saturated other than (where appropriate) at a linking sp^2 carbon atom, it is to be understood that the ring is linked via a C=C double bond.


In another embodiment, (Rc1) is as defined above other than the optional phenyl substituent on (1-6C)alkyl is optionally substituted as for AR1 defined hereinafter; and (Rc2c), is as defined above and further includes carboxy as an optional substituent on R^{13} as (1-10C)alkyl.

(TAf) When T is an optionally substituted N-linked (fully unsaturated) 5-membered heteroaryl ring system containing 1, 2 or 3 nitrogen atoms, it is preferably selected from a group of formula (TAf1) to (TAf6) below (particularly (TAf1), (TAf2), (TAf4) and (TAf5), and especially (TAf1) and/or (TAf2)). The above preferred values of (TAf) are particularly preferred when present in Q1 or Q2, especially Q1, and when X is -O-.




15


(TAf1)




(TAf2)




(TAf3)



(TAf4)



(TAf5)



(TAf6)

20 wherein :

R^6 is selected (independently where appropriate) from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, (1-4C)alkanoyl, carbamoyl and cyano;


- 10 -

R^4 and R^5 are independently selected from hydrogen, halo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), (1-4C)alkanoyl, (1-4C)alkoxycarbonyl, (2-4C)alkanoyloxy-(1-4C)alkyl, benzoxy-(1-4C)alkyl, (2-4C)alkanoylamino, -CONR^vR^w, -NR^vR^w and (1-4C)alkyl {optionally substituted by hydroxy, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), (1-4C)alkoxycarbonyl, (1-4C)alkanoylamino, -CONR^vR^w, -NR^vR^w; wherein R^vR^w is hydrogen or (1-4C)alkyl; R^w is hydrogen or (1-4C)alkyl};

or R^4 is selected from one of the groups in (TAfa) to (TAfc) below, or (where appropriate) one of R^4 and R^5 is selected from the above list of R^4 and R^5 values, and the other is

10 selected from one of the groups in (TAfa) to (TAfc) below :-

(TAfa) a group of the formula (TAfa1)



(TAfa1)

wherein Z^0 is hydrogen or (1-4C)alkyl;

15 X^0 and Y^0 are independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, halo, cyano, nitro, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), R^vR^wNSO₂-, trifluoromethyl, pentafluoroethyl, (1-4C)alkanoyl and -CONR^vR^w [wherein R^v is hydrogen or (1-4C)alkyl; R^w is hydrogen or (1-4C)alkyl]; or

one of X^0 and Y^0 is selected from the above list of X^0 and Y^0 values, and the other is

20 selected from phenyl, phenylcarbonyl, -S(O)_q-phenyl (q is 0, 1 or 2), N-(phenyl)carbonyl, phenylaminosulfonyl, AR₂, (AR₂)-CO-, (AR₂)-S(O)_q- (q is 0, 1 or 2), N-(AR₂)carbonyl and (AR₂)aminosulfonyl; wherein any phenyl group in (TAfa) may be optionally substituted by up to three substituents independently selected from (1-4C)alkyl, cyano, trifluoromethyl, nitro, halo and (1-4C)alkylsulfonyl;

25 (TAfb) an acetylene of the formula \equiv -H or \equiv -(1-4C)alkyl;

(TAfc) -X¹-Y¹-AR₂, -X¹-Y¹-AR_{2a}, -X¹-Y¹-AR_{2b}, -X¹-Y¹-AR₃, -X¹-Y¹-AR_{3a} or -X¹-Y¹-AR_{3b};

wherein X¹ is a direct bond or -CH(OH)- and

- 11 -

Y^1 is $-(CH_2)_m-$, $-(CH_2)_n-NH-(CH_2)_m-$, $-CO-(CH_2)_m-$, $-CONH-(CH_2)_m-$, $-C(=S)NH-(CH_2)_m-$ or $-C(=O)O-(CH_2)_m-$;

or wherein X^1 is $-(CH_2)_n-$ or $-CH(Me)-(CH_2)_m-$ and

Y^1 is $-(CH_2)_m-NH-(CH_2)_m-$, $-CO-(CH_2)_m-$, $-CONH-(CH_2)_m-$, $-C(=S)NH-(CH_2)_m-$,

5 $-C(=O)O-(CH_2)_m-$ or $-S(O)_q-(CH_2)_m-$;

or wherein X^1 is $-CH_2O-$, $-CH_2NH-$ or $-CH_2N((1-4C)alkyl)-$ and

Y^1 is $-CO-(CH_2)_m-$, $-CONH-(CH_2)_m-$ or $-C(=S)NH-(CH_2)_m-$; and additionally Y^1 is

$-SO_2-$ when X^1 is $-CH_2NH-$ or $-CH_2N((1-4C)alkyl)-$, and Y^1 is $-(CH_2)_m-$ when X^1 is $-CH_2O-$ or $-CH_2N((1-4C)alkyl)-$; wherein n is 1, 2 or 3; m is 0, 1, 2 or 3 and q is 0, 1 or 2; and when Y^1

10 is $-(CH_2)_m-NH-(CH_2)_m-$ each m is independently selected from 0, 1, 2 or 3.

It is to be understood that when a value for $-X^1-$ is a two-atom link and is written, for example, as $-CH_2NH-$ it is the left hand part ($-CH_2-$ here) which is bonded to the group of formula (TAf1) to (TAf6) and the right hand part ($-NH-$ here) which is bonded to $-Y^1-$ in the definition in (TAfc). Similarly, when $-Y^1-$ is a two-atom link and is written, for example, as -


15 $CONH-$ it is the left hand part of $-Y^1-$ ($-CO-$ here) which is bonded to the right hand part of $-X^1-$, and the right hand part of $-Y^1-$ ($-NH-$ here) which is bonded to the AR2, AR2a, AR2b, AR3, AR3a or AR3b moiety in the definition in (TAfc).

Preferably R^6 is hydrogen or (1-4C)alkyl, and R^4 and R^5 are independently selected from hydrogen, (1-4C)alkyl or one of R^4 and R^5 is selected from group (TAfa). Other


20 preferable substituents on the (TAf1) to (TAf6) are illustrated in the accompanying Examples.

(TAg) When T is a carbon linked tropol-3-one or tropol-4-one, optionally substituted in a position not adjacent to the linking position (TAg), it is preferably selected from a group of formula (TAg1), (TAg2) or (TAg3). The above preferred values of (TAg) are particularly


25 preferred when present in Q1 or Q2, especially Q1, and when X is $-O-$.



(TAg1)



(TAg2)



(TAg3)

- 12 -

wherein R^7 is selected from

(*TAga*)hydrogen, (1-4C)alkyl {optionally substituted by one or two substituents (excluding geminal disubstitution) independently selected from fluoro, hydroxy, (1-4C)alkoxy and -NRvRw}}; or

5 (*TAgb*) R^8 -O-, R^8 -S-, R^8 -NH- or R^8R^8 -N-;

wherein R^8 is selected (independently where appropriate) from hydrogen, (1-4C)alkyl or (3-8C)cycloalkyl {both optionally substituted by one or two substituents (excluding geminal disubstitution) independently selected from hydroxy, (1-4C)alkoxy, (1-4C)alkoxycarbonyl and -NRvRw}, (2-4C)alkenyl {optionally substituted by one or two -NRvRw substituents},

10 (1-4C)alkanoyl {optionally substituted by one or two substituents independently selected from -NRvRw and hydroxy}, phenyl-(1-4C)alkyl or pyridyl-(1-4C)alkyl {the phenyl and pyridyl (preferably pyridin-4-yl) rings being optionally substituted by one or two -NRvRw substituents}; or


(*TAgc*)morpholino, thiomorpholino, pyrrolidino {optionally independently substituted in the

15 3- and/or 4-positions by (1-4C)alkyl}, piperidino substituted in the 4-position by R^9 -, R^9 -O-, R^9 -S-, R^9 -NH- or R^9R^9 -N-; wherein R^9 is selected (independently where appropriate) from hydrogen, (1-4C)alkyl {optionally substituted by one or two (excluding geminal disubstitution) hydroxy, (1-4C)alkoxy, (1-4C)alkoxycarbonyl or -NRvRw} and piperazino {optionally substituted in the 4-position by (1-4C)alkyl, (3-8C)cycloalkyl, (1-4C)alkanoyl,


20 (1-4C)alkoxycarbonyl or (1-4C)alkylsulfonyl, and optionally independently substituted in the 3- and/or 5-positions by (1-4C)alkyl}; wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen or (1-4C)alkyl.

(**TC**) Preferred values for the optional substituents and groups defined in (TCa) to (TCc) are


25 defined by formulae (TC1) to (TC4) :-




(TC1)



(TC2)



(TC3)



(TC4)

- 13 -

wherein in (TC1) : $>A_3-B_3-$ is $>C(Rq)-CH(Rr)-$ and G is $-O-$, $-S-$, $-SO-$, $-SO_2-$ or $>N(Rc)$;

wherein in (TC2) : m_1 is 0, 1 or 2; $>A_3-B_3-$ is $>C=C(Rr)-$ or $>C(Rq)-CH(Rr)-$ and G is $-O-$, $-S-$, $-SO-$, $-SO_2-$ or $>N(Rc)$;

wherein in (TC3) : m_1 is 0, 1 or 2; $>A_3-B_3-$ is $>C(Rq)-CH(Rr)-$ (other than when Rq and Rr
5 are both together hydrogen) and G is $-O-$, $-S-$, $-SO-$, $-SO_2-$ or $>N(Rc)$;

wherein in (TC4) : n_1 is 1 or 2; o_1 is 1 or 2 and $n_1 + o_1 = 2$ or 3; $>A_3-B_3-$ is $>C=C(Rr)-$ or
 $>C(Rq)-CH(Rr)-$ or $>N-CH_2-$ and G is $-O-$, $-S-$, $-SO-$, $-SO_2-$ or $>N(Rc)$; R_p is hydrogen, (1-
4C)alkyl (other than when such substitution is defined by $>A_3-B_3-$), hydroxy, (1-4C)alkoxy or
(1-4C)alkanoyloxy;

10 wherein in (TC1), (TC2) and (TC4); m_1 , n_1 and o_1 are as defined hereinbefore :

$>A_3-B_3-$ is $>N-CH_2-$ and G is $>C(R^{11})(R^{12})$, $>C=O$, $>C-OH$, $>C-(1-4C)alkoxy$, $>C=N-OH$,
 $>C=N-(1-4C)alkoxy$, $>C=N-NH-(1-4C)alkyl$, $>C=N-N((1-4C)alkyl)_2$ (the last two (1-
4C)alkyl groups above in G being optionally substituted by hydroxy) or $>C=N-N-CO-(1-4C)alkoxy$;
wherein $>$ represents two single bonds;

15 R_q is hydrogen, hydroxy, halo, (1-4C)alkyl or (1-4C)alkanoyloxy;

R_r is (independently where appropriate) hydrogen or (1-4C)alkyl;

R¹¹ is hydrogen, (1-4C)alkyl, fluoro(1-4C)alkyl, (1-4C)alkyl-thio-(1-4C)alkyl or hydroxy-(1-
4C)alkyl and R¹² is $-[C(Rr)(Rr)]_{m_2}-N(Rr)(Rc)$ wherein m_2 is 0, 1 or 2;

and, other than the ring substitution defined by G, $>A_3-B_3-$ and R_p, each ring system may be
20 optionally further substituted on a carbon atom not adjacent to the link at $>A_3-$ by up to two
substituents independently selected from (1-4C)alkyl, fluoro(1-4C)alkyl (including
trifluoromethyl), (1-4C)alkyl-thio-(1-4C)alkyl, hydroxy-(1-4C)alkyl, amino, amino-(1-
4C)alkyl, (1-4C)alkanoylamino, (1-4C)alkanoylamino-(1-4C)alkyl, carboxy, (1-
4C)alkoxycarbonyl, AR-oxymethyl, AR-thiomethyl, oxo (=O) (other than when G is $>N-Rc$
25 and R_c is group (Rc2) defined hereinbefore) or independently selected from R_c; and also
hydroxy or halo (the last two optional substituents only when G is $-O-$ or $-S-$);
wherein AR is as defined for formula (IP) hereinafter; R_c is selected from groups (Rc1) to
(Rc5) defined hereinbefore.


For the avoidance of doubt, $()_{m_1}$, $()_{n_1}$ and $()_{o_1}$ indicate $(-CH_2-)_{m_1}$, $(-CH_2-)_{n_1}$ and
30 $(-CH_2-)_{o_1}$ respectively (optionally substituted as described above).

In the above definition of (TC1) to (TC4) and of the further optional substituents, AR

- 14 -

is preferably AR₂, and the further optional substituents are preferably not selected from the values listed for R_c. A preferred value for G is >N(R_c) or >C(R¹¹)(R¹²).

Particularly preferred values for the optional substituents and groups defined in (TCa) to (TCc), and (TC1) to (TC4) are contained in the following definitions (TC5) to (TC11) :-



10 wherein R_c has any of the values listed hereinbefore or hereinafter.

Especially preferred are (TC5), (TC6), (TC7) and (TC9), most especially (TC5) in which R_c has any of the values listed hereinbefore or hereinafter (especially R¹³CO- with the preferable R¹³ values given hereinafter). In (TC5) R_c is preferably selected from the group (Rc2), especially R¹³CO- with the preferable R¹³ values given hereinafter. In (TC7) R_c is


15 preferably selected from group (Rc3) or (Rc4).

The above preferred values of (TCa) to (TCc) are particularly preferred when present in Q1 or Q2, especially Q1, and when X is -O- (especially when HET is isoxazole).

(TDa) When T is a bicyclic spiro-ring system as defined in (TDa), it is preferably selected

20 from a group of formula (TDa1) to (TDa9). The above preferred values of (TDa) are particularly preferred when present in Q1 or Q2, especially Q1, and when X is -O-.

- 15 -



wherein;

- (i) the A₄ linking group is a nitrogen atom or an sp³ or sp² carbon atom (with the double bond, where appropriate, orientated in either direction); and
- 5 (ii) one of the ring carbon atoms at positions marked * and ** is replaced by one of the following groups -NRC-, >CH-NHRc, >CH-NRc-(1-4C)alkyl, >CH-CH₂-NHRc, >CH-CH₂-NRc-(1-4C)alkyl [wherein a central -CH₂- chain link is optionally mono- or di-substituted by (1-4C)alkyl]; with the provisos that positions marked * are not replaced by -NH- in the ring containing the A₄ link when A₄ is a nitrogen atom or an sp² carbon atom, and that positions
 10 marked * are not replaced by -NH- in the three membered ring in (TDa1), (TDa4) and (TDa5);
 and
- (iii) the ring system is optionally (further) substituted on an available ring carbon atom by up to two substituents independently selected from (1-4C)alkyl, fluoro(1-4C)alkyl (including trifluoromethyl), (1-4C)alkyl-thio-(1-4C)alkyl, hydroxy-(1-4C)alkyl, amino, amino-(1-
 15 4C)alkyl, (1-4C)alkanoylamino, (1-4C)alkanoylamino-(1-4C)alkyl, carboxy, (1-4C)alkoxycarbonyl, AR₂-oxymethyl, AR₂-thiomethyl, oxo (=O) (other than when the ring contains an >N-Rc and Rc is group (Rc2)) and also hydroxy or halo;

- 16 -

wherein Rc has any of the values listed hereinbefore or hereinafter.

(TDb) When T is a 7-, 8- or 9-membered bicyclic ring system containing a bridge of 1, 2 or 3 carbon atoms as defined in (TDb), it is preferably selected from a group defined by the ring skeletons shown in formulae (TDb1) to (TDb14) :-

7-membered ring skeletons




[4,1,0]

(TDb1)




[3,2,0]

(TDb2)



[3,1,1]


(TDb3)



[2,2,1]


(TDb4)

8-membered ring skeletons



[3,3,0]

(TDb5)



[4,2,0]

(TDb6)




[4,1,1]

(TDb7)



[3,2,1]


(TDb8)



[2,2,2]


(TDb9)

9-membered ring skeletons



[4,3,0]

(TDb10)




[5,2,0]

(TDb11)



[4,2,1]

(TDb12)



[3,3,1]

(TDb13)



[3,2,2]

(TDb14)

wherein;


- 10 (i) the ring system contains 0, 1 or 2 ring nitrogen atoms (and optionally a further O or S ring heteroatom), and when present the ring nitrogen, O or S heteroatom/s are at any position other than as part of the 3-membered ring in (TDb1);
- (ii) the ring system is linked via a ring nitrogen atom or a ring sp^3 or sp^2 carbon atom (with the double bond, where appropriate, orientated in either direction) from any position in
- 15 either ring [other than from a bridgehead position or from an sp^2 carbon atom in the 4-membered ring in (TDb2), (TDb6) and (TDb11)];

- 17 -

- (iii) one of the ring carbon atoms at a position not adjacent to the linking position, is replaced (other than when the ring contains an O or S heteroatom) by one of the following groups -NRc- [not at a bridgehead position], >C(H)-NHRc, >C(H)-NRc-(1-4C)alkyl, >C(H)-CH₂-NHRc, >C(H)-CH₂-NRc-(1-4C)alkyl [wherein the hydrogen atom shown in brackets is not present when the replacement is made at a bridgehead position and wherein a central -CH₂- chain link is optionally mono- or di-substituted by (1-4C)alkyl]; with the proviso that when the ring system is linked via a ring nitrogen atom or an sp² carbon atom any replacement of a ring carbon atom by -NRc-, O or S is at least two carbon atoms away from the linking position; and
- 10 (iv) the ring system is optionally (further) substituted on an available ring carbon atom as for the bicyclic spiro-ring systems described in (TDa); wherein Rc has any of the values listed hereinbefore or hereinafter.

It will be appreciated that unstable anti-Bredt compounds are not contemplated in this definition (i.e. compounds with structures (TDb3), (TDb4), (TDb7), (TDb8), (TDb9), (TDb12), (TDb13) and (TDb14) in which an sp² carbon atom is directed towards a bridgehead position).

Particularly preferred values of (TDb) are the following structures of formula (TDb4), (TDb8) and/or (TDb9); wherein Rc has any of the values listed hereinbefore or hereinafter. The above preferred values of (TDb) are particularly preferred when present in Q1 or Q2, especially Q1, and when X is -O-.




In another embodiment there is provided a compound of the formula (I) which is defined by the formula (IP) below, or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein

25 X is -O-, -S-, -SO- or -SO₂-;

- 18 -

HET is a C-linked 5-membered heteroaryl ring containing 2 or 3 heteroatoms independently selected from N, O and S (with the proviso that there are no O-O, O-S or S-S bonds), which ring is optionally substituted on any available C atom (provided that when a N atom is adjacent to the X-link, there is no substitution on any C atom that is adjacent to this N atom) by 1 or 2 substituents independently selected from (1-4C)alkyl, amino, (1-4C)alkylamino, (1-4C)alkoxy and halogen, and/or on an available N atom (provided that the ring is not thereby quaternised), by (1-4C)alkyl;



(IP)

10

wherein: R^2 and R^3 are independently hydrogen or fluoro;

Rp is hydrogen, (1-4C)alkyl, hydroxy, (1-4C)alkoxy or (2-4C)alkanoyloxy;

>A-B- is of the formula $>C=C(Rr)-$, $>CHCH(Rr)-$, $>C(OH)CH(Rr)-$ or $>N-CH_2-$

(> represents two single bonds) wherein Rr is hydrogen or (1-4C)alkyl;

15 D is -O-, -S-, -SO-, -SO₂- or >NRcp;

Rp1 and Rp2 are independently oxo (=O) [but not when Rcp is group (PC) below], (1-

4C)alkyl, (1-4C)alkanoylamino-(1-4C)alkyl, hydroxy-(1-4C)alkyl, carboxy, (1-

4C)alkoxycarbonyl, AR-oxymethyl, AR-thiomethyl (wherein AR is as defined hereinbelow)

or independently as defined for Rcp hereinbelow with the proviso that Rp1 and Rp2 are not

20 phenyl, benzyl, AR (as defined hereinbelow), a tetrazole ring system, cyclopentyl or

cyclohexyl; and when D is -O- or -S-, Rp1 and Rp2 are additionally independently hydroxy or bromo;

wherein Rcp is selected from (PA) to (PE) below :-

(PA) hydrogen, cyano, 2-((1-4C)alkoxycarbonyl)ethenyl, 2-cyanoethenyl, 2-cyano-2-

25 ((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl;

(PB) phenyl, benzyl, AR (as defined hereinbelow) or a tetrazole ring system [optionally mono-substituted in the 1- or 2- position of the tetrazole ring by (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl or (1-4C)alkanoyl] wherein the tetrazole ring system is joined to the nitrogen in

>NRcp by a ring carbon atom;

(PC) $R^{13p}CO-$, $R^{13p}SO_2-$ or $R^{13p}CS-$ wherein R^{13p} is selected from (PCa) to (PCf) :-

(PCa) AR (as defined hereinbelow);

(PCb) cyclopentyl or cyclohexyl, 1,3-dioxolan-4-yl, 1,3-dioxan-4-yl or 1,4-dioxan-2-yl

5 [optionally mono- or di-substituted by substituents independently selected from (1-4C)alkyl (including geminal disubstitution), hydroxy (but excluding 1,3-dioxolan-4-yl, 1,3-dioxan-4-yl or 1,4-dioxan-2-yl substituted by hydroxy), (1-4C)alkoxy, (1-4C)alkylthio, acetamido, (1-4C)alkanoyl, cyano and trifluoromethyl];

(PCc) hydrogen, (1-4C)alkoxycarbonyl, trifluoromethyl, amino, (1-4C)alkylamino,
10 di((1-4C)alkyl)amino, 2-(5- or 6-membered heteroaryl)ethenyl, 2-(5- or 6-membered (partially) hydrogenated heteroaryl)ethenyl, 2-phenylethenyl [wherein the heteroaryl or phenyl substituent is optionally substituted on an available carbon atom by up to three substituents independently selected from (1-4C)alkoxy, halo, cyano and (for the phenyl substituent only) (1-4C)alkylsulfonyl];

15 (PCd) (1-10C)alkyl [optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy and amino, or optionally monosubstituted by cyano, halo, (1-10C)alkoxy, trifluoromethyl, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkanoyl, (1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-

20 (1-4C)alkyl-N-(2-6C)alkanoylamino, (1-4C)alkylS(O)_pNH-, (1-4C)alkylS(O)_p- ((1-4C)alkyl)N-, fluoro(1-4C)alkylS(O)_pNH-, fluoro(1-4C)alkylS(O)_p((1-4C)alkyl)N-, phosphono, (1-4C)alkoxy(hydroxy)phosphoryl, di-(1-4C)alkoxyphosphoryl, (1-4C)alkylS(O)_q-, phenyl, naphthyl, phenoxy, naphthoxy, phenylamino, naphthylamino, phenylS(O)_q-, naphthylS(O)_q- [wherein said phenyl and naphthyl groups are optionally

25 substituted by up to three substituents independently selected from (1-4C)alkoxy, halo and cyano], or CY (as defined hereinbelow), wherein p is 1 or 2 and q is 0, 1 or 2];

(PCE) $R^{14p}C(O)O(1-6C)alkyl$ wherein R^{14p} is an optionally substituted 5- or 6-membered heteroaryl, optionally substituted phenyl, (1-4C)alkylamino, benzyloxy-(1-4C)alkyl or optionally substituted (1-10C)alkyl;

30 (PCf) $R^{15p}O-$ wherein R^{15p} is benzyl or optionally substituted (1-6C)alkyl;

- 20 -

- (PD) RdOC(Re)=CH(C=O)- , RfC(=O)C(=O)- , RgN=C(Rh)C(=O)- or $\text{RiNHC(Rj)=CHC(=O)-}$ wherein Rd is (1-6C)alkyl; Re is hydrogen or (1-6C)alkyl, or Rd and Re together form a (3-4C)alkylene chain; Rf is hydrogen, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxy(1-6C)alkyl, amino, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy, hydroxy(2-6C)alkoxy, (1-4C)alkylamino(2-6C)alkoxy, di-(1-4C)alkylamino(2-6C)alkoxy; Rg is (1-6C)alkyl, hydroxy or (1-6C)alkoxy; Rh is hydrogen or (1-6C)alkyl; Ri is hydrogen, (1-6C)alkyl, optionally substituted phenyl or an optionally substituted 5- or 6-membered heteroaryl [and (partially) hydrogenated versions thereof] and Rj is hydrogen or (1-6C)alkyl;
- 10 (PE) $\text{R}^{16p}\text{CH(R}^{17p})\text{(CH}_2\text{)}_{mp}$ - wherein mp is 0 or 1; R^{17p} is fluoro, cyano, (1-4C)alkoxy, (1-4C)alkylsulfonyl, (1-4C)alkoxycarbonyl or hydroxy, (provided that when mp is 0, R^{17p} is not fluoro or hydroxy) and R^{16p} is hydrogen or (1-4C)alkyl; wherein AR is optionally substituted phenyl, optionally substituted phenyl(1-4C)alkyl, optionally substituted naphthyl, optionally substituted 5- or 6-membered heteroaryl;
- 15 wherein AR is also an optionally substituted 5/6 or 6/6 bicyclic heteroaryl ring system, in which the bicyclic heteroaryl ring systems may be linked via an atom in either of the rings comprising the bicyclic system, and wherein both the mono- and bicyclic heteroaryl ring systems are linked via a ring carbon atom and may be (partially) hydrogenated; wherein CY is selected from :-
- 20 (i) cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl or cyclohexenyl ring;
- (ii) 5- or 6-membered heteroaryl, 5- or 6-membered heteroaryloxy, 5- or 6-membered heteroaryl-S(O)_q-, 5- or 6-membered heteroaryl-amino [and (partially) hydrogenated versions thereof] and
- (iii) 5/6 or 6/6 bicyclic heteroaryl, 5/6 or 6/6 bicyclic heteroaryloxy, 5/6 or 6/6 bicyclic
- 25 heteroaryl-S(O)_q-, 5/6 or 6/6 bicyclic heteroaryl-amino [and (partially) hydrogenated versions thereof]; wherein q is 0, 1 or 2 and any of the afore-mentioned ring systems in CY may be optionally substituted by up to three substituents independently selected from halo, (1-4C)alkyl [including geminal disubstitution when CY is a cycloalkyl or cycloalkenyl ring in (i)], acyl, oxo and nitro-(1-4C)alkyl.
- 30 For the avoidance of doubt, phosphono is -P(O)(OH)₂; (1-4C)alkoxy(hydroxy)-phosphoryl is a mono-(1-4C)alkoxy derivative of -O-P(O)(OH)₂; and di-(1-

4C)alkoxyphosphoryl is a di-(1-4C)alkoxy derivative of $-O-P(O)(OH)_2$.

In this embodiment of formula (IP) a '5- or 6-membered heteroaryl' and 'heteroaryl (monocyclic) ring' means a 5- or 6-membered aryl ring wherein (unless stated otherwise) 1, 2 or 3 of the ring atoms are selected from nitrogen, oxygen and sulfur. Unless stated otherwise, 5 such rings are fully aromatic. Particular examples of 5- or 6-membered heteroaryl ring systems are furan, pyrrole, pyrazole, imidazole, triazole, pyrimidine, pyridazine, pyridine, isoxazole, oxazole, isothiazole, thiazole and thiophene.

Particular examples of 5-membered heteroaryl rings containing 2 or 3 heteroatoms independently selected from N, O and S (with the proviso that there are no O-O, O-S or S-S 10 bonds; and in an alternative embodiment, also no N-S bonds) are pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole; and also in an alternative embodiment, isothiazole, 1,2,5-thiadiazole, 1,2,4-thiadiazole or 1,2,3-thiadiazole.

In this embodiment of formula (IP) a '5/6 or 6/6 bicyclic heteroaryl ring system' and 15 'heteroaryl (bicyclic) ring' means an aromatic bicyclic ring system comprising a 6-membered ring fused to either a 5 membered ring or another 6 membered ring, the bicyclic ring system containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur. Unless stated otherwise, such rings are fully aromatic. Particular examples of 5/6 and 6/6 bicyclic ring systems are indole, benzofuran, benzimidazole, benzothiophene, benzisothiazole, 20 benzoxazole, benzisoxazole, pyridoimidazole, pyrimidoimidazole, quinoline, quinoxaline, quinazoline, phthalazine, cinnoline and naphthyridine.

Particular optional substituents for alkyl, phenyl (and phenyl containing moieties) and naphthyl groups and ring carbon atoms in heteroaryl (mono or bicyclic) rings in R^{1p} , R^{1sp} , R_i and AR include halo, (1-4C)alkyl, hydroxy, nitro, carbamoyl, (1-4C)alkylcarbamoyl, di-((1- 25 4C)alkyl)carbamoyl, cyano, trifluoromethyl, trifluoromethoxy, amino, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-4C)alkyl $S(O)_q$ (q is 0, 1 or 2), carboxy, (1-4C)alkoxycarbonyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkanoyl, (1-4C)alkoxy, (1-4C)alkyl $S(O)_2$ amino, (1-4C)alkanoylamino, benzoylamino, benzoyl, phenyl (optionally substituted by up to three substituents selected from halo, (1-4C)alkoxy or cyano), furan, pyrrole, pyrazole, imidazole, 30 triazole, pyrimidine, pyridazine, pyridine, isoxazole, oxazole, isothiazole, thiazole, thiophene, hydroxyimino(1-4C)alkyl, (1-4C)alkoxyimino(1-4C)alkyl, hydroxy-(1-4C)alkyl, halo-(1-

- 22 -

4C)alkyl, nitro(1-4C)alkyl, amino(1-4C)alkyl, cyano(1-4C)alkyl, (1-4C)alkanesulfonamido, aminosulfonyl, (1-4C)alkylaminosulfonyl and di-((1-4C)alkyl)aminosulfonyl. The phenyl and naphthyl groups and heteroaryl (mono- or bicyclic) rings in R^{14p}, Ri and AR may be mono- or di-substituted on ring carbon atoms with substituents independently selected from the above list of particular optional substituents.

In this specification the term 'alkyl' includes straight chained and branched structures. For example, (1-6C)alkyl includes propyl, isopropyl and tert-butyl. However, references to individual alkyl groups such as "propyl" are specific for the straight chained version only, and references to individual branched chain alkyl groups such as "isopropyl" are specific for the branched chain version only. A similar convention applies to other radicals, for example halo(1-4C)alkyl includes 1-bromoethyl and 2-bromoethyl.

There follow particular and suitable values for certain substituents and groups referred to in this specification. These values may be used where appropriate with any of the definitions and embodiments disclosed hereinbefore, or hereinafter.

Examples of (1-4C)alkyl and (1-5C)alkyl include methyl, ethyl, and propyl and isopropyl; examples of (1-6C)alkyl include methyl, ethyl, propyl, isopropyl, pentyl and hexyl; examples of (1-10C)alkyl include methyl, ethyl, propyl, isopropyl, pentyl, hexyl, heptyl, octyl and nonyl; examples of (1-4C)alkanoylamino-(1-4C)alkyl include formamidomethyl, acetamidomethyl and acetamidoethyl; examples of hydroxy(1-4C)alkyl and hydroxy(1-6C)alkyl include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 3-hydroxypropyl; examples of (1-4C)alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl; examples of 2-((1-4C)alkoxycarbonyl)ethenyl include 2-(methoxycarbonyl)ethenyl and 2-(ethoxycarbonyl)ethenyl; examples of 2-cyano-2-((1-4C)alkyl)ethenyl include 2-cyano-2-methylethenyl and 2-cyano-2-ethylethenyl; examples of 2-nitro-2-((1-4C)alkyl)ethenyl include 2-nitro-2-methylethenyl and 2-nitro-2-ethylethenyl; examples of 2-((1-4C)alkylaminocarbonyl)ethenyl include 2-(methylaminocarbonyl)ethenyl and 2-(ethylaminocarbonyl)ethenyl; examples of (2-4C)alkenyl include allyl and vinyl; examples of (2-4C)alkynyl include ethynyl and 2-propynyl; examples of (1-4C)alkanoyl include formyl, acetyl and propionyl; examples of (1-4C)alkoxy include methoxy, ethoxy and propoxy; examples of (1-6C)alkoxy and (1-10C)alkoxy include methoxy, ethoxy, propoxy and pentoxy; examples of (1-4C)alkylthio

include methylthio and ethylthio; examples of (1-4C)alkylamino include methylamino, ethylamino and propylamino; examples of di-((1-4C)alkyl)amino include dimethylamino, N-ethyl-N-methylamino, diethylamino, N-methyl-N-propylamino and dipropylamino; examples of halo groups include fluoro, chloro and bromo; examples of (1-4C)alkylsulfonyl include

5 methylsulfonyl and ethylsulfonyl; examples of (1-4C)alkoxy-(1-4C)alkoxy and (1-6C)alkoxy-(1-6C)alkoxy include methoxymethoxy, 2-methoxyethoxy, 2-ethoxyethoxy and 3-methoxypropoxy; examples of

(1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy include 2-(methoxymethoxy)ethoxy, 2-(2-methoxyethoxy)ethoxy; 3-(2-methoxyethoxy)propoxy and 2-(2-ethoxyethoxy)ethoxy;

10 examples of (1-4C)alkylS(O)₂amino include methylsulfonylamino and ethylsulfonylamino; examples of (1-4C)alkanoylamino and (1-6C)alkanoylamino include formamido, acetamido and propionylamino; examples of (1-4C)alkoxycarbonylamino include methoxycarbonylamino and ethoxycarbonylamino; examples of N-(1-4C)alkyl-N-(1-6C)alkanoylamino include N-methylacetamido, N-ethylacetamido and N-

15 methylpropionamido; examples of (1-4C)alkylS(O)_pNH- wherein p is 1 or 2 include methylsulfinylamino, methylsulfonylamino, ethylsulfinylamino and ethylsulfonylamino; examples of (1-4C)alkylS(O)_p((1-4C)alkyl)N- wherein p is 1 or 2 include methylsulfinylmethylamino, methylsulfonylmethylamino, 2-(ethylsulfinyl)ethylamino and 2-(ethylsulfonyl)ethylamino; examples of fluoro(1-4C)alkylS(O)_pNH- wherein p is 1 or 2

20 include trifluoromethylsulfinylamino and trifluoromethylsulfonylamino; examples of fluoro(1-4C)alkylS(O)_p((1-4C)alkyl)NH- wherein p is 1 or 2 include trifluoromethylsulfinylmethylamino and trifluoromethylsulfonylmethylamino examples of (1-4C)alkoxy(hydroxy)phosphoryl include methoxy(hydroxy)phosphoryl and ethoxy(hydroxy)phosphoryl; examples of di-(1-4C)alkoxyphosphoryl include di-

25 methoxyphosphoryl, di-ethoxyphosphoryl and ethoxy(methoxy)phosphoryl; examples of (1-4C)alkylS(O)_q- wherein q is 0, 1 or 2 include methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl and ethylsulfonyl; examples of phenylS(O)_q and naphthylS(O)_q- wherein q is 0, 1 or 2 are phenylthio, phenylsulfinyl, phenylsulfonyl and naphthylthio, naphthylsulfinyl and naphthylsulfonyl respectively; examples of benzyloxy-(1-

30 4C)alkyl include benzyloxymethyl and benzyloxyethyl; examples of a (3-4C)alkylene chain are trimethylene or tetramethylene; examples of (1-6C)alkoxy-(1-6C)alkyl include

methoxymethyl, ethoxymethyl and 2-methoxyethyl; examples of **hydroxy-(2-6C)alkoxy** include 2-hydroxyethoxy and 3-hydroxypropoxy; examples of **(1-4C)alkylamino-(2-6C)alkoxy** include 2-methylaminoethoxy and 2-ethylaminoethoxy; examples of **di-(1-4C)alkylamino-(2-6C)alkoxy** include 2-dimethylaminoethoxy and 2-diethylaminoethoxy;

5 examples of **phenyl(1-4C)alkyl** include benzyl and phenethyl; examples of **(1-4C)alkylcarbamoyl** include methylcarbamoyl and ethylcarbamoyl; examples of **di((1-4C)alkyl)carbamoyl** include di(methyl)carbamoyl and di(ethyl)carbamoyl; examples of **hydroxyimino(1-4C)alkyl** include hydroxyiminomethyl, 2-(hydroxyimino)ethyl and 1-(hydroxyimino)ethyl; examples of **(1-4C)alkoxyimino-(1-4C)alkyl** include

10 methoxyiminomethyl, ethoxyiminomethyl, 1-(methoxyimino)ethyl and 2-(methoxyimino)ethyl; examples of **halo(1-4C)alkyl** include, halomethyl, 1-haloethyl, 2-haloethyl, and 3-halopropyl; examples of **nitro(1-4C)alkyl** include nitromethyl, 1-nitroethyl, 2-nitroethyl and 3-nitropropyl; examples of **amino(1-4C)alkyl** include aminomethyl, 1-aminoethyl, 2-aminoethyl and 3-aminopropyl; examples of **cyano(1-4C)alkyl** include

15 cyanomethyl, 1-cyanoethyl, 2-cyanoethyl and 3-cyanopropyl; examples of **(1-4C)alkanesulfonamido** include methanesulfonamido and ethanesulfonamido; examples of **(1-4C)alkylaminosulfonyl** include methylaminosulfonyl and ethylaminosulfonyl; and examples of **di-(1-4C)alkylaminosulfonyl** include dimethylaminosulfonyl, diethylaminosulfonyl and N-methyl-N-ethylaminosulfonyl; examples of **(1-4C)alkanesulfonyloxy** include methylsulfonyloxy, ethylsulfonyloxy and propylsulfonyloxy;

20 examples of **(1-4C)alkanoyloxy** include acetoxy; examples of **(1-4C)alkylaminocarbonyl** include methylaminocarbonyl and ethylaminocarbonyl; examples of **di((1-4C)alkyl)aminocarbonyl** include dimethylaminocarbonyl and diethylaminocarbonyl; examples of **(3-8C)cycloalkyl** include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl;

25 examples of **(4-7C)cycloalkyl** include cyclobutyl, cyclopentyl and cyclohexyl; examples of **di(N-(1-4C)alkyl)aminomethylimino** include dimethylaminomethylimino and diethylaminomethylimino.

Particular values for AR2 include, for example, for those AR2 containing one heteroatom, furan, pyrrole, thiophene; for those AR2 containing one to four N atoms,

30 pyrazole, imidazole, pyridine, pyrimidine, pyrazine, pyridazine, 1,2,3- & 1,2,4-triazole and tetrazole; for those AR2 containing one N and one O atom, oxazole, isoxazole and oxazine;

- 25 -

for those AR2 containing one N and one S atom, thiazole and isothiazole;

for those AR2 containing two N atoms and one S atom, 1,2,4- and 1,3,4-thiadiazole.

Particular examples of AR2a include, for example, dihydropyrrole (especially 2,5-dihydropyrrol-4-yl) and tetrahydropyridine (especially 1,2,5,6-tetrahydropyrid-4-yl).

- 5 Particular examples of AR2b include, for example, tetrahydrofuran, pyrrolidine, morpholine (preferably morpholino), thiomorpholine (preferably thiomorpholino), piperazine (preferably piperazino), imidazoline and piperidine, 1,3-dioxolan-4-yl, 1,3-dioxan-4-yl, 1,3-dioxan-5-yl and 1,4-dioxan-2-yl.

- Particular values for AR3 include, for example, bicyclic benzo-fused systems
 10 containing a 5- or 6-membered heteroaryl ring containing one nitrogen atom and optionally 1-3 further heteroatoms chosen from oxygen, sulfur and nitrogen. Specific examples of such ring systems include, for example, indole, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzisothiazole, benzoxazole, benzisoxazole, quinoline, quinoxaline, quinazoline, phthalazine and cinnoline.

- 15 Other particular examples of AR3 include 5/5-, 5/6 and 6/6 bicyclic ring systems containing heteroatoms in both of the rings. Specific examples of such ring systems include, for example, purine and naphthyridine.

- Further particular examples of AR3 include bicyclic heteroaryl ring systems with at least one bridgehead nitrogen and optionally a further 1-3 heteroatoms chosen from oxygen,
 20 sulfur and nitrogen. Specific examples of such ring systems include, for example, 3H-pyrrolo[1,2-a]pyrrole, pyrrolo[2,1-b]thiazole, 1H-imidazo[1,2-a]pyrrole, 1H-imidazo[1,2-a]imidazole, 1H,3H-pyrrolo[1,2-c]oxazole, 1H-imidazo[1,5-a]pyrrole, pyrrolo[1,2-b]isoxazole, imidazo[5,1-b]thiazole, imidazo[2,1-b]thiazole, indolizine, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyridine,
 25 pyrrolo[1,2-b]pyridazine, pyrrolo[1,2-c]pyrimidine, pyrrolo[1,2-a]pyrazine, pyrrolo[1,2-a]pyrimidine, pyrido[2,1-c]-s-triazole, s-triazole[1,5-a]pyridine, imidazo[1,2-c]pyrimidine, imidazo[1,2-a]pyrazine, imidazo[1,2-a]pyrimidine, imidazo[1,5-a]pyrazine, imidazo[1,5-a]pyrimidine, imidazo[1,2-b]-pyridazine, s-triazolo[4,3-a]pyrimidine, imidazo[5,1-b]oxazole and imidazo[2,1-b]oxazole. Other specific
 30 examples of such ring systems include, for example, [1H]-pyrrolo[2,1-c]oxazine, [3H]-oxazolo[3,4-a]pyridine, [6H]-pyrrolo[2,1-c]oxazine and pyrido[2,1-c][1,4]oxazine. Other

- 26 -

specific examples of 5/5- bicyclic ring systems are imidazooxazole or imidazothiazole, in particular imidazo[5,1-b]thiazole, imidazo[2,1-b]thiazole, imidazo[5,1-b]oxazole or imidazo[2,1-b]oxazole.

Particular examples of AR3a and AR3b include, for example, indoline,

5 1,3,4,6,9a-hexahydropyrido[2,1c][1,4]oxazin-8-yl, 1,2,3,5,8,8a-hexahydroimidazo[1,5a]pyridin-7-yl, 1,5,8,8a-tetrahydrooxazolo[3,4a]pyridin-7-yl, 1,5,6,7,8,8a-hexahydrooxazolo[3,4a]pyridin-7-yl, (7aS)[3H,5H]-1,7a-dihydropyrrolo[1,2c]oxazol-6-yl, (7aS)[5H]-1,2,3,7a-tetrahydropyrrolo[1,2c]imidazol-6-yl, (7aR)[3H,5H]-1,7a-dihydropyrrolo[1,2c]oxazol-6-yl, [3H,5H]-pyrrolo[1,2-c]oxazol-6-yl, 10 [5H]-2,3-dihydropyrrolo[1,2-c]imidazol-6-yl, [3H,5H]-pyrrolo[1,2-c]thiazol-6-yl, [3H,5H]-1,7a-dihydropyrrolo[1,2-c]thiazol-6-yl, [5H]-pyrrolo[1,2-c]imidazol-6-yl, [1H]-3,4,8,8a-tetrahydropyrrolo[2,1-c]oxazin-7-yl, [3H]-1,5,8,8a-tetrahydrooxazolo[3,4-a]pyrid-7-yl, [3H]-5,8-dihydrooxazolo[3,4-a]pyrid-7-yl and 5,8-dihydroimidazo[1,5-a]pyrid-7-yl.

15 Particular values for AR4 include, for example, pyrrolo[a]quinoline, 2,3-pyrroloisoquinoline, pyrrolo[a]isoquinoline, 1H-pyrrolo[1,2-a]benzimidazole, 9H-imidazo[1,2-a]indole, 5H-imidazo[2,1-a]isoindole, 1H-imidazo[3,4-a]indole, imidazo[1,2-a]quinoline, imidazo[2,1-a]isoquinoline, imidazo[1,5-a]quinoline and imidazo[5,1-a]isoquinoline.

20 The nomenclature used is that found in, for example, "Heterocyclic Compounds (Systems with bridgehead nitrogen), W.L.Mosby (Interscience Publishers Inc., New York), 1961, Parts 1 and 2.

Where optional substituents are listed such substitution is preferably not geminal disubstitution unless stated otherwise. If not stated elsewhere suitable optional substituents for 25 a particular group are those as stated for similar groups herein.

Suitable substituents on AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1 and CY2 are (on an available carbon atom) up to three substituents independently selected from (1-4C)alkyl {optionally substituted by (preferably one) substituents selected independently from hydroxy, trifluoromethyl, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2) (this last 30 substituent preferably on AR1 only), (1-4C)alkoxy, (1-4C)alkoxycarbonyl, cyano, nitro, (1-4C)alkanoylamino, -CONR^vR^w or -NR^vR^w}, trifluoromethyl, hydroxy, halo, nitro, cyano,

- 27 -

thiol, (1-4C)alkoxy, (1-4C)alkanoyloxy, dimethylaminomethyleneaminocarbonyl, di(N-(1-4C)alkyl)aminomethylimino, carboxy, (1-4C)alkoxycarbonyl, (1-4C)alkanoyl, (1-4C)alkylSO₂amino, (2-4C)alkenyl {optionally substituted by carboxy or (1-4C)alkoxycarbonyl}, (2-4C)alkynyl, (1-4C)alkanoylamino, oxo (=O), thioxo (=S), (1-4C)alkanoylamino {the (1-4C)alkanoyl group being optionally substituted by hydroxy}, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2) {the (1-4C)alkyl group being optionally substituted by one or more groups independently selected from cyano, hydroxy and (1-4C)alkoxy}, -CONR_vR_w or -NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl].

Further suitable substituents on AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1 and CY2 (on an available carbon atom), and also on alkyl groups (unless indicated otherwise) are up to three substituents independently selected from trifluoromethoxy, benzoylamino, benzoyl, phenyl {optionally substituted by up to three substituents independently selected from halo, (1-4C)alkoxy or cyano}, furan, pyrrole, pyrazole, imidazole, triazole, pyrimidine, pyridazine, pyridine, isoxazole, oxazole, isothiazole, thiazole, thiophene, hydroxyimino(1-4C)alkyl, (1-4C)alkoxyimino(1-4C)alkyl, halo-(1-4C)alkyl, (1-4C)alkanesulfonamido, -SO₂NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl].

Preferable optional substituents on Ar2b as 1,3-dioxolan-4-yl, 1,3-dioxan-4-yl, 1,3-dioxan-5-yl or 1,4-dioxan-2-yl are mono- or disubstitution by substituents independently selected from (1-4C)alkyl (including geminal disubstitution), (1-4C)alkoxy, (1-4C)alkylthio, acetamido, (1-4C)alkanoyl, cyano, trifluoromethyl and phenyl].

Preferable optional substituents on CY1 & CY2 are mono- or disubstitution by substituents independently selected from (1-4C)alkyl (including geminal disubstitution), hydroxy, (1-4C)alkoxy, (1-4C)alkylthio, acetamido, (1-4C)alkanoyl, cyano, and trifluoromethyl.

Suitable substituents on AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4 and AR4a are (on an available nitrogen atom, where such substitution does not result in quaternization) (1-4C)alkyl, (1-4C)alkanoyl {wherein the (1-4C)alkyl and (1-4C)alkanoyl groups are optionally substituted by (preferably one) substituents independently selected from cyano, hydroxy, nitro, trifluoromethyl, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2), (1-4C)alkoxy, (1-4C)alkoxycarbonyl, (1-4C)alkanoylamino, -CONR_vR_w or -NR_vR_w [wherein R_v is hydrogen

or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl}}, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxycarbonyl or oxo (to form an N-oxide).

Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, fumarate, hydrochloride, citrate, maleate, tartrate and (less preferably) 5 hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine, tris-(2-hydroxyethyl)amine, N-methyl D-glucamine and amino acids 10 such as lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically-acceptable salt is the sodium salt.

However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically-acceptable or not.

15 The compounds of the formula (I) may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the formula (I). A prodrug may be used to alter or improve the physical and/or pharmacokinetic profile of the parent compound and can be formed when the parent compound contains a suitable group or substituent which can be derivatised to form a prodrug. Examples of pro-drugs include in- 20 vivo hydrolysable esters of a compound of the formula (I) or a pharmaceutically-acceptable salt thereof.

Various forms of prodrugs are known in the art, for examples see:


- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);
- 25 b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 113-191 (1991);
- c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);
- d) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, 77, 285 (1988); and
- 30 e) N. Kakeya, *et al.*, Chem Pharm Bull, 32, 692 (1984).

An in-vivo hydrolysable ester of a compound of the formula (I) or a pharmaceutically-acceptable salt thereof containing carboxy or hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically-acceptable esters for carboxy
5 include (1-6C)alkoxymethyl esters for example methoxymethyl, (1-6C)alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, (3-8C)cycloalkoxycarbonyloxy(1-6C)alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolan-2-onylmethyl esters for example 5-methyl-1,3-dioxolan-2-ylmethyl; and (1-6C)alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the
10 compounds of this invention.


An in-vivo hydrolysable ester of a compound of the formula (I) or a pharmaceutically-acceptable salt thereof containing a hydroxy group or groups includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a result of the in-vivo hydrolysis of the ester breakdown to give
15 the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of in-vivo hydrolysable ester forming groups for hydroxy include (1-10C)alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, (1-10C)alkoxycarbonyl (to give alkyl carbonate esters), di-(1-4C)alkylcarbamoyle and N-(di-(1-4C)alkylaminoethyl)-N-(1-4C)alkylcarbamoyle (to give
20 carbamates), di-(1-4C)alkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include chloromethyl or aminomethyl, (1-4C)alkylaminomethyl and di-((1-4C)alkyl)aminomethyl, and morpholino or piperazino linked from a ring nitrogen atom via a methylene linking group to the 3- or 4-position of the benzoyl ring.

Certain suitable in-vivo hydrolysable esters of a compound of the formula (I) are
25 described within the definitions listed in this specification, for example esters described by the definition (Rc2d), and some groups within (Rc2c). Suitable in-vivo hydrolysable esters of a compound of the formula (I) are described as follows. For example, a 1,2-diol may be cyclised to form a cyclic ester of formula (PD1) or a pyrophosphate of formula (PD2) :

- 30 -




(PD1)



(PD2)

Particularly interesting are such cyclised pro-drugs when the 1,2-diol is on a (1-4C)alkyl chain linked to a carbonyl group in a substituent of formula R_c borne by a nitrogen atom in (TC4). Esters of compounds of formula (I) wherein the HO- function/s in (PD1) and (PD2) are protected by (1-4C)alkyl, phenyl or benzyl are useful intermediates for the preparation of such pro-drugs.

Further in-vivo hydrolysable esters include phosphoramidic esters, and also compounds of formula (I) in which any free hydroxy group independently forms a phosphoryl (n_{pd} is 1) or phosphiryl (n_{pd} is 0) ester of the formula (PD3) :



(PD3)

Useful intermediates for the preparation of such esters include compounds containing a group/s of formula (PD3) in which either or both of the -OH groups in (PD3) is independently protected by (1-4C)alkyl (such compounds also being interesting compounds in their own right), phenyl or phenyl-(1-4C)alkyl (such phenyl groups being optionally substituted by 1 or 2 groups independently selected from (1-4C)alkyl, nitro, halo and (1-4C)alkoxy).

Thus, prodrugs containing groups such as (PD1), (PD2) and (PD3) may be prepared by reaction of a compound of formula (I) containing suitable hydroxy group/s with a suitably protected phosphorylating agent (for example, containing a chloro or dialkylamino leaving group), followed by oxidation (if necessary) and deprotection.


When a compound of formula (I) contains a number of free hydroxy group, those groups not being converted into a prodrug functionality may be protected (for example, using a t-butyl-dimethylsilyl group), and later deprotected. Also, enzymatic methods may be used

to selectively phosphorylate or dephosphorylate alcohol functionalities.

Other interesting in-vivo hydrolysable esters include, for example, those in which R_c is defined by, for example, R¹⁴C(O)O(1-6C)alkyl-CO- (wherein R¹⁴ is for example, benzyloxy-(1-4C)alkyl, or phenyl). Suitable substituents on a phenyl group in such esters include, for example, 4-(1-4C)piperazino-(1-4C)alkyl, piperazino-(1-4C)alkyl and morpholino-(1-4C)alkyl.

Where pharmaceutically-acceptable salts of an in-vivo hydrolysable ester may be formed this is achieved by conventional techniques. Thus, for example, compounds containing a group of formula (PD1), (PD2) and/or (PD3) may ionise (partially or fully) to form salts with an appropriate number of counter-ions. Thus, by way of example, if an in-vivo hydrolysable ester prodrug of a compound of formula (I) contains two (PD3) groups, there are four HO-P- functionalities present in the overall molecule, each of which may form an appropriate salt (i.e. the overall molecule may form, for example, a mono-, di-, tri- or tetra-sodium salt).

The compounds of the present invention have a chiral centre at the C-5 position of the oxazolidinone ring. The pharmaceutically active enantiomer is of the formula (IA):



The present invention includes the pure enantiomer depicted above or mixtures of the 5R and 5S enantiomers, for example a racemic mixture. If a mixture of enantiomers is used, a larger amount (depending upon the ratio of the enantiomers) will be required to achieve the same effect as the same weight of the pharmaceutically active enantiomer. For the avoidance of doubt the enantiomer depicted above is the 5R enantiomer.

Furthermore, some compounds of the formula (I) may have other chiral centres. It is to be understood that the invention encompasses all such optical and diastereo-isomers, and racemic mixtures, that possess antibacterial activity. It is well known in the art how to prepare optically-active forms (for example by resolution of the racemic form by recrystallisation techniques, by chiral synthesis, by enzymatic resolution, by

biotransformation or by chromatographic separation) and how to determine antibacterial activity as described hereinafter.

The invention relates to all tautomeric forms of the compounds of the formula (I) that possess antibacterial activity.

5 It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess antibacterial activity.

It is also to be understood that certain compounds of the formula (I) may exhibit
10 polymorphism, and that the invention encompasses all such forms which possess antibacterial activity.

As stated before, we have discovered a range of compounds that have good activity against a broad range of Gram-positive pathogens including organisms known to be resistant to most commonly used antibiotics. Physical and/or pharmacokinetic properties, for example
15 increased stability to mammalian peptidase metabolism and a favourable toxicological profile are important features. The following compounds possess particularly favourable physical and/or pharmacokinetic properties and are preferred.

Particularly preferred compounds of the invention comprise a compound of formula (I) or of formula (IP), or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester
20 thereof, wherein the substituents Q, X, HET, T and other substituents mentioned above have values disclosed hereinbefore, or any of the following values (which may be used where appropriate with any of the definitions and embodiments disclosed hereinbefore or hereinafter):

Preferably Q is selected from Q1, Q2, Q4, Q6 and Q9; especially Q1, Q2 and Q9;
25 more particularly Q1 and Q2; and most preferably Q is Q1.

Preferably T is selected from (TAf), (TDb) or (TC); especially groups (TCb) and (TCc); more particularly (TC2), (TC3) and (TC4); and most preferably (TC5), (TC7) or (TC9), and most particularly (TC5). Especially preferred is each of these values of T when present in Q1 and Q2, particularly in Q1.

30 Preferable values for other substituents (which may be used where appropriate with any of the definitions and embodiments disclosed hereinbefore or hereinafter) are :-

- 33 -

- (a) Preferably X is -O-;
- (a1) In another aspect X is -S-;
- (b) Preferably HET is pyrazole, imidazole, oxazole, isoxazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, isothiazole or 1,2,5-thiadiazole. Yet more preferably HET is
 - 5 pyrazol-3-yl, imidazol-2-yl, oxazol-2-yl, isoxazol-3-yl, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, isothiazol-3-yl or 1,2,5-thiadiazol-3-yl;
- (b1) Especially preferred is HET as isoxazole (optionally substituted as disclosed hereinbefore), particularly isoxazol-3-yl;
- (b2) In another embodiment HET is as defined hereinbefore or hereinafter, but excluding
 - 10 thiazole and thiadiazole; and in another embodiment HET is as defined hereinbefore or hereinafter, but excluding isothiazole and thiadiazole;
- (b3) Preferably HET is unsubstituted;
- (c) Preferably Rp is hydrogen;
- (d) Preferably Rp1 and Rp2 are independently selected from hydrogen, (1-4C)alkyl,
 - 15 carboxy, (1-4C)alkoxycarbonyl, hydroxymethyl, (1-4C)alkoxymethyl or carbamoyl;
- (e) Most preferably Rp1 and Rp2 are hydrogen;
- (f) Preferably one of R² and R³ is hydrogen and the other fluoro;
- (g) In another aspect both R² and R³ are fluoro;
- (h) Preferably >A-B- is of the formula >C=CH- (i.e. Rr is preferably hydrogen) or
 - 20 >N-CH₂-;
- (i) Preferably D is -O- or >NRcp;
- (j) Preferably Rcp is AR, R^{13p}CO-, R^{13p}SO₂-, R^{13p}CS-;
- (k) More preferably Rcp is AR (most preferably benzyl, pyrimidyl, pyridinyl, pyridazinyl or pyrazinyl) or R^{13p}CO- (especially R^{13p}CO-);
- 25 (l) Preferably AR is 5- or 6-membered heteroaryl; more preferably AR is 6-membered heteroaryl, such as pyridinyl;
- (m) Preferred substituents for phenyl and carbon atoms in heteroaryl (mono- and bicyclic) ring systems in AR, R^{14p} and Ri include halo, (1-4C)alkyl, hydroxy, nitro, amino, cyano, (1-4C)alkylS(O)_p- and (1-4C)alkoxy;
- 30 (n) Preferably the optionally substituted ring systems in AR, R^{14p} and Ri are unsubstituted;
- (n1) In another embodiment in the definition of R^{13p} in (PC) of embodiment (IP), 1,3-

dioxolan-4-yl and 1,4-dioxan-2-yl are excluded.

- (o) Preferably R^{13p} is (1-4C)alkoxycarbonyl, hydroxy(1-4C)alkyl, (1-4C)alkyl (optionally substituted by one or two hydroxy groups, or by an (1-4C)alkanoyl group), (1-4C)alkylamino, dimethylamino(1-4C)alkyl, (1-4C)alkoxymethyl, (1-4C)alkanoylmethyl, (1-4C)alkanoyloxy(1-4C)alkyl, (1-5C)alkoxy or 2-cyanoethyl;
- (p) More preferably R^{13p} is 1,2-dihydroxyethyl, 1,3-dihydroxyprop-2-yl, 1,2,3-trihydroxyprop-1-yl, methoxycarbonyl, hydroxymethyl, methyl, methylamino, dimethylaminomethyl, methoxymethyl, acetoxymethyl, methoxy, methylthio, naphthyl, tert-butoxy or 2-cyanoethyl;
- 10 (p1) Yet more preferably R^{13p} is 1,2-dihydroxyethyl, 1,3-dihydroxyprop-2-yl or 1,2,3-trihydroxyprop-1-yl;
- (q) Preferred optional substituents for (1-10C)alkyl in R^{14p} are hydroxy, cyano, amino, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-4C)alkylS(O)_p- (wherein p is 1 or 2), carboxy, (1-4C)alkoxycarbonyl, (1-4C)alkoxy, piperazino or morpholino;
- 15 (r) Preferred optional substituents for (1-6C)alkyl in R^{15p} are hydroxy, (1-4C)alkoxy, cyano, amino, (1-4C)alkylamino, di((1-2C)alkyl)amino, (1-4C)alkylS(O)_p- (wherein p is 1 or 2);
- (s) Preferably 5- or 6-membered heteroaryl in R^{14p} is pyridinyl or imidazol-1-yl;
- (t) Preferably R^{15p} is (1-6C)alkyl; most preferably R^{15p} is tert-butyl or methyl;
- 20 (u) Preferably R^{17p} is cyano or fluoro;
- (v) Preferably R^{16p} is hydrogen;
- (w) Preferably CY is naphthoxy, especially naphth-1-oxy or naphth-2-oxy.

Where preferable values are given for substituents in a compound of formula (IP), the corresponding substituents in a compound of formula (I) have the same preferable values


- 25 (thus, for example, R^{13} and Rc in formula (I) correspond with R_{cp} and R^{13p} in formula (IP), and similarly for groups D and G). For compounds of formula (I) preferred values for Rc are those in group (Rc2). The preferred values for R^{13p} listed above for compounds of formula (IP) are also preferred values for R^{13} in compounds of formula (I). In the definition of (Rc2c) the AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing groups are preferably
- 30 excluded.

In another aspect, HET is a C-linked 5-membered heteroaryl ring containing 2 or 3


- 35 -

heteratoms independently selected from N, O and S (with the proviso that there are no O-O, O-S, S-S or N-S bonds), which ring is optionally substituted on any available C atom (provided that when a N atom is adjacent to the X-link, there is no substitution on any C atom that is adjacent to this N atom) by 1 or 2 substituents independently selected from (1-4C)alkyl, amino, (1-4C)alkylamino, (1-4C)alkoxy and halogen, and/or on an available N atom (provided that the ring is not thereby quaternised), by (1-4C)alkyl.


In another aspect, HET is selected from the formulae (HET1) to (HET3) below :-



(HET1)



(HET2)



(HET3)


10

wherein A₂ is carbon or nitrogen and B₂ is O, S or N (with a maximum of 3 hetero atoms per ring), with carbon or nitrogen ring atoms being optionally substituted as described for HET hereinbefore (preferably with no substitution on any carbon atom that is adjacent to the specified N atom).

In another embodiment HET is as defined herein and also optionally substituted on an available suitable C atom by (1-4C)alkoxycarbonyl.

The above HET definitions are especially preferred in embodiment (IP), and with preferable value (n1) of R^{13p}.

Especially preferred compounds of the present invention are of the formula (IB):



(IB)


- 36 -

wherein HET is isoxazol-3-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl or 1,2,5-thiadiazol-3-yl; R^2 and R^3 are independently hydrogen or fluoro; and R_{p1} and R_{p2} are independently hydrogen, hydroxy, bromo, (1-4C)alkyl, carboxy, (1-4C)alkoxycarbonyl, hydroxymethyl, (1-4C)alkoxymethyl or carbamoyl; or pharmaceutically-acceptable salts thereof.

- 5 Further especially preferred compounds of the invention are of the formula (IB) wherein HET is isoxazol-3-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl or 1,2,5-thiadiazol-3-yl; R^2 and R^3 are independently hydrogen or fluoro; and R_{p1} and R_{p2} are independently hydrogen, AR-oxymethyl or AR-thiomethyl (wherein AR is phenyl, phenyl-(1-4C)alkyl, naphthyl, furan, pyrrole, pyrazole, imidazole, triazole, pyrimidine, pyridazine, pyridine,
10 isoxazole, oxazole, isothiazole, thiazole or thiophene); or pharmaceutically-acceptable salts thereof.

Of the above especially preferred compounds of the invention of the formula (IB), particularly preferred compounds are those wherein R_{p1} and R_{p2} are hydrogen are particularly preferred.

- 15 Further, especially preferred compounds of the invention are of the formula (IC):



(IC)

- wherein HET is isoxazol-3-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl or 1,2,5-thiadiazol-3-yl; R^2 and R^3 are independently hydrogen or fluoro; R_{p1} and R_{p2} are independently hydrogen,
20 AR-oxymethyl or AR-thiomethyl (wherein AR is phenyl, phenyl-(1-4C)alkyl, naphthyl, furan, pyrrole, pyrazole, imidazole, triazole, pyrimidine, pyridazine, pyridine, isoxazole, oxazole, isothiazole, thiazole or thiophene), (1-4C)alkyl, carboxy, (1-4C)alkoxycarbonyl, hydroxymethyl, (1-4C)alkoxymethyl or carbamoyl and R_{cp} is cyano, pyrimidin-2-yl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl or R_{cp} is of the formula $R^{13p}CO-$, $R^{13p}SO_2-$ or
25 $R^{13p}CS-$ (wherein R^{13p} is hydrogen, (1-5C)alkyl [optionally substituted by one or more groups each independently selected from hydroxy and amino, or optionally monosubstituted by (1-4C)alkoxy, (1-4C)alkylS(O)_q-, (1-4C)alkylamino, (1-4C)alkanoyl, naphthoxy, (2-

6C)alkanoylamino or (1-4C)alkylS(O)_pNH- wherein p is 1 or 2 and q is 0, 1 or 2], imidazole, triazole, pyrimidine, pyridazine, pyridine, isoxazole, oxazole, isothiazole, thiazole, pyridoimidazole, pyrimidoimidazole, quinoxaline, quinazoline, phthalazine, cinnoline or naphthyridine, or R^{13p} is of the formula R^{14p}C(O)O(1-6C)alkyl wherein R^{14p} is (1-6C)alkyl), or
 5 Rcp is of the formula RfC(=O)C(=O)- wherein Rf is (1-6C)alkoxy; or pharmaceutically-acceptable salts thereof.

Of the above especially preferred compounds of the invention of the formula (IC), those wherein HET is isoxazol-3-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl or 1,2,5-thiadiazol-3-yl; R² and R³ are independently hydrogen or fluoro; R_{p1} and R_{p2} are independently
 10 hydrogen, AR-oxymethyl or AR-thiomethyl (wherein AR is phenyl, phenyl-(1-4C)alkyl, naphthyl, furan, pyrrole, pyrazole, imidazole, triazole, pyrimidine, pyridazine, pyridine, isoxazole, oxazole, isothiazole, thiazole or thiophene), (1-4C)alkyl, carboxy, (1-4C)alkoxycarbonyl, hydroxymethyl, (1-4C)alkoxymethyl or carbamoyl and Rcp is cyano, pyrimidin-2-yl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl or Rcp is of the formula
 15 R^{13p}CO-, R^{13p}SO₂- or R^{13p}CS- (wherein R^{13p} is hydrogen, (1-5C)alkyl [optionally substituted by one or more groups each independently selected from hydroxy and amino, or optionally monosubstituted by (1-4C)alkoxy, (1-4C)alkylS(O)_q, (1-4C)alkylamino, (1-4C)alkanoyl, (2-6C)alkanoylamino or (1-4C)alkylS(O)_pNH- wherein p is 1 or 2 and q is 0, 1 or 2], pyridine, or R^{13p} is of the formula R^{14p}C(O)O(1-6C)alkyl wherein R^{14p} is (1-6C)alkyl), or Rcp is of the
 20 formula RfC(=O)C(=O)- wherein Rf is (1-6C)alkoxy; or pharmaceutically-acceptable salts thereof are further preferred.

Of the above especially preferred compounds of the invention of the formula (IC), particularly preferred compounds are those wherein HET is isoxazol-3-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl or 1,2,5-thiadiazol-3-yl; R² and R³ are independently hydrogen or fluoro;
 25 R_{p1} and R_{p2} are hydrogen, and Rcp is pyridin-2-yl (optionally substituted with cyano) or Rcp is of the formula R^{13p}CO- (wherein R^{13p} is hydrogen, 1,3-dioxolan-4-yl (optionally disubstituted with (1-4C)alkyl) or (1-5C)alkyl [optionally substituted by one or more hydroxy groups] or R^{13p} is of the formula R^{14p}C(O)O(1-6C)alkyl wherein R^{14p} is (1-6C)alkyl)); or pharmaceutically-acceptable salts thereof.

30 Of the above especially preferred compounds of the invention of the formula (IC), particularly preferred compounds are those wherein Rcp is of the formula R^{13p}CO- (wherein

R^{13p} is hydrogen, 1,3-dioxolan-4-yl (optionally disubstituted with (1-4C)alkyl) or (1-5C)alkyl [substituted by two hydroxy groups]; or pharmaceutically-acceptable salts thereof.

In another aspect of the invention all of the compounds of formula (IB) or (IC) described above are further preferred when HET is isoxazol-3-yl, isothiazol-3-yl or 1,2,5-thiadiazol-3-yl.

In yet another aspect the invention relates to all of the compounds of formula (IB) or (IC) described above wherein HET is isoxazol-3-yl or 1,2,4-oxadiazol-3-yl.

In yet another aspect the invention relates to all of the compounds of formula (IB) or (IC) described above wherein HET is isoxazol-3-yl.

In another aspect of the invention there are provided preferred compounds of the formula (IP) wherein -X-HET is isoxazol-3-yloxy, 1,2,4-oxadiazol-3-yloxy, isothiazol-3-yloxy, 1,2,5-thiadiazol-3-yloxy; >A-B- is >N-CH₂- and D is NR_{cp} wherein R_{cp} is a 6-membered heteroaryl ring containing 1, 2 or 3 ring nitrogen atoms as the only ring heteroatoms, linked via a ring carbon atom and optionally substituted on a ring carbon atom by one, two or three substituents independently selected from (1-4C)alkyl, halo, trifluoromethyl, (1-4C)alkyl S(O)_q- (wherein q is 0, 1 or 2), (1-4C)alkylS(O)₂amino, (1-4C)alkanoylamino, carboxy, hydroxy, amino, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, di-(N-(1-4C)alkyl)carbamoyl, (1-4C)alkoxy, cyano or nitro; or pharmaceutically-acceptable salts thereof.

In all of the above aspects and preferred compounds of formula (IB) or (IC), in-vivo hydrolysable esters are preferred, especially phosphoryl esters (as defined by formula (PD3) with npd as 1).

In all of the above definitions the preferred compounds are as shown in formula (IA), i.e. the pharmaceutically active (5(R)) enantiomer.

Particular compounds of the present invention include the following (and the individual isomers where a mixture of isomers is possible) :-

5(R)-Isoxazol-3-yloxymethyl-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one;

5(R)-(5-Methylisoxazol-3-yloxymethyl)-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one;

5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(R,S)-yl)carbonyl)-5,6-

- tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one;
- 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R,S),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)-oxazolidin-2-one;
- 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-formyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one;
- 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-acetoxyacetyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one;
- 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-hydroxyacetyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one;
- 10 5(R)-Isoxazol-3-yloxymethyl-3-(4-(4-(5-cyanopyrid-2-yl)piperazin-1-yl)-3-fluorophenyl)oxazolidin-2-one;
- 5(R)-Isothiazol-3-yloxymethyl-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one;
- 5(R)-(1,2,5-Thiadiazol-3-yloxymethyl)-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one; or pharmaceutically-acceptable salts thereof.

Of the above compounds, especially preferred is (and the individual isomers thereof) :-
 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R,S),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)-oxazolidin-2-one; or pharmaceutically-acceptable salts or in-vivo hydrolysable esters thereof.

- 20 Also preferred are the 3-fluorophenyl analogues of the particular 3,5-difluoro compounds mentioned above.

Other preferred Examples if not already specifically mentioned are Example Nos. 1, 2, 7, 14, 48, 148, 151 and 23.

Also preferred is the compound (and the individual isomers thereof) :-

- 25 5(R)-Isothiazol-3-yloxymethyl-3-(4-(1-(2(R,S),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)-oxazolidin-2-one; or pharmaceutically-acceptable salts or in-vivo hydrolysable esters thereof.

- Most particularly preferred Examples are Example Nos. 12, 18, 19, 20, 21 and 22 or pharmaceutically-acceptable salts. In-vivo hydrolysable esters of Examples 12 and 18 are
 30 preferred, especially phosphoryl esters.

Thus, preferred are the compounds, or pharmaceutically-acceptable salts thereof :-

5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-diphosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one;

5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-diphosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one.

5 Also preferred are the compounds, or pharmaceutically-acceptable salts thereof :-

5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-phosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one;

5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-phosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one.

10 Also preferred are the compounds, or pharmaceutically-acceptable salts thereof :-

5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(3-hydroxy-2(S)-phosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one;

5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(3-hydroxy-2(S)-phosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one.

15 Suitable pharmaceutically-acceptable salts of the last two named compounds and of Example Nos. 19, 20, 21 and 22 are the mono- and di- salts of the mono-phosphoryl ester compounds and the mono-, di-, tri- and tetra- salts of the di-phosphoryl ester compounds (Examples 19 and 21). Particularly preferred salts are the sodium salts.

Process section :

20 In a further aspect the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof. It will be appreciated that during certain of the following processes certain substituents may require protection to prevent their undesired reaction. The skilled chemist will appreciate when such protection is required, and how such protecting groups may be put in place, and
25 later removed.

For examples of protecting groups see one of the many general texts on the subject, for example, 'Protective Groups in Organic Synthesis' by Theodora Green (publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting
30 group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

Thus, if reactants include, for example, groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

Examples of the use of resins as a protecting group are illustrated in Examples 135 & 136 herein.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

5 A compound of the formula (I), or a pharmaceutically-acceptable salt or an *in vivo* hydrolysable ester thereof, may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, when used to prepare a compound of the formula (I), or a pharmaceutically-acceptable salt or an *in vivo* hydrolysable ester thereof, are provided as a further feature of the invention and are illustrated by the
10 following representative examples. Necessary starting materials may be obtained by standard procedures of organic chemistry (see, for example, Advanced Organic Chemistry (Wiley-Interscience), Jerry March). The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively, necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of
15 an organic chemist. Information on the preparation of necessary starting materials or related compounds (which may be adapted to form necessary starting materials) may also be found in the following Patent and Application Publications, the contents of the relevant process sections of which are hereby incorporated herein by reference :

WO99/02525; WO98/54161; WO97/37980; WO97/30981 (& US5,736,545); WO97/21708
20 (& US5,719,154); WO97/10223; WO97/09328; WO96/35691; WO96/23788; WO96/15130; WO96/13502; WO95/25106 (& US5,668,286); WO95/14684 (& US5,652,238); WO95/07271 (& US5,688,792); WO94/13649; WO94/01110; WO93/23384 (& US5,547,950 & US 5,700,799); WO93/09103 (& US5,565,571, US5,654,428, US5,654,435, US5,756,732 & US5,801,246); US5,231,188; US5,247,090; US5,523,403; WO97/27188; WO97/30995;
25 WO97/31917; WO98/01447; WO98/01446; WO99/10342; WO99/10343; WO99/11642; European Patent Application Nos. 0,359,418 and 0,609,905; 0,693,491 A1 (& US5,698,574); 0,694,543 A1 (& AU 24985/95); 0,694,544 A1 (& CA 2,154,024); 0,697,412 A1 (& US5,529,998); 0,738,726 A1 (& AU 50735/96); 0,785,201 A1 (& AU 10123/97); German Patent Application Nos. DE 195 14 313 A1 (& US5,529,998); DE 196 01 264 A1 (& AU
30 10098/97); DE 196 01 265 A1 (& AU 10097/97); DE 196 04 223 A1 (& AU 12516/97); DE 196 49 095 A1 (& AU 12517/97).

- 43 -


The following Patent and Application Publications may also provide useful information and the contents of the relevant process sections are hereby incorporated herein by reference :

- FR 2458547; FR 2500450(& GB 2094299, GB 2141716 & US 4,476,136); DE 2923295 (&
 5 GB 2028306, GB 2054575, US4,287,351, US4,348,393, US4,413,001, US4,435,415 &
 US4,526,786), DE 3017499 (& GB 2053196, US4,346,102 & US4,372,967);
 US4,705,799; European Patent Application Nos. 0,312,000; 0,127,902; 0,184,170; 0,352,781;
 0,316,594;

The skilled organic chemist will be able to use and adapt the information contained
 10 and referenced within the above references to obtain necessary starting materials.

Thus, the present invention also provides that the compounds of the formulae (I) and pharmaceutically-acceptable salts and *in vivo* hydrolysable esters thereof, can be prepared by a process (a) to (i) as follows (wherein the variables are as defined above unless otherwise stated) :

- 15 (a) by modifying a substituent in or introducing a substituent into another compound of formula (I);
 (b) by reaction of a compound of formula (II)



(II)

- 20 wherein Yp is hydroxy with a compound of the formula (b1) HET-OH or (b2) HET-Lg, wherein Lg is a suitable leaving group;
 (c) by reaction of a compound of formula (II) wherein Yp is a leaving group, for example halogen, mesylate or tosylate, with a metal alkoxide compound of the formula HET-OM where M is an alkali metal, or another metal, such as silver, known to promote O-alkylation;
 25 (d) by reaction of a compound of the formula Q-Zp wherein Zp is an isocyanate or amine group with an epoxide of the formula CH₂(O)CH-CH₂O-HET;
 (e) when X is -S- by a process analogous to process (c) wherein (e1) a metal thioxide compound of the formula HET-SM where M is an alkali metal, or another metal, such as

silver, known to promote S-alkylation; or (e2) alternatively by a process analogous to process (c) using HET-SH and a compound of formula (II) in which Yp is a suitable leaving group;


(f) when X is -SO- or -SO₂- by oxidation of a compound wherein X is -S-;

(g) by conversion to a non-quaternary compound of a compound of formula (I) in which
5 the ring HET bears a quaternary nitrogen;


(h) when HET is an isoxazole ring by reaction of a compound of the formula (II) in which Yp is -O-CH=N-OH with an acetylene;

(i) by reaction of a urethane compound of formula (III) with a compound of formula (IV)

10



(III)



(IV)

wherein R²¹ is (1-6C)alkyl or benzyl; and thereafter if necessary :

(i) removing any protecting groups; (ii) forming a pharmaceutically-acceptable salt; (iii)

15 forming an *in vivo* hydrolysable ester.

General guidance on reaction conditions and reagents may be obtained in Advanced Organic Chemistry, 4th Edition, Jerry March (publisher : J.Wiley & Sons), 1992. Necessary starting materials may be obtained by standard procedures of organic chemistry, such as described in this process section, in the Examples section or by analogous procedures within
20 the ordinary skill of an organic chemist. Certain references are also provided (see above) which describe the preparation of certain suitable starting materials, for particular example see International Patent Application Publication No. WO 97/37980, the contents of which are incorporated here by reference. Processes analogous to those described in the references may also be used by the ordinary organic chemist to obtain necessary starting materials.

25 (a) Methods for converting substituents into other substituents are known in the art. For example an alkylthio group may be oxidised to an alkylsulfinyl or alkylsulfonyl group, a cyano group reduced to an amino group, a nitro group reduced to an amino group, a hydroxy group alkylated to a methoxy group, a hydroxy group thiomethylated to an arylthiomethyl or a heteroarylthiomethyl group (see, for example, Tet.Lett., 585, 1972), a carbonyl group

converted to a thiocarbonyl group (eg. using Lawesson's reagent) or a bromo group converted to an alkylthio group. It is also possible to convert one Rc group into another Rc group as a final step in the preparation of a compound of the formula (I).


One compound of formula (I) may be converted into another compound of formula (I) by reacting a compound of formula (I) in which T is halo with a suitable compound to form another value of T. Thus, for example, T as halo may be displaced by suitable vinyl, aromatic, tropolone and nitrogen-linked systems as T by reaction using known Pd(0) coupling techniques.

Further examples of converting substituents into other substituents are contained in the accompanying non-limiting Examples.

(b1) When HET-OH is used reaction (b1) is performed under Mitsunobu conditions, for example, in the presence of tri-n-butylphosphine and diethyl azodicarboxylate (DEAD) in an organic solvent such as THF, and in the temperature range 0°C - 60°C, but preferably at ambient temperature. Details of Mitsunobu reactions are contained in Tet. Letts., 31, 699, (1990); The Mitsunobu Reaction, D.L.Hughes, Organic Reactions, 1992, Vol.42, 335-656 and Progress in the Mitsunobu Reaction, D.L.Hughes, Organic Preparations and Procedures International, 1996, Vol.28, 127-164.

(b2) When HET-Lg is used reaction (b2) is performed using a suitably reactive HET and under basic conditions (using a base such as 1,8-diazabicyclo[5,4,0]undec-7-ene) which are sufficiently mild not to destroy the oxazolidinone ring structure. The skilled organic chemist will appreciate which suitable leaving group Lg (such as chloro or bromo) and reaction conditions to use.

Compounds of the formula (II) wherein Yp is hydroxy may be obtained by reacting a compound of the formula (III) with a compound of formula (V):



wherein R²¹ is (1-6C)alkyl or benzyl and R²² is (1-4C)alkyl or -S(O)_q(1-4C)alkyl where q is 0, 1 or 2. Preferably R²² is (1-4C)alkyl.

Compounds of the formula (II), (III) and (V) may be prepared by the skilled chemist, for example as described in International Patent Application Publication Nos. WO95/07271, WO97/27188, WO 97/30995, WO 98/01446 and WO 98/01446, the contents of which are hereby incorporated by reference, and by analogous processes.

- 5 If not commercially available, compounds of the formula HET-OH and HET-Lg may be prepared by procedures which are selected from standard chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the procedures described in the Examples. For example, standard chemical techniques are as described in Houben Weyl, Methoden der Organische Chemie, E8a, Pt.I (1993), 45-225, B.J.Wakefield (for isoxazoles) and E8c, Pt.I (1994), 409-525, U.Kraatz (for 1,2,4-oxadiazoles). Also, for example, 3-hydroxyisoxazole may be prepared by cyclisation of $\text{CH}\equiv\text{C-CO-NHOH}$ (prepared from $\text{CH}\equiv\text{C-CO-O-(1-4C)alkyl}$) as described in Chem.Pharm.Bull.Japan, 14, 92, (1966).

- (c) & (e) Reactions (c) and (e) are performed conveniently at a temperature in the range
15 25-60°C in a solvent such as NMP or DMF.

A compound of the formula (II) wherein Yp is fluoro may be prepared by reacting a compound of the formula (II) wherein Yp is hydroxy (hydroxy compound) with a fluorinating agent such as diethylaminosulfur trifluoride in an organic solvent such as dichloromethane in the temperature range of 0°C to ambient temperature.

- 20 When Yp is chloro. the compound of the formula (II) may be formed by reacting the hydroxy compound with a chlorinating agent. For example, by reacting the hydroxy compound with thionyl chloride, in a temperature range of ambient temperature to reflux, optionally in a chlorinated solvent such as dichloromethane or by reacting the hydroxy compound with carbon tetrachloride/triphenyl phosphine in dichloromethane, in a temperature
25 range of 0°C to ambient temperature. A compound of the formula (II) wherein Yp is chloro or iodo may also be prepared from a compound of the formula (II) wherein Yp is mesylate or tosylate, by reacting the latter compound with lithium chloride or lithium iodide and crown ether, in a suitable organic solvent such as THF, in a temperature range of ambient temperature to reflux

- 30 When Yp is (1-4C)alkanesulfonyloxy or tosylate the compound (II) may be prepared by reacting the hydroxy compound with (1-4C)alkanesulfonyl chloride or tosyl chloride in the

presence of a mild base such as triethylamine or pyridine.

Compounds of the formula HET-OM and HET-SM may be prepared by the skilled chemist from the corresponding HET-OH or HET-SH compound, using a suitable base, such as sodium hydride, silver carbonate, sodium carbonate or an alkoxide.

5 When X is -S- and a process is used that is analogous to process (c) but using HET-SH and a compound of formula (II) in which Yp is a suitable leaving group, a suitable leaving group is, for example, mesylate and a suitable base for the reaction is a base such as 1,8-diazabicyclo[5,4,0]undec-7-ene (see for example, Example 153).

(d) Reaction (d) is performed under conditions analogous to those described in the
10 following references which disclose how suitable and analogous starting materials may be obtained.

Compounds of the formula Q-Zp wherein Zp is an isocyanate may be prepared by the skilled chemist, for example by analogous processes to those described in Walter A. Gregory et al in J.Med.Chem. 1990, 33, 2569-2578 and Chung-Ho Park et al in J.Med.Chem. 1992, 35,
15 1156-1165. Compounds of the formula Q-Zp wherein Zp is a urethane (see process (i)) may be prepared by the skilled chemist, for example by analogous processes to those described in International Patent Application Publication Nos. WO 97/30995 and WO 97/37980.

A similar reaction to reaction (d) may be performed in which Q-Zp wherein Zp is a amine group is reacted with the epoxide (optionally in the presence of an organic base), and
20 the product is reacted with, for example, phosgene to form the oxazolidinone ring. Such reactions and the preparation of starting materials in within the skill of the ordinary chemist with reference to the above-cited documents disclosing analogous reactions and preparations.

Epoxides of the formula $\text{CH}_2(\text{O})\text{CH}-\text{CH}_2\text{O}-\text{HET}$ may be prepared from the corresponding $\text{CH}_2=\text{CH}-\text{CH}_2-\text{O}-\text{HET}$ compound. Certain such epoxide and alkene
25 intermediates are novel and are provided as a further feature of the invention. For example, when HET is isoxazol-3-yl, 3-(2,3-oxiranepropyloxy)isoxazole may be prepared from 3-allyloxyisoxazole. Asymmetric epoxidation may be used to give the desired optical isomer.

(f) When X is -SO- or -SO₂- the oxidation of a compound wherein X is -S- may be achieved by oxidising with standard reagents known in the art for the oxidation of a thio
30 group to a sulfinyl or sulfonyl group. For example, a thio group may be oxidised to a sulfinyl group with a peracid such as m-chloroperoxybenzoic acid and oxidising agents such as

potassium permanganate can be used to convert a thio group to a sulfonyl group.

- (g) The conversion to a non-quaternary compound of a compound of formula (I) in which the ring HET bears a quaternary nitrogen may be achieved under thermal conditions suitable to achieve elimination of the quaternary group (for example, a methyl group will be
5 eliminated as a methyl halide).

A compound of formula (I) in which the ring HET bears a quaternary nitrogen may be prepared in a similar manner to the conditions described for reaction (c), although a suitably quaternised HET compound, substituted in the alpha position next to nitrogen by a leaving group (such as halogen), and a compound of the formula (II) in which Yp is -OH or -
10 SH, is used. Such starting materials are readily prepared by the ordinary organic chemist.

A compound of formula (I) in which the ring HET bears a quaternary nitrogen may also be prepared in a similar manner to the conditions described in Chem.Pharm.Bull.Japan, 27, 2415-2423, (1979), by reaction of an N-alkylated HET-OH or HET-SH compound in the keto-form (with the keto (oxo or thioxo) group in the alpha position next to nitrogen) with a
15 compound of formula (II) in which Yp is a leaving group such as mesylate.

- (h) When the HET ring is isoxazole it may be built up as a final step from a compound of the formula (II) in which Yp is -O-CH=N-OH by reaction under standard conditions with an acetylene (see for example, Acta Chem. Scand 47, 1004, 1993).

- (i) A compound of formula (III) is reacted with a compound of formula (IV) using similar
20 conditions to those for reaction of a compound of the formula (III) with a compound of formula (V) described above. If not commercially available, the preparation of suitable starting materials of formulae (III) and (IV) is as described above, or by using analogous processes.

The removal of any protecting groups, the formation of a pharmaceutically-acceptable
25 salt and/or the formation of an *in vivo* hydrolysable ester are within the skill of an ordinary organic chemist using standard techniques. Furthermore, details on these steps, for example the preparation of in-vivo hydrolysable ester prodrugs has been provided in the section above on such esters, and in certain of the following non-limiting Examples.

When an optically active form of a compound of the formula (I) is required, it may be
30 obtained by carrying out one of the above procedures using an optically active starting material (formed, for example, by asymmetric induction of a suitable reaction step), or by

resolution of a racemic form of the compound or intermediate using a standard procedure, or by chromatographic separation of diastereoisomers (when produced). Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates.

Similarly, when a pure regioisomer of a compound of the formula (I) is required, it
5 may be obtained by carrying out one of the above procedures using a pure regioisomer as a starting material, or by resolution of a mixture of the regioisomers or intermediates using a standard procedure.

According to a further feature of the invention there is provided a compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof for use
10 in a method of treatment of the human or animal body by therapy.

According to a further feature of the present invention there is provided a method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester
15 thereof.

The invention also provides a compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, for use as a medicament; and the use of a compound of the formula (I) of the present invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, in the manufacture of a medicament for use in the
20 production of an antibacterial effect in a warm blooded animal, such as man.

In order to use a compound of the formula (I), an in-vivo hydrolysable ester or a pharmaceutically-acceptable salt thereof, including a pharmaceutically-acceptable salt of an in-vivo hydrolysable ester, (hereinafter in this section relating to pharmaceutical composition "a compound of this invention") for the therapeutic (including prophylactic) treatment of
25 mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I), an in-vivo hydrolysable ester or a pharmaceutically-acceptable salt thereof, including a pharmaceutically-acceptable salt of an
30 in-vivo hydrolysable ester, and a pharmaceutically-acceptable diluent or carrier.

- 50 -

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous
5 or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, aerosols (or sprays), drops and sterile injectable aqueous or oily solutions or suspensions.

In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain or be co-administered (simultaneously, sequentially or
10 separately) with one or more known drugs selected from other clinically useful antibacterial agents (for example, β -lactams or aminoglycosides) and/or other anti-infective agents (for example, an antifungal triazole or amphotericin). These may include carbapenems, for example meropenem or imipenem, to broaden the therapeutic effectiveness. Compounds of this invention may also contain or be co-administered with bactericidal/permeability-
15 increasing protein (BPI) products or efflux pump inhibitors to improve activity against gram negative bacteria and bacteria resistant to antimicrobial agents.

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 1mg and 1g of a compound of this invention, preferably between 100mg and 1g of a
20 compound. Especially preferred is a tablet or capsule which contains between 50mg and 800mg of a compound of this invention, particularly in the range 100mg to 500mg.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection, for example an injection which contains between 0.1% w/v and 50% w/v (between 1mg/ml and 500mg/ml) of a compound of this
25 invention.

Each patient may receive, for example, a daily intravenous, subcutaneous or intramuscular dose of 0.5 mg kg^{-1} to 20 mg kg^{-1} of a compound of this invention, the composition being administered 1 to 4 times per day. In another embodiment a daily dose of 5 mg kg^{-1} to 20 mg kg^{-1} of a compound of this invention is administered. The intravenous,
30 subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time.

Alternatively each patient may receive a daily oral dose which may be approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

- A pharmaceutical composition to be dosed intravenously may contain advantageously
5 (for example to enhance stability) a suitable bactericide, antioxidant or reducing agent, or a suitable sequestering agent.

In the above other, pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

10 Antibacterial Activity :

- The pharmaceutically-acceptable compounds of the present invention are useful antibacterial agents having a good spectrum of activity in vitro against standard Gram-positive organisms, which are used to screen for activity against pathogenic bacteria. Notably, the pharmaceutically-acceptable compounds of the present invention show activity against
15 enterococci, pneumococci and methicillin resistant strains of *S.aureus* and coagulase negative staphylococci. The antibacterial spectrum and potency of a particular compound may be determined in a standard test system.

- The (antibacterial) properties of the compounds of the invention may also be demonstrated and assessed in-vivo in conventional tests, for example by oral and/or
20 intravenous dosing of a compound to a warm-blooded mammal using standard techniques.

The following results were obtained on a standard in-vitro test system. The activity is described in terms of the minimum inhibitory concentration (MIC) determined by the agar-dilution technique with an inoculum size of 10^4 CFU/spot. Typically, compounds are active in the range 0.01 to 256 $\mu\text{g/ml}$.

- 25 Staphylococci were tested on agar, using an inoculum of 10^4 CFU/spot and an incubation temperature of 37°C for 24 hours - standard test conditions for the expression of methicillin resistance.

- Streptococci and enterococci were tested on agar supplemented with 5% defibrinated horse blood, an inoculum of 10^4 CFU/spot and an incubation temperature of 37°C in an
30 atmosphere of 5% carbon dioxide for 48 hours - blood is required for the growth of some of the test organisms.

- 52 -

<u>Organism</u>		<u>MIC (μg/ml)</u>			
		<u>Example 4</u>	<u>Example 12</u>	<u>Example 18</u>	<u>Example 151</u>
Staphylococcus aureus:					
5	Oxford	0.25	0.25	0.25	0.13
	Novb. Res	0.50	0.5	0.25	0.25
	MRQR	0.50	0.5	0.5	0.25
Coagulase Negative Staphylococci					
10	MS	0.13	0.13	0.13	0.13
	MR	0.50	0.5	0.5	0.25
Streptococcus pyogenes					
	C203	0.50	0.5	0.25	0.25
	Enterococcus faecalis	1.00	1.00	0.5	0.25
	Bacillus subtilis	0.25	0.25	0.25	0.13

15 Novb. Res = Novobiocin resistant

MRQR = methicillin resistant quinolone resistant

MR = methicillin resistant

MS = methicillin sensitive

Certain Reference Examples described hereinafter (for example, Reference Examples 9,
20 10, 11, 30, 38 & 39) may also possess useful activity.

The invention is now illustrated but not limited by the following Examples in which
unless otherwise stated :-

- i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids by filtration;
- 25 (ii) operations were carried out at ambient temperature, that is typically in the range 18-26°C and in air unless otherwise stated, or unless the skilled person would otherwise work under an inert atmosphere;
- (iii) column chromatography (by the flash procedure) was used to purify compounds and was performed on Merck Kieselgel silica (Art. 9385) unless otherwise stated;
- 30 (iv) yields are given for illustration only and are not necessarily the maximum attainable;
- (v) the structure of the end-products of the formula (I) were generally confirmed by NMR

and mass spectral techniques [proton magnetic resonance spectra were generally determined in DMSO-D6 unless otherwise stated using a Varian Gemini 2000 spectrometer operating at a field strength of 300 MHz, or a Bruker AM250 spectrometer operating at a field strength of 250 MHz; chemical shifts are reported in parts per million downfield from tetramethylsilane as an internal standard (δ scale) and peak multiplicities are shown thus: s, singlet; d, doublet; AB or dd, doublet of doublets; t, triplet; m, multiplet; fast-atom bombardment (FAB) mass spectral data were generally obtained using a Platform spectrometer (supplied by Micromass) run in electrospray and, where appropriate, either positive ion data or negative ion data were collected];

- 10 (vi) intermediates were not generally fully characterised and purity was in general assessed by thin layer chromatographic, infra-red (IR), mass spectral (MS) or NMR analysis; and
(vii) in which the following abbreviations may be used :-

® is a Trademark; DMF is N,N-dimethylformamide; DMA is N,N-dimethylacetamide;
TLC is thin layer chromatography; HPLC is high pressure liquid chromatography;
15 MPLC is medium pressure liquid chromatography; DMSO is dimethylsulfoxide;
CDCl₃ is deuterated chloroform; MS is mass spectroscopy; ESP is electrospray;
THF is tetrahydrofuran; TFA is trifluoroacetic acid; NMP is N-methylpyrrolidone;
HOBT is 1-hydroxy-benzotriazole; EtOAc is ethyl acetate; MeOH is methanol;
phosphoryl is (HO)₂-P(O)-O-; phosphiryl is (HO)₂-P-O-; EDC is 1-(3-
20 dimethylaminopropyl)-3-ethylcarbodiimide (hydrochloride); PTSA is para-
toluenesulfonic acid.

Example 1: 5(R)-Isoxazol-3-yloxymethyl-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one

Diisopropylazodicarboxylate (248mg, 1.22 mmol) was added dropwise, at ambient temperature, to a stirred solution of 5(R)-hydroxymethyl-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one (International Patent Application Publication WO 97/09328) (300mg, 1.02mmol), 3-hydroxyisoxazole (104mg, 1.22mmol) and triphenylphosphine (340mg, 1.30mmol) in THF (8.0ml). The resulting solution was stirred at ambient temperature for 30 minutes before evaporating the solvent to give an oil which was purified by flash chromatography (Merck 9385 silica, EtOAc / iso-hexane (7:3) eluant) to give the title product (219mg, 59%) as a crystalline solid.

¹H-NMR (300MHz, CDCl₃): δ = 2.45–2.55 (m, 2H), 3.88–4.00 (m, 3H), 4.17 (t, 1H), 4.33 (m, 2H), 4.50 (dd, 1H), 4.58 (dd, 1H), 5.04 (m, 1H), 6.01 (d, 1H), 6.06 (m, 1H), 7.22–7.32 (m, 2H), 7.42 (d, 1H), 8.15 (d, 1H). MS: ESP⁺ (M+H)⁺ = 361.

Example 2: 5(R)-(5-Methylisoxazol-3-yloxymethyl)-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one

5(R)-hydroxymethyl-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one (300mg, 1.02mmol), 3-hydroxy-5-methylisoxazole (120mg, 1.21mmol), triphenylphosphine (270mg, 1.03mmol) and diisopropylazodicarboxylate (204mg, 1.01mmol) were reacted in THF (8.0ml) using the general method of Example 1. The resultant product was purified by flash chromatography (Merck 9385 silica, EtOAc / isohexane (7:3) eluant) to give the title product (176mg, 46%) as a crystalline solid.

¹H-NMR (300MHz, CDCl₃): δ = 2.34 (s, 3H), 2.45–2.55 (m, 2H), 3.86–4.00 (m, 3H), 4.14 (t, 1H), 4.32 (m, 2H), 4.46 (dd, 1H), 4.54 (dd, 1H), 5.02 (m, 1H), 5.65 (s, 1H), 6.05 (m, 1H), 7.20–7.32 (m, 2H), 7.42 (d, 1H). MS: ESP⁺ (M+H)⁺ = 375.

Reference Example 1: 3,5-Difluoro-4-(1-benzyl-4-hydroxyhexahydropyrid-4-yl)aniline

nBuLi (1.32M in hexanes, 350ml, 0.462 mol) was added dropwise over 20 minutes to a solution of N,N-(1,2-bis(dimethylsilyl)ethane)-3,5-difluoroaniline, (108.4g, 0.40mol, J. Org. Chem., 60, 5255-5261 (1995)) in 800ml dry THF at -70°C under argon. After stirring for a further 4 hours at -70°C, N-benzyl-4-piperidone (87.8g, 0.46mol) in 270ml dry THF was added dropwise over 40 minutes at the same temperature and the reaction allowed to stir to

ambient temperature overnight. Solvent was removed in vacuo and the resultant product treated with ice and conc.HCl and extracted with ether. The aqueous acidic phase was then treated with 40% NaOH with cooling, extracted with ether (and worked up by washing with water, with brine and drying with an anhydrous drying agent such as magnesium sulfate or sodium sulfate before evaporation - this work up procedure is referred to as work up in the usual manner hereinafter) to give 144.7g of a sludge. Analysis by TLC using 10% MeOH/dichloromethane on silica indicated that the desired alcohol was present as approximately 90% of the product, and the crude product was used without further purification. MS: ESP+ (M+H) = 319.

10

Reference Example 2: 3,5-Difluoro-4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)aniline

The crude product from Reference Example 1 (144.7g) was suspended in 400ml conc.HCl and heated at reflux with stirring for 18 hours. TLC showed all starting material had reacted, and after cooling in ice the reaction mixture was taken to pH 11 with conc. NH₃ (aq) and extracted three times with dichloromethane. Usual work-up gave 119.5g of a viscous oil. TLC indicated a purity of ca. 80% and the crude product was used without further purification. MS: ESP+ (M+H) = 301.

Reference Example 3: N-Benzoyloxycarbonyl-3,5-difluoro-4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)aniline

The crude aniline from Reference Example 2 (3.2g, 10.7mmol) in 10ml of acetone was added in one portion to a stirred solution of sodium dihydrogen phosphate (3.0g) in 30ml water. The resulting mixture was cooled to 5-10°C and a solution of benzylchloroformate (2.18g, 1.8ml, 12.8mmol) in 10ml of acetone was added dropwise. The mixture was stirred for a further hour at ice-bath temperature and then at ambient temperature for 2 hours. The mixture was diluted with 80ml water, basified with conc.NH₃(aq) and extracted with EtOAc. Usual work-up gave a viscous oil which was purified by flash chromatography (Merck 9385 silica, EtOAc/isohexane (3:7 eluant) and triturated with isohexane to give a solid (1.53g 33%). MS: ESP+ (M+H) = 434.

30

Reference Example 4: 5(R)-Hydroxymethyl-3-(4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

The benzylurethane from Reference Example 3 (5.54g, 12.76mmol) in 50ml dry THF was cooled to -70°C under nitrogen and 8.80ml of 1.6M nBuLi in hexanes (14.08mmol) added dropwise at the same temperature. After 20 minutes at the same temperature a solution of (R)-glycidyl butyrate (2.00g, 13.88mmol in 5ml THF) was added dropwise and the mixture stirred for 30 minutes at -70°C, and then stirred to ambient temperature overnight. After quenching with 100ml 10% ammonium chloride, the mixture was extracted with EtOAc and usual work-up to give an oily solid, which was purified by flash chromatography (Merck C60 silica, 5% MeOH/dichloromethane eluant) to give a crystalline solid (4.40g, 86%). MS: ESP+ (M+H) = 401.

¹H-NMR (250MHz, DMSO-d₆): δ = 2.32 (m, 2H), 2.63 (t, 2H), 3.05 (m, 2H), 3.50-3.72 (m, 4H), 3.82 (dd, 1H), 4.06 (t, 1H), 4.73 (m, 1H), 5.18 (t, 1H), 5.78 (m, 1H).

15 Reference Example 5: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

Reference Example 4 (2.6g, 6.5mmol), 3-hydroxyisoxazole (0.60g, 7.06mmol), triphenylphosphine (1.96g, 7.48mmol) and diisopropylazodicarboxylate (1.44g, 7.13mmol) in THF (40ml) were reacted using the general method of Example 1. The resultant product was purified by flash chromatography (Merck 9385 silica, EtOAc / isohexane (3:2) eluant initially, then repeated using methyl tert-butylether eluant) to give the title product (2.6g, 86%) as a gum. MS: ESP⁺ (M+H)⁺ = 468.

25 Reference Example 6: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

Reference Example 5 (2.6g, 5.57mmol) in dichloromethane (40ml) was cooled, under an atmosphere of nitrogen, in an ice-water bath then 1-chloroethyl chloroformate (0.80g, 5.59mmol) added dropwise via syringe. The resulting solution was stirred at ice temperature for 1 hour before isolating the intermediate product (carbamate) by flash chromatography (Merck 9385 silica, EtOAc / isohexane (1:1) eluant). The resulting gum was taken up in MeOH (40ml) and refluxed for 1 hour. Evaporation of the solvent after this time gave the title product (1.46g, 64%) as a crystalline solid.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.54 (m, 2H), 3.27 (m, 2H), 3.72 (m, 2H), 3.92 (dd, 1H), 4.20 (t, 1H), 4.38-4.52 (m, 2H), 5.10 (m, 1H), 5.88 (m, 1H), 6.38 (d, 1H), 7.37 (m, 2H), 8.68 (d, 1H), 9.39 (s(broad), 2H). MS: ESP⁺ (M+H)⁺=378.

5 **Example 3: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(R,S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (160mg, 0.84mmol) was added portionwise at ambient temperature to a stirred mixture of Reference Example 6 (300mg, 0.72mmol), (R/S)-2,3-O-isopropylideneglyceric acid (122mg, 0.84mmol) and
10 triethylamine (73mg, 0.72mmol) in dichloromethane (6ml). The resulting mixture was stirred for 3 hours then left to stand overnight before washing with water. The dichloromethane solution was purified by flash chromatography (Merck 9385 silica, EtOAc / isohexane (3:1) eluant) to give the title product (143mg, 39%) as a crystalline solid. MS: ESP⁺ (M+H)⁺=506.
¹H-NMR (300MHz, CDCl₃): δ = 1.41 (s, 6H), 2.35-2.65 (m, 2H), 3.65-3.80 (m, 1H), 3.92-
15 4.00 (m, 2H), 4.10-4.22 (m, 3H), 4.22-4.45 (m, 1H), 4.45-4.62 (m, 3H), 4.75 (t, 1H), 5.05 (m, 1H), 5.80-5.91 (m, 1H), 6.01 (d, 1H), 7.18 (m, 2H), 8.16 (d, 1H).

Example 4: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R,S)-3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)-oxazolidin-2-one

20 Example 3 (194mg, 0.38mmol) in a mixture of THF (3ml) and 1N hydrochloric acid (1ml) was left to stand at ambient temperature for 4 days. The solvent was then evaporated to give an oil which was purified by flash chromatography (Merck 9385 silica, 10% MeOH / dichloromethane eluant) to give the title product (144mg, 80%) as a crystalline solid. MS: ESP⁺ (M+H)⁺=466.
25 ¹H-NMR (300MHz, DMSO-d₆): δ = 2.20-2.46 (m, 2H), 3.40-3.63 (m, 2H), 3.63-3.85 (m, 2H), 3.92 (dd, 1H), 4.10 (m, 1H), 4.18 (t, 1H), 4.26-4.52 (m, 4H), 4.68 (m, 1H), 4.96 (m, 1H), 5.10 (m, 1H), 5.86 (m, 1H), 6.37 (d, 1H), 7.34 (m, 2H), 8.68 (d, 2H).

30 **Example 5: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-formyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**

Reference Example 6 (300mg, 0.72mmol) and triethylamine (102mg, 1.01mmol) in ethyl formate (10ml) were refluxed for 12 hours, and then evaporated to give an oil which was

purified by flash chromatography (Merck 9385 silica, 4% MeOH / dichloromethane eluant) to give the title product (261mg, 89%) as a crystalline solid.

¹H-NMR (300MHz, CDCl₃): δ = 2.18 & 2.37 (2s, 2H), 3.20-3.40 (m (partially obscured), 2H), 3.57-3.66 (m, 2H), 3.92 (m, 1H), 4.05 & 4.10 (2m, 2H), 4.20 (t, 1H), 4.38-4.54 (m, 2H), 5.10 (m, 1H), 5.86 & 5.90 (2m, 1H), 6.37 (d, 1H), 7.32 (m, 2H), 8.10 & 8.18 (2s, 1H), 8.68 (d, 1H). MS: ESP⁺ (M+H)⁺ = 406.

Example 6: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-acetoxyacetyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

10 Reference Example 6 (400mg, 0.97mmol), triethylamine (205mg, 2.03mmol) and 4-(dimethylamino)pyridine (30mg) in dichloromethane (10ml) were cooled in an ice-water bath then acetoxyacetyl chloride (145mg, 1.06mmol) was added dropwise via syringe. The mixture was stirred at ice temperature for 2 hours then purified by flash chromatography (Merck 9385 silica, 2.5% MeOH / dichloromethane eluant) to give the title product (430mg, 93%) as a
15 crystalline solid.

¹H-NMR (300MHz, CDCl₃): δ = 2.20 (s, 3H), 2.40-2.56 (m, 2H), 3.59 (t, 1H), 3.82 (t, 1H), 3.95 (dd, 1H), 4.08 & 4.25 (2m, 2H), 4.12 (t, 1H), 4.50 (dd, 1H), 4.58 (dd, 1H), 4.74 & 4.78 (2s, 2H), 5.05 (m, 1H), 5.80 & 5.88 (2m, 1H), 6.00 (d, 1H), 7.19 (m, 2H), 8.17 (d, 1H). MS: ESP⁺ (M+H)⁺ = 478.

20

Example 7: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-hydroxyacetyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

Example 6 (280mg, 0.59mmol) and potassium carbonate (150mg, 1.09mmol) in MeOH (6ml) were stirred at ambient temperature for 4 hours. Water (30ml) was added to give a crystalline
25 solid, which was filtered, washed with water and dried to give the title product (215mg, 84%). MS: ESP⁺ (M+H)⁺ = 436.

¹H-NMR (300MHz, DMSO d-6): δ = 2.22-2.42 (m, 2H), 3.52 (m, 1H), 3.68 (m, 1H), 3.92 (dd, 1H), 4.00-4.24 (m, 5H), 4.40-4.52 (m, 2H), 4.52-4.76 (m, 1H), 5.10 (m, 1H), 5.86 (m, 1H), 6.36 (d, 1H), 7.35 (m, 2H), 8.68 (d, 2H).

30

Reference Example 7: 5(R)-Hydroxymethyl-3-(4-(4-(5-cyanopyrid-2-yl)piperazin-1-yl)-3-fluorophenyl)oxazolidin-2-one

5(R)-hydroxymethyl-3-(3-fluoro-4-(4-*t*-butoxycarbonylpiperazin-1-yl)phenyl)oxazolidin-2-one (International Patent Application Publication WO 93/23384, 43.1 g, 0.11 M) was
5 suspended by stirring in ethanol (1000 ml) under nitrogen. An ethanol solution of hydrogen chloride (3.8 M, 400 ml) was added slowly, and the mixture was stirred at ambient temperature for 18 hours. The resulting precipitate was filtered, washed with diethyl ether (3 x 250 ml), and dried, to give 5(R)-hydroxymethyl-3-(3-fluoro-4-(piperazin-1-yl)phenyl)oxazolidin-2-one hydrochloride. A further crop was obtained by evaporation of the
10 mother liquors to give a total yield of 38.7 g.

¹H-NMR (300MHz, DMSO-D₆) δ: 3.17 (m, 8H); 3.53 (dd, 1H); 3.64 (dd, 1H); 3.79 (dd, 1H); 4.03 (t, 1H); 4.66 (m, 1H); 7.10 (t, 1H); 7.21 (dd, 1H); 7.52 (dd, 1H); 9.39 (br s, 2H).
MS: ESP+ (M+H)⁺ = 296.

15 5(R)-hydroxymethyl-3-(3-fluoro-4-(piperazin-1-yl)phenyl)oxazolidin-2-one hydrochloride (25 g, 75.4 mmol) was suspended by stirring in acetonitrile (700 ml) under nitrogen, and triethylamine (16.8 g, 166 mmol) added. The mixture was stirred for 10 minutes and then 2-chloro-5-cyanopyridine (10.3 g, 75.4 mmol) added, and the mixture heated under reflux for 18 hours. After cooling, the resultant solid was filtered, washed with water (3 x 500 ml) and
20 diethyl ether (2 x 500 ml) to give 5(R)-hydroxymethyl-3-(4-(4-(5-cyanopyrid-2-yl)piperazin-1-yl)-3-fluorophenyl)oxazolidin-2-one. A further crop was obtained by evaporation of the mother liquors to give a total yield of 23.2 g. MS: ESP+ (M+H)⁺ = 398.

¹H-NMR (300MHz, DMSO-D₆) δ: 3.03 (t, 4H); 3.54 (m, 1H); 3.63(m, 1H); 3.78 (t overlapping m, 5H); 4.03 (t, 1H); 4.66 (m, 1H); 5.18 (t, 1H); 6.97 (d, 1H); 7.07 (t, 1H);
25 7.20 (dd, 1H); 7.53 (dd, 1H); 7.85 (dd, 1H); 8.49 (d, 1H).

Example 8 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-(4-(5-cyanopyrid-2-yl)piperazin-1-yl)-3-fluorophenyl)oxazolidin-2-one

Reference Example 7 (397mg, 1mmol), 3-hydroxyisoxazole (85mg, 1.1mmol) and polymer
30 bound triphenylphosphine (3mmol/g, 416mg, 1.25mmol) were suspended with stirring in 10ml dry THF and diisopropylazodicarboxylate (242mg, 1.2mmol) added dropwise by syringe, and the mixture stirred at ambient temperature for 1 hour. The mixture was filtered,

evaporated to dryness, and dissolved in EtOAc and purified by chromatography (on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 80 to 100% EtOAc in *isohexane*) to give the title product (93 mg). MS: ESP+: (M+H)⁺ = 465.

¹H-NMR (300MHz, DMSO-D₆) δ: 3.06 (t, 4H); 3.80 (t, 4H); 3.87 (dd, 1H); 4.16 (t, 1H);
5 4.42 (dd, 1H); 4.48 (dd, 1H); 5.04 (m, 1H); 6.37 (d, 1H); 6.97 (d, 1H); 7.08 (t, 1H); 7.20 (dd, 1H); 7.51 (dd, 1H); 7.86 (dd, 1H); 8.49 (d, 1H); 8.67 (d, 1H).

Example 9: 5(R)-Isothiazol-3-yloxymethyl-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one

10 Diisopropylazodicarboxylate (227mg, 1.12mmol) was added dropwise, at ambient temperature, to a stirred solution of 5(R)-hydroxymethyl-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one (300mg, 1.02mmol; see Example 1), 3-hydroxyisothiazole (114mg, 1.13mmol) and triphenylphosphine (304mg, 1.16mmol) in THF (8.0ml). The resulting solution was stirred at room temperature for 30 minutes before
15 evaporating the solvent to give an orange oil. It was purified by flash chromatography (Merck 9385 silica, EtOAc / *isohexane* (3:2)) to give the title product (257mg, 67%) as a colourless crystalline solid. MS: ESP⁺ (M+H)⁺ = 377.

¹H-NMR (300MHz, CDCl₃): δ = 2.45-2.55 (m, 2H), 3.94 (t, 2H), 3.98 (dd, 1H), 4.14 (t, 1H), 4.32 (m, 2H), 4.61-4.72 (m, 2H), 5.04 (m, 1H), 6.07 (m, 1H), 6.62 (d, 1h), 7.22-7.30 (m, 2H),
20 7.42 (dd, 1H), 8.48 (d, 1H).

Example 10: 5(R)-(1,2,5-Thiadiazol-3-yloxymethyl)-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one

A solution of 5(R)-hydroxymethyl-3-(3-fluoro-4-(3,6-dihydro-(2H)-pyran-4-yl)phenyl)oxazolidin-2-one (0.275g, 0.93mmol; see Example 1), 3-hydroxy-1,2,5-thiadiazole (Weinstock et al, J.Org. Chem., 32, 2823 (1967)) (0.112g, 1.1mmol), and triphenylphosphine (0.288g, 1.1mmol) was stirred in dry THF (7ml) at ambient temperature and
25 diisopropylazodicarboxylate (0.22g, 1.1mmol) in dry THF (1.0ml) added dropwise over ten minutes. After 1.5 hours, tlc (70% EtOAc/*isohexane*) showed essentially complete reaction.
30 The reaction mixture was evaporated in vacuo and purified by chromatography (Merck 9385 silica, 50% EtOAc / *isohexane* eluant) to give the title product (256mg, 73%) as a colourless solid mp, 46-8 C.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.40 (m, 1H), 3.78 (m, 3H), 3.96 (dd, 1H), 4.20 (m, 3H), 4.64 (m, 2H), 5.10 (m, 1H), 6.08 (s, 1H), 7.35 (m, 2H), 7.50 (d, 1H), 8.41 (s, 1H). MS: ESP⁺ (M+H)⁺ = 377.

5 **Reference Example 8: 5(R)-(1,2,5-Thiadiazol-3-yloxymethyl)-3-phenyloxazolidin-2-one**

Diisopropylazodicarboxylate (4.45g, 22mmol) was added dropwise to a stirred solution of 5(R)-hydroxymethyl-3-phenyloxazolidin-2-one (Gregory et al, J. Med. Chem., 32, 1673 (1989); 4.25g, 22mmol), triphenyl phosphine (5.76g, 22mmol) and 3-hydroxy-1,2,5-thiadiazole (Weinstock et al, J. Org. Chem., 32, 2823 (1967)) (2.04g, 20mmol) in 30ml THF, 10 in an ice-bath. After stirring at ambient temperature for two hours and evaporating in vacuo, the resulting oil was purified by chromatography (Merck 9385 silica. Gradient elution from isohexane to ca. 50% EtOAc/isohexane to give a white solid. Further purification by flash chromatography on silica using 1% MeOH/dichloromethane was necessary to remove remaining diisopropylcarboxyhydrazine yielding the title product as a white crystalline solid 15 (4.7g, 83%). MS: ESP⁺ (M+H)⁺ = 278.

¹H-NMR (300MHz, CDCl₃): δ = 4.0 (dd, 1H), 4.21 (t, 1H), 4.6-4.77 (m, 2H), 5.04 (m, 1H), 7.17 (t, 1H), 7.39 (m, 2H), 7.56 (d, 2H), 8.0 (s, 1H).

20 **Reference Example 9: 5(R)-(1,2,5-Thiadiazol-3-yloxymethyl)-3-(4-iodophenyl)oxazolidin-2-one**

Silver trifluoroacetate (0.727g, 3.29mmol) was added to a stirred solution of the compound of Reference Example 8 (0.70g, 2.53mmol) in chloroform/ acetonitrile (6ml/4ml) at ambient temperature. Iodine (0.67g, 2.64 mmol) was then added in portions. The resulting brown mixture was then stirred for 65h with protection from light. A yellow solid was filtered off, 25 washing with chloroform. The filtrate and washings were evaporated in vacuo, the residue redissolved in EtOAc and washed with dilute ammonium hydroxide, water and brine. Dried over sodium sulfate and evaporated in vacuo to give a pale yellow solid on standing. Trituration with ether gave the title product as an off-white solid (0.749g, 73%).

¹H-NMR (300MHz, DMSO-d₆): δ = 3.95 (dd, 1H), 4.19 (t, 1H), 4.67 (m, 2H), 5.1 (m, 1H), 7.37 30 (d, 2H), 7.69 (d, 2H), 8.4 (s, 1H). MS: ESP⁺ (M+H)⁺ = 404.

Reference Example 10 : 5(R)-Isoxazol-3-ylloxymethyl-3-(4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Prepared by the general method of Example 1 using as starting material 5(R)-hydroxymethyl-3-(4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one (WO97/30995; 4.0g, 10.5mmol), 3-hydroxyisoxazole (1.0g, 11.8mmol), triphenylphosphine (3.24g, 12.4mmol) and diisopropylazodicarboxylate (2.36g, 11.7mmol) in tetrahydrofuran (60ml). Purified by flash chromatography (Merck 9385 silica; tert-butyl methyl ether / EtOAc / MeOH (70:30:0.5) eluant) to give the product (3.0g, 64%) as a colourless crystalline solid. MS: $\text{ESP}^+ (\text{M}+\text{H})^+ = 450$.

10

Reference Example 11 : 5(R)-Isoxazol-3-ylloxymethyl-3-(4-(1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Prepared by the general method of Reference Example 6 using Reference Example 10 (7.09g, 15.8mmol) and 1-chloroethyl chloroformate (2.26g, 15.8mmol) in dichloromethane (120ml) to give the product (3.71g, 59%) as a pale yellow crystalline solid. MS: $\text{ESP}^+ (\text{M}+\text{H})^+ = 360$. $^1\text{H-NMR}$ (300MHz, DMSO-d_6): $\delta = 2.64$ (m, 2H), 3.22-3.30 (m, 2H), 3.72 (m, 2H), 3.92 (dd, 1H), 4.21 (t, 1H), 4.40-4.55 (m, 2H), 5.10 (m, 1H), 6.02 (m, 1H), 6.38 (d, 1H), 7.32-7.44 (m, 2H), 7.52 (d, 1H), 8.68 (d, 1H), 9.30 (s(br), 2H).

Example 11 : 5(R)-Isoxazol-3-ylloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

1,3 Dicyclohexylcarbodiimide (550mg, 2.67mmol) was added in one go at ambient temperature to a stirred solution of (S)-2,3-O-isopropylidene-glyceric acid (390mg, 2.67mmol) and 1-hydroxybenzotriazole (410mg, 2.58mmol) in dichloromethane (10ml). The resulting suspension was stirred for 1hr then a further 10ml dichloromethane was added, followed by Reference Example 11 (1.0g, 2.53mmol) and N,N-diisopropylethylamine (326mg, 2.53mmol). The reaction was stirred at ambient temperature for 18hr then filtered. The filtrate was washed with water (2X) and brine then purified by flash chromatography (Merck 9385 silica; 2% MeOH in dichloromethane eluant) to give the product (754mg, 61%) as a colourless crystalline solid. MS: $\text{ESP}^+ (\text{M}+\text{H})^+ = 488$.

30

$^1\text{H-NMR}$ (300MHz, CDCl_3): $\delta = 1.44$ (s, 6H), 2.45-2.72 (m, 2H), 3.62-3.76 (m, 1H), 3.89-

4.05 (m, 2H), 4.10-4.20 (m, 3H), 4.24-4.38 (m, 1H), 4.44-4.62 (m, 3H), 4.75 (m, 1H), 5.04 (m, 1H), 5.97 (m, 1H), 6.00 (d, 1H), 7.25 (m, 2H), 7.45 (d, 1H), 8.15 d, 1H).

Example 12 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Prepared by the general method of Example 4 using Example 11 (754mg, 1.55mmol) in a mixture of THF (15ml) and 1N hydrochloric acid (5ml). Purified by flash chromatography (Merck 9385 silica; 10% MeOH in dichloromethane eluant) to give the product (486mg, 70%) as a colourless crystalline solid, mp 140-143°C.

10 ¹H-NMR (300MHz, DMSO-d₆): d = 2.42 (m, 2H), 3.40-3.60 (m, 2H), 3.62-3.85 (m, 2H), 3.92 (dd, 1H), 4.10-4.30 (m, 3H), 4.30-4.56 (m, 3H), 4.79 (m, 1H), 4.94 (m, 1H), 5.09 (m, 1H), 6.00 (m, 1H), 6.37 (d, 1H), 7.28-7.44 (m, 2H), 7.50 (d, 1H), 8.66 (d, 1H). MS: ESP⁺ (M+H)⁺ = 448.

HPLC: Chiralpak AD (250mm x 4.6mm i.d.), 100% MeOH eluant, 1ml/min. flow rate: ret.

15 time = 42.5 min.

Example 13 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(R)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Prepared by the general method of Example 11 using (R)-2,3-O-isopropylidene glyceric acid (390mg, 2.67mmol), 1-hydroxybenzotriazole (410mg, 2.58mmol), dicyclohexylcarbodiimide (550mg, 2.67mmol), Reference Example 11 (1.0g, 2.53mmol) and N,N-diisopropylethylamine (326mg, 2.53mmol) in dichloromethane (20ml). Purified by flash chromatography (Merck 9385 silica; 2% MeOH in dichloromethane eluant) to give the product (682mg, 55%) as a colourless crystalline solid. MS: ESP⁺ (M+H)⁺ = 488.

25 ¹H-NMR(300MHz, CDCl₃): d = 1.44 (s, 6H), 2.45-2.72 (m, 2H), 3.62-3.76 (m, 1H), 3.89-4.05 (m, 2H), 4.10-4.20 (m, 3H), 4.24-4.38 (m, 1H), 4.44-4.62 (m, 3H), 4.75 (m, 1H), 5.04 (m, 1H), 5.97 (m, 1H), 6.00 (d, 1H), 7.25 (m, 2H), 7.45 (d, 1H), 8.15 d, 1H).

Example 14 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Prepared by the general method of Example 12 using Example 13 (682mg, 1.40mmol) in a mixture of THF (15ml) and 1N hydrochloric acid (5ml). Purified by flash chromatography

(Merck 9385 silica; 10% MeOH in dichloromethane eluant) to give the product (466mg, 74%) as a colourless crystalline solid: mp 136-140°C.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.42 (m, 2H), 3.40-3.60 (m, 2H), 3.62-3.85 (m, 2H), 3.92 (dd, 1H), 4.10-4.30 (m, 3H), 4.30-4.56 (m, 3H), 4.79 (m, 1H), 4.94 (m, 1H), 5.09 (m, 1H), 6.00 (m, 1H), 6.37 (d, 1H), 7.28-7.44 (m, 2H), 7.50 (d, 1H), 8.66 (d, 1H). MS: ESP⁺ (M+H)⁺ = 448.

HPLC: Chiralpak AD (250mm x 4.6mm i.d.), 100% MeOH eluant, 1ml/min. flow rate: ret. time = 18.5 min.

10 **Example 15 : 5(R)-Isoxazol-3-ylloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(R)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**

1,3 Dicyclohexylcarbodiimide (315mg, 1.53mmol) was added in one go at ambient temperature to a stirred mixture of Reference Example 6 (660mg, 1.45mmol), (R)-2,3-O-isopropylidinediglyceric acid (240mg, 1.64mmol) and pyridine (115mg, 1.45mmol) in 15 dichloromethane (15ml). The resulting mixture was stirred at ambient temperature for 18hr then purified by flash chromatography (Merck 9385 silica; EtOAc / isohexane (3:1) eluant) to give the product (315mg, 43%) as a colourless crystalline solid.

20 **Example 16 : 5(R)-Isoxazol-3-ylloxymethyl-3-(4-(1-(2(R),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**

Prepared by the general method of Example 14 using Example 15 (315mg, 0.62mmol) in a mixture of THF (6ml) and 1N hydrochloric acid (2ml). Purified by flash chromatography (Merck 9385 silica; 10% MeOH in dichloromethane eluant) to give the product (208mg, 72%) as a colourless crystalline solid: mp 128-134 °C.

25 ¹NMR (300MHz, DMSO-d₆): δ 2.20-2.46 (m, 2H), 3.40-3.63 (m, 2H), 3.63-3.85 (m, 2H), 3.92 (dd, 1H), 4.10 (m, 1H), 4.18 (t, 1H), 4.26-4.52 (m, 1H), 4.68 (m, 1H), 4.96 (m, 1H), 5.10 (m, 1H), 5.86 (m, 1H), 6.37 (d, 1H), 7.34 (m, 2H), 8.68 (d, 2H).

MS: ESP⁺ (M+H)⁺ = 466.

HPLC: Chiralpak AD (250mm x 4.6mm i.d.), 100% MeOH eluant, 1ml/min. flow rate: ret. 30 time = 11.2min.

Example 17 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

Prepared by the general method of Example 15 using 1,3 dicyclohexylcarbodiimide (315mg, 1.53mmol), Reference Example 6 (660mg, 1.45mmol), (S)-2,3-O-isopropylidene-glyceric acid (240mg, 1.64mmol) and pyridine (115mg, 1.45mmol) in dichloromethane (15ml). Purified by flash chromatography (Merck 9385 silica; EtOAc / isohexane (3:1) eluant) to give the product (282mg, 38%) as a colourless crystalline solid. MS: $ESP^+ (M+H)^+ = 506$.

1H -NMR (300MHz, DMSO- d_6): δ = 1.32 (s, 3H), 1.34 (s, 3H), 2.25-2.50 (m, 2H), 3.63-3.87 (m, 2H), 3.95 (dd, 1H), 4.02-4.32 (m, 4H), 4.43-4.55 (m, 2H), 4.92 (m, 1H), 5.12 (m, 1H), 5.89 (m, 1H), 6.37 (d, 1H), 7.35 (d, 2H), 8.68 (d, 1H).

Example 18 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

Prepared by the general method of Example 16 using Example 17 (282mg, 0.56mmol) in a mixture of THF (6ml) and 1N hydrochloric acid (2ml). Purified by flash chromatography (Merck 9385 silica; 10% MeOH in dichloromethane eluant) to give the product (183mg, 70%) as a colourless crystalline solid: mp 136-142 °C.

1 NMR (300MHz, DMSO- d_6): δ 2.20-2.46 (m, 2H), 3.40-3.63 (m, 2H), 3.63-3.85 (m, 2H), 3.92 (dd, 1H), 4.10 (m, 1H), 4.18 (t, 1H), 4.26-4.52 (m, 1H), 4.68 (m, 1H), 4.96 (m, 1H), 5.10 (m, 1H), 6.37 (d, 1H), 7.34 (m, 2H), 8.68 (d, 2H).

MS: $ESP^+ (M+H)^+ = 466$.

HPLC: Chiralpak AD (250mm x 4.6mm i.d.), 100% MeOH eluant, 1ml/min. flow rate: ret. time = 38.4 min.


Reference Example 12: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-di-(di-*t*-butoxyphosphoryl)propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Di-*tert*-butyl N,N diethylphosphoramidite (1.67g, 6.24mmol) was added dropwise at room temperature, under an atmosphere of nitrogen, to a stirred suspension of Example 12 (1.0g, 2.24mmol) and 1H-tetrazole (1.4g, 20.0mmol) in tetrahydrofuran (40ml). The resulting mixture was stirred for 2hr. then cooled to -40°C and treated portionwise with 3-chloroperoxybenzoic acid (1.9g 60% strength, 6.6mmol). The reaction was stirred at -40 to -

20°C for 1hr. then diluted with EtOAc (150ml), washed successively with 10% aqueous sodium bisulfite solution, sat. sodium bicarbonate solution and water, dried over magnesium sulfate and evaporated to give a colourless oil. Purified by flash chromatography (Merck 9385 silica, 20-30% acetonitrile / EtOAc) to give the product (625mg, 34%) as a colourless foam.

- 5 ¹H-NMR (300MHz, CDCl₃): δ = 1.48 (m, 36H), 2.45-2.70 (m, 2H), 3.58-3.71 & 3.73-3.86 (m, 1H), 3.92-4.10 (m, 2H), 4.10-4.38 (m, 5H), 4.47-4.62 (m, 2H), 4.97-5.08 (m, 1H), 5.22-5.32 (m, 1H), 5.88 (m, 1H), 6.02 (d, 1H), 7.18-7.28 (m, 2H), 7.43 (d, 1H), 8.16 (d, 1H). MS: ESP⁺ (M+H)⁺ = 832.

10 **Example 19: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-diphosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one**



- A 4M solution of HCl in dioxane (6ml) was added in one go at room temperature to a stirred solution of Reference Example 12 (600mg, 0.72mmol) in dioxane (6ml). The resulting yellow mixture was stirred 1hr. then concentrated under reduced pressure. Trituration with diethyl ether gave a yellow solid which was filtered, washed with ether, dried and then dissolved in water and lyophilized to a pale yellow solid (435mg).

- ¹H-NMR (300MHz, DMSO-d₆ + CD₃COOD): δ = 2.35-2.50 (m, 2H), 3.52-3.68 & 3.70-3.85 (m, 2H), 3.90 (dd, 1H), 4.05-4.35 (m, 5H), 4.35-4.53 (m, 2H), 5.05 (m, 1H), 5.10-5.25 (m, 1H), 5.98 (m, 1H), 6.25 (d, 1H), 7.25-7.40 (m, 2H), 7.45 (dd, 1H), 8.54 (d, 1H). MS: ESP⁺ (M+H)⁺ = 608.


25 **Reference Example 13: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-(di-tert-butoxyphosphoryl)propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one**

To a stirred solution of the starting material Example 12 (600mg, 1.34mmol) and 1H-tetrazole (310mg, 4.43mmol) in THF (30ml) under nitrogen was added di-tert-butyl N,N-diethylphosphoramidite (368mg, 1.48mmol) over a few minutes. After stirring for 90 minutes

the solution was cooled to -40°C and 3-chloroperoxybenzoic acid (425mg 60% strength, 1.48mmol) added in portions. The reaction mixture was allowed to warm to ambient temperature and stirred for 30 minutes. EtOAc was added, the solution washed with sodium metabisulfite, sodium bicarbonate and brine solutions, the organic phase dried over anhydrous magnesium sulfate and evaporated in vacuo. The crude product was purified by flash chromatography (Merck 9385 silica, 10-20% acetonitrile / EtOAc) to give the title compound (165mg, 19%) as a colourless gum.

$^1\text{H-NMR}$ (300MHz, CDCl_3): δ = 1.48 (s, 9H), 1.50 (s, 9H), 2.45-2.80 (m, 2H), 3.61-3.86 (m, 2H), 3.96 (dd, 1H), 4.02-4.12 (m, 3H), 4.16 (t, 1H), 4.22-4.30 (m, 2H), 4.47-4.61 (m, 2H), 4.64-4.77 (m, 1H), 5.03 (m, 1H), 6.00 (m, 1H), 6.03 (d, 1H), 7.20-7.30 (m, 2H), 7.46 (d, 1H), 8.16 (d, 1H). MS: ESP^+ $(\text{M}+\text{H})^+ = 640$.

Example 20: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-phosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one



15

TFA (2ml) was added dropwise at room temperature to a stirred solution of Reference Example 13 (165mg, 0.26mmol) in dichloromethane (8ml). The resulting yellow solution was stirred 30 min. then evaporated under reduced pressure to a yellow foam. Trituration with diethyl ether gave the title compound (120mg) as a yellow solid.

$^1\text{H-NMR}$ (300MHz, $\text{DMSO-d}_6 + \text{CD}_3\text{COOD}$): δ = 2.30-2.50 (m, 2H), 3.50-3.65 & 3.65-3.82 (m, 2H), 3.92 (dd, 1H), 3.97-4.40 (m, 5H), 4.40-4.62 (m, 3H), 5.05 (m, 1H), 6.00 (m, 1H), 6.28 (d, 1H), 7.25-7.43 (m, 2H), 7.48 (d, 1H), 7.57 (d, 1H).

MS: ESP^+ $(\text{M}+\text{H})^+ = 528$.

25

**Reference Example 14: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-di-(di-
t-butylphosphoryl)propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-
difluorophenyl)oxazolidin-2-one**

The title compound was prepared, with only non-critical variations, by the method for


- 5 Reference Example 12 on a 4.3mM scale, using as starting material Example 18.

Yield = 1.86g (51%).

NMR (300Mz, DMSO-d₆): δ 1.42 (s, 36H), 2.5 (m, partially obscured), 3.3 - 3.9 (m, 4H), 3.94 (d of d, 1H), 4.1 (s, 2H), 4.21 (t, 1H), 4.48 (m, 2H), 5.14 (m, 2H), 5.90 (s, 1H), 6.38 (s, 1H), 7.37 (d, 2H), 8.70 (s, 1H). MS: ESP+ (M+H)=850.

10

**Example 21: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-diphosphoryl-propanoyl)-
1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**



The title compound was prepared, with only non-critical variations, by the method for

- 15 Example 19 on a 1.4mM scale, using as starting material Reference Example 14.

Yield = 735mg (98%).

NMR (300Mz, DMSO-d₆): δ = 2.5 (m, partially obscured), 3.57 & 3.77 (2m, 2H), 3.91 (d of d, 1H), 4.0 - 4.4 (m, 4H), 4.18 (t, 1H), 4.58 (m, 2H), 5.1 (m, 2H), 5.85 (s, 1H), 6.36 (s, 1H), 7.35 (d, 2H), 8.78 (s, 1H). MS: ESP+ (M+H)=626.

20

**Reference Example 15: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-(di-
t-butylphosphoryl)propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-
difluorophenyl)oxazolidin-2-one**

To a stirred solution of the starting material Example 18 (1.02g, 2.2mmol) and tetrazole


- 25 (462mg, 6.6mg) in THF (30ml) at ambient temperature under nitrogen, was added di-tert-butyl N,N diethylphosphoramidite (575mg, 2.31mmol) over ~2 minutes. After stirring for 90 minutes the solution was cooled to -40°C and m-chloroperbenzoic acid (2.5mmol, 480mg of 90% strength) was added in portions. The reaction mixture was allowed to warm to ambient

temperature and stir for 30 minutes. EtOAc was added and the mixture was washed with aqueous sodium metabisulfite, saturated sodium bicarbonate and brine solutions. The organic phase was dried over anhydrous MgSO_4 and evaporated under reduced pressure. The title compound was isolated by MPLC (EtOAc) as a brittle glass (406mg, 28%). MS : ESP+

5 (M+H) = 658; ESP- (M-H) = 656.

NMR (300Mz, DMSO-d6): δ 1.42 (s, 18H), 2.5 (m, partially obscured), 3.55 - 3.95 (m, 4H), 3.95 (d of d, 1H), 4.0 - 4.15 (m, 2H), 4.25 (t, 1H), 4.50 (m, 2H), 4.63 (m, 1H), 5.14 (m, 1H), 5.54 (d, 1H), 5.91 (s, 1H), 6.40 (s, 1H), 7.37 (d, 2H), 8.70 (1H, s).

10 **Example 22: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-phosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**



To a stirred solution of the starting material Reference Example 15 (100mg, 0.15mmol) in dioxan (1ml) was added 4M HCl / dioxan (3ml). The solution was stirred at ambient

15 temperature for 30 mins. and then evaporated. The residue was triturated well with ether giving the title compound as a white powder (80mg, 96%).

NMR (300Mz, DMSO-d6): 2.43 (m, partially obscured), 3.6 - 4.35 (m, 8H), 4.35 - 4.60 (m, 3H), 5.09 (m, 1H), 5.85 (s, 1H), 6.30 (s, 1H), 7.31 (d, 2H), 8.60 (s, 1H).

MS: ESP+ (M+H) = 546.

20

Example 23: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(cyclo-2(S),3-diphosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

To a stirred partial solution of the starting material Example 21 (100mg, 0.16mmol) in THF (8ml) was added dicyclohexyl carbodiimide (40mg, 0.195mmol). DMF(4ml) was added to

25 give a clear solution. After stirring for 18hrs at ambient temperature, more DCCI (40mg, 0.195mmol) was added. The reaction was essentially complete by HPLC (Partisil SAX 10 μ column, 0.0M to 0.3M pH6.5 phosphate buffer gradient) after a further 3hrs. The solvent was evaporated and the residue was taken into water and filtered. The filtrate was

chromatographed by MPLC (0 -25% acetonitrile / water gradient on Mitsubishi HP20SS polystyrene resin) and the title compound was obtained by freeze drying after partial evaporation to remove acetonitrile.

Yield = 49mg (50%). MS : ESP- (M-H) = 606.

- 5 NMR (300MHz, DMSO-d₆): δ = 2.4 (m, partially obscured), 3.7 - 4.0 (m, 3H), 4.18 (m, 4H), 4.48 (m, 3H), 5.05 (m, 1H), 5.19 & 5.30 (2m, 1H), 5.85 (s, 1H), 6.30 (s, 1H), 7.31(d, 2H), 8.59 (s, 1H).

Example 24: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(4-hydroxybutanoyl)-1,2,5,6-

10 **tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**

To a stirred solution of Reference Example 6 (0.223 g, 0.54 mmol), 4-hydroxybutyric acid sodium salt (0.082 g, 0.65 mmol) and HOBT (0.087 g, 0.65 mmol) in DMF (5 ml) was added EDC (0.124 g, 0.65 mmol). The mixture was stirred for 4 days and then evaporated. The residue was purified by MPLC [5% MeOH/CH₂Cl₂ as eluant] to give after trituration with

- 15 diethyl ether, as a white solid (0.141 g, 56%).

¹H-NMR (300MHz, DMSO-d₆): δ = 1.63 (m, 2H), 2.29 (m, 1H), 2.38 (m, 2H), 3.25 (d, 1H), 3.40 (m, 2H), 3.62 (m, 2H), 3.91 (dd, 1H), 4.10 (d, 1H), 4.19 (t, 2H), 4.44 (m, 3H), 5.09 (m, 1H), 5.84 (s, 1H), 6.38 (d, 1H), 7.36 (d, 2H) and 8.70 (d, 1H).

MS: ESP⁺ (M+H)⁺ = 464.

20

Example 25: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(4-methoxybutanoyl)-1,2,5,6-

tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

To a stirred solution of Reference Example 6 (0.285 g, 0.69 mmol), 2-(2-methoxyethoxy)acetic acid (0.111 g, 0.83 mmol), triethylamine (0.070 g, 0.096 ml, 0.69

- 25 mmol) and HOBT (0.112 g, 0.83 mmol) in dichloromethane (5 ml) was added EDC (0.159 g, 0.83 mmol). The mixture was stirred for 17h and then the solution was washed with water (10 ml), dried and evaporated. The residue was purified by MPLC [3% MeOH/CH₂Cl₂ as eluant] to give a colourless oil (0.201 g, 61%).

- ¹H-NMR (300MHz, DMSO-d₆): δ = 2.36 (d, 2H), 3.25 (s, 3H), 3.45 (m, 2H), 3.59 (m, 4H),
30 3.92 (dd, 1H), 4.09 (m, 2H), 4.18 (m, 3H), 4.45 (m, 2H), 5.09 (m, 1H), 5.86 (s, 1H), 6.38 (d, 1H), 7.35 (d, 2H) and 8.69 (d, 1H).

Reference Example 16: 6-Hydroxymethyl-2-phenyl-1,3-dioxane

(D,L)-Malic acid (5.0 g, 37 mmol) in dry THF (25 ml) under nitrogen was treated with trimethyl borate (12.5 ml) and borane-dimethylsulfide (2.0M in THF) (60 ml, 120 mmol) dropwise at 0 °C. After the addition was complete stirring was continued at 0 °C for 5min.

- 5 During which time a white precipitate formed. The ice-bath was removed and stirring continued overnight. After 17h the solution was slowly treated with MeOH (30 ml) and then evaporated. The residue was purified by MPLC [10% MeOH/CH₂Cl₂ as eluant] to give the triol (3.57 g). This was dissolved in benzaldehyde (150ml) containing tosic acid (0.64 g, 3.37 mmol) and stirred for 60h and then evaporated. The residue was dissolved in
- 10 dichloromethane, washed with saturated aqueous sodium hydrogen carbonate, dried and evaporated. The residue was purified by MPLC [20→45% EtOAc/hexanes eluant] to give the product as an oil (1.47 g, 22%). MS: ESP⁺ (M+H)⁺ = 195.

¹H-NMR (300MHz, DMSO-d₆): δ = 1.50 (d, 1H), 1.62 (ddd, 1H), 3.38 (dd, 1H), 3.48 (dd, 1H), 3.90 (m, 2H), 4.14 (dd, 1H), 4.70 (t, 1H), 5.49 (s, 1H) and 7.38 (m, 5H).

15

Reference Example 17: 6-Carboxy-2-phenyl-1,3-dioxane

To a stirred solution of the alcohol Reference Example 16 (1.47 g, 7.60 mmol) in aqueous sodium hydroxide (7.60 mmol, 0.304 g in 30 ml) at 0°C was added potassium permanganate (1.80 g, 11.4 mmol) portionwise. After 3.5h the mixture was filtered and acidified to pH 2.

- 20 The solution was saturated with sodium chloride and extracted with EtOAc (4 x 50 ml), dried and evaporated to a residue. This white solid was dissolved in dichloromethane and extracted with ammonium hydroxide (2 x 15 ml). The basic extracts were acidified at 0 °C to pH 2 with conc. hydrochloric acid, and the acidic mixture extracted with dichloromethane (2 x 50 ml). The organics were dried and evaporated to give the acid as a gum (0.15 g, 10%). MS: ESP⁺
- 25 (M+H)⁺ = 209.

¹H-NMR (300MHz, DMSO-d₆): δ = 1.82 (m, 2H), 3.96 (m, 1H), 4.18 (dd, 1H), 4.50 (dd, 1H), 5.58 (s, 1H), 7.40 (m, 5H) and 12.82 (s, 1H).

- Example 26: 5(R)-Isoxazol-3-ylloxymethyl-3-(4-(1-(2(R,S)-phenyl-1,3-dioxan-4(R,S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**
- 30

To a stirred solution of Reference Example 6 (0.220 g, 0.53 mmol), Reference Example 17 (0.133 g, 0.64 mmol), triethylamine (0.054 g, 0.074 ml, 0.53 mmol) and HOBT (0.086 g, 0.64

mmol) in dichloromethane (6 ml) was added EDC (0.123 g, 0.64 mmol). The mixture was stirred for 60h and then the solution was washed with 2N HCL (10 ml), brine (10 ml), dried and evaporated. The residue was purified by MPLC [4% MeOH/CH₂Cl₂ as eluant] to give an oil (0.246 g, 82%). MS: ESP⁺ (M+H)⁺ = 568.

- 5 ¹H-NMR (300MHz, DMSO-d₆): δ = 1.59 (d, 1H), 2.10 (m, 1H), 2.33 (m, 2H), 3.55 (m, 1H), 3.78 (m, 1H), 3.90 (dd, 1H), 4.07 (m, 2H), 4.15 (m, 3H), 4.45 (m, 2H), 4.90 (m, 1H), 5.10 (m, 1H), 5.71 (d, 1H), 5.88 (s, 1H), 6.38 (d, 1H), 7.38 (m, 7H) and 8.70 (d, 1H).

Reference Example 18: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(3-t-butoxycarbonylamino-2(R,S)-hydroxy-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

- To a stirred solution of Reference Example 6 (0.091 g, 0.22 mmol), (D,L)-N-BOC-isoserine (0.054 g, 0.27 mmol), triethylamine (0.022 g, 0.031 ml, 0.22 mmol) and HOBT (0.036 g, 0.27 mmol) in dichloromethane (3 ml) was added EDC (0.052 g, 0.27 mmol). The mixture was stirred for 18h and then the solution was washed with 2N HCL (10 ml), brine (10 ml), dried and evaporated. The residue was purified by MPLC [3% MeOH/CH₂Cl₂ as eluant] to give the product as a tan solid (0.047 g, 38%).
- MS: ESP⁺ (M+H)⁺ = 565.

Example 27: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(3-amino-2(R,S)-hydroxy-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

- Reference Example 18 (0.047 g, 0.083 mmol) was dissolved in EtOAc (3 ml) saturated with hydrogen chloride and stirred for 18h. The solution was evaporated and triturated with EtOAc to give the product as an off-white solid (0.034 g, 88%).
- 25 ¹H-NMR (300MHz, DMSO-d₆): δ = 2.30 (d, 2H), 3.70 (m, 2H), 3.90 (dd, 1H), 4.51 (m, 4H), 4.44 (m, 2H), 4.60 (m, 1H), 5.10 (m, 1H), 5.90 (s, 1H), 6.37 (d, 1H), 7.30 (s, 1H), 7.38 (s, 1H), 7.89 (s, 3H) and 8.69 (d, 1H). MS: ESP⁺ (M+H)⁺ = 465.

Example 28: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R,S)-phenyl-1,3-dioxan-5(R,S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

To a stirred solution of Reference Example 6 (0.344 g, 0.83 mmol), 5-carboxy-2-phenyl-1,3-dioxan (JOC, 1997, 62, 4029) (0.208 g, 1.00 mmol), triethylamine (0.084 g, 0.116 ml, 0.83

mmol) and HOBT (0.135 g, 0.100 mmol) in dichloromethane (10 ml), was added EDC (0.192 g, 1.00 mmol). The mixture was stirred for 24h and then the solution was washed with 2N HCL (10 ml), brine (10 ml), dried and evaporated. The residue was purified by MPLC [2% MeOH/CH₂Cl₂ as eluant] to give the product as an oil (0.357 g, 76%).

- 5 ¹H-NMR (300MHz, DMSO-d₆): δ = 2.38 (d, 2H), 2.99 (s, 1H), 3.70 (d, 2H), 3.90-4.55 (m, 10H), 5.10 (m, 1H), 5.55 (s, 1H), 5.90(s, 1H), 6.37 (d, 1H), 7.40 (m, 7H) and 8.68 (d, 1H).
MS: ESP⁺ (M+H)⁺ = 568

Example 29: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(3-hydroxy-2-hydroxymethyl-

10 **propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**

Example 28 (0.155 g, 0.27 mmol) in dichloromethane (4 ml) at 0 °C was treated with boron trichloride-dimethyl sulfide (2.0M in CH₂Cl₂) (0.40 ml, 0.81 mmol) for 4.5h. MeOH (1 ml) was added until all solids had dissolved. The solution was then evaporated and the residue purified by MPLC [6% MeOH/CH₂Cl₂] as eluant] to give after trituration with diethyl ether, a

- 15 white solid (0.025 g, 19%). MS: ESP⁺ (M+H)⁺ = 480.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.40 (d, 2H), 3.15 (m, 1H), 3.40 (m, 6H), 3.79 (d, 2H), 3.98 (dd, 1H), 4.19 (s, 1H), 4.26 (dd, 1H), 4.34 (s, 1H), 4.51 (m, 2H), 5.15 (m, 1H), 5.93 (m, 1H), 6.43 (d, 1H), 7.40 (s, 1H), 7.44 (s, 1H) and 8.74 (d, 1H).

20 **Example 30: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2,3-propenoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**

Acryloyl chloride (0.747 g, 0.67 ml, 8.25 mmol) in dichloromethane (5 ml) at 0 °C was treated with Reference Example 6 (0.682 g, 1.65 mmol) in dichloromethane (5 ml) containing DMAP (0.201 g, 1.65 mmol) and triethylamine (0.333 g, 0.46 ml, 3.39 mmol). The solution was

- 25 stirred for 1.5h. The solution was washed with 2N HCL (10 ml), saturated aqueous sodium hydrogen carbonate (10 ml), brine (10 ml), dried and evaporated. The residue was purified by MPLC [2% MeOH/CH₂Cl₂ as eluant] to give a white solid (0.471 g, 66%). MS: ESP⁺ (M+H)⁺ = 432.

- ¹H-NMR (300MHz, DMSO-d₆): δ = 2.40 (d, 2H), 3.80 (d, 2H), 3.99 (dd, 1H), 4.25 (m, 3H),
30 4.54 (m, 2H), 5.16 (m, 1H), 5.75 (d, 1H), 5.93 (s, 1H), 6.20 (d, 1H), 6.45 (s, 1H), 6.88 (m, 1H), 7.42 (s, 1H), 7.48 (s, 1H) and 8.75 (d, 1H).

Reference Example 19 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2,3(R,S)-epoxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

n-Butyllithium (1.6M in hexanes) (0.65 ml, 1.04 mmol) was added to a solution of *tert*-butylhydroperoxide (5.5M in decane) (0.26 ml, 1.43 mmol) in THF (5 ml) at -78 °C. The mixture was stirred for 5 min. A solution of the acrylamide, Example 30 (0.408 g, 0.95 mmol) in dry THF (2 ml) was added and stirring continued with the ice-bath removed until the temperature reached *ca.* 0 °C whereupon a water ice-bath was put in place. Solid sodium sulfite (0.080 g, 0.30 mmol) was added and stirring continued for 15min. Dichloromethane (10 ml) was added and the mixture filtered through Celite and then evaporated. The residue was purified by MPLC [2% MeOH/CH₂Cl₂ as eluant] to give the product as a gum (0.378 g, 89%).

¹H-NMR (300MHz, DMSO-d₆): δ = 2.46 (d, 2H), 2.87 (m, 1H), 3.00 (m, 1H), 3.67-4.04 (m, 4H), 4.17 (s, 1H), 4.27 (t, 1H), 4.40 (d, 1H), 4.52 (m, 2H), 5.16 (m, 1H), 5.95 (s, 1H), 6.43 (s, 1H), 7.40 (s, 1H), 7.45 (s, 1H) and 8.76 (d, 1H).

MS: ESP⁺ (M+H)⁺ = 448.

Example 31: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R,S)-hydroxy-3-morpholinopropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

Reference Example 19 (0.073 g, 0.16 mmol) and morpholine (0.014 g, 0.014 ml, 0.16 mmol) were refluxed in isopropanol (1 ml) for 1h. and then heated at 50 °C for 2h. The solution was allowed to cool to RT overnight and then evaporated. The residue was purified by MPLC [4% MeOH/CH₂Cl₂ as eluant] to give a white foam (0.056 g, 66%).

¹H-NMR (300MHz, DMSO-d₆): δ = 2.41 (d, 2H), 2.60 (m, 6H), 3.60 (d, 4H), 3.78 (m, 2H), 4.00 (dd, 1H), 4.17 (s, 1H), 4.26 (dd, 1H), 4.34 (s, 1H), 4.56 (m, 3H), 5.04 (dd, 1H), 5.15 (m, 1H), 5.94 (s, 1H), 6.43 (d, 1H), 7.40 (s, 1H), 7.44 (s, 1H) and 8.74 (s, 1H). MS: ESP⁺ (M+H)⁺ = 535.

Reference Example 20: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R,S)-hydroxy-3-(2-tert-butylidimethylsilyloxy)pyrrolidin-1-yl)propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

Reference Example 19 (0.149 g, 0.333 mmol) and 2-tert-butylidimethylsilyloxy pyrrolidine
5 (0.067 g, 0.333 mmol) in isopropanol (3 ml) were heated at 60 °C until TLC indicated
completion. The solution was evaporated and the residue was purified by MPLC [3→10%
MeOH/CH₂Cl₂ as eluant] to give a colourless gum (0.173 g, 80%). MS: ESP⁺ (M+H)⁺ = 649.
¹H-NMR (300MHz, DMSO-d₆): δ = 0.00 (s, 6H), 0.82 (s, 9H), 1.50 (m, 1H), 1.98 (m, 1H),
2.23-2.95 (m, 8H), 3.71 (s, 2H), 3.90 (dd, 1H), 4.08 (s, 1H), 4.17 (t, 1H), 4.30 (s, 2H), 4.45
10 (m, 3H), 5.03 (m, 2H), 5.83 (s, 1H), 6.33 (d, 1H), 7.30 (s, 1H), 7.34 (s, 1H) and 8.64 (s, 1H).

Example 32: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R,S)-hydroxy-3-(2-hydroxypyrrolidino)propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

15 The silyl ether Reference Example 20, (0.169 g, 0.26 mmol) in dry THF (5 ml) at 0 °C was
treated with tetrabutylammonium fluoride (1.0M in THF) (0.52 ml, 0.52 mmol) and then
stirred for 5h. The solution was evaporated and the residue was purified by MPLC [3→6%
MeOH/CH₂Cl₂ as eluant] to give a white solid (0.104 g, 75%).
¹H-NMR (300MHz, DMSO-d₆): δ = 1.54 (s, 1H), 1.92 (m, 1H), 2.30 (m, 3H), 2.50-2.88 (m,
20 5H), 3.63 (m, 2H), 3.89 (dd, 1H), 4.13 (m, 4H), 4.45 (m, 3H), 4.65 (s, 1H), 5.05 (m, 2H), 5.86
(s, 1H), 6.35 (d, 1H), 7.34 (s, 1H), 7.38 (s, 1H) and 8.68 (d, 1H).
MS: ESP⁺ (M+H)⁺ = 535.

**Reference Example 21: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R,S)-phenyl-1,3-dioxan-
25 5(R,S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)-oxazolidin-2-one**

To a stirred solution of Reference Example 11 (0.368 g, 0.93 mmol) the acid, 5-carboxy-2-
phenyl-1,3-dioxan (JOC, 1997, 62, 4029) (0.232 g, 1.12 mmol), triethylamine (0.094 g, 0.129
ml, 0.93 mmol) and HOBt (0.151 g, 1.12 mmol) in dichloromethane (11 ml) was added EDC
(0.215 g, 1.12 mmol). The mixture was stirred for 20h and then the solution was washed with
30 2N HCL (10 ml), brine (10 ml), dried and evaporated. The residue was purified by MPLC
[2% MeOH/CH₂Cl₂ as eluant] to give an oil (0.475 g, 93%).

¹H-NMR (300MHz, DMSO-d₆): δ = 2.62 (m, 2H), 3.48 (m, 1H), 3.70 (m, 1H), 3.82 (m, 1H), 3.93-4.60 (m, 10H), 5.14 (m, 1H), 5.60 (s, 1H), 6.08 (s, 1H), 6.42 (d, 1H), 7.46 (m, 8H) and 8.76 (d, 1H). MS: ESP⁺ (M+H)⁺ = 550.

5 **Example 33: 5(R)-Isoxazol-3-ylloxymethyl-3-(4-(1-(3-hydroxy-2-hydroxymethyl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one**

Reference Example 21 (0.475 g, 0.87 mmol) was stirred in 80% acetic acid/water (10 ml) for 24h. The precipitate slowly dissolved. The solution was evaporated and purified by MPLC [5% MeOH/CH₂Cl₂ as eluant] to give after trituration with diethyl ether, a white powder

10 (0.284 g, 71%). MS: ESP⁺ (M+H)⁺ = 462.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.51 (d, 2H), 3.15 (m, 1H), 3.58 (m, 4H), 3.78 (m, 2H), 3.99 (dd, 1H), 4.26 (d, 2H), 4.28 (t, 1H), 4.54 (m, 2H), 4.65 (m, 2H), 5.15 (m, 1H), 6.06 (s, 1H), 6.43 (d, 1H), 7.35-7.63 (m, 3H) and 8.76 (d, 1H).

15 **Reference Example 22: 5(R,S)-Carboxymethyl-2,2-dimethyl-4-oxo-1,3-dioxolane**

(D,L)-Malic acid (12.41 g, 92.6 mmol) and PTSA (2.32 g, 9.26 mmol) in 2,2-dimethoxypropane (35 ml) were stirred for 5 days. The solution was evaporated and the residue was purified by MPLC [25% EtOAc/isohexane as eluant] to give a colorless gum (11.48 g, 71%).

20 ¹H-NMR (300MHz, DMSO-d₆): δ = 1.58 (s, 3H), 1.60 (s, 3H), 2.82 (m, 2H), 4.85 (t, 1H) and 12.64 (s, 1H).

Example 34: 5(R)-Isoxazol-3-ylloxymethyl-3-(4-(1-(2,2-dimethyl-4-oxo-1,3-dioxolan-5(R,S)-ylacetyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)-oxazolidin-2-one

25 To a stirred solution of Reference Example 11 (0.384 g, 0.97 mmol), the acid (Reference Example 22) (0.203 g, 1.17 mmol), triethylamine (0.098 g, 0.135 ml, 0.97 mmol) and HOBt (0.158 g, 1.17 mmol) in dichloromethane (11 ml) was added EDC (0.225 g, 1.17 mmol). The mixture was stirred for 60h and then the solution was dried and evaporated. The residue was purified by MPLC [3% MeOH/CH₂Cl₂ as eluant] to give an oil (0.356 g, 71%). MS: ESP⁺

30 (M+H)⁺ = 516.

¹H-NMR (300MHz, DMSO-d₆): δ = 1.57 (s, 3H), 1.60 (s, 3H), 2.53 (d, 2H), 3.02 (m, 2H), 3.70 (m, 2H), 4.00 (dd, 1H), 4.19 (d, 2H), 4.25 (t, 1H), 4.52 (m, 2H), 4.89 (t, 1H), 5.15 (m, 1H), 6.05 (s, 1H), 6.44 (d, 1H), 7.36-7.63 (m, 3H) and 8.75 (d, 1H).

5 **Example 35: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(3-carboxy-3(R,S)-hydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one**

Example 34 (0.345 g, 0.67 mmol) was stirred in 80% acetic acid/water (5 ml) for 20h. The acetonide slowly dissolved and then the product slowly precipitated. Diethyl ether (10 ml) was added and the solid collected by filtration to give a white solid (0.300 g, 94%). MS: ESP

10 (M-H)⁺ = 474.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.52 (d, 2H), 2.80 (m, 2H), 3.71 (s, 2H), 4.00 (dd, 1H), 4.20 (d, 2H), 4.28 (t, 1H), 4.41 (t, 1H), 4.55 (m, 2H), 5.15 (m, 1H), 6.08 (s, 1H), 6.46 (d, 1H), 7.35-7.62 (m, 3H) and 8.77 (d, 1H).

15 **Reference Example 23: 5(R,S)-Methylaminocarbonylmethyl-2,2-dimethyl-4-oxo-1,3-dioxolane**

The acid Reference Example 22 (2.84 g, 16.32 mmol) was heated under reflux in thionyl chloride (25 ml) for 1.25h under nitrogen. The solution was evaporated and azeotroped with toluene (2 x). A portion of the crude acid chloride (5.44 mmol) was dissolved in

20 dichloromethane (5 ml), treated with methylamine (2.0M in THF) (5.44 ml, 10.88 mmol) and stirred for 1.5h. The resultant suspension was diluted, washed with 2N HCL (10 ml), brine (10 ml), dried and evaporated. The residue was purified by MPLC [5% MeOH/CH₂Cl₂ as eluant] to give a pale tan solid (0.393 g, 39%).

¹H-NMR (300MHz, DMSO-d₆): δ = 1.56 (s, 6H), 2.66 (m, 2H), 2.68 (s, 3H), 4.82 (t, 1H) and
25 7.95 (s, 1H), MS: ESP⁺ (M+H)⁺ = 188.

Reference Example 24: 2(R,S)-hydroxy-3-methylaminocarbonylpropanoic acid

The amide Reference Example 23 (0.392 g, 2.10 mmol) was stirred in MeOH (4 ml) containing PTSA (0.053 g, 0.21 mmol) for 5 days. The solution was evaporated and the
30 residue was purified by MPLC [5% MeOH/CH₂Cl₂ as eluant] to give the methyl ester (0.284 g). This was dissolved in MeOH/water (3:1) (4 ml), treated with lithium hydroxide (0.370 g, 8.82 mmol) and stirred for 15min. The mixture was diluted with water (20 ml), treated with

Dowex 50W-X8(H), stirred for 5min, filtered and evaporated to in vacuo to give a gum (0.216 g, 83%).

¹H-NMR (300MHz, DMSO-d₆): δ = 2.38 (dd, 1H), 2.49 (dd, 1H), 2.64 (s, 3H), 3.54 (br s, 1H), 4.34 (m, 1H), 7.87 (m, 1H) and 12.53 (br s, 1H). MS: ESP⁺ (M-H)⁺ = 146.

5

Example 36: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R,S)-hydroxy-3-methylaminocarbonylpropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

To a stirred solution of Reference Example 11 (0.175 g, 0.44 mmol), the acid Reference
10 Example 24 (0.078 g, 0.53 mmol), triethylamine (0.044 g, 0.061 ml, 0.44 mmol) and HOBT (0.072 g, 0.53 mmol) in dichloromethane (6 ml) was added EDC (0.102 g, 0.53 mmol). The mixture was stirred for 16h. TLC indicated incomplete reaction and more acid (0.138 g, 0.94 mmol), HOBT (0.127 g, 0.94 mmol) and EDC (0.180 g, 0.94 mmol) was added. After 5h the solution was evaporated. The residue was purified by MPLC [5→15% MeOH/CH₂Cl₂ as
15 eluant] to give an oil (0.070 g, 33%). MS: ESP⁺ (M+H)⁺ = 489.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.44 (m, 4H), 2.63 (d, 3H), 3.66 (m, 1H), 3.77 (s, 1H), 4.00 (dd, 1H), 4.22 (m, 3H), 4.54 (m, 2H), 4.79 (m, 1H), 5.15 (m, 1H), 5.38 (d, 1H), 6.10 (s, 1H), 6.48 (d, 1H), 7.35-7.64 (m, 3H), 7.88 (s, 1H) and 8.79 (d, 1H).

20 **Example 37: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(3(R,S)-hydroxy-3-methylaminocarbonylpropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one**

To a stirred solution of Example 35 (0.070 g, 0.15 mmol) and HOBT (0.020 g, 0.15 mmol) in dichloromethane (4 ml) was added EDC (0.028 g, 0.15 mmol) and then methylamine (2.0M in
25 THF) (0.23 ml, 0.45 mmol). The mixture was stirred for 22h and then purified by MPLC [5% MeOH/CH₂Cl₂ as eluant] to give after trituration with diethyl ether a white solid (0.01g, 14%).

¹H-NMR (300MHz, DMSO-d₆): δ = 2.48 (d, 2H), 2.65 (d, 3H), 2.69 (m, 2H), 3.69(m, 2H), 3.94 (dd, 1H), 4.17 (m, 2H), 4.20 (t, 1H), 4.30 (m, 1H), 4.48 (m, 2H), 5.08 (m, 1H), 5.61 (m, 1H), 6.00 (s, 1H), 6.39 (d, 1H), 7.38 (m, 2H), 7.50 (d, 1H), 7.78 (m, 1H) and 8.70 (d, 1H).

30 MS: ESP⁺ (M+H)⁺ = 489.

Reference Example 25: 5(R,S)-(2-(2-Methoxyethoxy)ethoxy)carbonylmethyl-2,2-dimethyl-4-oxo-1,3-dioxolane

The acid (Reference Example 22) (2.75 g, 15.80 mmol) in dichloromethane (15 ml) at 0 °C was treated with oxalyl chloride (2.99 g, 2.1 ml, 23.71 mmol) and stirred with a drop of *DMF* for 2h. The solution was evaporated. A portion of the crude acid chloride (1.90 g, 9.84 mmol) in dichloromethane (20 ml) at 0 °C containing 4-DMAP (1.20 g, 9.84 mmol) was treated with 2-(2-methoxyethoxy)ethanol (4.72 g, 4.70 ml, 39.36 mmol) and stirred overnight. The solution was washed with 2N HCL (2 x 15 ml), brine (10 ml), dried and evaporated. The residue was purified by MPLC [3% MeOH/CH₂Cl₂ as eluant] to give an oil (0.785 g, 29%).

10 ¹H-NMR (300MHz, DMSO-d₆): δ = 1.54 (s, 6H), 2.89 (t, 2H), 3.27 (s, 3H), 3.43 (m, 2H), 3.53 (m, 2H), 3.60 (m, 2H), 4.19 (m, 2H) and 4.84 (t, 1H).

Reference Example 26: 2(R,S)-Hydroxy-3-(2-(2-methoxyethoxy)ethoxy)carbonyl-propanoic acid

15 Reference Example 25 (0.785 g, 2.84 mmol) was stirred in 80% acetic acid/water (5 ml) for 5 days. The solution was evaporated to give an orange oil (0.600 g, 89%).

¹H-NMR (300MHz, DMSO-d₆): δ = 2.54 (dd, 1H), 2.72 (dd, 1H), 3.26 (s, 3H), 3.42 (m, 2H), 3.52 (m, 2H), 3.59 (m, 2H), 4.13 (m, 2H), 4.30 (m, 1H), 5.49 (s, 1H) and 12.58 (s, 1H). MS: ESP⁺ (M-H)⁺ = 235.

20

Example 38: 5(R)-Isoxazol-3-ylloxymethyl-3-(4-(1-(2(R,S)-hydroxy-3-(2-(2-methoxyethoxy)ethoxy)carbonylpropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

To a stirred solution of Reference Example 11 (0.329 g, 0.79 mmol), the acid Reference

25 Example 26 (0.225 g, 0.95 mmol), triethylamine (0.079 g, 0.110 ml, 0.79 mmol) and HOBT (0.129 g, 0.95 mmol) in dichloromethane (10 ml) was added EDC (0.183 g, 0.95 mmol). The mixture was stirred for 48h and then the solution was dried and evaporated. The residue was purified by MPLC [5% MeOH/CH₂Cl₂ as eluant] to give a white solid (0.283 g, 62%).

¹H-NMR (300MHz, DMSO-d₆): δ = 2.52 (d, 2H), 2.60 (dd, 1H), 2.85 (dd, 1H), 3.31 (s, 3H),

30 3.50 (m, 2H), 3.60 (m, 2H), 3.68 (m, 2H), 3.80 (m, 2H), 4.00 (dd, 1H), 4.10-4.40 (m, 5H), 4.54 (m, 2H), 4.76 (m, 1H), 5.15 (m, 1H), 5.64 (m, 1H), 6.09 (s, 1H), 6.43 (d, 1H), 7.43 (m, 2H), 7.58 (d, 1H) and 8.75 (d, 1H). MS: ESP⁺ (M+H)⁺ = 578.

Example 39: 5(R)-Isoxazol-3-yloxymethyl-3-(4-morpholino-3-fluoro-phenyl)oxazolidin-2-one

- Prepared by the general method of Example 1 using as starting material 5(R)-hydroxymethyl-3-(4-morpholino-3-fluoro-phenyl)oxazolidin-2-one (WO95/07271; 300mg, 1.01mmol), 3-hydroxyisoxazole (95mg, 1.12mmol), diisopropylazodicarboxylate (225mg, 1.11mmol) and triphenylphosphine (305mg, 1.16mmol) in THF (5ml). Purified by flash chromatography (Merck 9385 silica, EtOAc / isohexane (7/3)) to give the title compound (254mg, 69%) as a colourless solid.
- 10 ¹H-NMR (300MHz, CDCl₃): δ = 3.05 (m, 4H), 3.88 (m, 4H), 3.94 (dd, 1H), 4.14 (t, 1H), 4.47-4.62 (m, 2H), 5.01 (m, 1H), 6.00 (d, 1H), 6.94 (t, 1H), 7.15 (dd, 1H), 7.46 (d, 1H), 8.15 (d, 1H). MS: ESP⁺ (M+H)⁺ = 364.

Reference Example 27: 5(R)-Hydroxymethyl-3-(4-iodophenyl)oxazolidin-2-one

- 15 3-Phenyl-oxazolidin-2-one (U.S.Patent 4705799; 3.0g, 15.5mmol), silver trifluoroacetate (4.5g, 20.4mmol) and iodine (4.7g, 18.5mmol) in a mixture of acetonitrile (30ml) and chloroform (30ml) were stirred at room temperature for 72 hr then a further 1g silver trifluoroacetate and 1g iodine added and stirring continued for 18hr. The mixture was then filtered and the filtrate evaporated to give an orange oil which was purified by flash
- 20 chromatography (Merck 9385 silica, 5% MeOH / dichloromethane) followed by recrystallisation from EtOAc / isohexane to give the title compound (1.85g, 38%) as a colourless solid. MS: ESP⁺ (M+H)⁺ = 320.
- ¹H-NMR (300MHz, DMSO-d₆): δ = 3.53 (m, 1H), 3.47 (m, 1H), 3.78 (dd, 1H), 4.05 (t, 1H), 4.69 (m, 1H), 5.18 (t, 1H), 7.38 (d, 2H), 7.69 (d, 2H).

25

Reference Example 28: 5(R)-Isoxazol-3-yloxymethyl-3-(4-iodophenyl)oxazolidin-2-one

- Prepared by the general method of Example 1 using (1.85g, 5.80mmol), 3-hydroxyisoxazole (0.55g, 6.47mmol), diisopropylazodicarboxylate (1.29g, 6.39mmol) and triphenylphosphine (1.75g, 6.68mmol) in THF (30ml). Purified by flash chromatography (Merck 9385 silica,
- 30 EtOAc / isohexane (1/1)) to give the title compound (1.45g, 64%) as a colourless solid. MS: ESP⁺ (M+H)⁺ = 387.

¹H-NMR (300MHz, CDCl₃): δ = 3.94 (dd, 1H), 4.13 (t, 1H), 4.46-4.61 (m, 2H), 5.03 (m, 1H), 6.00 (d, 1H), 7.34 (d, 2H), 7.69 (d, 2H), 8.15 (d, 1H).

Reference Example 29: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-tert-butoxycarbonyl-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one

Lithium chloride (1.0g, 23.6mmol), triphenylarsine (0.95g, 3.10mmol) and tris(dibenzylideneacetone) dipalladium(0) (0.7g, 0.76mmol) were added at room temperature, under an atmosphere of nitrogen, to a stirred solution of Reference Example 28 (3.0g, 7.77mmol) in DMF (50ml, degassed). The resulting mixture was stirred for 15min then N-
10 tert-butoxycarbonyl-4-trimethylstannyl-1,2,5,6-tetrahydropyridine (3.0g, 8.67mmol; prepared from N-tert-butoxycarbonyl-4-triflate-1,2,5,6-tetrahydropyridine (WO97/30995) reacted with hexamethyltin using a Pd(0) catalyst) in DMF (10ml) added in one go. The reaction was stirred and heated at 50°-55°C for 3hr, cooled to room temperature then treated with a 2N aqueous solution of potassium fluoride (8ml). After stirring for 30min the solvent was
15 evaporated (50°, high vac.) then the residue partitioned between dichloromethane and water, filtered and the dichloromethane layer separated. Washed with water (2X) and sat. brine, dried over magnesium sulfate and evaporated to an orange viscous oil. Purified by flash chromatography (Merck 9385 silica, EtOAc / isohexane (3/2)) to give the title compound as a pale yellow solid. MS: ESP⁺ (M+H)⁺ = 442.

20

Reference Example 30: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1,2,5,6-tetrahydropyrid-4-yl)-phenyl)oxazolidin-2-one

Reference Example 29 (2.1g, 4.76mmol) in MeOH (30ml) (partial solution) was treated at room temperature with an approx. 4M solution of HCl in ethanol and the resulting mixture
25 stirred 4hr then left to stand 16hr. Diethyl ether (50ml) was then added and the resulting pale yellow solid filtered, washed with ether and dried: 1.71g (95% yield) - title compound as the hydrochloride salt.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.66 (m, 2H), 3.30 (m, partially obscured by DMSO, 2H), 3.73 (m, 2H), 3.92 (dd, 1H), 4.20 (t, 1H), 4.41-4.53 (m, 2H), 5.08 (m, 1H), 6.16 (m, 1H),
30 6.35 (d, 1H), 7.49 (d, 2H), 7.57 (d, 2H), 8.68 (d, 1H), 9.30 (s(br), 2H). MS: ESP⁺ (M+H)⁺ = 342. Free base isolated by treating with aqueous sodium hydroxide solution and extraction with dichloromethane to give title compound as a yellow solid.

Reference Example 31: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(R)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one

1,3 Dicyclohexylcarbodiimide (298mg, 1.45mmol) was added in one go at room temperature
5 to a stirred solution of (R)-2,3-O-isopropylidenglyceric acid (235mg, 1.40mmol 87% purity)
and 1-hydroxybenzotriazole (218mg, 1.42mmol) in dichloromethane (15ml). The resulting
suspension was stirred 1hr then a further 5ml dichloromethane was added followed by
Reference Example 30 (500mg, 1.47mmol), stirred 16hr, filtered and the filtrate washed with
water and sat. brine. Purified by flash chromatography (Merck 9385 silica, 2.5% MeOH /
10 dichloromethane) to give the title compound (395mg, 57%) as a colourless solid. MS: ESP⁺
(M+H)⁺ = 470.

Reference Example 32: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one

15 Prepared by the general method of Reference Example 31, using Reference Example 30
(500mg, 1.47mmol), 1,3 dicyclohexylcarbodiimide (298mg, 1.45mmol), (S)-2,3-O-
isopropylidenglyceric acid (235mg, 1.40mmol 87% purity) and 1-hydroxybenzotriazole
(218mg, 1.42mmol) in dichloromethane (15ml). Purified by flash chromatography (Merck
9385 silica, 2.5% MeOH / dichloromethane) to give the title compound (408mg, 59%) as a
20 colourless solid. MS: ESP⁺ (M+H)⁺ = 470.

Example 40: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one

Prepared by the general method of Example 4 using Reference Example 31 (395mg,
25 0.84mmol) in 1N hydrochloric acid (3ml) and THF (9ml). Purified by flash chromatography
(Merck 9385 silica, 8% MeOH / dichloromethane) to give the title compound (203mg, 56%)
as a colourless solid, mp=138°-144°C.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.40-2.56 (m, partially obscured by DMSO, 2H), 3.40-
3.63 and 3.63-3.88 (m, 4H), 3.92 (dd, 1H), 4.11 (m, 2H), 4.20 (t, 1H), 4.30-4.54 (m, 3H),
30 4.68 (m, 1H), 4.92 (m, 1H), 5.07 (m, 1H), 6.15 (m, 1H), 6.37 (d, 1H), 7.46 (d, 2H), 7.53 (d,
2H), 8.68 (d, 1H). MS: ESP⁺ (M+H)⁺ = 430.

Example 41: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one

Prepared by the general method of Example 4 using Reference Example 32 (408mg, 0.87mmol) in 1N hydrochloric acid (3ml) and THF (9ml). Purified by flash chromatography
5 (Merck 9385 silica, 8% MeOH / dichloromethane) to give the title compound (124mg, 33%) as a colourless solid, mp=200°-202°C(dec).

¹H-NMR (300MHz, DMSO-d₆): δ = 2.38-2.56 (2H), 3.20-3.40 (m, partially obscured by DMSO, 2H), 3.54 (m, 1H), 3.64-3.85 (m, 1H), 3.92 (dd, 1H), 4.12 (m, 2H), 4.20 (t, 1H), 4.30-4.55 (m, 3H), 5.07 (m, 1H), 6.15 (m, 1H), 6.37 (d, 1H), 7.46 (d, 2H), 7.53 (d, 2H), 8.66
10 (d,1H). MS: ESP⁺ (M+H)⁺= 430.

Example 42: 5(R)-Isoxazol-3-yloxymethyl-3-(4-methylthiophenyl)oxazolidin-2-one

Prepared by the general method of Example 1 using 5(R)-hydroxymethyl-3-(4-methylthiophenyl)oxazolidin-2-one (650mg, 2.72mmol; prepared from the reaction of 4-
15 methylthioaniline and (R)-glycidyl butyrate), 3-hydroxyisoxazole (243mg, 2.86mmol), diisopropylazodicarboxylate (577mg, 2.86mmol) and triphenylphosphine (770mg, 2.94mmol) in THF (10ml). Purified by flash chromatography (Merck 9385 silica, EtOAc / isohexane (1/1)) to give the title compound 507mg, 61%) as a colourless solid. MS: ESP⁺ (M+H)⁺= 307.
¹H-NMR (300MHz, CDCl₃): δ = 2.47 (s, 3H), 3.97 (dd, 1H), 4.15 (t, 1H), 4.47-4.62 (m, 2H),
20 5.02 (m, 1H), 6.00 (d, 1H), 7.30 (d, 2H), 7.49 (d, 2H), 8.14 (d, 1H).

Example 43: 5(R)-Isoxazol-3-yloxymethyl-3-(4-methylsulfinylphenyl)oxazolidin-2-one
and Example 44: 5(R)-Isoxazol-3-yloxymethyl-3-(4-methylsulfonylphenyl)oxazolidin-2-one

25 3-Chloroperoxybenzoic acid (282mg, 70% strength, 1.14mmol) was added to a solution of Example 42 (340mg, 1.11mmol) in dichloromethane (10ml) at -40°C. The reaction was stirred at -30° to -40°C for 3hr then diluted with more dichloromethane (10ml), washed with aq. sodium bisulfite solution, sat. aq. sodium bicarbonate solution and water, dried over magnesium sulfate and evaporated to a colourless oil. Purified by flash chromatography
30 (Merck 9385 silica, 5% MeOH / dichloromethane) to give Example 43 (275mg, 77%) and Example 44 (31mg), both as colourless solids.

Example 43: MS: ESP⁺ (M+H)⁺= 323.

¹H-NMR (300MHz, CDCl₃): δ = 2.73 (s, 3H), 4.06 (dd, 1H), 4.22 (t, 1H), 4.50-4.65 (m, 2H), 5.08 (m, 1H), 6.00 (d, 1H), 7.69 (d, 2H), 7.77 (d, 2H), 8.15 (d, 1H).

Example 44: MS: ESP⁺ (M+H)⁺ = 339.

¹H-NMR (300MHz, DMSO-d₆): δ = 3.14 (s, 3H), 3.98 (dd, 1H), 4.26 (t, 1H), 4.43-4.54 (m, 2H), 5.10 (m, 1H), 6.34 (d, 1H), 7.80 (d, 2H), 7.92 (d, 2H), 8.66 (d, 1H).

Example 45: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R,S)-hydroxy-3-(1-imidazolyl)propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)-oxazolidin-2-one

10 Reference Example 19 (200mg, 0.45mmol) and 1H-imidazole (34mg, 0.50mmol) in 2-propanol (2ml) were refluxed for 8hr then the resulting solution cooled to room temperature and purified by flash chromatography (Merck 9385 silica, 10% MeOH / dichloromethane) to give the title compound (83mg, 36%) as a colourless solid.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.25-2.50 (m, 2H), 3.55-3.83 (m, 2H), 3.95 (dd, 1H), 4.00-4.40 (m, 5H), 4.44-4.56 (m, 2H), 4.56-4.68 (m, 1H), 5.11 (m, 1H), 5.65 (d) and 5.75 (d) (1H), 5.87 (m, 1H), 6.37 (d, 1H), 6.85 (m, 1H), 7.15 (m, 1H), 7.36 (d, 2H), 7.58 (m, 1H), 8.68 (d, 1H). MS: ESP⁺ (M+H)⁺ = 516.

Example 46: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(R,S)-hydroxy-3-(1,2,4-triazol-1-yl)propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)-oxazolidin-2-one

20 Prepared by the general method of Example 45 using Reference Example 19 (200mg, 0.45mmol) and 1H-1,2,4-Triazole (35mg, 0.50mmol) in 2-propanol (2ml). Purified by flash chromatography (Merck 9385 silica, 10% MeOH / dichloromethane) to give the title compound (84mg, 36%) as a colourless solid. MS: ESP⁺ (M+H)⁺ = 517.

25 ¹H-NMR (300MHz, DMSO-d₆): δ = 2.25-2.50 (m, 2H), 3.55-3.85 (m, 2H), 3.95 (dd, 1H), 4.00-4.40 (m, 5H), 4.40-4.55 (m, 2H), 4.68-4.82 (m, 1H), 5.12 (m, 1H), 5.77 (d) and 5.81 (d) (1H), 5.90 (m, 1H), 6.77 (d, 1H), 7.35 (d, 2H), 7.95 (s, 1H), 8.44 (s, 1H), 8.68 (d, 1H).

Example 47: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-acetoxypromionyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

30 (S)-2-Acetoxypromionyl chloride (126mg, 0.84mmol) was added dropwise at room temperature to a stirred suspension of Reference Example 11 (300mg, 0.76mmol) and N,N

diisopropyl ethylamine (210mg, 1.63mmol) in dichloromethane (10ml). The reaction was stirred at room temperature for 2hr then purified by flash chromatography (Merck 9385 silica, 2.5% MeOH / dichloromethane) to give the title compound (322mg, 90%) as a colourless solid. MS: ESP⁺ (M+H)⁺ = 474.

- 5 ¹H-NMR (300MHz, CDCl₃): δ = 1.48 (s) and 1.51 (s) (3H), 2.14 (s, 3H), 2.50-2.74 (m, 2H), 3.68 (m) and 3.96 (m) (3H), 4.05-4.36 (m, 3H), 4.47-4.62 (m, 2H), 5.04 (m, 1H), 5.35-5.55 (m, 1H), 5.97 (m, 1H), 6.00 (d, 1H), 7.20-7.30 (m, 2H), 7.45 (d, 1H), 8.15 (d, 1H).

Example 48: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxypropanoyl)-1,2,5,6-

10 **tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one**

Example 47 (200mg, 0.42mmol) in 10ml of a saturated solution of ammonia in MeOH was stirred at room temperature for 18hr then cooled in ice-water before filtering the resulting colourless solid. Washed with ice-cold MeOH and diethyl ether then dried to give the title compound (156mg, 86%). MS: ESP⁺ (M+H)⁺ = 432.

- 15 ¹H-NMR (300MHz, DMSO-d₆): δ = 1.23 (s) and 1.25 (s) (3H), 2.33-2.50 (m, 2H), 3.52-3.85 (m, 2H), 3.93 (dd, 1H), 4.02-4.38 (m, 3H), 4.40-4.60 (m, 2H), 4.85-5.00 (m, 1H), 5.11 (m, 1H), 6.03 (m, 1H), 6.38 (d, 1H), 7.33 (dd, 1H), 7.41 (t, 1H), 7.52 (dd, 1H), 8.68 (d, 1H).

Example 49: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-acetoxyacetyl-1,2,5,6-tetrahydropyrid-

20 **4-yl)-3-fluorophenyl)oxazolidin-2-one**

Prepared by the general method of Example 6 using Reference Example 11 (300mg, 0.76mmol), acetoxyacetyl chloride (114mg, 0.83mmol), triethylamine (88mg, 0.87mmol) and 4-(dimethylamino) pyridine (25mg) in dichloromethane 10ml). Purified by chromatography (bond elut (silica, 10g), 1-2% MeOH / dichloromethane) to give the title compound (230mg,

- 25 66%) as a colourless solid. MS: ESP⁺ (M+H)⁺ = 460.

¹H-NMR (300MHz, CDCl₃): δ = 2.20 (s, 3H), 2.50-2.66 (m, 2H), 3.60 (t) and 3.83 (t) (2H), 3.96 (dd, 1H), 4.10 (m) and 4.24 (m) (2H), 4.15 (t, 1H), 4.50-4.64 (m, 2H), 4.77 (s) and 4.81 (s) (2H), 5.04 (m, 1H), 5.90-6.00 (m, 1H), 6.00 (d, 1H), 7.21-7.30 (m, 2H), 7.45 (d, 1H), 8.15 (d, 1H).

Example 50: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-hydroxyacetyl-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Prepared by the general method of Example 48 using Example 49 (170mg, 0.37mmol) in 10ml of a saturated solution of ammonia in MeOH to give the title compound (121mg, 79%) as a colourless solid. MS: ESP⁺ (M+H)⁺ = 418.

¹H-NMR (300MHz, CDCl₃): δ = 2.52-2.62 (m, 2H), 3.48 (t) and 3.65 (t) (2H), 3.87 (t) and 3.95 (m) (3H), 4.16 (t, 1H), 4.22 (dd, 1H), 4.30 (m, 1H), 4.48-4.62 (m, 2H), 5.04 (m, 1H), 5.92 (m) and 6.00 (m) (1H), 6.00 (d, 1H), 7.20-7.30 (m, 2H), 7.43 (d, 1H), 8.15 (d, 1H).

10 **Example 51: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-(3-pyridin-1-iummethyl-benzoyloxy)-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one chloride**

Example 12 (0.40g, 0.89mmol) was suspended in dichloromethane (20ml), and pyridine (0.07g, 0.89mmol), 4-dimethylaminopyridine (0.2g) was added. 3-chloromethylbenzoyl chloride was added dropwise and the reaction mixture was stirred at room temperature for 2hr. The resulting solution was washed with water, dried (MgSO₄) and purified by chromatography (Merck 9385 silica, 5-10% MeOH in CH₂Cl₂) to give the title compound as a pale yellow solid (0.30g, 42%) after trituration with diethyl ether.

15 ¹H-NMR (300MHz, DMSO-d₆): δ = 2.43 (partially obscured by DMSO, 2H), 3.64- 4.52 (m, 10H), 4.74 (m, 1H), 5.08 (m, 1H), 5.98 (m, 3H), 6.37 (m, 1H), 7.35 (m, 2H), 7.46- 7.63 (m, 2H), 7.81 (m, 1H), 8.00 (m, 1H), 8.16 (m, 2H), 8.54- 8.65 (m, 2H), 8.68 (m, 1H), 9.26 (M, 2H). MS: ESP⁺ (M)⁺ = 643

25 **Example 52: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-(3-chloromethyl-benzoyloxy)-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one**

Example 12 (0.50g, 1.12M) was suspended in dichloromethane (20ml), and triethylamine (0.11g, 0.16mmol) was added. 3-chloromethylbenzoyl chloride was added dropwise and the reaction mixture was stirred at room temperature for 2hr. The resulting solution was washed with water, dried (MgSO₄) and purified by chromatography (Merck 9385 silica, 4-5% MeOH in CH₂Cl₂) to give the title compound as a yellow solid (0.46g, 69%) after trituration with diethyl ether and isohexane, also containing some di- substituted derivative.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.45 (partially obscured by DMSO, 2H), 3.65- 3.98 (m, 3H), 3.98- 4.25 (m, 2H), 4.31- 4.55 (m, 4H), 4.70- 4.87 (m, 4H), 5.07 (m, 1H), 5.71 (m, 1H), 6.04 (m, 1H), 6.41 (m, 1H), 7.28- 7.46 (m, 2H), 7.46- 7.59 (m, 2H), 7.71 (m, 1H), 7.87- 8.12 (m, 2H), 8.72 (m, 1H). MS: ESP⁺ (M+H)⁺ = 600.

5

Example 53: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-(3-morpholinomethyl-benzoyloxy)-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Example 52 (0.10g, 0.17mmol), was stirred in DMF (3ml), sodium iodide (ca. 10mg) and morpholine (0.07g, 0.67mmol) was added and the reaction mixture was heated at 50°C for 10 5hr. The DMF was removed by evaporation and the residue was taken up in dichloromethane, washed with water, dried (MgSO₄) and purified by chromatography (Merck 9385 silica, 5-10% MeOH in CH₂Cl₂) to give the title compound as an off white solid (65mg, 60%), after trituration with isohexane and diethyl ether.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.27 (m, 4H), 2.41 (partially obscured by DMSO, 2H), 15 3.40- 3.59 (m, 6H), 3.63- 3.98 (m, 3H), 3.98- 4.57 (m, 7H), 4.74 (m, 1H), 5.08 (m, 1H), 5.67 (m, 1H), 6.04 (m, 1H), 6.39 (m, 1H), 7.28- 7.64 (m, 5H), 7.88 (m, 2H), 8.72 (m, 1H). MS: ESP⁺ (M+H)⁺ = 651.

Example 54: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-(3-(4-methylpiperazinomethyl)benzoyloxy)propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Prepared by the general method of Example 53, using Example 52 (0.10g, 0.17mmol), sodium iodide (ca. 10mg) and N-methylpiperazine (0.07g, 0.67mmol). Purified by chromatography (Merck 9385 silica, 5-10% MeOH in CH₂Cl₂- 10% MeOH + 1% ammonia in CH₂Cl₂), to give 25 the title compound as white solid (55mg, 50%) after trituration with isohexane.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.44 (partially obscured by DMSO, 5H), 2.62 (m, 4H), 3.21- 3.35 (partially obscured by water, 4H), 3.55 (m, 2H), 3.65- 3.84 (m, 2H), 3.92 (dd, 1H), 4.08- 4.25 (m, 2H), 4.34 (m, 1H), 4.45 (m, 4H), 4.75 (m, 1H), 5.08 (m, 1H), 5.62 (m, 1H), 6.02 (broad s, 1H), 6.36 (m, 1H), 7.28- 7.60 (m, 5H), 7.88 (m, 2H), 8.68 (m, 1H). MS: ESP⁺ 30 (M+H)⁺ = 664.

Example 55: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-(3-di-n-butylaminomethylbenzoyloxy)propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Prepared by the general method of Example 53, using Example 52 (0.10g, 0.17mmol), sodium iodide (ca. 10mg) and di-N-butylamine (0.07g, 0.67mmol). Purified by chromatography (Merck 9385 silica, 5-10% MeOH in CH₂Cl₂- 10% MeOH + 1% ammonia in CH₂Cl₂), to give the title compound as white solid (54mg, 47%) after trituration with isohexane.

¹H-NMR (300MHz, DMSO-d₆): δ = 0.71-0.89 (m, 6H), 1.13-1.43 (m, 8H), 2.31 (partially obscured by DMSO, 6H), 3.33 (partially obscured by water, 2H), 3.42- 3.59 (m, 2H), 3.67- 3.97 (m, 3H), 3.97- 4.56 (m, 5H), 4.74 (m, 1H), 5.08 (m, 1H), 5.67 (m, 1H), 6.03 (broad s, 1H), 6.38 (m, 1H), 7.28- 7.63 (m, 5H), 7.87 (m, 2H), 8.69 (m, 1H). MS: ESP⁺ (M+H)⁺ = 693.

Example 56: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-n-propyl-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Reference Example 11 (500mg, 1.26mmol) was stirred in MeOH (10ml) and glacial acetic acid (~0.5ml) was added to pH4. Propanal (80.7mg, 1.39mmol) was added dropwise, and the reaction was stirred for 40 minutes. To the stirred solution, sodium cyanoborohydride was added (83.4mg, 1.33mmol) portionwise. The reaction was stirred for a further 30 minutes at room temperature. The reaction was quenched with 10% NaOAc and extracted with dichloromethane and the combined organic phases were dried over MgSO₄ and evaporated under reduced pressure. The resulting brown oil was triturated with ether to yield the title compound as an orange solid (300.6mg, 59%). MS: ESP⁺ (M+H)⁺ = 402.

¹H-NMR (300MHz, DMSO-d₆): δ = 0.85 (t, 3H), 1.46 (m, 2H), 2.32 (t, 2H), 2.40 (broad s, 2H), 2.57 (t, 2H), 3.04 (d, 2H), 3.93 (dd, 1H), 4.19 (t, 1H), 4.48 (m, 2H), 5.08 (m, 1H), 5.97 (broad s, 1H), 6.37 (d, 1H), 7.29-7.40 (m, 2H), 7.49 (dd, 1H), 8.70 (d, 1H).

Example 57: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2-hydroxyethyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

To a stirred partial solution of Reference Example 11 (318mg, 0.80mmol) and NaHCO₃ (169mg, 2.01mmol) in ethanol (5ml) under an atmosphere of nitrogen, 2-bromoethanol (151mg, 1.21mmol) was added dropwise. The reaction was then refluxed for 20 hours. Water

was added (200ml) and the reaction extracted with EtOAc and the combined organic phases were washed with sat NaCl and then dried over MgSO₄ and evaporated under reduced pressure. The resulting yellow oil was triturated with ether to give the title compound as a yellow solid (163mg, 50%).

- 5 ¹H-NMR (300MHz, DMSO-d₆): δ = 2.40 (broad s, 2H), 2.49 (Obscured by DMSO, 2H), 2.63 (t, 2H), 3.09 (d, 2H), 3.52 (m, 2H), 3.91 (dd, 1H), 4.19 (t, 1H), 4.39 (m, 1H), 4.45 (m, 2H), 5.05 (m, 1H), 5.96 (broad s, 1H), 6.37 (d, 2H), 7.25-7.38 (m, 2H), 7.47 (dd, 1H), 8.68 (d, 2H). MS: ESP⁺ (M+H)⁺ = 404.

10 **Example 58: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2-acetoxyethyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one**

To a stirred solution of Example 57 (103mg, 0.26mmol) and triethylamine (77.4mg, 0.77mmol) in dichloromethane (10ml) at 0°C and under an atmosphere of nitrogen, was added dropwise acetyl chloride (60.2mg, 0.77mmol). The reaction was then allowed to warm to ambient temperature and stir for 1 hour. Water was added and the organic phase separated, washed with sat NaCl and then dried over MgSO₄ and evaporated under reduced pressure. This yielded the title compound as a clear orange glass (110mg, 97%). MS: ESP⁺ (M+H)⁺ = 446.

- 15 ¹H-NMR (300MHz, DMSO-d₆): 2.09 (s, 3H), 2.50 (broad s, 2H), 2.74 (m, 4H), 3.20 (broad s, 2H), 3.99 (m, 1H), 4.19-4.29 (m, 3H), 4.53 (m, 2H), 5.14 (m, 1H), 6.04 (broad s, 1H), 6.46 (d, 1H), 7.34-7.49 (m, 2H), 7.55 (dd, 1H), 8.75 (d, 1H).

Example 59: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxan-5-yl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

- 25 To a stirred partial solution of Reference Example 11 (600mg, 1.52mmol) in MeOH (15ml), at 0°C was added dropwise 2,2-dimethyl-1,3-dioxan-5-one (218mg, 1.67mmol). The reaction was allowed to warm to ambient temperature and stirred for 40 minutes. Sodium cyanoborohydride (100.4mg, 1.60mmol) was then added portionwise and the reaction stirred for a further 48 hours. The reaction was quenched with 10% NaOAc and extracted with dichloromethane and the combined organic phases were dried over MgSO₄ and evaporated under reduced pressure. The reaction was then purified by MPLC (Merck 9385 silica, 5%
- 30

MeOH in dichloromethane). The solvent was removed to yield an orange oil which was triturated with ether to give the title compound as an orange solid (295mg, 41%). MS: ESP+ (M+H)⁺ = 474.

¹H-NMR (300MHz, DMSO-d₆): δ = 1.29 (s, 3H), 1.35 (s, 3H), 2.39 (broad s, 2H), 2.58 (m, 1H), 2.74 (m, 2H), 3.22 (d, 2H), 3.78 (m, 2H), 3.92 (m, 3H), 4.20 (t, 1H), 4.45 (m, 2H), 5.05 (m, 1H), 5.95 (broad s, 1H), 6.38 (d, 1H), 7.29-7.40 (m, 2H), 7.48 (dd, 1H), 8.69 (d, 1H).

Example 60: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(1-(hydroxymethyl)-2-hydroxyethyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

To a stirred solution of Example 59 (203mg, 0.43mmol) in THF (15ml) was added 1N HCl (10ml). The reaction was allowed to stir at ambient temperature for 18 hours. The reaction was basified with ammonia solution until aqueous layer was pH12. The reaction was extracted with EtOAc and the combined organic phases were washed with sat NaCl and then dried over MgSO₄ and evaporated under reduced pressure. The resulting yellow oil was triturated with ether to give the title compound as a pale yellow solid (167mg, 90%). MS: ESP+ (M+H)⁺ = 434.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.39 (broad s, 2H), 2.59 (m, 1H), 2.84 (m, 2H), 3.38 (d, 2H), 3.51 (m, 4H), 3.91 (dd, 1H), 4.20 (t, 1H), 4.30 (broad s, 2H), 4.48 (m, 2H), 5.08 (m, 1H), 5.96 (broad s, 1H), 6.37 (d, 1H), 7.27-7.38 (m, 2H), 7.48 (dd, 1H), 8.69 (d, 1H).

Reference Example 33: 3,5-difluoro-4-(1-methyl-4-hydroxyhexahydropyrid-4-yl)-aniline

To a stirred solution of 3,5-difluoroaniline (7.0g, 54mmol) in anhydrous THF (250ml) under an atmosphere of nitrogen and cooled to -74°C was added dropwise ⁿBuLi (1.45M in hexanes, 78.6ml, 0.114mol) over a period of 10 minutes. The reaction was allowed to stir at -74°C for 30 minutes. Chlorotrimethylsilane (12.4g, 0.114mol), in anhydrous THF (100ml) was added dropwise over a period of 10 minutes. The solution was allowed to warm to ambient temperature and then stir for 40 minutes. The reaction was then cooled again to -74°C and ⁿBuLi (1.45M in hexanes, 43.0ml, 62.4mmol) was added dropwise over a period of 10 minutes. After stirring for a further 3.5 hours at -74°C, N-methyl-4-piperidone (7.90g, 70.5mmol) in anhydrous THF (50ml) was added dropwise over a period of 10 minutes. The reaction was allowed to stir to ambient temperature over the weekend. The reaction was

- 91 -

acidified with 10% HCl to pH<1 and extracted with diethyl ether. The aqueous phase was separated and treated with 40% NaOH to pH12 then extracted with diethyl ether and the combined organic phases were washed with sat NaCl and then dried over MgSO₄ and evaporated under reduced pressure. The resulting brown oil was triturated with cyclohexane to give the title compound as a pale yellow solid (9.30g, 71%).

¹H-NMR (300MHz, DMSO-d₆): δ = 1.87-2.05 (m, 4H), 2.10 (s, 3H), 2.25-2.42 (m, 4H), 4.70 (s, 1H), 5.54 (s, 2H), 6.07 (dd, 2H). MS: ESP+ (M+H)⁺ = 243; ESP- (M+H)⁻ = 241.

Reference Example 34: 3,5-difluoro-4-(1-methyl-1,2,5,6-tetrahydropyrid-4-yl)-aniline

10 Prepared by the general method of Reference Example 2 using Reference Example 33 (9.0g, 37mmol) and conc. HCl (35ml). Yield = 8.20g, 98%. MS: ESP+ (M+H)⁺ = 225.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.25 (s, 5H), 2.50 (partially obscured by DMSO, 2H), 2.93 (m, 2H), 5.60 (broad s, 1H), 5.66 (s, 2H), 6.15 (dd, 2H).

15 **Reference Example 35: N-Benzoyloxycarbonyl-3,5-difluoro-4-(1-methyl-1,2,5,6-tetrahydropyrid-4-yl)aniline**

To a stirred solution of Reference Example 34 (8.20g, 35.7mmol) in dichloromethane (250ml) and pyridine (4.00ml, 49.4mmol) under an atmosphere of nitrogen at -10°C was added dropwise benzyl chloroformate (7.49g, 43.9mmol) in dichloromethane. The reaction was allowed to warm to ambient temperature and stir for 2 hours. Water and ice was added and the organic phase separated, washed with sat NaCl and then dried over MgSO₄ and evaporated under reduced pressure. The resulting brown oil was purified by MPLC (Merck 9385 silica, 4-8% MeOH in dichloromethane). The solvent was removed to yield a yellow oil which was triturated with cyclohexane to give the title compound as a pale yellow solid (7.60g, 58%).

25 MS:ESP+ (M+H)⁺ = 359.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.29 (m, 5H), 2.54 (Partially obscured by DMSO, 2H), 2.90 (m, 2H), 5.15 (s, 2H), 5.73 (broad s, 1H), 7.15 (dd, 2H), 7.31-7.44 (m, 5H), 10.18 (s, 1H).

Reference Example 35A : 5(R)-Hydroxymethyl-3-(4-(1-methyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)-oxazolidin-2-one

To a stirred solution of Reference Example 35 (7.25g, 20.3mmol) in anhydrous THF (100ml) under an atmosphere of nitrogen and cooled to -74°C was added dropwise ⁿBuLi (1.45M in hexanes, 14.9ml, 21.7mmol) over a period of 10 minutes. The reaction was allowed to stir at -74°C for 30 minutes. R-glycidyl butyrate (3.18g, 22.1mmol) was added in one portion and the reaction was allowed to warm to ambient temperature and stir overnight. MeOH (10ml) was added and the reaction allowed to stir for 10 minutes. Water was added (150ml) and the reaction extracted with EtOAc and the combined organic phases were washed with sat NaCl and then dried over MgSO₄ and evaporated under reduced pressure. The resulting oil was triturated with ether to give the title compound as a pale yellow solid (4.51, 69%).

¹H-NMR (300MHz, DMSO-d₆): δ = 2.25 (s, 3H), 2.31 (broad s, 2H), 2.53 (partially obscured by DMSO, 2H), 2.98 (m, 2H), 3.55 (m, 1H), 3.67 (m, 1H), 3.82 (dd, 1H), 4.06 (t, 1H), 4.71 (m, 1H), 5.21 (m, 1H), 5.78 (broad s, 1H), 7.32 (dd, 2H).

MS: ESP⁺ (M+H)⁺ = 325.

There is no Example 61.

Example 62: 5(R)-Isoxazol-3-ylloxymethyl-3-(4-(1-methyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

Reference Example 35A (1.0g, 3.10mmol), 3-hydroxyisoxazole (0.39, 4.59mmol), triphenylphosphine (1.21g, 4.63mmol) and diisopropylazodicarboxylate (1.17g, 4.64mmol) in anhydrous THF (60ml) were reacted using the general method of Example 1. The resultant product was purified by MPLC (Merck 9385 silica, 5% MeOH in dichloromethane). The solvent was removed to yield a clear orange glass (0.93g, 77%). MS: ESP⁺ (M+H)⁺ = 392.

¹H-NMR (300MHz, DMSO-d₆): δ = 2.25 (s, 3H), 2.30 (broad s, 2H), 2.54 (Partially obscured by DMSO, 2H), 2.97 (m, 2H), 3.90 (dd, 1H), 4.19 (t, 1H), 4.46 (m, 2H), 5.09 (m, 1H), 5.78 (broad s, 1H), 6.37 (d, 1H), 7.31 (dd, 2H), 8.68 (d, 1H).

Example 63: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-acetamidopropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

To a solution of Reference Example 11 (500mg, 1.25mmol) in anhydrous DMF (25ml), stirred at room temperature, was added in sequence : N-methylmorpholine(220μl, 2.0mmol),
5 N-acetyl-L-isoserine, 220mg, 1.5mmol), 1-hydroxybenzotriazole (213mg, 1.5mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (287mg, 1.5mmol) and stirred for 18h. The DMF was removed by hi-vac rotary evaporation and the residue purified by MPLC (Merck 9385 Silica, eluting with 5%MeOH / CH₂Cl₂) to give the title compound as a white solid (430mg, 70%) upon trituration with diethyl ether. MS: ES⁺. (M+H)⁺ = 489.
10 NMR (300MHz DMSO-d₆) δ/ppm: 1.78(s, 3H), 2.21(m, 2H), 3.10(m, 1H), 3.30(m, 1H), 3.70(m, 2H), 3.92(dd, 1H), 4.08(dd, 2H), 4.21(m, 2H), 4.43(m, 2H), 5.08(m, 1H), 5.18(t, 1H), 6.00 (br s, 1H), 6.38(d, 1H), 7.28-7.41(m, 2H), 7.50(dd, 1H), 7.92(m, 1H), 8.65(d, 1H).

Reference Example 36: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-tert-butoxycarbonylamino-3-hydroxy-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

Prepared using the method of Example 63 using the following quantities of reagents:-
Reference Example 11 (1.00g, 2.5mmol); DMF (50ml); : N-methylmorpholine(440μl, 4.0mmol); N-BOC-L-serine(616mg, 3.0mmol); 1-hydroxybenzotriazole(425mg, 3.0mmol); 1-
20 (3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (575mg, 3.0mmol). Yielding the title compound as a white foam (1.32g, 96%)
NMR (300MHz DMSO-d₆) δ/ppm: (300MHz DMSO-d₆) δ/ppm:
1.37(s, 9H), 2.40(m, partly obscured, 2H), 3.46(m, 1H), 3.57(m, 1H), 3.70(m, 2H), 3.93(dd, 1H), 4.06(s, 1H), 4.20(m, 2H), 4.46(m, 3H), 4.81(t, 1H), 5.08(m, 1H), 6.02(br s, 1H), 6.38(d, 1H), 6.86
25 (dd, 1H), 7.35(m, 2H), 7.50(d, 1H), 8.69(d, 1H).
MS: ES⁺. (M+H)⁺ = 547.

Reference Example 37: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-amino-3-hydroxy-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

30 TFA (2.0ml) was added to Reference Example 36 (250mg, 0.46mmol) with some gas evolution and stirred at room temperature for 5 minutes, producing a yellow solution. The

excess TFA was removed by rotary evaporation and the title compound (230mg, 89%) obtained as a pale yellow solid upon trituration with diethyl ether. MS: ES⁺. (M+H)⁺ = 447.

Example 64: 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-acetamido-3-hydroxy-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

To a stirred solution of Reference Example 37 (168mg, 0.3mmol) and sodium bicarbonate (totalling 202mg, 2.4mmol) in acetone/water (10ml, 1:1), cooled at 0°C, under N₂ was added drop-wise, acetyl chloride (totalling 70.6mg, 0.90mmol) in acetone (1.0ml) and stirred for 5 hours. The acetone was removed by rotary evaporation, water and 1N. HCl solution added to pH=5 and extracted with CH₂Cl₂ (3x), the organic phases were separated, and the title compound obtained as a white solid (30mg, 20%) following MPLC (Merck 9385 silica, eluting with 10% MeOH / CH₂Cl₂) and trituration with diethyl ether. MS: (M+H)⁺ = 489.

NMR (400MHz DMSO-d₆) δ/ppm: (300MHz DMSO-d₆) δ/ppm: 1.84(s, 3H), 2.47(d, partially obscured, 2H), 3.46(m, 1H), 3.62(m, 1H), 3.73(m, 2H), 3.96(t, 1H), 4.10-4.30(m, 3H), 4.50(m, 2H), 4.88(m, 2H), 5.11(m, 1H), 6.03(br s, 1H), 6.40(d, 1H), 7.35(dd, 1H), 7.41(m, 1H), 7.52(dd, 1H), 8.07(t, 1H), 8.70(d, 1H).

Example 65: 3-(4-(3-Hydroxy-1-azetidiny)-3-fluorophenyl)-5(R)-(isoxazol-3-yl-oxymethyl)oxazolidin-2-one

3-(4-(3-*t*-Butyldimethylsilyloxy-1-azetidiny)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (230 mg, 0.5 mmol) was dissolved in tetrahydrofuran (10 ml), and cooled under nitrogen to 0°. A solution of tetra-*n*-butylammonium fluoride (1 M, 1 ml, 1 mmol) was added and the mixture allowed to come to ambient temperature. Water (2 ml) was added, and the mixture evaporated to dryness. The residue was purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 2.5% MeOH in dichloromethane. Relevant fractions were combined and evaporated, then redissolved in EtOAc and the desired product (96 mg) precipitated by addition of *iso*hexane.

MS (ESP): 350 (MH⁺) for C₁₆H₁₆FN₃O₅,

NMR (DMSO-d₆) δ: 3.52 (t, 2H); 3.83 (dd, 1H); 4.09 (overlapping m, 3H); 4.45 (m, 2H);

4.51 (quintet, 1H); 5.00 (m, 1H); 5.53 (d, 1H); 6.37 (d, 1H); 6.56 (t, 1H); 7.11 (dd, 1H); 7.37 (dd, 1H); 8.66 (d, 1H).

The intermediate for this compound was prepared as follows :

5 3-(4-(3-*t*-Butyldimethylsilyloxy-1-azetidiny)-3-fluorophenyl)-5(R)-(isoxazol-3-yl-oxymethyl)oxazolidin-2-one

3-(4-(3-*t*-Butyldimethylsilyloxy-1-azetidiny)-3-fluorophenyl)-5(R)-hydroxymethyloxazolidin-2-one (WO 96/13502; 2.47 g, 6.25 mmol), 3-hydroxyisoxazole (580 mg, 6.86 mmol), and tributylphosphine (1.58 g, 7.8 mmol) were dissolved by stirring in dry tetra-
10 hydrofuran (100 ml) under nitrogen. The mixture was cooled in an ice-bath, and 1,1'-(azodicarbonyl)dipiperidine (1.96 g, 7.8 mmol) added dropwise over 10 minutes. The solution was stirred 18 hours, allowing the temperature to rise to ambient. Reduced azo compound was filtered off, and the solution evaporated to dryness and the residue triturated with ether. The residue was purified by chromatography on a silica flash column, eluting with a gradient
15 from 50 to 75% EtOAc in isohexane. Relevant fractions were combined and evaporated to the product as an oil (1.31 g).

NMR (DMSO- d_6) δ : 0.00 (s, 6H); 0.79 (s, 9H); 3.47 (t, 2H); 3.77 (dd, 1H); 4.07 (t, 1H); 4.11 (t, 2H); 4.39 (m, 2H); 4.65 (quintet, 1H); 4.95 (m, 1H); 6.30 (d, 1H); 6.53 (t, 1H); 7.06 (dd, 1H); 7.33 (dd, 1H); 8.61 (d, 1H).

20

Example 66: 3-(4-(3-Oxo-1-azetidiny)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one

3-(4-(3-Hydroxy-1-azetidiny)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (349 mg, 1 mmol) was dissolved in dry DMSO(5 ml) under nitrogen, and treated with
25 pyridine sulfur trioxide complex (502 mg, 3.15 mmol) in dry DMSO(5 ml) over 10 minutes. The solution was stirred 3 hours, poured into water (100 ml), and extracted with EtOAc (3 x 50 ml). The organic extracts were washed with water (3 x 50 ml), saturated brine (50 ml), and dried (magnesium sulfate). The residue was purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 5% MeOH
30 in dichloromethane. Relevant fractions were combined, evaporated, and the residue triturated with diethyl ether to give the desired product (227 mg).

MS (ESP): 348 (MH⁺) for C₁₆H₁₄FN₃O₅; 380 (MH⁺ + MeOH) for C₁₇H₁₈FN₃O₆.

NMR (DMSO-d₆) δ : 3.89 (dd, 1H); 4.16 (t, 1H); 4.47 (m, 2H); 4.76 (s, 4H); 5.04 (m, 1H); 6.38 (d, 1H); 6.77 (d, 1H); 7.21 (dd, 1H); 7.49 (dd, 1H); 8.67 (d, 1H).

5 **Example 67: 3-(4-(4-*t*-Butoxycarbonyl-piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one**

3-(4-(4-*t*-Butoxycarbonyl-piperazin-1-yl)-3-fluorophenyl)-5(R)-hydroxymethyloxazolidin-2-one (WO 93/23384; 10 g, 25.3 mmol), 3-hydroxyisoxazole (2.58 g, 30 mmol), and triphenylphosphine (9.95 g, 37.8 mmol) were dissolved in anhydrous tetrahydrofuran (300 ml), and cooled under nitrogen to 4°. Diisopropylazodicarboxylate (6.04 g, 30 mmol) was added dropwise over 10 minutes, and stirring was continued at the same temperature for 2 hours. The mixture was evaporated to dryness, and the residue purified by flash chromatography on silica, eluting with 50% EtOAc in *isohexane*. Relevant fractions were combined and evaporated to give the desired product (10.2 g).

15 MS (ESP): 463 (MH⁺) for C₂₂H₂₇FN₄O₆

NMR (DMSO-d₆) δ : 1.39 (s, 9H); 2.91 (t, 4H); 3.45 (t, 4H); 3.87 (dd, 1H); 4.14 (t, 1H); 4.44 (m, 2H); 5.03 (m, 1H); 6.35 (d, 1H); 7.06 (t, 1H); 7.18 (dd, 1H); 7.36 (dd, 1H); 8.66 (d, 1H).

20 **Example 68: 3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)-oxazolidin-2-one dihydrochloride**

3-(4-(4-*t*-Butoxycarbonyl-piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)-oxazolidin-2-one (10.24 g, 22 mmol) was suspended in ethanol (150 ml), and a solution of hydrogen chloride in ethanol (5M, 75 ml) added at 0°. A complete solution occurred, and the solution was left to stir 18 hours at ambient temperature, as product precipitated. After dilution with anhydrous diethyl ether (200 ml), the product (8.91 g) was filtered off.

Microanalysis: Found: C, 46.9, H, 4.8, N, 12.2%; C₁₇H₁₉FN₄O₄·2HCl requires C, 46.9, H, 4.6, N, 12.9%. MS (ESP): 363 (MH⁺) for C₁₇H₁₉FN₄O₄

NMR (DMSO-d₆) δ : 3.19 (s, 8H); 3.87 (dd, 1H); 4.16 (t, 1H); 4.45 (m, 2H); 5.03 (m, 1H); 6.36 (d, 1H); 7.11 (t, 1H); 7.22 (dd, 1H); 7.51 (dd, 1H); 8.68 (d, 1H); 9.47 (br, 2H).

Example 69: 3-(4-(4-(2(R),3-Dihydroxypropanovyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

A solution of 2,2-dimethyl-1,3-dioxolane-4(R)-carboxylic acid (162 mg, 1.1 mmol) in dichloromethane (20 ml) under nitrogen was cooled with stirring to 4°, and treated

5 successively with dicyclohexylcarbodiimide (227 mg, 1.1 mmol) and 1-hydroxybenzotriazole (147 mg, 1.1 mmol), then stirred at the same temperature for 1 hour.

N,N-Diisopropylethylamine (129 mg, 1 mmol) was added, followed by 3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one dihydrochloride (399 mg, 0.92 mmol). The mixture was stirred for 2 hours, allowing the temperature to rise to ambient.

10 Solid was filtered off, and the organic solution washed with water (2 x 20 ml), dried over magnesium sulfate and evaporated to dryness. The residue was purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 10% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (82 mg). MS (ESP): 451 (MH⁺) for C₂₀H₂₃FN₄O₇

15 NMR (DMSO-d₆) δ: 2.93 (br m, 4H); 3.49 (m, 2H); 3.66 (br m, 4H); 3.88 (dd, 1H); 4.14 (t, 1H); 4.34 (m, 1H); 4.43 (m, 2H); 4.67 (m, 1H); 4.92 (d, 1H); 5.04 (m, 1H); 6.36 (d, 1H); 7.06 (t, 1H); 7.20 (dd, 1H); 7.51 (dd, 1H); 8.67 (d, 1H).

Example 70: 3-(4-(4-(2(S),3-dihydroxypropanovyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

20 Using the same procedure and scale as Example 69, but starting from 2,2-dimethyl-1,3-dioxolane-4(S)-carboxylic acid, the title compound (75 mg) was obtained.

MS (ESP): 451 (MH⁺) for C₂₀H₂₃FN₄O₇

NMR (DMSO-d₆) δ: 2.93 (br m, 4H); 3.45 (m, 1H); 3.53 (m, 1H); 3.65 (br m, 4H); 3.87 (dd, 1H); 4.16 (t, 1H); 4.34 (dd, 1H); 4.45 (m, 2H); 4.67 (t, 1H); 4.92 (d, 1H); 5.04 (m, 1H); 6.37 (d, 1H); 7.07 (t, 1H); 7.20 (dd, 1H); 7.51 (dd, 1H); 8.67 (d, 1H).

Example 71: 3-(4-(4-(2-(2-Methoxyethoxy)ethoxy)acetyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

30 To a solution of 3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)-oxazolidin-2-one dihydrochloride (399 mg, 0.92 mmol) in pyridine (10 ml) was added

triethylamine (0.31 ml, 2.2 mmol) and 2-(2-(2-methoxyethoxy)ethoxy)acetyl chloride (197 mg, 1 mmol). The mixture was stirred for 18 hours, evaporated to dryness, the residue dissolved in dichloromethane, and purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 10% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (95 mg).

MS (ESP): 523 (MH⁺) for C₂₄H₃₁FN₄O₈

NMR (DMSO-d₆) δ: 2.93 (br m, 4H); 3.21 (s, 3H); 3.41 (t, 2H); 3.47 (t, 2H); 3.54 (overlapping m, 8H); 3.87 (dd, 1H); 4.14 (t, 1H); 4.16 (s, 2H); 4.45 (m, 2H); 5.03 (m, 1H); 6.36 (d, 1H); 7.06 (t, 1H); 7.20 (dd, 1H); 7.51 (dd, 1H); 8.67 (d, 1H).

Example 72: 3-(4-(4-(3-Hydroxy-2-hydroxymethylpropanoyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-(4-(2-Phenyl-1,3-dioxan-5-ylcarbonyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (450 mg, 0.82 mmol) was dissolved in a mixture of acetic acid and water (4:1, 10 ml) and stirred at ambient temperature for 18 hours. After evaporation to dryness, the residue was azeotroped with toluene (15 ml), and the residual gum purified by chromatography on a 20 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 5 to 10% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (237 mg). MS (ESP): 465 (MH⁺) for C₃₁H₂₃FN₄O₇, NMR (DMSO-d₆) δ: 2.94 (br d, 4H); 3.05 (quintet, 1H); 3.47 (m, 4H); 3.65 (br d, 4H); 3.87 (dd, 1H); 4.15 (t, 1H); 4.46 (m, 2H); 4.56 (t, 2H); 5.03 (m, 1H); 6.34 (d, 1H); 7.06 (t, 1H); 7.19 (dd, 1H); 7.50 (dd, 1H); 8.67 (d, 1H).

The intermediate for this compound was prepared as follows :

3-(4-(4-(2-Phenyl-1,3-dioxan-5-ylcarbonyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

To a stirred solution of 2-phenyl-1,3-dioxan-5-ylcarboxylic acid (478 mg, 2.3 mmol) and N-hydroxysuccinimide (291 mg, 2.5 mmol) in anhydrous dichloromethane (25 ml) at 0° was added dicyclohexylcarbodiimide (522 mg, 2.5 mmol). After sitting 1 hour at 0°, N,N-diisopropylethylamine (623 mg, 4.8 mmol) was added, followed by 3-(4-(piperazin-1-

yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one dihydrochloride (1 g, 2.3 mmol) in portions over 5 minutes. The temperature was allowed to rise to ambient, and stirring continued for 3 hours. Solid was filtered off, washed with dichloromethane (2 x 20 ml), and the combined organics evaporated to dryness. The residue was purified by

5 chromatography on a 20 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 10% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the required product (890 mg) as a mixture of *cis* and *trans* isomers.

MS (ESP): 553 (MH⁺) for C₂₈H₂₉FN₄O₇

NMR (DMSO-d₆) δ: 2.93 (br d, 4H); 3.58 (br, 4H); 3.87 (dd, 1H); 3.96-4.30 (overlapping
10 m, 6H); 4.45 (m, 2H); 5.03 (m, 1H); 5.53 (2 x s, 1H); 6.36 (d, 1H); 7.06 (t, 1H); 7.21 (dd, 1H); 7.34 (m, 5H); 7.51 (dd, 1H); 8.66 (d, 1H).

Example 73: 3-(4-(4-Acetoxyacetyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yl-oxymethyl)oxazolidin-2-one

15 3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one dihydrochloride (1.29 g, 3 mmol) was suspended in dichloromethane (25 ml) under nitrogen at ambient temperature. Triethylamine (1.06 g, 10.5 mmol) was added, to give a solution after 15 minutes. The mixture was cooled to 4°, and acetoxyacetyl chloride (410 mg, 3 mmol) was added dropwise. The mixture was stirred for 18 hours at ambient temperature, washed with
20 water (2 x 20 ml), saturated brine (20 ml), and dried (magnesium sulfate). The residue was purified by chromatography on a 20 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 5% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (1.16 g). MS (ESP): 463 (MH⁺) for C₂₁H₂₃FN₄O₇

25 NMR (DMSO-d₆) δ: 2.07 (s, 3H); 2.94 (br, 4H); 3.53 (br d, 4H); 3.87 (dd, 1H); 4.16 (t, 1H); 4.45 (m, 2H); 4.78 (s, 2H); 5.03 (m, 1H); 6.36 (d, 1H); 7.08 (t, 1H); 7.21 (dd, 1H); 7.48 (dd, 1H); 8.66 (d, 1H).

Example 74: 3-(4-(4-Hydroxyacetyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

30 3-(4-(4-(Acetoxyacetyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)-

oxazolidin-2-one (0.93 g, 2 mmol) and potassium carbonate (417 mg, 3 mmol) were stirred at ambient temperature under nitrogen in MeOH (20 ml) for 4 hours. The mixture was evaporated to dryness, dissolved in dichloromethane (80 ml), washed with water (2 x 30 ml), saturated brine (30 ml), and dried (magnesium sulfate). Filtration and evaporation gave the
5 desired product (0.59 g).

MS (ESP): 421 (MH⁺) for C₁₉H₂₁FN₄O₆

NMR (DMSO-d₆) δ: 2.93 (br, 4H); 3.48 (br s, 2H); 3.60 (br s, 2H); 3.86 (dd, 1H); 4.11 (d, 2H); 4.15 (t, 1H); 4.45 (m, 2H); 4.58 (d, 1H); 5.04 (m, 1H); 6.37 (d, 1H); 7.06 (t, 1H); 7.21 (dd, 1H); 7.51 (dd, 1H); 8.66 (d, 1H).

10

Example 75: 3-(4-(4-Acetylpiperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one

The title compound was prepared using essentially the method of Example 73, starting from 3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one
15 dihydrochloride (0.59 g, 1.35 mmol) and acetyl chloride. Purification by chromatography, eluting with a gradient increasing in polarity from 0 to 2.5% MeOH in dichloromethane gave the desired product (142 mg).

MS (ESP): 405 (MH⁺) for C₁₉H₂₁FN₄O₅

NMR (DMSO-d₆) δ: 2.02 (s, 3H); 2.93 (br d, 4H); 3.55 (br, 4H); 3.87 (dd, 1H); 4.16 (t, 1H); 4.45 (m, 2H); 5.04 (m, 1H); 6.36 (d, 1H); 7.06 (t, 1H); 7.20 (dd, 1H); 7.51 (dd, 1H);
20 8.66 (d, 1H).

Example 76: 3-(4-(4-((3R)-3-Hydroxy-4-trimethylammoniobutanoyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one chloride

25 3-(4-(4-((3R)-3-Acetoxy-4-trimethylammoniobutanoyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one chloride (200 mg, 0.33 mmol) and potassium carbonate (67 mg, 0.49 mmol) were stirred at ambient temperature under nitrogen in MeOH (20 ml) for 5 hours. The mixture was evaporated to dryness, the solid triturated with water, filtered and washed with water (20 ml) to give the desired product (137 mg). MS (ESP): 506

30 (M⁺) for C₂₄H₃₃FN₅O₆

NMR (DMSO-d₆) δ: 2.51 (dd, 1H); 2.65 (dd, 1H); 2.93 (br d, 4H); 3.14 (s, 9H); 3.61 (br

s, 4H); 3.87 (dd, 1H); 4.17 (t, 1H); 4.47 (m, 3H); 5.05 (m, 1H); 5.74 (br, 1H); 6.38 (d, 1H); 7.07 (t, 1H); 7.23 (dd, 1H); 7.52 (dd, 1H); 8.69 (d, 1H).

The intermediate for this compound was prepared as follows :

5

3-(4-(4-((3R)-3-Acetoxy-4-trimethylammoniobutanoyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one chloride

(3R)-3-Acetoxy-4-trimethylammoniobutanoic acid (527 mg, 2.2 mmol, see J. Org. Chem., 1967, 32, 3989) was stirred in thionyl chloride (3 ml) at ambient temperature for 3 hours, giving a solution. Excess thionyl chloride was evaporated, and the residue azeotroped with toluene, before dissolving in anhydrous dichloromethane (10 ml). This solution was added dropwise to a solution of 3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one dihydrochloride (0.87 g, 2 mmol) and triethylamine (404 mg, 4 mmol) in anhydrous dichloromethane (10 ml) at 4°. The mixture was stirred for 18 hours at ambient temperature, then evaporated to dryness. The residue was dissolved in brine (20 ml) and purified by chromatography on an HP20SS resin column, eluting with a gradient increasing in polarity from 0 to 10% in acetonitrile in water. Relevant fractions were combined, evaporated to dryness, dissolved in de-ionised water (50 ml), and freeze-dried to give the required product (0.39 g). MS (ESP): 548 (M⁺) for C₂₆H₃₅FN₅O₇,
15
20 NMR (DMSO-d₆) δ: 2.05 (s, 3H); 2.82 (d, 2H); 2.94 (br m, 4H); 3.12 (s, 9H); 3.55 (br m, 4H); 3.58-3.78 (overlapping m, 2H); 3.87 (dd, 1H); 4.17 (t, 1H); 4.46 (m, 2H); 5.04 (m, 1H); 5.49 (m, 1H); 6.38 (d, 1H); 7.06 (t, 1H); 7.21 (dd, 1H); 7.51 (dd, 1H); 8.68 (d, 1H).

Example 77: 3-(4-(4-Methoxycarbonyl-piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one dihydrochloride (866 mg, 2 mmol) was suspended in dichloromethane (40 ml) under nitrogen at ambient temperature. Triethylamine (707 mg, 7 mmol) was added, followed by methyl chloroformate (190 mg, 2 mmol). The mixture was stirred for 2 hours at ambient temperature, washed with water (2 x 50 ml), saturated brine (50 ml), and dried (magnesium sulfate). After
30

filtration and evaporation, the residue was triturated with diethyl ether to give the desired product (689 mg).

MS (ESP): 421 (MH⁺) for C₁₉H₂₁FN₄O₆

NMR (DMSO-d₆) δ : 2.93 (t, 4H); 3.52 (t d, 4H); 3.62 (s, 3H); 3.89 (dd, 1H); 4.16 (t, 1H);
5 4.46 (m, 2H); 5.04 (m, 1H); 6.37 (d, 1H); 7.08 (t, 1H); 7.20 (dd, 1H); 7.52 (dd, 1H); 8.67 (d, 1H).

Example 78: 3-(4-(4-(3-(4-Imidazolyl)acryloyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

- 10 3-(4-Imidazolyl)acrylic acid (690 mg, 5 mmol) was suspended in anhydrous dichloromethane (5 ml) under nitrogen, and thionyl chloride (10 ml) and one drop of *DMF* added. The mixture was stirred at ambient temperature for 18 hours, excess thionyl chloride was evaporated, and the residue azeotroped with dichloromethane (2 x 50 ml). The acid chloride was suspended in dichloromethane (30 ml), cooled to 4°, and a solution of 3-(4-(piperazin-1-yl)-3-
15 fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one dihydrochloride (866 mg, 2 mmol) and triethylamine (2.02 g, 20 mmol) in anhydrous dichloromethane (25 ml) added dropwise. The mixture was stirred for 18 hours at ambient temperature, and insoluble material filtered. The organic layer was treated with water (50 ml), further insoluble material removed, then washed with brine and dried over magnesium sulfate. After evaporation to dryness, the
20 residue was dissolved in ethanol (5 ml) and treated with an excess of ethanol saturated with hydrogen chloride, to precipitate the desired product as a hydrochloride salt (122 mg).

Microanalysis: Found: C, 48.2, H, 5.0, N, 14.4%; C₂₃H₂₃FN₆O₅·2HCl·H₂O requires C, 48.1, H, 4.7, N, 14.4%. MS (ESP): 483 (MH⁺) for C₂₃H₂₃FN₆O₅

NMR (DMSO-d₆) δ : 3.01 (br, 4H); 3.86 (complex, overlapped by H₂O, ~5H); 4.16 (t, 1H);
25 4.45 (m, 2H); 5.04 (m, 1H); 6.36 (d, 1H); 7.08 (t, 1H); 7.21 (dd, 1H); .42 (d, 1H); 7.51 (dd, 1H); 7.71 (d, 1H); 7.97 (s, 1H); 8.66 (d, 1H); 9.20 (s, 1H).

Example 79: 3-(4-(4-(4-Imidazolylacetyl)-piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

- 30 Using the procedure of Example 78, but starting with 4-imidazolylacetic acid hydrochloride salt (810 mg, 5 mmol), the acid chloride was prepared and reacted with the piperazine. After

18 hours reaction, the mixture was diluted with saturated sodium carbonate solution (20 ml). The organic layer was washed with water (2 x 50 ml), then brine (30 ml) and dried over magnesium sulfate. The residue was purified by chromatography on a 40 g silica Mega Bond Elut® column, eluting with 10% MeOH in dichloromethane. Relevant fractions were
5 combined and evaporated, the residue dissolved in ethanol (5 ml) and treated with an excess of ethanol saturated with hydrogen chloride, then excess of diethyl ether to precipitate the desired product as a hydrochloride salt (124 mg).

Microanalysis: Found: C, 47.3, H, 5.1, N, 14.8%; $C_{22}H_{23}FN_6O_5 \cdot 2HCl \cdot H_2O$ requires C, 47.0, H, 4.8, N, 15.0%. MS (ESP): 471 (MH^+) for $C_{22}H_{23}FN_6O_5$,

10 NMR (DMSO- d_6) δ : 2.95 (br m, 2H); 3.03 (br m, 2H); 3.63 (br m, 2H); 3.68 (br m, 2H); 3.95 (s + m, overlapped by H_2O , ~3H); 4.17 (t, 1H); 4.45 (m, 2H); 5.04 (m, 1H); 6.36 (d, 1H); 7.08 (t, 1H); 7.22 (dd, 1H); 7.44 (s, 1H); 7.52 (dd, 1H); 8.67 (d, 1H); 9.01 (s, 1H); 14.38 (br 2H).

15 **Example 80: 3-(4-(4-(3-(4-Imidazolyl)propanoyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one**

3-(4-(4-(3-(1-Triphenylmethyl-4-imidazolyl)propanoyl)-piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (460 mg, 0.63 mmol), was dissolved in a mixture of ethanol (20 ml) and MeOH (10 ml), cooled to 0° and treated with a solution of hydrogen
20 chloride in ethanol (3.8 M, 5 ml). After stirring 48 hours at ambient temperature, the pH was adjusted to 8 with triethylamine, and the mixture evaporated to dryness. The residue was purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient from 0 to 20% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (60 mg). MS (ESP): 485 (MH^+) for $C_{23}H_{25}FN_6O_5$,
25 NMR (DMSO- d_6) δ : 2.59 (t, 2H); 2.74 (t, 2H); 2.92 (br, 4H); 3.60 (br, 4H); 3.90 (dd, 1H); 4.16 (t, 1H); 4.46 (m, 2H); 5.06 (m, 1H); 6.38 (d, 1H); 6.76 (s, 1H); 7.06 (t, 1H); 7.22 (dd, 1H); 7.59 (s, 1H); 7.63 (dd, 1H); 8.67 (d, 1H); 11.72 (br 1H).

The intermediates for this compound were prepared as follows :

3-(4-(4-(3-(1-Triphenylmethyl-4-imidazolyl)propanoyl)-piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-ylloxymethyl)oxazolidin-2-one

3-(1-Triphenylmethyl-4-imidazolyl)propionic acid (420 mg, 1.1 mmol) was suspended in dichloromethane (10 ml) under nitrogen, and treated successively with dicyclohexyl-
 5 carbodiimide (227 mg, 1.1 mmol) and 1-hydroxybenzotriazole (149 mg, 1.1 mmol), then stirred at ambient temperature for 30 minutes. To it was added a solution of 3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-ylloxymethyl)oxazolidin-2-one dihydrochloride (435 mg, 1 mmol) and *N,N*-diisopropylethylamine (258 mg, 2 mmol) in dichloromethane (5 ml). The mixture was stirred for 18 hours at the same temperature, solid filtered off, and the organic
 10 phase purified by chromatography on a 20 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 15% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (460 mg).

MS (ESP): 727 (MH⁺) for C₄₂H₃₉FN₆O₅

NMR (DMSO-d₆) δ: 2.61 (t, 2H); 2.70 (t, 2H); 2.87 (br, 4H); 3.54 (br, 4H); 3.88 (dd, 1H);
 15 4.17 (t, 1H); 4.45 (m, 2H); 5.06 (m, 1H); 6.37 (d, 1H); 6.66 (d, 1H); 7.03 (t, 1H); 7.06 (d, 6H); 7.21 (dd, 1H); 7.25 (s, 1H); 7.36 (m, 9H); 7.52 (dd, 1H); 8.67 (d, 1H).

3-(1-Triphenylmethyl-4-imidazolyl)propionic acid

3-(4-Imidazolyl)propionic acid (1.0 g, 7.1 mmol) was suspended in a mixture of dichloro-
 20 methane (5 ml) and acetonitrile (25 ml). Trimethylsilyl chloride (781 mg, 7.2 mmol) was added and the mixture refluxed for 4 hours. Triethylamine (1 ml) was added, and refluxing continued for 15 minutes. Cooled, triethylamine (1 ml) added followed by chlorotriphenylmethane (1.99 g, 7.1 mmol) in dichloromethane (10 ml), and the mixture stirred at ambient temperature for 2 hours. MeOH (20 ml) was added, the mixture stirred for
 25 30 minutes, then evaporated to dryness. Water (50 ml) was added to the residue, and the pH adjusted to 8-8.5 with triethylamine. The precipitate was filtered off, washed with diethyl ether, and dried to give the desired product (2.25g). MS (ESP): 383 (MH⁺) for C₂₅H₂₂N₂O₂
NMR (DMSO-d₆) δ: 2.48 (t, 2H); 2.77 (t, 2H); 6.65 (s, 1H); 7.08 (d, 6H); 7.29 (s, 1H); 7.36 (m, 9H); 12.10 (br, 1H).

Example 81: 3-(4-(4-Methanesulfonyl-piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one dihydrochloride (433 mg, 1 mmol) in pyridine (15 ml) and dichloromethane (15 ml) was
5 treated with triethylamine (353 mg, 3.5 mmol) and stirred for 30 minutes at ambient temperature. Methanesulfonyl chloride (138 mg, 1.2 mmol) was added and the mixture stirred for 18 hours. The mixture was diluted with dichloromethane (50 ml), washed with water (2 x 25 ml), saturated brine (25 ml), and dried (magnesium sulfate). After evaporation to dryness and azeotrope with toluene (10 ml), the residue was triturated with diethyl ether
10 to give the desired product (365 mg).

MS (ESP): 441 (MH⁺) for C₁₈H₂₁FN₄O₆S

NMR (DMSO-d₆) δ: 2.91 (s, 3H); 3.05 (br m, 4H); 3.26 (br m, 4H); 3.87 (dd, 1H); 4.15 (t, 1H); 4.42 (dd, 1H); 4.48 (dd, 1H); 5.05 (m, 1H); 6.36 (d, 1H); 7.10 (t, 1H); 7.21 (dd, 1H); 7.48 (dd, 1H); 8.66 (d, 1H).

15

Example 82: 3-(4-(4-Chloroacetyl-piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

Chloroacetyl chloride (114 mg, 1 mmol) was added to a stirred solution of 3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one dihydrochloride (435 mg,
20 1 mmol) and triethylamine (302 mg, 3 mmol) in dichloromethane (10 ml) at ambient temperature. After 10 minutes the reaction was purified by direct chromatography on a 10 g silica Mega Bond Elut® column, eluting with dichloromethane. Relevant fractions were combined and evaporated to give the desired product (390 mg). MS (ESP): 439 (MH⁺) for C₁₉H₂₀ClFN₄O₅
25 NMR (DMSO-d₆) δ: 2.93 (br m, 2H); 2.99 (br m, 2H); 3.59 (br m, 4H); 3.87 (dd, 1H); 4.16 (t, 1H); 4.40 (s, 2H); 4.46 (m, 2H); 5.04 (m, 1H); 6.36 (d, 1H); 7.07 (t, 1H); 7.21 (dd, 1H); 7.51 (dd, 1H); 8.66 (d, 1H).

30

Example 83: 3-(4-(4-Morpholinoacetyl-piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

The preparation of Example 82 was repeated up to the stage of forming the chloro-acetylamide. The mixture was then cooled to 0° and treated with morpholine (0.262 mg, 3 mmol), then stirred 48 hours allowing the temperature to rise to ambient. The reaction was evaporated to dryness, and purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient from 0 to 10% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product after trituration with diethyl ether (420 mg).

10 **MS (ESP):** 490 (MH⁺) for C₂₃H₂₈FN₅O₆

NMR (CDCl₃) δ: 2.52 (br m, 4H); 3.03 (m, 4H); 3.23 (s, 2H); 3.71 (m, 4H); 3.77 (m, 4H); 3.93 (dd, 1H); 4.14 (t, 1H); 4.50 (dd, 1H); 4.57 (dd, 1H); 5.01 (m, 1H); 6.00 (d, 1H); 6.92 (t, 1H); 7.26 (dd, 1H); 7.47 (dd, 1H); 8.16 (d, 1H).

15 **Example 84: 3-(4-(4-((2S,4R)-1-Acetyl-4-hydroxy-2-pyrrolidinylcarbonyl)-piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one**

A suspension of (2S,4R)-1-acetyl-4-hydroxy-2-pyrrolidinecarboxylic acid (173 mg, 1 mmol) in dichloromethane (10 ml) and DMF (2 ml) under nitrogen was treated successively with dicyclohexylcarbodiimide (227 mg, 1.1 mmol) and 1-hydroxybenzotriazole (149 mg, 1.1 mmol), then stirred at ambient temperature for 1 hour. A solution of 3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one dihydrochloride (435 mg, 1 mmol) and N,N-diisopropylethylamine (258 mg, 2 mmol) in dichloromethane (5 ml) was added, and the mixture stirred for 18 hours. Solid was filtered off, the organic solution evaporated to dryness, and the residue purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 15% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product after trituration with diethyl ether (210 mg).

MS (ESP): 518 (MH⁺) for C₂₄H₂₈FN₅O₇

NMR (CDCl₃) δ: 2.08 (s, 3H); 2.16 (m, 3H); 2.45 (m, 1H); 3.05 (m, 3H); 3.19 (m, 1H); 3.62 (overlapping m, 2H); 3.91 (dd overlapping m, 4H); 4.13 (t, 1H); 4.49 (dd, 1H); 4.56 (dd, 1H); 4.66 (m, 1H); 5.01 (overlapping m, 2H); 5.99 (d, 1H); 6.92 (t, 1H); 7.27 (dd,

1H); 7.48 (dd, 1H); 8.15 (d, 1H).

Example 85: 3-(4-(4-((2*S*,4*R*)-1-Methyl-4-hydroxy-2-pyrrolidinylcarbonyl)-piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

- 5 A solution of 3-(4-(piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one dihydrochloride (435 mg, 1 mmol) and *N,N*-diisopropylethylamine (258 mg, 2 mmol) in *DMF* (2 ml) was added to a stirred solution of (2*S*,4*R*)-1-methyl-4-hydroxy-2-pyrrolidinecarboxylic acid (145 mg, 1 mmol; see *Angewandte Chemie*, 1995, 9, 1095) and *O*-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (380 mg, 1 mmol)
- 10 in *DMF* (5 ml) under nitrogen at ambient temperature. *N,N*-Diisopropylethylamine (387 mg, 3 mmol) was added, and the mixture stirred at ambient temperature for 18 hours. After evaporation to dryness, the residue was partitioned between water (5 ml) and dichloromethane (10 ml). The separated organic layer was evaporated, and the residue purified by
- 15 chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 10% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (256 mg). MS (ESP): 490 (MH⁺) for C₂₃H₂₈FN₅O₆
- NMR (CDCl₃) δ: 1.96 (m, 1H); 2.07 (m, 1H); 2.36 (m, 1H); 2.38 (s, 3H); 3.02 (m, 4H); 3.33 (dd, 1H); 3.71 (overlapping m, 5H); 3.89 (dd, 1H); 4.18 (t, 1H); 4.30 (m, 1H); 4.46 (m, 1H); 4.53 (dd, 1H); 4.59 (m, 1H); 5.03 (m, 1H); 6.28 (d, 1H); 7.08 (t, 1H); 7.20 (dd,
- 20 1H); 7.46 (dd, 1H); 8.57 (d, 1H).

Example 86: 3-(4-((3*R*)-3-Amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one

- 3-(4-((3*R*)-3-*t*-Butoxycarbonylamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one (108 mg, 0.23 mmol) was dissolved in dichloromethane (7 ml) under
- 25 nitrogen and treated with TFA (3 ml) at ambient temperature. The mixture was stirred 48 hours, evaporated to dryness, and azeotroped with toluene (2 x 10 ml). The resulting gum was taken up in ethanol (5 ml), and a solution of hydrogen chloride in ethanol (3.8M, 2 ml).
- Excess diethyl ether was added to precipitate the title compound as its hydrochloride (80 mg).
- 30 MS (ESP): 363 (MH⁺) for C₁₇H₁₉FN₄O₄
- NMR (DMSO-d₆) δ: 1.99 (m, 1H); 2.23 (m, 1H); 3.25 (m, 1H); 3.41 (m, 1H); 3.52 (m,

2H); 3.84 (dd, 1H); 4.14 (t, 1H); 4.42 (m overlapping H₂O, ~3H); 5.02 (m, 1H); 6.37 (d, 1H); 6.79 (t, 1H); 7.15 (dd, 1H); 7.44 (dd, 1H); 8.34 (br, 2H); 8.68 (d, 1H).

The intermediates for this compound were prepared as follows :

5

3-Fluoro-4-((3*R*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)nitrobenzene

3,4-Difluoronitrobenzene (16.03 g, 0.101 M) was dissolved in acetonitrile (300 ml), and treated with *N,N*-diisopropylethylamine (32.63 g, 0.253 M) and (3*R*)-3-*t*-butoxycarbonylaminopyrrolidine (20.65 g, 0.111 M). The mixture was stirred and heated to reflux for 18
10 hours. Solvent was evaporated, and the residue treated with EtOAc (300 ml) and water (200 ml). The organic layer was washed with water (150 ml), citric acid solution (10% in water, 2 x 150 ml), and dried (magnesium sulfate). Evaporation gave the desired product as a yellow solid (32.7 g), of sufficient quality for use without purification. MS (ESP): 326 (MH⁺) for C₁₅H₂₀FN₃O₄

15 NMR (CDCl₃) δ : 1.43 (s, 9H); 1.85 (m, 1H); 2.25 (m, 1H); 3.44 (dt, 1H); 3.65 (overlapping m, 2H); 3.84 (dm, 1H); 4.34 (br m, 1H); 4.69 (br, 1H); 6.53 (t, 1H); 7.87 (dd, 1H); 7.92 (dd, 1H).

5-Amino-2-((3*R*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)fluorobenzene

20 3-Fluoro-4-((3*R*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)nitrobenzene (32.7 g, 0.101 M) was dissolved in EtOAc (500 ml) treated with palladium catalyst (10% on carbon, 7.5 g) and hydrogenated at atmospheric pressure until the theoretical uptake of gas. After filtration through celite and evaporation, the required product was obtained as a red gum of sufficient quality for use without purification (29.85 g).

25 MS (ESP): 296 (MH⁺) for C₁₅H₂₂FN₃O₂

NMR (CDCl₃) δ : 1.44 (s, 9H); 1.82 (m, 1H); 2.27 (m, 1H); 3.11 (m, 2H); 3.37 (m, 2H); 3.43 (br, 2H); 4.27 (br m, 1H); 4.82 (br, 1H); 6.38 (dd, 1H); 6.44 (dd, 1H); 6.57 (t, 1H).

5-Ethoxycarbonylamino-2-((3*R*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)fluorobenzene

30 5-Amino-2-((3*R*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)fluorobenzene (27.33 g, 0.093 M) was dissolved in dry pyridine (150 ml) and cooled under nitrogen with stirring to 0°. Ethyl

chloroformate (11.01, 0.102 M) was added dropwise, and the mixture stirred 30 minutes at the same temperature. Ice-water (250 ml) was added, and stirring continued for 1 hour. The resulting precipitate was collected, washed thoroughly with water, and dried, to give the desired product of sufficient quality for use without purification (33.6 g). MS (ESP): 368

5 (MH⁺) for C₁₈H₂₆FN₃O₄

NMR (DMSO-d₆) δ : 1.21 (t, 3H); 1.36 (s, 9H); 1.90 (m, 1H); 2.05 (m, 1H); 3.04 (m, 1H); 3.20 (m, 1H); 3.32 (m, 1H); 3.40 (m, 1H); 4.02 (br, 1H); 4.05 (q, 2H); 6.62 (t, 1H); 7.02 (d, 1H); 7.08 (d, 1H); 7.22 (d, 1H); 9.38 (br, 1H).

10 3-(3-Fluoro-4-((3R)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)phenyl)-5(R)-hydroxymethyl-oxazolidin-2-one

5-Ethoxycarbonylamino-2-((3R)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)fluorobenzene (33.6 g, 0.092 M) was dissolved in dry tetrahydrofuran (300 ml) under nitrogen, cooled to -70°, and treated dropwise over 30 minutes with a solution of lithium *t*-butoxide (1 M in

15 tetrahydrofuran, 100.7 ml), keeping the temperature below -65°. After stirring for 5 minutes, (*R*)-glycidylbutyrate (14.52 g, 0.101 M) was added, and stirring continued at -65° for 1 hour, before allowing the temperature to rise to ambient over 16 hours. The mixture was treated with MeOH (50 ml), stirred at ambient temperature for 1 hour, and the precipitate collected and washed well with tetrahydrofuran to give the desired product (21.8 g).

20 MS (ESP): 396 (MH⁺) for C₁₉H₂₆FN₃O₅

NMR (DMSO-d₆) δ : 1.36 (s, 9H); 1.80 (m, 1H); 2.07 (m, 1H); 3.09 (m, 1H); 3.26 (t, 1H); 3.35 (m, 1H); 3.49 (m, 2H); 3.62 (m, 1H); 3.73 (dd, 1H); 3.98 (t, 1H); 4.04 (m, 1H); 4.63 (m, 1H); 5.15 (t, 1H); 6.70 (t, 1H); 7.09 (dd overlapping br, 2H); 7.39 (dd, 1H).

25 3-(4-((3R)-3-*t*-Butoxycarbonylamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one

3-(3-Fluoro-4-((3R)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)phenyl)-5(R)-hydroxymethyl-oxazolidin-2-one (5 g, 12.7 mmol), 3-hydroxyisoxazole (2.15 g, 25.3 mmol), and 1,1'-(azo-dicarbonyl)dipiperidine (6.39 g, 25.3 mmol) were suspended by stirring in dry tetrahydrofuran

30 (100 ml) under nitrogen and cooled to 5° in an ice-bath. Tributylphosphine (5.12 g, 25.3 mmol) was added dropwise over 20 minutes, and the solution stirred 18 hours, allowing the

temperature to rise to ambient. Reduced azo compound was filtered off, and the solution evaporated to dryness and the residue triturated with ether. The residue was purified by chromatography on a 90 g Biotage silica column, eluting with a gradient from 50 to 75% EtOAc in *isohexane*. Relevant fractions were combined and evaporated to give the product
5 (3.92 g).

MS (ESP): 463 (MH⁺) for C₂₂H₂₇FN₄O₆

NMR (DMSO-d₆) δ : 1.38 (s, 9H); 1.81 (m, 1H); 2.08 (m, 1H); 3.10 (m, 1H); 3.25 (t, 1H);
3.36 (m, 1H); 3.48 (m, 1H); 3.84 (dd, 1H); 4.05 (m, 1H); 4.12 (t, 1H); 4.44 (m, 2H); 5.02
(m, 1H); 6.36 (d, 1H); 6.71 (t, 1H); 7.11 (dd overlapping br, 2H); 7.38 (dd, 1H); 8.66 (d,
10 1H).

Example 87: 3-(4-(1,4-Dioxa-8-azaspiro[4,5]decan-8-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy)methyl)oxazolidin-2-one

3-(4-(1,4-Dioxa-8-azaspiro[4,5]decan-8-yl)-3-fluorophenyl)-5(R)-hydroxymethyl-oxazolidin-
15 2-one (3.52 g, 10 mmol), 3-hydroxyisoxazole (893 mg, 10.05 mmol), and triphenylphosphine
(3.03 g, 12 mmol) were dissolved by stirring in dry tetrahydrofuran (75 ml) under nitrogen.
The mixture was cooled in an ice-bath, and diisopropylazodicarboxylate (2.33 g, 12 mmol)
added dropwise over 10 minutes. The solution was stirred 18 hours, allowing the temperature
to rise to ambient. The mixture was diluted with EtOAc (750 ml), the organic layer washed
20 with water (3 x 500 ml), dried (magnesium sulfate) and evaporated. The residue was purified
by MPLC on silica, eluting with a gradient between 0.25% and 1% MeOH in
dichloromethane. Relevant fractions were combined and evaporated to give product (3.58 g).

MS (ESP): 420 (MH⁺) for C₂₀H₂₂FN₃O₆

NMR (DMSO-d₆) δ : 1.73 (t, 4H); 3.03 (t, 4H); 3.86 (dd, 1H); 3.90 (s, 4H); 4.14 (t, 1H);
25 4.42 (dd, 1H); 4.47 (dd, 1H); 5.03 (m, 1H); 6.35 (d, 1H); 7.08 (t, 1H); 7.17 (dd, 1H); 7.47
(dd, 1H); 8.65 (d, 1H).

The intermediates for this compound were prepared as follows :

30 **4-(1,4-Dioxa-8-azaspiro[4,5]decan-8-yl)-3-fluoronitrobenzene**

3,4-Difluoronitrobenzene (15.53 g, 0.098 M) was dissolved in acetonitrile (150 ml), and

- 111 -

treated with *N,N*-diisopropylethylamine (31.5 g, 0.244 M) and 1,4-dioxo-8-aza-spiro[4,5]decane (15.36 g, 0.107 M). The mixture was stirred and heated to reflux for 18 hours. After cooling, product precipitated as a yellow solid, and was filtered off (16.1 g); further product could be obtained by concentrating the residues (8.43 g).

5 MS (ESP): 283 (MH^+) for $C_{13}H_{15}FN_2O_4$

NMR ($CDCl_3$) δ : 1.86 (t, 4H); 3.41 (t, 4H); 4.00 (s, 4H); 6.91 (t, 1H); 7.89 (dd, 1H); 7.96 (dd, 1H).

5-Amino-2-(1,4-dioxo-8-azaspiro[4,5]decan-8-yl)fluorobenzene

10 Starting from 4-(1,4-dioxo-8-azaspiro[4,5]decan-8-yl)-3-fluoronitrobenzene (24.48 g, 0.087 M), the title compound was prepared by essentially the same technique as the corresponding intermediate of Example 86 (19.3 g).

MS (ESP): 253 (MH^+) for $C_{13}H_{17}FN_2O_2$

NMR ($DMSO-d_6$) δ : 1.69 (t, 4H); 2.84 (t, 4H); 3.86 (s, 4H); 4.91 (s, 2H); 6.28 (m, 2H);

15 6.75 (t, 1H).

5-Ethoxycarbonylamino-2-(1,4-dioxo-8-azaspiro[4,5]decan-8-yl)fluorobenzene

Starting from 5-amino-2-(1,4-dioxo-8-azaspiro[4,5]decan-8-yl)fluorobenzene (19.26 g, 0.076 M), the title compound was prepared by essentially the same technique as the corresponding
20 intermediate of Example 86 (20.5 g).

MS (ESP): 325 (MH^+) for $C_{16}H_{21}FN_2O_4$

NMR ($DMSO-d_6$) δ : 1.21 (t, 3H); 1.71 (t, 4H); 2.96 (t, 4H); 3.88 (s, 4H); 4.09 (q, 2H);

6.95 (t, 1H); 7.09 (dd, 1H); 7.27 (dd, 1H); 9.54 (s, 1H).

25 3-(4-(1,4-Dioxo-8-azaspiro[4,5]decan-8-yl)-3-fluorophenyl)-5(R)-hydroxymethyloxazolidin-2-one

Starting from 5-ethoxycarbonylamino-2-(1,4-dioxo-8-azaspiro[4,5]decan-8-yl)fluorobenzene (22.9 g, 0.071 M), the title compound was prepared by essentially the same technique as the corresponding intermediate of Example 86 (17.8 g).

MS (ESP): 353 (MH⁺) for C₁₇H₂₁FN₂O₅

NMR (DMSO-d₆) δ: 1.83 (t, 4H); 3.09 (t, 4H); 3.69 (dd, 1H); 3.82 (dd, 1H); 3.88 (dd, 1H); 3.96 (s, 4H); 4.07 (t, 1H); 4.72 (m, 1H); 4.92 (s, 1H); 7.05 (t, 1H); 7.15 (dd, 1H); 7.46 (dd, 1H).

5

Example 88: 3-(4-(4-Oxopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one

3-(4-(1,4-Dioxo-8-azaspiro[4,5]decan-8-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one (3.58 g, 8.52 mmol) was dissolved in a mixture of glacial acetic acid
10 (50 ml) and water (50 ml), and heated at 50° for 12 hours. Solvent was evaporated, the residue azeotroped with toluene (50 ml), then partitioned between EtOAc (150 ml) and water (100 ml). The organic layer was washed with saturated aqueous sodium bicarbonate solution (2 x 100 ml), water (100 ml), dried (magnesium sulfate) and evaporated. The residue was
15 purified by chromatography on a 90 g silica Biotage column. eluting with a gradient from 5:1 EtOAc to isohexane to EtOAc. Relevant fractions were combined to give the desired product (2.84 g).

MS (ESP): 376 (MH⁺) for C₁₈H₁₈FN₃O₅

NMR (CDCl₃) δ: 2.61 (t, 4H); 3.37 (t, 4H); 3.93 (dd, 1H); 4.14 (t, 1H); 4.50 (dd, 1H);
4.57 (dd, 1H); 5.02 (m, 1H); 6.00 (d, 1H); 6.98 (t, 1H); 7.14 (dd, 1H); 7.49 (dd, 1H); 8.15
20 (d, 1H).

Example 89: 3-(4-(4-Hydroxypiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one

3-(4-(4-Oxopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one
25 (173 mg, 0.46 mmol) was dissolved in ethanol (5 ml), treated with sodium borohydride (18 mg, 0.48 mmol) and refluxed 1 hour. Solvent was evaporated, the residue treated with water (5 ml), neutralised with 1 N hydrochloric acid, extracted with dichloromethane (3 x 10 ml), and dried (magnesium sulfate). Evaporation gave the desired product (76 mg). MS (ESP):
378 (MH⁺) for C₁₈H₂₀FN₃O₅
30 NMR (CDCl₃) δ: 1.60 (br, ~1H); 1.76 (m, 2H); 2.05 (m, 2H); 2.85 (m, 2H); 3.32 (m, 2H);
3.85 (m, 1H); 3.91 (dd, 1H); 4.12 (t, 1H); 4.48 (dd, 1H); 4.55 (dd, 1H); 4.98 (m, 1H); 6.00

(d, 1H); 6.98 (br, 1H); 7.11 (dd, 1H); 7.42 (dd, 1H); 8.12 (d, 1H).

Example 90: 3-(4-(4-Aminopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one

5 3-(4-(4-Oxopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (375 mg, 1 mmol) was dissolved in MeOH (10 ml), treated with ammonium acetate (771 mg, 10 mmol) and sodium cyanoborohydride (440 mg, 7 mmol) and refluxed 4 hours. The mixture was neutralised with 1 N hydrochloric acid, water (15 ml) added, and extracted with dichloromethane (3 x 15 ml), and dried (magnesium sulfate). Evaporation gave the desired
10 product (334 mg).

MS (ESP): 377 (MH⁺) for C₁₈H₂₁FN₄O₄

NMR (CDCl₃) δ: 1.53 (br, 4H); 1.94 (m, 2H); 2.77 (overlapping m, 3H); 3.38 (m, 2H); 3.92 (dd, 1H); 4.13 (t, 1H); 4.47 (dd, 1H); 4.55 (dd, 1H); 4.99 (m, 1H); 6.00 (d, 1H); 6.94 (t, 1H); 7.12 (dd, 1H); 7.40 (dd, 1H); 8.15 (d, 1H).

15

Example 91: 3-(4-(4-Hydroxymino-piperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-(4-Oxopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (125 mg, 0.33 mmol) was dissolved in MeOH (5 ml) and dichloromethane (5 ml), and stirred
20 at ambient temperature under nitrogen. The mixture was treated with hydroxylamine hydrochloride (27 mg, 0.39 mmol) and sodium acetate (65 mg, 0.79 mmol) and stirring continued for 4 hours. The mixture was filtered, evaporated, and the residue partitioned between water (10 ml), and dichloromethane (10 ml). The organic layer was washed with saturated sodium bicarbonate (10 ml), water (10 ml), dried (magnesium sulfate) and
25 evaporated to dryness. The residue was purified by chromatography on a 5 g silica Mega Bond Elut® column, eluting with 1% MeOH in dichloromethane. Relevant fractions were combined to give the desired product (74 mg). MS (ESP): 391 (MH⁺) for C₁₈H₁₉FN₄O₅,
NMR (DMSO-d₆) δ: 2.36 (t, 2H); 2.62 (t, 2H); 3.02 (t, 2H); 3.08 (t, 2H); 3.87 (dd, 1H); 4.16 (t, 1H); 4.42 (dd, 1H); 4.49 (dd, 1H); 5.04 (m, 1H); 6.37 (d, 1H); 7.08 (t, 1H); 7.21 (dd, 1H); 7.50 (dd, 1H); 8.67 (d, 1H); 10.38 (s, 1H).

Example 92: 3-(4-(4-Methoxycarbonylaminoiminopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-(4-Oxopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (125 mg, 0.33 mmol) was dissolved in MeOH (5 ml) and dichloromethane (5 ml), methyl carbazate (34 mg, 0.37 mmol) added, and the mixture stirred at ambient temperature under nitrogen for 18 hours. The mixture was evaporated, and the residue purified by chromatography on a 5 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 1% MeOH in dichloromethane. Relevant fractions were combined to give the desired product (98 mg).

10 MS (ESP): 448 (MH⁺) for C₂₀H₂₂FN₅O₆

NMR (CDCl₃) δ: 2.53 (t, 2H); 2.67 (t, 2H); 3.18 (t, 2H); 3.22 (t, 2H); 3.83 (s, 3H); 3.92 (dd, 1H); 4.14 (t, 1H); 4.49 (dd, 1H); 4.57 (dd, 1H); 5.01 (m, 1H); 6.01 (d, 1H); 6.96 (t, 1H); 7.13 (dd, 1H); 7.47 (dd, 1H); 7.79 (s, 1H); 8.16 (d, 1H).

15 **Example 93: 3-(4-(4-(2-Hydroxyethyl)aminoiminopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one**

3-(4-(4-Oxopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (125 mg, 0.33 mmol) was dissolved in MeOH (5 ml) and dichloromethane (5 ml), 2-hydroxyethylhydrazine (29 mg, 0.37 mmol) added, and the mixture stirred at ambient

20 temperature under nitrogen for 18 hours. The mixture was evaporated, and the residue purified by chromatography on a 5 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 1.5% MeOH in dichloromethane. Relevant fractions were combined to give the desired product (98 mg). MS (ESP): 434 (MH⁺) for C₂₀H₂₄FN₅O₅,
NMR (DMSO-d₆) δ: 2.34 (t, 2H); 2.43 (t, 2H); 3.04 (m, 4H); 3.47 (q, 2H); 3.76 (q, 1H);
25 3.87 (dd, 1H); 4.16 (t, 1H); 4.43 (overlapping m, 4H); 5.04 (m, 1H); 5.73 (br, 1H); 6.37 (d, 1H); 7.07 (t, 1H); 7.18 (dd, 1H); 7.50 (dd, 1H); 8.67 (d, 1H).

Example 94: 3-(4-(4-Methanesulfonaminopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-(4-Aminopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (249 mg, 0.66 mmol) in dichloromethane (20 ml) was cooled in an ice-bath, treated with triethylamine (140 mg, 1.4 mmol) and methanesulfonyl chloride (160 mg, 1.4 mmol), and stirred 18 hours, allowing the temperature to rise to ambient. The solution was washed with water (3 x 5 ml), and the residue after evaporation purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 5% MeOH in dichloromethane. Relevant fractions were combined to give the desired product (38 mg).

10 **MS (ESP):** 455 (MH⁺) for C₁₉H₂₃FN₄O₆S
NMR (CDCl₃) δ: 1.74 (m, 2H); 2.12 (m, 2H); 2.78 (t, 2H); 3.01 (s, 3H); 3.34 (d, 2H); 3.47 (m, 1H); 3.91 (dd, 1H); 4.12 (t, 1H); 4.34 (d, 1H); 4.48 (dd, 1H); 4.56 (dd, 1H); 4.99 (m, 1H); 5.99 (d, 1H); 6.92 (t, 1H); 7.11 (dd, 1H); 7.43 (dd, 1H); 8.14 (d, 1H).

15 **Example 95: 3-(4-(4-Methoxycarbonylaminopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one**

Using essentially the technique of Example 94, starting with 3-(4-(4-aminopiperidin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (249 mg, 0.66 mmol) and methyl chloroformate (70 mg, 0.74 mmol) in place of methanesulfonyl chloride, gave the

20 desired product (125 mg) after chromatography.

MS (ESP): 435 (MH⁺) for C₂₀H₂₃FN₄O₆
NMR (CDCl₃) δ: 1.65 (m, 2H); 2.06 (m, 2H); 2.78 (td, 2H); 3.34 (dm, 2H); 3.67 (s overlapping br, 4H); 3.92 (dd, 1H); 4.11 (t, 1H); 4.48 (dd, 1H); 4.55 (dd, 1H); 4.63 (m, 1H); 4.99 (m, 1H); 5.99 (d, 1H); 6.93 (t, 1H); 7.11 (dd, 1H); 7.43 (dd, 1H); 8.15 (d, 1H).

25

Example 96: 3-(4-((3R)-3-Methoxycarbonylamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

Using essentially the technique of Example 94, starting with 3-(4-((3R)-3-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one hydrochloride

30 (249 mg, 0.62 mmol), the title compound (189 mg) was obtained without need of chromatography. **MS (ESP):** 441 (MH⁺) for C₁₈H₂₁FN₄O₆S

NMR (DMSO-d₆) δ : 1.94 (m, 1H); 2.25 (m, 1H); 3.02 (s, 3H); 3.27 (m, 1H); 3.38 (t, 1H); 3.45 (t, 1H); 3.61 (m, 1H); 3.92 (dd, 1H); 4.05 (m, 1H); 4.19 (t, 1H); 4.48 (dd, 1H); 4.54 (dd, 1H); 5.08 (m, 1H); 6.37 (d, 1H); 6.83 (t, 1H); 7.19 (dd, 1H); 7.45, 7.48 (dd overlapping br, 2H); 8.76 (d, 1H).

5

Example 97: 3-(4-((3R)-3-Methanesulfonamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

Using essentially the technique of Example 94, starting with 3-(4-((3R)-3-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one hydrochloride
10 (232 mg, 0.58 mmol), and methyl chloroformate (66 mg, 0.7 mmol) in place of methanesulfonyl chloride, gave the desired product (182 mg) without need of chromatography.

MS (ESP): 421 (MH⁺) for C₁₉H₂₁FN₄O₆

NMR (DMSO-d₆) δ : 1.89 (m, 1H); 2.18 (m, 1H); 3.21 (m, 1H); 3.36 (m, 1H); 3.43 (m, 1H); 3.56 (m, 1H); 3.59 (s, 3H); 3.92 (dd, 1H); 4.19 (t overlapping m, 2H); 4.48 (dd, 1H);
15 4.55 (dd, 1H); 5.08 (m, 1H); 6.46 (d, 1H); 6.80 (t, 1H); 7.17 (dd, 1H); 7.48 (dd, 1H); 7.53 (d, 1H); 8.77 (d, 1H).

Example 98: 3-(3-Fluoro-4-(imidazol-1-yl)phenyl)-5(R)-(isoxazol-3-yloxymethyl)-oxazolidin-2-one











20 3-(3-Fluoro-4-(imidazol-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one (WO'96/23788; 280 mg, 1 mmol), 3-hydroxyisoxazole (94 mg, 1.1 mmol), and triphenylphosphine (330 mg, 1.25 mmol) were suspended by stirring in dry tetrahydrofuran (10 ml) under nitrogen at ambient temperature. Diisopropylazodicarboxylate (308 mg, 1.5 mmol) was added dropwise over 10 minutes. The suspension dissolved, and stirring was continued at the same
25 temperature for 2 hours. The mixture was evaporated to dryness, and the residue purified by chromatography on a 20 g silica Mega Bond Elut® columns, eluting with a gradient increasing in polarity from 50 to 100% EtOAc in isohexane. Relevant fractions were combined and evaporated to give the desired product (206 mg). MS (ESP): 345 (MH⁺) for C₁₆H₁₃FN₄O₄

30 NMR (DMSO-d₆) δ : 3.97 (dd, 1H); 4.24 (dd, 1H); 4.48 (m, 2H); 5.11 (m, 1H); 6.37 (d, 1H); 7.11 (d, 1H); 7.47 (dd, 1H); 7.52 (d, 1H); 7.66 (t, 1H); 7.74 (dd, 1H); 7.99 (s, 1H);

8.66 (d, 1H).

Examples 99-103

In a multiple parallel synthesis, using the conditions of the intermediate in Example 65, the same ratios of reagents, the appropriate hydroxymethyl starting material, and purifying as before on 10 g Mega Bond Elut® columns the following compounds were prepared.

Example	Starting Material	Moles Used	Product	Weight of Product	Foot notes
99		0.3 mmol		20 mg	1,6
100		0.7 mmol		70 mg	2,6
101		0.5 mmol		50 mg	3,7
102		0.6 mmol		110 mg	4,8
103		0.2 mmol		70 mg	5,9

Footnotes :

1. **MS (ESP):** 346 (MH⁺) for C₁₅H₁₂FN₅O₄
- 10 2. **MS (ESP):** 346 (MH⁺) for C₁₅H₁₂FN₅O₄
NMR (DMSO-d₆) δ: 3.97 (dd, 1H); 4.26 (dd, 1H); 4.48 (m, 2H); 5.11 (m, 1H); 6.37 (d, 1H); 7.53 (dd, 1H); 7.74 (dd, 1H); 7.83 (t, 1H); 8.13 (s, 2H); 8.69 (d, 1H).
3. **MS (ESP):** 326 (MH⁺) for C₁₇H₁₅N₃O₄
NMR (DMSO-d₆) δ: 3.93 (dd, 1H); 4.22 (t, 1H); 4.47 (m, 2H); 5.06 (m, 1H); 6.22 (m, 2H); 6.37 (d, 1H); 7.31 (m, 2H); 7.60 (dd, 4H); 8.68 (d, 1H).
4. **MS (ESP):** 369 (MH⁺) for C₁₈H₁₃FN₄O₄

NMR (DMSO-d₆) δ : 3.96 (dd, 1H); 4.23 (t, 1H); 4.47 (m, 2H); 5.10 (m, 1H); 6.37 (d, 1H); 6.70 (m, 1H); 7.28 (m, 1H); 7.47 (dd, 1H); 7.64 (t, 1H); 7.74 (dd, 1H); 7.99 (m, 1H); 8.67 (d, 1H).

5. MS (ESP): 405 (MH⁺) for C₁₉H₂₁FN₄O₅

5 NMR (DMSO-d₆) δ : 1.04 (t, 3H); 3.35 (t + m, 6H); 3.59 (s, 2H); 3.87 (dd, 1H); 4.16 (t, 1H); 4.45 (m, 2H); 5.03 (m, 1H); 6.36 (d, 1H); 7.05 (t, 1H); 7.21 (dd, 1H); 7.53 (dd, 1H); 8.68 (d, 1H).

6. Starting material described in WO 96/23788.

7. The intermediate for this compound was prepared as follows :

10

1-(4-Ethoxycarbonylaminophenyl)pyrrole

Ethyl chloroformate (0.38 ml) was added dropwise to a stirred solution of 1-(4-amino-phenyl)pyrrole (0.56 g, 3.54 mmol, Corelli et al., Farmaco. Ed. Sci., 1983, 38, 219) in pyridine (5 ml) at 5-10°C for 15 minutes. The cooling bath was removed and stirring

15 continued for 1.5 hours. The mixture was evaporated and the residue was purified by flash column chromatography on silica gel, eluting with a gradient of 1-4% MeOH in dichloromethane to give the title product (0.43 g) as a solid.

MS (ESP): (MH⁺) 231 for C₁₃H₁₄N₂O₂

NMR (CDCl₃) δ : 1.33 (t, 3H); 4.25 (q, 2H); 6.32 (t, 2H); 6.60 (s, 1H); 7.02 (t, 2H);

20 7.32-7.42 (m, 4H).

(5S)-3-(4-(1-Pyrrolyl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one

To a solution of 1-(4-ethoxycarbonylaminophenyl)pyrrole (0.45 g, 2.14 mmol) in dry tetrahydrofuran (30 ml) at -60°C under nitrogen, was added dropwise a solution of *n*-butyl lithium in (1.6 M in isohexane, 1.3 ml). The mixture was stirred for 20 minutes before (*R*)-glycidylbutyrate (0.3 g, 2.1 mmol) in tetrahydrofuran (2 ml) was added dropwise. The mixture was allowed to warm to room temperature, stirred for 16 hours and partitioned between EtOAc and saturated ammonium chloride solution. The organic layer was washed with brine, dried (magnesium sulfate) and evaporated. The residue was recrystallised from

30 ethanol to give the title product (0.21 g), mp 179-181°C. MS (ESP): 259 (MH⁺) for

C₁₄H₁₄N₂O₃

NMR (DMSO- d_6) δ : 3.5-3.75 (m, 2H); 3.87 (m, 1H); 4.12 (t, 1H); 4.70 (m, 1H); 5.18 (t, 1H); 6.24 (t, 2H); 7.31 (t, 2H); 7.5-7.7 (m, 4H).

$C_{14}H_{14}N_2O_3$ requires C: 65.1, H: 5.46, N: 10.8%; found: C: 64.5, H: 5.5, N: 10.6%.

- 5 8. The intermediate for this compound was prepared as follows :

3-Fluoro-4-(3-cyano-1-pyrrolyl)nitrobenzene

3-Cyanopyrrole (3.6 g, 39.1 mmol, CE Loader *et al*, Can. J. Chem., 1981, **59**, 2673) and 3,4-difluoronitrobenzene (6.5g, 40.9 mmol) were dissolved in DMF (50 ml) and cooled in an ice-
10 bath. The mixture was stirred and sodium hydride (60% in oil, 1.6 g, 40 mmol) added over 20 minutes. After allowing the mixture to come to ambient temperature, it was heated to 65° for 1 hour. Solvent was evaporated, the residue triturated with water, and filtered. The crude solide was purified by flash chromatography on silica, eluting with dichloromethane. Relevant fractions were combined to give the title product (3.75 g), mp 117-119°.

- 15 MS (ESP): 230 (MH⁺) for $C_{11}H_6FN_3O_2$

NMR (CDCl₃) δ : 6.68 (s, 1H); 7.09 (m, 1H); 7.61 (overlapping m, 2H); 8.20 (overlapping m, 2H).

5-Amino-2-(3-cyano-1-pyrrolyl)fluorobenzene

20 3-Fluoro-4-(3-cyano-1-pyrrolyl)nitrobenzene (5.3 g, 22.9 mmol) was dissolved in hot MeOH (250 ml) and palladium catalyst (10% on charcoal, 700 mg) added under a nitrogen atmosphere. The mixture was cooled and hydrogenated at atmospheric pressure for 3.5 hours. After filtration through celite, the solution was evaporated to dryness to give title product in sufficient purity for the next stage (4.6 g).

- 25 MS (ESP): 202 (MH⁺) for $C_{11}H_8FN_3$

NMR (CDCl₃) δ : 3.93 (br s, 2H); 6.50 (m, 3H); 6.82 (s, 1H); 7.10 (t, 1H); 7.31 (s, 1H).

5-Ethoxycarbonylamino-2-(3-cyano-1-pyrrolyl)fluorobenzene

5-Amino-2-(3-cyano-1-pyrrolyl)fluorobenzene (4.6 g, 22.9 mmol) was stirred in dry pyridine
30 (50 ml) 0°. Ethyl chloroformate (2.66 g, 24.5 mmol) was added, and stirring continued for 20 minutes at the same temperature before allowing the temperature to rise to ambient over 2

- 120 -

hours. Solvent was evaporated, the residue treated with iced water (50 ml), filtered off, and dried. Crystallisation of the crude product from ethanol (200 ml) gave the title product (4.9 g) mp 188-190°.

MS (ESP): 274 (MH⁺) for C₁₄H₁₂FN₃O₂

5 NMR (DMSO-d₆) δ: 1.26 (t, 3H); 4.16 (q, 2H); 6.69 (m, 1H); 7.23 (m, 1H); 7.33 (dd, 1H); 7.53 (t, 1H); 7.59 (dd, 1H); 7.92 (m, 1H); 10.04 (br s, 1H).

(5S)-3-(3-Fluoro-4-(3-cyano-1-pyrrolyl)phenyl)-5(R)-hydroxymethylloxazolidin-2-one

5-Ethoxycarbonylamino-2-(3-cyano-1-pyrrolyl)fluorobenzene (4.8 g, 17.6 mmol) was
10 dissolved in dry tetrahydrofuran (200 ml) under nitrogen, cooled to -70°, and treated with a solution of *n*-butyllithium (1.6 M in isohexane, 11.0 ml). After stirring for 45 minutes at -70°, (*R*)-glycidylbutyrate (2.8 g, 19.4 mmol) dissolved in tetrahydrofuran (5 ml) was added at -70°. Stirring was continued for 18 hours allowing the temperature to rise to ambient. Saturated ammonium chloride solution (50 ml) was added and the mixture extracted with EtOAc (250
15 ml, then 2 x 100 ml). The combined extracts were washed with brine (60 ml), dried (magnesium sulfate) and evaporated, and the residue purified by crystallisation from ethanol to give the desired product (3.9 g), mp 157-159°. MS (ESP): 302 (MH⁺) for C₁₅H₁₂FN₃O₃
NMR (DMSO-d₆) δ: 3.58 (dd, 1H); 3.71 (dd, 1H); 3.88 (dd, 1H); 4.14 (t, 1H); 4.75 (m, 1H); 5.21 (t, 1H); 6.72 (m, 1H); 7.28 (m, 1H); 7.49 (dd, 1H); 7.65 (t, 1H); 7.76 (dd, 1H);
20 7.79 (m, 1H).

9. Starting material described in WO 97/27188.

Example 104: 3-(4-(4-Hydroxymethylimidazol-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-

25 ylloxymethyl)oxazolidin-2-one

3-(4-(4-*t*-Butyldimethylsilyloxymethylimidazol-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-ylloxymethyl)oxazolidin-2-one (0.59 g, 1.2 mmol) in anhydrous tetrahydrofuran (15 ml) was cooled to 0°. A solution of tetra-*n*-butylammonium fluoride (1 M, 5 ml, 5 mmol) was added and the mixture stirred 3 hours as the temperature rose to ambient. The mixture was
30 evaporated to dryness, redissolved in dichloromethane (50 ml), washed with water (3 x 25 ml), and dried over magnesium sulfate. After filtration and evaporation the residue was

purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 10% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (245 mg). MS (ESP): 375 (MH⁺) for C₁₇H₁₅FN₄O₅,

- 5 NMR (DMSO-d₆) δ: 3.96 (dd, 1H); 4.26 (t, 1H); 4.40 (d, 2H); 4.48 (m, 2H); 4.99 (t, 1H); 5.11 (m, 1H); 6.39 (d, 1H); 7.35 (s, 1H); 7.47 (dd, 1H); 7.66 (t, 1H); 7.75 (dd, 1H); 7.93 (s, 1H); 8.70 (d, 1H).

The intermediate for this compound was prepared as follows.

10

- 3-(4-(4-*t*-Butyldimethylsilyloxymethylimidazol-1-yl)-3-fluorophenyl)-5(R)-hydroxymethyloxazolidin-2-one (WO 99/10343, 1.57 g, 3.72 mmol), 3-hydroxyisoxazole (350 mg, 4.1 mmol), and tributylphosphine (934 mg, 4.6 mmol) were dissolved by stirring in dry tetrahydrofuran (100 ml) under nitrogen. The mixture was cooled in an ice-bath, and 1,1'-(azodicarbonyl)dipiperidine (1.16 g, 4.6 mmol) added dropwise over 10 minutes. The solution was stirred 18 hours, allowing the temperature to rise to ambient. Reduced azo compound was filtered off, and the solution evaporated to dryness and the residue triturated with ether. The ether layer was evaporated, dissolved in dichloromethane and purified by chromatography on a 40 g silica Mega Bond Elut® column, eluting with a dichloromethane, then 1% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give (5*S*)-3-(4-(4-*t*-butyldimethylsilyloxymethylimidazol-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-ylloxymethyl)oxazolidin-2-one as an oil (0.59 g).
- 15
- 20

MS (ESP): 489 (MH⁺) for C₂₃H₂₉FN₄O₅Si

- NMR (CDCl₃) δ: 0.00 (s, 6H); 0.79 (s, 9H); 3.90 (dd, 1H); 4.07 (t, 1H); 4.38 (dd, 1H); 4.48 (dd, 1H); 4.63 (s, 2H); 4.92 (m, 1H); 5.88 (d, 1H); 6.98 (s, 1H); 7.21 (dd, 1H); 7.27 (t, 1H); 7.57 (dd, 1H); 7.61 (s, 1H); 8.03 (d, 1H).
- 25

Example 105: 3-(3-Fluoro-4-(2-methyl-imidazol-1-yl)phenyl)-5(R)-(isoxazol-3-yl-oxymethyl)oxazolidin-2-one

- 30 Using essentially the same procedure as for the intermediate of Example 65, but starting with 3-(3-fluoro-4-(2-methyl-imidazol-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one (202

mg, 0.69 mmol), and purifying by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 2.5% MeOH in dichloromethane, the title compound was prepared (137 mg).

MS (ESP): 359 (MH⁺) for C₁₇H₁₅FN₄O₄

- 5 NMR (DMSO-d₆) δ: 2.16 (s, 3H); 4.00 (dd, 1H); 4.27 (t, 1H); 4.49 (m, 2H); 5.12 (m, 1H); 6.40 (d, 1H); 6.94 (d, 1H); 7.23 (d, 1H); 7.50 (dd, 1H); 7.57 (t, 1H); 7.77 (dd, 1H); 8.71 (d, 1H).

The intermediates for this compound were prepared as follows :

10

3-Fluoro-4-(2-methyl-imidazol-1-yl)nitrobenzene

- 2-Methylimidazole (9.02 g, 0.11 M) and N,N-diisopropylethylamine (32.2 g, 0.25 M) were dissolved in acetonitrile (160 ml), and 3,4-difluoronitrobenzene (15.9g, 0.1 M) added. The mixture was stirred and heated to reflux under nitrogen for 24 hours. Solvent was evaporated, 15 the residue dissolved in EtOAc (300 ml), washed with water (150 ml), brine (150 ml), and dried (magnesium sulfate). The residue was recrystallised from a mixture of EtOAc (25 ml) and cyclohexane (150 ml) with the addition of charcoal to give the title compound (11.5 g), mp 106-107°.

MS (ESP): 222 (MH⁺) for C₁₀H₈FN₃O₂

- 20 NMR (DMSO-d₆) δ: 2.25 (s, 3H); 7.00 (d, 1H); 7.35 (t, 1H); 7.87 (t, 1H); 8.23 (dd, 1H); 8.43 (dd, 1H).

5-Amino-2-(2-methyl-imidazol-1-yl)fluorobenzene

- 3-Fluoro-4-(2-methyl-imidazol-1-yl)nitrobenzene (40 g, 0.181 M) was dissolved in a mixture 25 of MeOH (200 ml) and tetrahydrofuran (800 ml), cooled to 0° under nitrogen, and treated with ammonium formate (57 g, 0.905 M) followed by palladium on charcoal (10%, 2 g). The mixture was stirred at ambient temperature for 18 hours, filtered through celite, celite washed with MeOH (100 ml), and filtrate evaporated to dryness. The residue was partitioned between EtOAc (800 ml) and 10% aqueous sodium bicarbonate (250 ml). The organic layer was 30 separated, washed with brine (250 ml), dried (magnesium sulfate) and evaporated to give title compound (34.6 g).

MS (ESP): 192 (MH^+) for $C_{10}H_{10}FN_3$

NMR (DMSO- d_6) δ : 2.08 (s, 3H); 5.68 (s, 2H); 6.45 (overlapping m, 2H); 6.84 (d, 1H); 7.03 (overlapping m, 2H).

5 5-Benzyloxycarbonylamino-2-(2-methyl-imidazol-1-yl)fluorobenzene

5-Amino-2-(2-methyl-imidazol-1-yl)fluorobenzene (34.25 g, 0.179 M) was dissolved in dry dichloromethane (600 ml) under nitrogen, and cooled to -5° . Pyridine (17.7 g, 0.224 M) was added, followed by benzyl chloroformate (33.7 g, 0.197 M) over 20 minutes. The mixture was stirred and the temperature allowed to rise to ambient over 16 hours. Aqueous sodium bicarbonate (5%, 250 ml) was added, the organic layer separated, the aqueous layer re-extracted with dichloromethane (2 x 300 ml), and combined extracts dried (magnesium sulfate). After filtration and evaporation, the residue was recrystallised from toluene (400 ml) to give title product (54.5 g).

MS (ESP): 326 (MH^+) for $C_{18}H_{16}FN_3O_2$

15 NMR (DMSO- d_6) δ : 2.13 (s, 3H); 5.18 (s, 2H); 6.89 (s, 1H); 7.17 (s, 1H); 7.41 (overlapping m, 7H); 7.73 (dd, 1H); 10.21 (br, 1H).

(5S)-3-(3-Fluoro-4-(2-methyl-imidazol-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one

5-Benzyloxycarbonylamino-2-(2-methyl-imidazol-1-yl)fluorobenzene (54 g, 0.166 M) was dissolved in a mixture of dry tetrahydrofuran (600 ml) and 1,3-dimethyl-2,4,5,6-tetrahydro-2(1H)-pyrimidinone (100 ml) under nitrogen, cooled to -70° , and treated with a solution of *n*-butyllithium (1.6 M in *isohexane*, 114 ml), over 30 minutes. After stirring for 30 minutes at -70° , a solution of (*R*)-glycidylbutyrate (26.35 g, 0.183 M) in dry tetrahydrofuran (50 ml) was added over 15 minutes. Stirring was continued for 16 hours allowing the temperature to rise to ambient. The mixture was treated with aqueous sodium bicarbonate (5%, 500 ml) and EtOAc (800 ml), the organic layer separated, and the aqueous extracted with further EtOAc (3 x 750 ml). The combined extracts were dried (magnesium sulfate) and evaporated, and the resulting oil triturated with diethyl ether. The resulting solid was recrystallised from isopropanol to give the title compound (21.5 g). MS (ESP): 292 (MH^+) for $C_{14}H_{14}FN_3O_3$

25

30 NMR (DMSO- d_6) δ : 2.16 (s, 3H); 3.56 (dt, 1H); 3.69 (dt, 1H); 3.88 (dd, 1H); 4.15 (t, 1H); 4.74 (m, 1H); 5.24 (t, 1H); 6.92 (s, 1H); 7.20 (s, 1H); 7.48 (dd, 1H); 7.53 (t, 1H); 7.74

(dd, 1H).

Example 106: 3-(3-Fluoro-4-(4-methyl-imidazol-1-yl)phenyl)-5(R)-(isoxazol-3-yl-oxymethyl)oxazolidin-2-one

- 5 Using essentially the same procedure as for the intermediate of Example 65, but starting with 3-(3-fluoro-4-(4-methyl-imidazol-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one (see Example 141; 81 mg, 0.29 mmol), and purifying by chromatography on a 5 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 2.5% MeOH in dichloromethane, gave the title compound (80 mg). MS (ESP): 359 (MH⁺) for C₁₇H₁₅FN₄O₄
- 10 NMR (CDCl₃) δ: 2.30 (s, 3H); 4.02 (dd, 1H); 4.23 (t, 1H); 4.52 (dd, 1H); 4.60 (dd, 1H); 5.07 (m, 1H); 6.00 (d, 1H); 6.94 (s, 1H); 7.50 (overlapping m, 2H); 7.69 (dd, 1H); 7.77 (s, 1H); 8.16 (d, 1H).

- Example 107: 3-(3-Fluoro-4-(4-cyano-imidazol-1-yl)phenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one**
- 15 3-(3-Fluoro-4-(4-hydroximinomethyl-imidazol-1-yl)phenyl)-5(R)-(isoxazol-3-yloxymethyl)-oxazolidin-2-one (360 mg, 0.93 mmol) and acetic anhydride (3 ml) were heated under nitrogen at reflux for 2 hours. After cooling and pouring onto ice, the mixture was extracted into dichloromethane (3 x 15 ml), dried (magnesium sulfate) and evaporated. The residue was
- 20 purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 2.5% MeOH in dichloromethane, to give the desired compound (135 mg).

MS (ESP): 370 (MH⁺) for C₁₇H₁₂FN₅O₄

- NMR (DMSO-d₆) δ: 3.99 (dd, 1H); 4.27 (t, 1H); 4.49 (m, 2H); 5.12 (m, 1H); 6.37 (d, 1H); 7.52 (dd, 1H); 7.74 (t, 1H); 7.82 (dd, 1H); 8.29 (d, 1H); 8.56 (t, 1H); 8.69 (d, 1H).
- 25

The intermediate for this compound was prepared as follows :

- 3-(3-Fluoro-4-(4-aldehydo-imidazol-1-yl)phenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (WO 99/10343; 460 mg, 1.24 mmol), was dissolved in a mixture of ethanol (10 ml) and
- 30 water (2 ml), and treated with hydroxylamine hydrochloride (86 mg, 1.24 mmol) and

triethylamine (176 mg, 1.74 mmol). After stirring for 18 hours at ambient temperature the precipitated solid was filtered off, and the residue evaporated to dryness. Residue and precipitate were combined, washed with water (2 x 25 ml) and dried at 70° to give 3-(3-fluoro-4-(4-hydroximinomethyl-imidazol-1-yl)phenyl)-5(R)-(isoxazol-3-yloxymethyl)-oxazolidin-2-one (361 mg) as a 3:1 mixture of E and Z isomers. MS (ESP): 388 (MH⁺) for C₁₇H₁₄FN₅O₅,
NMR (DMSO-d₆) δ: 3.97 (dd, 1H); 4.26 (t, 1H); 4.45 (dd, 2H); 5.11 (m, 1H); 6.39 (d, 1H); 7.44 (s, 0.25H); 7.49 (dd, 1H); 7.73 (t, 1H); 7.77 (dd + s, 1.75H); 8.00 (s, 0.75H); 8.06 (s, 0.75H); 8.10 (s, 0.25H); 8.13 (s, 0.25H); 8.70 (d, 1H); 10.91 (s, 0.75H); 11.60 (s, 0.25H).

Example 108: 3-(4-(imidazol-1-yl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl) - oxymethyl)oxazolidin-2-one

3-(4-(imidazol-1-yl)-3-fluorophenyl)-5(R)-hydroxymethyloxazolidin-2-one (WO 96/23788; 500 mg, 1.8 mmol), 3-hydroxy-1,2,5-thiadiazole (221 mg, 2.17 mmol), and triphenylphosphine (707 mg, 2.7 mmol) were suspended in dry tetrahydrofuran (15 ml) under nitrogen by stirring. The mixture was cooled in an ice-bath, and diisopropylazodicarboxylate (545 mg, 2.7 mmol) added dropwise over 10 minutes. The solution was stirred 18 hours, allowing the temperature to rise to ambient. The mixture was diluted with dichloromethane (200 ml), and extracted with hydrochloric acid (1 M, 200 ml). The aqueous layer was washed with dichloromethane (2 x 100 ml), and the aqueous layer made basic with the minimum of concentrated ammonia solution. Organic material was extracted into dichloromethane (200 then 100 ml), dried (magnesium sulfate), and purified by chromatography on a 20 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 10% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the product (520 mg).

MS (ESP): 362 (MH⁺) for C₁₅H₁₂FN₅O₃S

NMR (DMSO-d₆) δ: 4.02 (dd, 1H); 4.26 (t, 1H); 4.66 (d, 1H); 4.71 (d, 1H); 5.15 (m, 1H); 7.11 (t, 1H); 7.48 (dd, 1H); 7.52 (m, 1H); 7.66 (t, 1H); 7.74 (dd, 1H); 7.98 (m, 1H); 8.43 (s, 1H).

Example 109: 3-(4-((3*R*)-3-Hydroxy-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-((3*R*)-3-*t*-Butyldimethylsilyloxy-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one (1.8 g, 3.77 mmol) was stirred in a mixture of acetic acid, water, and
5 tetrahydrofuran (3:1:1, 40 ml) at 90° for four hours. Solvent was evaporated, and the residue purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 10% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (420 mg) as a foam. MS (ESP): 364 (MH⁺) for C₁₇H₁₈FN₃O₅,
10 NMR (DMSO-d₆) δ: 1.82 (m, 1H); 1.97 (m, 1H); 3.10 (d, 1H); 3.25 (t, 1H); 3.40 (dd, 1H); 3.50 (m, 1H); 3.84 (dd, 1H); 4.12 (t, 1H); 4.32 (br, 1H); 4.43 (m, 2H); 4.87 (d, 1H); 5.02 (m, 1H); 6.36 (d, 1H); 6.70 (t, 1H); 7.10 (dd, 1H); 7.38 (dd, 1H); 8.67 (d, 1H).

The intermediates for this compound were prepared as follows :

15

3-Fluoro-4-((3*R*)-3-hydroxy-1-pyrrolidinyl)nitrobenzene

(3*R*)-3-Hydroxypyrrolidine hydrochloride (20 g, 0.163 M) was suspended by stirring in acetonitrile (200 ml) under nitrogen at 50 °, and treated with *N,N*-diisopropylethylamine (52.5 g, 0.41 M) and 3,4-difluoronitrobenzene (25.9 g, 0.153 M). The mixture was heated at 90° for
20 17 hours, then the solvent evaporated. The residue was dissolved in dichloromethane (500 ml) and washed with 5% aqueous sodium dihydrogen phosphate (300 ml), which caused partial precipitation. The precipitate was filtered, washed, and the combined aqueous layers re-extracted with dichloromethane (200 ml). The organic layers were evaporated, and the residue combined with the previously filtered material, and dried by azeotroping with toluene
25 to give the desired product (35 g), of sufficient quality for use without purification.

MS (ESP): 227 (MH⁺) for C₁₀H₁₁FN₂O₃

NMR (CDCl₃) δ: 1.89 (m, 1H); 1.97 (m, 1H); 3.47 (d, 1H); 3.61 (overlapping m, 3H); 4.35 (br m, 1H); 5.03 (d, 1H); 6.73 (t, 1H); 7.89 (overlapping m, 2H).

30 **3-Fluoro-4-((3*R*)-3-*t*-butyldimethylsilyloxy-1-pyrrolidinyl)nitrobenzene**

3-Fluoro-4-((3*R*)-3-hydroxy-1-pyrrolidinyl)nitrobenzene (35.8 g, 0.158 M) was dissolved in

- 127 -

DMF (200 ml), and treated with imidazole (21.6 g, 0.318 M) and *t*-butyldimethylsilyl chloride (35.7 g, 0.239 M) and stirred for 18 hours at ambient temperature under nitrogen. Solvent was evaporated, and the residue treated with EtOAc (300 ml) and water (200 ml). The organic layer was washed with water (150 ml) and dried (magnesium sulfate). Evaporation gave the desired product (54 g), of sufficient quality for use without purification.

MS (ESP): 341 (MH^+) for $C_{16}H_{25}FN_2O_3Si$

NMR ($CDCl_3$) δ : -0.02 (2 x s, 6H); 0.74 (s, 9H); 1.79 (br m, 1H); 1.97 (m, 1H); 3.27 (d, 1H); 3.53 (m, 2H); 3.68 (dt, 1H); 4.48 (br m, 1H); 6.69 (t, 1H); 7.83 (overlapping m, 2H).

10 5-Amino-2-((3*R*)-3-*t*-butyldimethylsilyloxy-1-pyrrolidinyl)fluorobenzene

3-Fluoro-4-((3*R*)-3-*t*-butyldimethylsilyloxy-1-pyrrolidinyl)nitrobenzene (54 g, 0.158 M) was treated in essentially the same way as the appropriate intermediate of Example 86, to give desired product required product of sufficient quality for use without purification (49 g). MS

(ESP): 311 (MH^+) for $C_{16}H_{27}FN_2OSi$

15 NMR ($DMSO-d_6$) δ : 0.00 (2 x s, 6H); 0.79 (s, 9H); 1.66 (m, 1H); 2.01 (m, 1H); 2.84 (d, 1H); 3.02 (dd, 1H); 3.12 (dd, 1H); 3.32 (m, 1H); 4.41 (m, 1H); 4.63 (s, 2H); 6.22 (dd, 1H); 6.29 (dd, 1H); 6.49 (t, 1H).

5-Ethoxycarbonylamino-2-((3*R*)-3-*t*-butyldimethylsilyloxy-1-pyrrolidinyl)fluorobenzene

20 5-Amino-2-((3*R*)-3-*t*-butyldimethylsilyloxy-1-pyrrolidinyl)fluorobenzene (49 g, 0.158 M) was treated in essentially the same way as the appropriate intermediate of Example 86, except that the product was isolated by extraction into dichloromethane, azeotrope with toluene, and crude product purified by dry column chromatography on silica, eluting with a gradient from 0-20% EtOAc in dichloromethane. Appropriate fractions were combined to give the
25 desired product (29.6 g)

MS (ESP): 383 (MH^+) for $C_{19}H_{31}FN_2O_3Si$

NMR ($DMSO-d_6$) δ : -0.02 (s, 3H); 0.01 (s, 3H); 0.78 (s, 9H); 1.16 (t, 3H); 1.72 (m, 1H); 1.98 (m, 1H); 2.97 (d, 1H); 3.18 (m, 1H); 3.27 (dd, 1H); 3.48 (m, 1H); 4.02 (q, 2H); 4.43 (m, 1H); 6.59 (t, 1H); 6.96 (dd, 1H); 7.17 (dd, 1H); 9.31 (s, 1H).

3-(4-((3*R*)-3-*t*-Butyldimethylsilyloxy-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-hydroxy-methyloxazolidin-2-one

5-Ethoxycarbonylamino-2-((3*R*)-3-*t*-butyldimethylsilyloxy-1-pyrrolidinyl)fluorobenzene (29.4 g, 0.077 M) was treated in essentially the same way as the appropriate intermediate of

- 5 Example 86, except that the product was isolated by extraction into EtOAc, and crude product purified by dry column chromatography on silica, eluting with a gradient from 0-20% MeOH in dichloromethane. Appropriate fractions were combined to give the desired product (29.6 g).

MS (ESP): 411 (MH⁺) for C₂₀H₃₁FN₂O₄Si

- 10 NMR (DMSO-d₆) δ: -0.01 (s, 3H); 0.02 (s, 3H); 0.79 (s, 9H); 1.73 (m, 1H); 2.00 (m, 1H); 3.02 (d, 1H); 3.23 (m overlapped by H₂O, 1H); 3.32 (dd, 1H); 3.50 (m, 2H); 3.57 (m, 1H); 3.69 (dd, 1H); 3.94 (t, 1H); 4.44 (m, 1H); 4.58 (m, 1H); 5.09 (t, 1H); 6.67 (t, 1H); 7.03 (dd, 1H); 7.34 (dd, 1H).

- 15 3-(4-((3*R*)-3-*t*-Butyldimethylsilyloxy-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one

3-(4-((3*R*)-3-*t*-Butyldimethylsilyloxy-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-hydroxy-methyloxazolidin-2-one (4.1 g, 10 mmol) was treated essentially as in Example 67, then purified by flash chromatography on silica, eluting with a gradient from 0-50% EtOAc in
20 dichloromethane, to give the desired product (2.0 g).

MS (ESP): 478 (MH⁺) for C₂₃H₃₂FN₃O₅Si

- NMR (DMSO-d₆) δ: 0.10 (s, 3H); 0.12 (s, 3H); 0.87 (s, 9H); 1.84 (m, 1H); 2.09 (m, 1H); 3.13 (d, 1H); 3.33 (m overlapped by H₂O, 1H); 3.43 (dd, 1H); 3.61 (m, 1H); 3.89 (dd, 1H); 4.18 (t, 1H); 4.49 (m, 2H); 4.55 (m, 1H); 5.07 (m, 1H); 6.44 (d, 1H); 6.78 (t, 1H); 7.15
25 (dd, 1H); 7.44 (dd, 1H); 8.72 (d, 1H).

Example 110: 3-(4-(3-Oxo-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one

- 3-(4-((3*R*)-3-Hydroxy-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)-
30 oxazolidin-2-one (700 mg, 1.9 mmol) was dissolved in DMSO(5 ml) under nitrogen and triethylamine (2.03 g, 20 mmol) added. A solution of sulfur trioxide pyridine complex (0.95

g, 6 mmol) in DMSO(5 ml) was added dropwise over 20 minutes. After stirring 1 hour at ambient temperature, the mixture was diluted with water (100 ml) and extracted into EtOAc (150 ml). The organics were washed with water (2 x 50 ml), brine (50 ml) and dried (magnesium sulfate). After evaporation, the residue was purified by chromatography on a 20 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 3% MeOH in dichloromethane. Relevant fractions were combined and evaporated, and the residue crystallised from ethanol (35 ml) to give product (176 mg). MS (ESP): 362 (MH⁺) for C₁₇H₁₆FN₃O₅,
5 NMR (DMSO-d₆) δ: 2.58 (t, 2H); 3.60 (t, 2H); 3.66 (d, 2H); 3.87 (dd, 1H); 4.15 (t, 1H);
10 4.45 (m, 2H); 5.03 (m, 1H); 6.36 (d, 1H); 6.94 (t, 1H); 7.20 (dd, 1H); 7.47 (dd, 1H); 8.67 (d, 1H).

Example 111: 3-(4-(3-Oximino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one

15 3-(4-(3-Oxo-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (124 mg, 0.34 mmol) was dissolved in a mixture of dichloromethane (10 ml) and MeOH (10 ml), and treated with a solution of hydroxylamine hydrochloride (220 mg, 3.17 mmol) and sodium acetate (500 mg) in water (2 ml). After stirring at ambient temperature for 4 hours, solvents were evaporated, and the residue triturated with water (10 ml), solid filtered and
20 dried to give the desired product (118 mg) as a single isomer of unknown geometry. MS (ESP): 377 (MH⁺) for C₁₇H₁₇FN₄O₅,
NMR (DMSO-d₆) δ: 2.67 (t, 2H); 3.41 (dd, 2H); 3.88 (dd, 1H); 3.96 (s, 2H); 4.16 (t, 1H);
4.46 (m, 2H); 5.04 (m, 1H); 6.38 (d, 1H); 6.91 (m, 1H); 7.18 (dd, 1H); 7.48 (dd, 1H); 8.69 (d, 1H); 10.72 (s, 1H).

25

Example 112: 3-(4-((3S)-3-Amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-((3S)-3-*t*-Butoxycarbonylamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (2.1 g, 4.54 mmol) was suspended by stirring in dichloromethane
30 (10 ml) under nitrogen and treated with a solution of hydrogen chloride in ethanol (4M, 50 ml) at ambient temperature. The mixture was stirred 1 hour, evaporated to a small volume,

and treated with a mixture of dichloromethane (30 ml) and diethyl ether (30 ml). The precipitate was filtered and washed with diethyl ether to give the title compound as its hydrochloride (2.0 g).

MS (ESP): 363 (MH⁺) for C₁₇H₁₉FN₄O₄

- 5 NMR (DMSO-d₆) δ : 2.03 (m, 1H); 2.25 (m, 1H); 3.26 (dd, 1H); 3.42 (m, 1H); 3.52 (m, 2H); 3.83 (dd overlapping m, 2H); 4.13 (t, 1H); 4.42 (m, 2H); 5.02 (m, 1H); 6.37 (d, 1H); 6.79 (t, 1H); 7.14 (dd, 1H); 7.44 (dd, 1H); 8.43 (br, 3H); 8.68 (d, 1H).

The intermediates for this compound were prepared as follows :

10

3-Fluoro-4-((3*S*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)nitrobenzene

Using essentially the technique for the equivalent intermediate in Example 86, but starting from (3*S*)-3-*t*-butoxycarbonylaminopyrrolidine (20 g, 0.108 M), gave the desired product as a yellow solid (33.5 g), of sufficient quality for use without purification. MS (ESP): 326

- 15 (MH⁺) for C₁₅H₂₀FN₃O₄

NMR (DMSO-d₆) δ : 1.36 (s, 9H); 1.87 (m, 1H); 2.08 (m, 1H); 3.36 (m, 1H); 3.54 (m, 1H); 3.62 (tm, 1H); 3.73 (m, 1H); 4.09 (m, 1H); 6.72 (t, 1H); 7.19 (d, 1H); 7.88 (overlapping m, 2H).

- 20 5-Amino-2-((3*S*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)fluorobenzene

Using essentially the technique for the equivalent intermediate in Example 86, but starting from 3-fluoro-4-((3*S*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)nitrobenzene (33.5 g, 0.103 M), gave the desired product as an oil of sufficient quality for use without purification (~30 g). MS (ESP): 296 (MH⁺) for C₁₅H₂₂FN₃O₂

- 25 NMR (DMSO-d₆) δ : 1.35 (s, 9H); 1.71 (m, 1H); 2.06 (m, 1H); 2.87 (dd, 1H); 3.05 (m, 1H); 3.11 (m, 1H); 3.26 (m overlapping H₂O, ~1H); 3.97 (m, 1H); 4.68 (s, 2H); 6.25 (dd, 1H); 6.31 (dd, 1H); 6.51 (t, 1H); 7.03 (d, 1H).

5-Ethoxycarbonylamino-2-((3*S*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)fluorobenzene

- 30 Using essentially the technique for the equivalent intermediate in Example 86, but starting from 5-amino-2-((3*S*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)fluorobenzene (30.4 g, 0.103

M), gave crude product after precipitation. This was purified by dissolving in toluene (500 ml), azeotrope until product began to precipitate, then cooling and adding *isohexane* (500 ml) to complete precipitation. Filtration gave the desired product (35.3 g). MS (ESP): 368 (MH⁺) for C₁₈H₂₆FN₃O₄

- 5 NMR (DMSO-d₆) δ : 1.21 (t, 3H); 1.37 (s, 9H); 1.77 (m, 1H); 2.06 (m, 1H); 3.04 (m, 1H); 3.20 (dd, 1H); 3.30 (m overlapping H₂O, 1H); 3.42 (tm, 1H); 4.02 (br, 1H); 4.08 (q, 2H); 6.63 (t, 1H); 7.02 (d, 1H); 7.08 (br, 1H); 7.22 (d, 1H); 9.38 (s, 1H).

3-(3-Fluoro-4-((3*S*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)-5(R)-hydroxymethyloxazolidin-

10 2-one

- 5-Ethoxycarbonylamino-2-((3*S*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)fluorobenzene (35.2 g, 0.096 M) was dissolved in dry tetrahydrofuran (400 ml) under nitrogen, cooled to -70°, and treated dropwise over 20 minutes with a solution of lithium *t*-butoxide, prepared from *t*-butanol (9.3 g, 123 mmol) in dry tetrahydrofuran (70 ml) and *n*-butyl lithium (66 ml, 1.6 M in
15 *isohexane*). After stirring for 20 minutes, (*R*)-glycidylbutyrate (15.2 g, 0.102 M) in tetrahydrofuran (20 ml) was added over 10 minutes, and the temperature allowed to rise to ambient over 16 hours. The mixture was treated with MeOH (10 ml), stirred at ambient temperature for 10 minutes, then treated with a mixture of 5% aqueous sodium bicarbonate (250 ml) and EtOAc (500 ml). The precipitate was collected and washed well with EtOAc
20 and water to give the desired product (19.5 g). The filtrate was separated into an organic layer, which was dried (magnesium sulfate) and evaporated. The residue was refluxed briefly with EtOAc (100 ml), cooled, and filtered to give further product (16.6 g).

MS (ESP): 396 (MH⁺) for C₁₉H₂₆FN₃O₅

- NMR (DMSO-d₆) δ : 1.37 (s, 9H); 1.79 (m, 1H); 2.07 (m, 1H); 3.08 (m, 1H); 3.24 (m
25 overlapping H₂O, ~1H); 3.36 (m, 1H); 3.48 (tm, 1H); 3.53 (d, 1H); 3.63 (d, 1H); 3.74 (dd, 1H); 3.99 (t, 1H); 4.04 (m, 1H); 4.63 (m, 1H); 5.15 (s, 1H); 6.71 (t, 1H); 7.08 (dd over-
lapping br, 2H); 7.39 (dd, 1H).

- 30 3-(4-((3*S*)-3-*t*-Butoxycarbonylamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxy-methyl)oxazolidin-2-one

The title compound was prepared using essentially the method of Example 67, starting from 3-(4-((3*S*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-hydroxymethyl)oxazolidin-2-one (3.95 g, 10 mmol), and purifying by flash chromatography on silica, eluting with a gradient increasing in polarity from 0 to 20% EtOAc in dichloromethane. Relevant fractions were combined, evaporated, and the residue recrystallised from toluene (100 ml) to give the desired product (2.34 g).

MS (ESP): 463 (MH⁺) for C₂₂H₂₇FN₄O₆

NMR (DMSO-d₆) δ : 1.37 (s, 9H); 1.81 (m, 1H); 2.08 (m, 1H); 3.10 (m, 1H); 3.24 (t, 1H); 3.35 (dd, 1H); 3.47 (dd, 1H); 3.83 (dd, 1H); 4.05 (m, 1H); 4.12 (t, 1H); 4.42 (dd, 1H); 4.48 (dd, 1H); 5.02 (m, 1H); 6.36 (d, 1H); 6.71 (t, 1H); 7.10 (dd overlapping br, 2H); 7.38 (dd, 1H); 8.66 (d, 1H).

Example 113: 3-(4-((3*S*)-3-Acetamido-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-((3*S*)-3-Amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)-oxazolidin-2-one hydrochloride salt (170 mg, 0.43 mmol) was stirred in a mixture of saturated sodium bicarbonate solution (5 ml) and dichloromethane (5 ml) in an ice-bath. Acetic anhydride (2 mmol) was added dropwise, and the mixture stirred 18 hours, allowing the temperature to rise to ambient. Dichloromethane (10 ml) was added, and the mixture filtered through phase separating paper, the organic layer evaporated, and crystallised from ethanol to give the desired product (108 mg).

MS (ESP): 405 (MH⁺) for C₁₉H₂₁FN₄O₅

NMR (DMSO-d₆) δ : 1.79 (s overlapping m, 4H); 2.11 (hextet, 1H); 3.11 (dt, 1H); 3.24 (t, 1H); 3.42 (dd, 1H); 3.50 (m, 1H); 3.84 (dd, 1H); 4.12 (t, 1H); 4.28 (m, 1H); 4.42 (dd, 1H); 4.47 (dd, 1H); 5.02 (m, 1H); 6.37 (d, 1H); 6.73 (t, 1H); 7.11 (dd, 1H); 7.39 (dd, 1H); 8.08 (d, 1H); 8.67 (d, 1H).

Example 114: 3-(4-((3*S*)-3-Methylsulfonamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

Using essentially the technique of Example 113, starting from 3-(4-((3*S*)-3-amino-1-

pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one hydrochloride salt (170 mg, 0.43 mmol) and methanesulfonyl chloride gave the desired product (114 mg) after trituration with diethyl ether and *isohexane*.

MS (ESP): 441 (MH⁺) for C₁₈H₂₁FN₄O₆S

5 NMR (DMSO-d₆) δ : 1.88 (hextet, 1H); 2.18 (hextet, 1H); 2.94 (s, 3H); 3.20 (m, 1H); 3.31 (t, 1H); 3.36 (m overlapped by H₂O, ~1H); 3.56 (m, 1H); 3.84 (dd, 1H); 3.98 (hextet, 1H); 4.12 (t, 1H); 4.42 (dd, 1H); 4.47 (dd, 1H); 5.02 (m, 1H); 6.37 (d, 1H); 6.74 (t, 1H); 7.12 (dd, 1H); 7.36 (d, 1H); 7.40 (dd, 1H); 8.68 (d, 1H).

10 **Example 115: 3-(4-((3S)-3-Methoxycarbonylamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one**

Using essentially the technique of Example 113, starting from 3-(4-((3S)-3-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one hydrochloride salt (170 mg, 0.43 mmol) and methyl chloroformate gave the desired product (114 mg) after

15 trituration with diethyl ether and *isohexane*.

MS (ESP): 421 (MH⁺) for C₁₉H₂₁FN₄O₆

NMR (DMSO-d₆) δ : 1.82 (hextet, 1H); 2.11 (hextet, 1H); 3.14 (m, 1H); 3.27 (m overlapped by H₂O, ~1H); 3.39 (dd, 1H); 3.49 (m, 1H); 3.53 (s, 3H); 3.84 (dd, 1H); 4.11 (t overlapping m, 2H); 4.42 (dd, 1H); 4.45 (dd, 1H); 5.02 (m, 1H); 6.37 (d, 1H); 6.72 (t, 1H);
20 7.11 (dd, 1H); 7.39 (dd, 1H); 7.42 (d, 1H); 8.67 (d, 1H).

Example 116: 3-(4-((3S)-3-Acetoxyacetyl-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

Using essentially the technique of Example 73, starting from 3-(4-((3S)-3-amino-1-

25 pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one hydrochloride salt (300 mg, 0.75 mmol) and acetoxyacetyl chloride gave the desired product (240 mg) after trituration with diethyl ether and *isohexane*.

MS (ESP): 463 (MH⁺) for C₂₁H₂₃FN₄O₇

NMR (DMSO-d₆) δ : 1.83 (hextet, 1H); 2.06 (s, 3H); 2.13 (hextet, 1H); 3.15 (m, 1H); 3.26 (m overlapped by H₂O, ~1H); 3.41 (dd, 1H); 3.50 (m, 1H); 3.84 (dd, 1H); 4.12 (t, 1H);
30

4.33 (dd, 1H); 4.43 (s, 2H); 4.45 (m, 2H); 5.03 (m, 1H); 6.36 (d, 1H); 6.74 (t, 1H); 7.11 (dd, 1H); 7.41 (dd, 1H); 8.24 (d, 1H); 8.66 (d, 1H).

Example 117: 3-(4-((3S)-3-Hydroxyacetyl-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-

5 (isoxazol-3-yloxymethyl)oxazolidin-2-one

Using essentially the technique of Example 74, starting from 3-(4-((3S)-3-acetoxyacetyl-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)-oxazolidin-2-one (140 mg, 0.3 mmol) gave the desired product (125 mg) after trituration with water, diethyl ether and drying.

10 **MS (ESP):** 421 (MH⁺) for C₁₉H₂₁FN₄O₆

NMR (DMSO-d₆) δ: 1.91 (hextet, 1H); 2.13 (hextet, 1H); 3.18 (m, 1H); 3.29 (m overlapped by H₂O, ~1H); 3.40 (dd, 1H); 3.49 (m, 1H); 3.79 (s, 2H); 3.84 (dd, 1H); 4.13 (t, 1H); 4.37 (dd, 1H); 4.46 (m, 2H); 5.02 (m, 1H); 5.36 (s, 1H); 6.36 (d, 1H); 6.74 (t, 1H); 7.11 (dd, 1H); 7.40 (dd, 1H); 7.84 (d, 1H); 8.67 (d, 1H).

15

Example 118: 3-(4-((3S)-3-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)carbonamido)-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-((3S)-3-Amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)-oxazolidin-2-one hydrochloride salt (270 mg, 0.67 mmol) was stirred in pyridine (5 ml) at
20 ambient temperature. A solution of 2,2-dimethyl-1,3-dioxolane-4(S)-carbonyl chloride (~50% strength, 270 mg, 0.85 mmol) in dichloromethane (2 ml) was added dropwise, and the mixture stirred 18 hours. Solvent was evaporated, and the residue partitioned between EtOAc (20 ml) and water (20 ml). The organic layer was washed with 5% aqueous sodium bicarbonate, brine, then dried (magnesium sulfate) and evaporated. The residue was
25 azeotroped with toluene (15 ml), and purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 100% EtOAc in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (205 mg).

MS (ESP): 491 (MH⁺) for C₂₃H₂₇FN₄O₇

30 **NMR (DMSO-d₆)** δ: 1.32 (s, 3H); 1.37 (s, 3H); 1.91 (hextet, 1H); 2.13 (hextet, 1H); 3.23 (m, 1H); 3.29 (m overlapped by H₂O, ~1H); 3.38 (m, 1H); 3.49 (m, 1H); 3.86 (dd, 1H);

3.94 (dd, 1H); 4.14 (t overlapping m, 2H); 4.37 (m, 1H); 4.43 (overlapping m, 3H); 5.04 (m, 1H); 6.40 (d, 1H); 6.76 (t, 1H); 7.14 (dd, 1H); 7.42 (dd, 1H); 8.00 (d, 1H); 8.69 (d, 1H).

Example 119: 3-(4-((3S)-3-(2(S),3-Dihydroxypropanoylamino)-1-pyrrolidinyl)-3-

5 fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-((3S)-3-(2,2-Dimethyl-1,3-dioxolane-4(S)-carbonamido)-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (170 mg, 0.35 mmol) was dissolved in tetrahydrofuran (6 ml), treated with 2 M aqueous hydrochloric acid (1 ml), and stirred at ambient temperature for 17 hours. After dilution with MeOH (10 ml), MP-

10 Carbonate scavenger resin (Argonaut Technologies, 2g) was added, and the mixture stirred 1 hour. Resin was filtered off, the filtrate evaporated, and the residue evaporated with MeOH/water (1:1, 10 ml, 3 times), and triturated with diethyl ether to give the desired product (125 mg). MS (ESP): 451 (MH⁺) for C₂₀H₂₃FN₄O₇,

NMR (DMSO-d₆) δ: 1.91 (hextet, 1H); 2.12 (hextet, 1H); 3.19 (m, 1H); 3.28 (m

15 overlapped by H₂O, ~1H); 3.46 (overlapping m, 3H); 3.56 (m, 1H); 3.84 (overlapping m, 2H); 4.13 (t, 1H); 4.33 (dd, 1H); 4.44 (m, 2H); 4.68 (t, 1H); 5.02 (m, 1H); 5.49 (d, 1H); 6.39 (d, 1H); 6.76 (t, 1H); 7.12 (dd, 1H); 7.43 (dd, 1H); 7.84 (d, 1H); 8.69 (d, 1H).

Example 120: 3-(4-((3S)-3-Amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-

20 thiadiazolyl)oxymethyl)oxazolidin-2-one

Using essentially the technique of Example 113, starting from 3-(4-((3S)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one (1 g, 2.09 mmol) gave the title product as its hydrochloride (850 mg). MS (ESP): 380 (MH⁺) for C₁₆H₁₈FN₅O₃S

25 NMR (DMSO-d₆) δ: 2.06 (m, 1H); 2.26 (m, 1H); 3.27 (dd, 1H); 3.42 (m overlapped by solvent, 1H); 3.54 (m, 2H); 3.82 (m, 1H); 3.89 (dd, 1H); 4.16 (t, 1H); 4.65 (m, 2H); 5.06 (m, 1H); 6.79 (t, 1H); 7.16 (dd, 1H); 7.45 (dd, 1H); 8.42 (s, 1H); 8.49 (br, 3H).

The intermediate for this compound was prepared as follows :

30 3-(4-((3S)-3-*t*-Butoxycarbonylamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one

The title compound was prepared using essentially the method of Example 67, starting from 3-(4-((3*S*)-3-*t*-butoxycarbonylamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-hydroxymethyl)oxazolidin-2-one (2.0 g, 5.06 mmol), and purifying by chromatography on a 90 g Biotage silica column, eluting with a gradient increasing in polarity from 0 to 5% EtOAc in dichloromethane. Relevant fractions were combined, evaporated, and the residue recrystallised from toluene (20 ml) to give the desired product (1.67 g).

MS (ESP): 480 (MH⁺) for C₂₁H₂₆FN₃O₅S

NMR (DMSO-d₆) δ : 1.37 (s, 9H); 1.81 (hextet, 1H); 2.08 (hextet, 1H); 3.11 (m, 1H); 3.26 (m overlapped by H₂O, ~1H); 3.37 (dd, 1H); 3.48 (t, 1H); 3.88 (dd, 1H); 4.05 (m, 1H); 4.14 (t, 1H); 4.64 (m, 2H); 5.06 (m, 1H); 6.71 (t, 1H); 7.11 (dd overlapping br, 2H); 7.48 (dd, 1H); 8.42 (s, 1H).

Example 121: 3-(4-((3*S*)-3-Acetamido-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one

The title compound was prepared using essentially the method of Example 115, starting from 3-(4-((3*S*)-3-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one hydrochloride salt (250 mg, 0.60 mmol). Work-up involved separating the organic layer, washing with aqueous sodium dihydrogen phosphate (2%), brine, and drying (magnesium sulfate). Evaporation gave the desired product (170 mg). MS (ESP):

422 (MH⁺) for C₁₈H₂₀FN₅O₄S

NMR (DMSO-d₆) δ : 1.79 (s overlapping m, 4H); 2.11 (hextet, 1H); 3.11 (m, 1H); 3.26 (m overlapped by H₂O, ~1H); 3.41 (dd, 1H); 3.49 (m, 1H); 3.88 (dd, 1H); 4.14 (t, 1H); 4.28 (dd, 1H); 4.65 (m, 2H); 5.07 (m, 1H); 6.74 (t, 1H); 7.11 (dd, 1H); 7.42 (dd, 1H); 8.08 (d, 1H); 8.42 (s, 1H).

Example 122: 3-(4-((3*S*)-3-Methanesulfonamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one

The title compound was prepared using essentially the method of Example 115, starting from 3-(4-((3*S*)-3-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one hydrochloride salt (250 mg, 0.60 mmol) and methanesulfonyl chloride. The same work-up gave the desired product (183 mg).

MS (ESP): 458 (MH⁺) for C₁₇H₂₀FN₅O₅S₂

NMR (DMSO-d₆) δ: 1.87 (hextet, 1H); 2.20 (hextet, 1H); 2.94 (s, 3H); 3.21 (m, 1H); 3.31 (t, 1H); 3.38 (m overlapped by H₂O, ~1H); 3.56 (m, 1H); 3.89 (dd, 1H); 3.98 (dd, 1H); 4.15 (t, 1H); 4.65 (m, 2H); 5.07 (m, 1H); 6.74 (t, 1H); 7.13 (dd, 1H); 7.36 (d, 1H); 7.40 (dd, 5 1H); 8.42 (s, 1H).

Example 123: 3-(4-((3S)-3-Acetoxyacetyl-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one

The title compound was prepared using essentially the method of Example 73, starting from
10 3-(4-((3S)-3-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one hydrochloride salt (350 mg, 0.84 mmol) and acetoxyacetyl chloride. Work-up involved separating the organic layer, washing with aqueous sodium dihydrogen phosphate (10%), aqueous sodium bicarbonate (5%), and drying (magnesium sulfate). Evaporation and trituration with diethyl ether/*iso*hexane (1:1, 10 ml) gave the desired product
15 (187 mg).

MS (ESP): 480 (MH⁺) for C₂₀H₂₂FN₅O₈

NMR (DMSO-d₆) δ: 1.86 (hextet, 1H); 2.07 (s, 3H); 2.14 (hextet, 1H); 3.16 (m, 1H); 3.26 (m overlapped by H₂O, ~1H); 3.42 (m, 1H); 3.51 (dd, 1H); 3.89 (dd, 1H); 4.14 (t, 1H); 4.33 (hextet, 1H); 4.43 (s, 2H); 4.67 (m, 2H); 5.07 (m, 1H); 6.76 (t, 1H); 7.14 (dd, 1H);
20 7.43 (dd, 1H); 8.26 (d, 1H); 8.45 (s, 1H).

Example 124: 3-(4-((3S)-3-hydroxyacetyl-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yl)oxymethyl)oxazolidin-2-one

The title compound was prepared using essentially the method of Example 74, starting from
25 3-(4-((3S)-3-acetoxyacetyl-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one (136 mg, 0.28 mmol). Evaporation of the reaction mixture and trituration of the residue with water gave the desired product (0.27 g). MS (ESP): 438 (MH⁺) for C₁₈H₂₀FN₅O₅S

NMR (DMSO-d₆) δ: 1.92 (hextet, 1H); 2.16 (hextet, 1H); ~3.20 (m, overlapped by H₂O, ~3H); 3.51 (m, overlapped by H₂O, ~1H); 3.81 (s, 2H); 3.91 (dd, 1H); 4.15 (t, 1H); 4.38 (hextet, 1H); 4.67 (m, 2H); 5.08 (m, 1H); 6.75 (t, 1H); 7.12 (dd, 1H); 7.41 (dd, 1H); 7.87
30

(d, 1H); 8.45 (s, 1H).

Example 125: 3-(4-((3S)-3-Methoxycarbonylamino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one

5 The title compound was prepared using essentially the method of Example 115, starting from 3-(4-((3S)-3-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one hydrochloride salt (152 mg, 0.37 mmol) and methyl chloroformate. Work-up and trituration with diethyl ether gave the desired product (53 mg). MS (ESP): 438 (MH⁺) for C₁₈H₂₀FN₅O₅S

10 NMR (DMSO-d₆) δ: 1.83 (hextet, 1H); 2.12 (hextet, 1H); 3.16 (m, 1H); 3.28 (m overlapped by H₂O, ~1H); 3.41 (dd, 1H); 3.53 (s overlapping m, 4H); 3.89 (dd, 1H); 4.08 (m, 1H); 4.14 (t, 1H); 4.64 (m, 2H); 5.06 (m, 1H); 6.74 (t, 1H); 7.12 (dd, 1H); 7.40 (dd, 1H); 7.43 (s, 1H); 8.45 (s, 1H).

15 **Example 126: 3-(4-((3S)-3-(2,2-Dimethyl-1,3-dioxolan-4(S)-ylcarbonamido)-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one**

The title compound was prepared using essentially the method of Example 115, starting from 3-(4-((3S)-3-amino-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one hydrochloride salt (336 mg, 0.81 mmol). Work-up and
20 chromatography gave the desired product (210 mg).

MS (ESP): 508 (MH⁺) for C₂₂H₂₆FN₅O₆S

NMR (DMSO-d₆) δ: 1.32 (s, 3H); 1.38 (s, 3H); 1.89 (hextet, 1H); 2.13 (hextet, 1H); 3.21 (m overlapped by H₂O, ~2H); 3.38 (t, 1H); 3.48 (m, 1H); 3.90 (dd, 1H); 3.92 (dd, 1H); 4.12 (dd, 1H); 4.14 (t, 1H); 4.37 (dd, 1H); 4.42 (t, 1H); 4.64 (m, 2H); 5.06 (m, 1H); 6.74 (t,
25 1H); 7.11 (dd, 1H); 7.40 (dd, 1H); 7.94 (d, 1H); 8.42 (d, 1H).

Example 127: 3-(4-((3S)-3-(2(S),3-Dihydroxypropanoylamino)-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one

The title compound was prepared using essentially the method of Example 119, starting from
30 3-(4-((3S)-3-((4S)-2,2-dimethyl-1,3-dioxolane-4-carbonamido)-1-pyrrolidinyl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one (165 mg, 0.33 mmol).

For work-up the aqueous organics were treated with solid potassium carbonate, filtered and evaporated to dryness and the residue triturated with diethyl ether to give the desired product (90 mg).

MS (ESP): 468 (MH⁺) for C₁₉H₂₂FN₅O₆S

- 5 NMR (DMSO-d₆) δ : 1.92 (hextet, 1H); 2.13 (hextet, 1H); 3.17 (m, 1H); 3.30 (m overlapped by H₂O, ~1H); 3.48 (overlapping m, 3H); 3.56 (m, 1H); 3.87 (m, 1H); 3.90 (dd, 1H); 4.14 (t, 1H); 4.34 (hextet, 1H); 4.66 (overlapping m, 3H); 5.07 (m, 1H); 5.48 (br, 1H); 6.76 (t, 1H); 7.13 (dd, 1H); 7.43 (dd, 1H); 7.85 (d, 1H); 8.46 (s, 1H).

10 **Example 128: 3-(4-(4-(6-Cyano-3-pyridazinyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-(isoxazol-3-yl)oxymethyloxazolidin-2-one**

- 3-(4-(4-(6-Cyano-3-pyridazinyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-hydroxy methyloxazolidin-2-one (398 mg, 1 mmol), 3-hydroxyisoxazole (93.5 mg, 1.1 mmol) and triphenylphosphine (328 mg, 1.25 mmol), were suspended with stirring in dry tetrahydrofuran
15 (10 ml). Diisopropylazodicarboxylate (242 mg, 1.2 mmol) was added dropwise by syringe, and the mixture stirred at ambient temperature for 30 minutes. The reaction mixture was filtered, evaporated to dryness, dissolved in EtOAc / isohexane (1:1), and applied to a 10 g silica Mega Bond Elut® column, eluting with a gradient from 75 to 100% EtOAc in isohexane. Relevant fractions were combined and evaporated to give the title compound (120
20 mg).

MS (ESP): 466 (MH⁺) for C₂₂H₂₀FN₇O₄

NMR (DMSO-d₆) δ : 3.08 (t, 4H); 3.89 (overlapping m, 5H); 4.16 (t, 1H); 4.45 (m, 2H); 5.05 (m, 1H); 6.37 (d, 1H); 7.10 (t, 1H); 7.21 (dd, 1H); 7.40 (d, 1H); 7.53 (dd, 1H); 7.88 (d, 1H); 8.67 (d, 1H).

25

The intermediates for this compound were prepared as follows :

- 3-(3-Fluoro-4-(piperazin-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one hydrochloride
3-(3-Fluoro-4-(4-*t*-butoxycarbonylpiperazin-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-
30 one (WO 93/23384; 43.1 g, 0.11 M) was suspended by stirring in ethanol (1000 ml) under nitrogen. An ethanol solution of hydrogen chloride (3.8 M, 400 ml) was added slowly, to give

a solution. The mixture was stirred at ambient temperature for 18 hours. The resulting precipitate was filtered, washed with diethyl ether (3 x 250 ml), and dried, to give the title product. A further crop was obtained by evaporation of the mother liquors. Total yield: 38.7 g.

5 MS (ESP): 296 (MH⁺) for C₁₄H₁₈FN₃O₃

NMR (DMSO-d₆) δ : 3.17 (m, 8H); 3.53 (dd, 1H); 3.64 (dd, 1H); 3.79 (dd, 1H); 4.03 (t, 1H); 4.66 (m, 1H); 7.10 (t, 1H); 7.21 (dd, 1H); 7.52 (dd, 1H); 9.39 (br s, 2H).

3-(4-(4-(6-cyano-3-pyridazinyl)piperazin-1-yl)-3-fluorophenyl)-5(R)-hydroxymethyl-

10 oxazolidin-2-one

3-(3-Fluoro-4-(piperazin-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one hydrochloride (6.63 g, 20 mmol) was suspended by stirring in acetonitrile (200 ml) under nitrogen, and triethylamine (4.44 g, 44 mmol) added. The mixture was stirred for 10 minutes, 3-chloro-6-cyanopyridazine (2.79 g, 20 mmol) added, and the mixture heated under reflux for 18 hours.

15 After cooling, solid was filtered, washed with water (3 x 150 ml) and diethyl ether (2 x 150 ml) to give the title product (6.3 g).

MS (ESP): 398 (MH⁺) for C₂₀H₂₀FN₅O₃

NMR (DMSO-d₆) δ : 3.03 (t, 4H); 3.54 (m, 1H); 3.63(m, 1H); 3.78 (t overlapping m, 5H); 4.03 (t, 1H); 4.66 (m, 1H); 5.18 (t, 1H); 6.97 (d, 1H); 7.07 (t, 1H); 7.20 (dd, 1H); 7.53 (dd, 20 1H); 7.85 (dd, 1H); 8.49 (d, 1H).

Example 129: 3-(3-Fluoro-4-(2-methyl-imidazol-1-yl)phenyl)-5(R)-(3-(1,2,5-thiadiazolyl)oxymethyl)oxazolidin-2-one

Using essentially the same procedure as for the intermediate of Example 65, but starting with 25 3-(3-fluoro-4-(2-methyl-imidazol-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one (582 mg, 2.0 mmol) and 3-hydroxy-1,2,5-thiadiazole (224 mg, 2.2 mmol), and purifying by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 10% MeOH in dichloro-methane, the title compound was prepared (160 mg).

30 MS (ESP): 376 (MH⁺) for C₁₆H₁₄FN₅O₃S

NMR (DMSO-d₆) δ : 2.15 (s, 3H); 4.02 (dd, 1H); 4.27 (t, 1H); 4.66 (dd, 1H); 4.72 (dd,

1H); 5.18 (m, 1H); 6.92 (d, 1H); 7.20 (d, 1H); 7.48 (dd, 1H); 7.55 (t, 1H); 7.74 (dd, 1H); 8.42 (s, 1H).

Example 130: 3-(4-(4-Hydroxymethylimidazol-1-yl)-3-fluorophenyl)-5(R)-(3--(1,2,5-

thiadiazolyl)methyl)oxazolidin-2-one

Essentially the same procedure as for the intermediate of Example 65 was used, but starting with 3-(4-(4-*t*-butyldimethylsilyloxymethylimidazol-1-yl)-3-fluoro-phenyl)-5(R)-hydroxymethyloxazolidin-2-one (842 mg, 2.0 mmol) and 3-hydroxy-1,2,5-thiadiazole (224 mg, 2.2 mmol). After filtration of reduced azo compound, the solution was treated with 10% TFA in acetonitrile (10 ml), evaporated to dryness and purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 20% MeOH in dichloromethane, to give the title compound (65 mg). MS (ESP): 392 (MH⁺) for C₁₆H₁₄FN₅O₄S

NMR (DMSO-d₆) δ: 4.02 (dd, 1H); 4.27 (t, 1H); 4.50 (s, 2H); 4.60 (br, 1H); 4.66 (dd, 1H); 4.72 (dd, 1H); 5.18 (m, 1H); 7.53 (dd, 1H); 7.69 (s, 1H); 7.74 (t, 1H); 7.80 (dd, 1H); 8.42 (s, 1H); 8.81 (s, 1H).

Example 131: 3-(4-(1-(2,2-Dimethyl-1,3-dioxolan-4(S)-ylmethoxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

3-(4-(1,2,5,6-Tetrahydro-4-pyridinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)-oxazolidin-2-one hydrochloride (144 mg, 0.36 mmol) was stirred in dichloromethane (5 ml) at ambient temperature, and treated with diisopropylethylamine (67 mg, 0.52 mmol) to give a solution. A solution of (4*S*)-2,2-dimethyl-4-(1,3-dioxolane)methyl 4-nitrophenyl carbonate (202 mg, 0.68 mmol) in dichloromethane (2.5 ml) was added dropwise, and the mixture stirred 18 hours. The mixture was diluted with dichloromethane (10 ml), and washed with water (4 x 15 ml). After drying (magnesium sulfate), the residue after evaporation was purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 5% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (152 mg). MS (ESP): 518 (MH⁺) for C₂₅H₂₈FN₃O₈

NMR (DMSO-d₆) δ: 1.26 (s, 3H); 1.31 (s, 3H); 2.43 (m, 2H); 3.56 (m, 2H); 3.69 (dd,

1H); 3.92 (dd, 1H); 4.02 (overlapping m, 4H); 4.11 (dd, 1H); 4.20 (t, 1H); 4.25 (m, 1H); 4.44 (dd, 1H); 4.49 (dd, 1H); 5.06 (m, 1H); 5.98 (br s, 1H); 6.36 (d, 1H); 7.31 (dd, 1H); 7.37 (t, 1H); 7.49 (dd, 1H); 8.66 (d, 1H).

5 **Example 132: 3-(4-(1-(2(S),3-Dihydroxypropyloxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one**

3-(4-(1-(2,2-Dimethyl-1,3-dioxolan-4(S)-ylmethoxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (130 mg, 0.25 mmol) was dissolved in tetrahydrofuran (5 ml), treated with 2 M aqueous hydrochloric acid (2 ml), and
10 stirred at ambient temperature for 72 hours. Excess potassium carbonate was added to remove acid and water, and the solution filtered. The filtrate was evaporated, and the residue purified by chromatography on a 10 g silica Biotage column, eluting with a gradient increasing in polarity from 0 to 10% MeOH in dichloromethane. Relevant fractions were combined and evaporated to give the desired product (103 mg). MS (ESP): 478 (MH⁺) for C₂₂H₂₄FN₃O₈
15 NMR (DMSO-d₆) δ : 2.42 (m, 2H); 3.37 (t, 2H); 3.57 (m, 2H); 3.65 (dd, 1H); 3.93 (overlapping m, 2H); 4.06 (overlapping m, 3H); 4.19 (t, 1H); 4.47 (m, 2H); 4.59 (t, 1H); 4.84 (d, 1H); 5.07 (m, 1H); 5.99 (br s, 1H); 6.37 (d, 1H); 7.32 (dd, 1H); 7.39 (t, 1H); 7.51 (dd, 1H); 8.78 (d, 1H).

20 **Example 133: 3-(4-(1-(2,2-Dimethyl-1,3-dioxolan-4(S)-ylmethoxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3,5-difluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one**

Using essentially the same procedure as for Example 131, but starting with 3-(4-(1,2,5,6-tetrahydro-4-pyridinyl)-3,5-difluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one
25 hydrochloride (151 mg, 0.36 mmol), gave the title compound (170 mg).

MS (ESP): 536 (MH⁺) for C₂₅H₂₇F₂N₃O₈

NMR (DMSO-d₆) δ : 1.26 (s, 3H); 1.32 (s, 3H); 2.31 (m, 2H); 3.58 (m, 2H); 3.69 (dd, 1H); 3.91 (dd, 1H); 4.03 (overlapping m, 4H); 4.12 (dd, 1H); 4.18 (t, 1H); 4.26 (m, 1H); 4.43 (m, 2H); 5.08 (m, 1H); 5.85 (br s, 1H); 6.37 (d, 1H); 7.34 (d, 2H); 8.67 (d, 1H).

30 **Example 134: 3-(4-(1-(2(S),3-Dihydroxypropyloxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3,5-difluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one**

- 143 -

Using essentially the same procedure as for Example 132, but starting with 3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(S)-ylmethoxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3,5-difluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (140 mg, 0.26 mmol), gave the title compound (116 mg). MS (ESP): 496 (MH⁺) for C₂₂H₂₃F₂N₃O₈

- 5 NMR (DMSO-d₆) δ : 2.32 (m, 2H); 3.36 (t, 2H); 3.59 (m, 2H); 3.66 (dd, 1H); 3.94 (overlapping m, 2H); 4.06 (overlapping m, 3H); 4.19 (t, 1H); 4.49 (m, 2H); 4.57 (t, 1H); 4.85 (d, 1H); 5.10 (m, 1H); 5.87 (br s, 1H); 6.37 (d, 1H); 7.34 (d, 2H); 8.78 (d, 1H).

Example 135: 3-(4-(1-(2-Hydroxyethoxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3-

10 **fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one**

Resin bound 3-(4-(1-(2-hydroxyethoxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (200 mg, 0.118 mmol) was swelled in dichloromethane (2 ml) over 1 hour. Solvent was drained, and the resin treated with TFA (1% in dichloromethane, 2 ml), to develop a red colour from bound trityl cation.

- 15 The resin was washed with dichloromethane (6 x 1 ml), and the combined washings evaporated to dryness, then azeotroped with 3 portions of *isohexane*/dichloromethane to give the title compound (46 mg) as a white powder.

MS (ESP): 448 (MH⁺) for C₂₁H₂₂FN₃O₇

- NMR (DMSO-d₆) δ : 2.42 (m, 2H); 3.56 (m, 4H); 3.92 dd, 1H); 4.02 (m, 4H); 4.19 (t, 1H);
20 4.45 (m, 2H); 5.07 (m, 1H); 5.98 (s, 1H); 6.36 (d, 1H); 7.32 (dd, 1H); 7.39 (t, 1H); 7.48 (dd, 1H); 8.66 (d, 1H).

The intermediate for this compound was prepared as follows :

25 **Resin bound 2-hydroxyethyl 4-nitrophenyl carbonate**

Ethylene glycol 2-chlorotrityl resin (Novabiochem, polystyrene backbone, 0.59 mmol/g, 400 mg, 0.236 mmol) was swelled in based washed dichloromethane (2 ml) over 30 minutes.

Solvent was drained, and a premixed solution of 4-nitrophenyl chloroformate (237 mg, 1.18 mmol) and triethylamine (357 mg, 3.54 mmol) in base washed dichloromethane (2 ml) was

- 30 added, and the mixture shaken for 18 hours. Solvent and reagents were drained, and the resin washed with dichloromethane (6 x 1 ml), then diethyl ether (2 x 2 ml) to give title product. IR

(single bead) ν : 1767 cm^{-1}

Resin bound 3-(4-(1-(2-hydroxyethoxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

- 5 Resin bound 2-hydroxyethyl 4-nitrophenyl carbonate (200 mg, 0.118 mmol) was swelled in based washed dichloromethane (2 ml) over 30 minutes. Solvent was drained, and a premixed solution of 1,2,5,6-tetrahydro-4-pyridinyl)-3-fluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)-oxazolidin-2-one hydrochloride (233 mg, 0.59 mmol) and diisopropylethylamine (227 mg, 1.77 mmol) in base washed dichloromethane (3 ml) was added, and the mixture shaken for 6
- 10 hours. Solvent and reagents were drained, and the resin washed with dichloromethane (6 x 1 ml), then diethyl ether (2 x 2 ml) to give title product. IR (single bead) ν : 1761, 1695 cm^{-1}

Example 136: 3-(4-(1-(2-Hydroxyethoxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3,5-difluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

- 15 Using the same technique as in Example 135 but starting from resin bound 3-(4-(1-(2-hydroxyethoxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3,5-difluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one (200 mg, 0.118 mmol), gave the title compound (44 mg) as a gum. MS (ESP): 466 (MH^+) for $\text{C}_{21}\text{H}_{21}\text{F}_2\text{N}_3\text{O}_7$
- NMR (DMSO- d_6) δ : 2.30 (m, 2H); 3.54 (m, 4H); 3.90 dd, 1H); 4.03 (m, 4H); 4.18 (t, 1H);
- 20 4.45 (m, 2H); 5.08 (m, 1H); 5.85 (s, 1H); 6.35 (d, 1H); 7.32 (d, 2H); 8.66 (d, 1H).

The intermediate for this compound was prepared as follows :

Resin bound 3-(4-(1-(2-hydroxyethoxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3,5-difluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one

- 25 Using the same technique as in Example 72 but using from 3-(4-(1-(2-hydroxyethoxycarbonyl)-1,2,5,6-tetrahydro-4-pyridinyl)-3,5-difluorophenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one hydrochloride (244 mg, 0.118 mmol), gave the title product. IR (single bead) ν : 1764, 1696 cm^{-1}
- 30 Example 137: 3-(4-(1-Benzyl-1,2,5,6-tetrahydro-4-pyridinyl)-3,5-difluorophenyl)-5-(3-methyl-5(R)-isoxazolylloxymethyl)oxazolidin-2-one

3-(4-(1-Benzyl-1,2,5,6-tetrahydro-4-pyridinyl)-3,5-difluorophenyl)-5(R)-hydroxy-methyloxazolidin-2-one (1.28 g, 3.2 mmol), 3-methyl-5-hydroxyisoxazole (291 mg, 3.5 mmol), and tributylphosphine (0.97 g, 4.8 mmol) were dissolved by stirring in dry tetrahydrofuran (20 ml) under nitrogen. The mixture was cooled in an ice-bath, and 1,1'-(azodicarbonyl)dipiperidine (1.21 g, 4.8 mmol) added dropwise over 10 minutes. The solution was stirred 18 hours, allowing the temperature to rise to ambient. Reduced azo compound was filtered off, and the solution evaporated to dryness. The residue was purified by chromatography on a 90 g Biotage silica column, eluting with 1:1 diethyl ether/dichloromethane. Relevant fractions were combined and evaporated to give the title product (0.58 g). Starting isoxazole described in Bull. Soc. Chim. France, 1970, 2690.

MS (ESP): 482 (MH⁺) for C₂₆H₂₅F₂N₃O₄

NMR (500 MHz, DMSO-d₆) δ : 2.20 (s, 3H); 2.43 (br s, 2H); 2.70 (t, 2H); 3.18 (m, 2H); 3.65 (s, 2H); 3.95 (dd, 2H); 4.13 (t, 1H); 4.40 (dd, 1H); 4.50 (dd, 1H); 4.97 (m, 1H); 5.15 (s, 1H); 5.81 (s, 1H); 7.13 (d, 2H); 7.26 (t, 1H); 7.33 (m, 2H); 7.37 (m, 1H).

15

Example 138: 3-(3-Fluoro-4-(4-methyl-imidazol-1-yl)phenyl)-5(R)-(5-(1,2,3-triazolyl)-thiomethyl)oxazolidin-2-one

3-(3-fluoro-4-(4-methyl-imidazol-1-yl)phenyl)-5(R)-methanesulfonyloxymethyloxazolidin-2-one (see Example 141; 369 mg, 1 mmol) and 5-mercapto-1,2,3-triazole sodium salt (186 mg, 1.5 mmol), were dissolved in DMF (7 ml), then heated at 75° for 1 hour. The mixture was diluted with sodium bicarbonate solution (5%, 25 ml), extracted with EtOAc (50 ml), washed with water (2 x 15 ml), brine (15 ml), dried (magnesium sulfate) and purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 10% MeOH in dichloromethane, to give the title compound (110 mg).

25 MS (ESP): 375 (MH⁺) for C₁₆H₁₅FN₆O₂S

NMR (DMSO-d₆) δ : 2.14 (s, 3H); 3.31 (m, 2H); 3.91 (dd, 1H); 4.26 (t, 1H); 4.89 (m, 1H); 7.22 (s, 1H); 7.42 (dd, 1H); 7.61 (t, 1H); 7.73 (dd, 1H); 7.87 (s, 1H); 8.02 (s, 1H); 15.23 (br, 1H).

30 **Example 139: 3-(3-Fluoro-4-(4-methyl-imidazol-1-yl)phenyl)-5(R)-(5-(1-methyl-tetrazyl)thiomethyl)oxazolidin-2-one**

Using the same technique as in Example 138 but starting from 1-methyl-5-mercapto-tetrazole (174 mg, 1.5 mmol), gave the title compound (220 mg).

MS (ESP): 390 (MH⁺) for C₁₆H₁₆FN₇O₂S

NMR (DMSO-d₆) δ: 2.16 (s, 3H); 3.73 (d, 2H); 3.96 (s overlapping dd, 4H); 4.28 (t, 1H);
5 5.04 (m, 1H); 7.22 (s, 1H); 7.45 (dd, 1H); 7.64 (t, 1H); 7.72 (dd, 1H); 7.87 (s, 1H).

Example 140: 3-(4-(4-Methylimidazol-1-yl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)methyl)oxazolidin-2-one

Sodium hydride (50% in oil, 72 mg, 1.5 mmol) was stirred in suspension in DMF (7 ml)
10 under nitrogen at ambient temperature. 3-Hydroxy-1,2,5-thiadiazole (153 mg, 1.5 mmol) was added and stirring continued for 10 minutes, then 3-(3-fluoro-4-(4-methyl-imidazol-1-yl)phenyl)-5(R)-methanesulfonyloxymethyloxazolidin-2-one (369 mg, 1 mmol) was added and the mixture heated at 75° for 2 hours. The mixture was diluted with sodium bicarbonate solution (5%, 25 ml), extracted with EtOAc (50 ml), washed with water (2 x 15 ml), brine (15
15 ml), dried (magnesium sulfate) and purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 10% MeOH in dichloromethane, to give the title compound (330 mg). MS (ESP): 376 (MH⁺) for C₁₆H₁₄FN₅O₃S

NMR (DMSO-d₆) δ: 2.17 (s, 3H); 4.02 (dd, 1H); 4.26 (t, 1H); 4.80 (m, 2H); 5.16 (m, 1H);
20 7.22 (s, 1H); 7.48 (dd, 1H); 7.63 (t, 1H); 7.77 (dd, 1H); 7.88 (s, 1H); 8.47 (s, 1H).

Example 141: 3-(4-(5-Methylimidazol-1-yl)-3-fluorophenyl)-5(R)-(3-(1,2,5-thiadiazolyl)methyl)oxazolidin-2-one

Sodium hydride (60% in oil, 110 mg, 2.75 mmol) was added to a solution 3-hydroxy-
25 isoxazole (229 mg, 2.7 mmol) in DMF (15 ml) under nitrogen at 0°, and the mixture stirred 15 minutes. A solution of 3-(3-fluoro-4-(5-methyl-imidazol-1-yl)phenyl)-5(R)-methanesulfonyloxymethyloxazolidin-2-one (680 mg, 1.8 mmol) in DMF (7 ml) was added, and the mixture stirred 18 hours at ambient temperature. Solvent was evaporated, the residue dissolved in EtOAc (50 ml), washed with water (2 x 30 ml), brine (15 ml), dried (magnesium
30 sulfate) and purified by chromatography on a 10 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 0 to 3% MeOH in dichloromethane, to give the

title compound (149 mg).

MS (ESP): 359 (MH⁺) for C₁₇H₁₅FN₄O₄

NMR (CDCl₃) δ: 2.12 (s, 3H); 4.03 (dd, 1H); 4.21 (t, 1H); 4.53 (dd, 1H); 4.61 (dd, 1H); 5.08 (m, 1H); 6.01 (d, 1H); 6.91 (d, 1H); 7.29 (dd, 1H); 7.36 (t, 1H); 7.48 (d, 1H); 7.71 (dd, 1H); 8.16 (d, 1H).

The intermediates for Examples 106, 140 & 141 were prepared as follows :

10 3-Fluoro-4-(4-methyl-imidazol-1-yl)nitrobenzene and 3-fluoro-4-(5-methyl-imidazol-1-yl)nitrobenzene

4-Methylimidazole (45.1 g, 0.55 M) and N,N-diisopropylethylamine (161 g, 1.25 M) were dissolved in acetonitrile (800 ml), and 3,4-difluoronitrobenzene (79.5g, 0.5 M) added. The mixture was stirred and heated to reflux under nitrogen for 24 hours. Solvent was evaporated, the residue dissolved in EtOAc (800 ml), washed with water (400 ml), brine (200 ml), and dried (magnesium sulfate). The residue was dissolved in toluene (250 ml), treated with charcoal, filtered, and diluted with hot cyclohexane (75 ml) to crystallise 3-fluoro-4-(4-methyl-imidazol-1-yl)nitrobenzene (64.7 g).

MS (ESP): 222 (MH⁺) for C₁₀H₈FN₃O₂

20 NMR (DMSO-d₆) δ: 2.18 (s, 3H); 7.29 (s, 1H); 7.92 (t, 1H); 8.07 (s, 1H); 8.18 (dd, 1H); 8.38 (dd, 1H).

The mother liquors were evaporated, and chromatographed on a 90 g Biotage silica column, eluting with a gradient from dichloromethane to 1:1 dichloromethane / acetonitrile. Relevant fractions were combined and evaporated to give a 2:1 mixture of the 5-methyl:4-methyl isomers (8 g). This was then subjected to HPLC on Merck Lichro Prep silica eluting with EtOAc / MeOH (95:5) at 400 ml/min to separate 3-fluoro-4-(5-methyl-imidazol-1-yl)nitrobenzene (5.2 g).

NMR (DMSO-d₆) δ: 2.09 (s, 3H); 6.87 (d, 1H); 7.81 (d, 1H); 7.87 (t, 1H); 8.23 (dd 1H); 8.42 (dd, 1H). MS (ESP): 222 (MH⁺) for C₁₀H₈FN₃O₂

30 5-Amino-2-(4-methyl-imidazol-1-yl)fluorobenzene

3-Fluoro-4-(4-methyl-imidazol-1-yl)nitrobenzene (64.7 g, 0.293 M) was dissolved in a

- 148 -

mixture of MeOH (200 ml) and tetrahydrofuran (800 ml), cooled to 0° under nitrogen, and treated with ammonium formate (99.3 g, 1.46 M) followed by palladium on charcoal (10%, 2.5 g). The mixture was stirred at ambient temperature for 48 hours, filtered through celite, celite washed with MeOH (200 ml), and filtrate evaporated to dryness. The residue was
5 partitioned between EtOAc (800 ml) and 10% aqueous sodium bicarbonate (250 ml). The organic layer was separated, washed with brine (250 ml), dried (magnesium sulfate) and evaporated to give title compound (50.6 g).

MS (ESP): 192 (MH⁺) for C₁₀H₁₀FN₃

NMR (DMSO-d₆) δ: 2.12 (s, 3H); 5.60 (br s, 2H); 6.42 (dd, 1H); 6.47 (dd, 1H); 6.98 (s,
10 1H); 7.11 (t, 1H); 7.60 (s, 1H).

5-Amino-2-(5-methyl-imidazol-1-yl)fluorobenzene

Using essentially the same procedure as for the 4-methyl isomer, but starting from 3-fluoro-4-(5-methyl-imidazol-1-yl)nitrobenzene (5.2 g, 23.5 mmol) gave the title product (3.45 g). MS
15 (ESP): 192 (MH⁺) for C₁₀H₁₀FN₃,

5-Benzyloxycarbonylamino-2-(4-methyl-imidazol-1-yl)fluorobenzene

5-Amino-2-(4-methyl-imidazol-1-yl)fluorobenzene (50.6 g, 0.265 M) was dissolved in dry dichloromethane (800 ml) under nitrogen, and cooled to -5°. Pyridine (26.1 g, 0.33 M) was
20 added, followed by benzyl chloroformate (49.9 g, 0.292 M) over 30 minutes. The mixture was stirred and the temperature allowed to rise to ambient over 16 hours. Aqueous sodium bicarbonate (5%, 350 ml) was added, the organic layer separated, and the aqueous layer re-extracted with dichloromethane (2 x 200 ml), and combined organics dried (magnesium sulfate). After filtration and evaporation, the residue was recrystallised from toluene (300 ml)
25 to give title product (80 g).

MS (ESP): 326 (MH⁺) for C₁₈H₁₆FN₃O₂

NMR (DMSO-d₆) δ: 2.15 (s, 3H); 5.16 (s, 2H); 7.13 (s, 1H); 7.31 (dd, 1H); 7.41 (m, 5H);
7.48 (t, 1H); 7.57 (dd, 1H); 7.78 (s, 1H); 10.15 (br s, 1H).

30 5-Benzyloxycarbonylamino-2-(5-methyl-imidazol-1-yl)fluorobenzene

Using essentially the same procedure as for the 4-methyl isomer, but starting from 5-amino-2-

(5-methyl-imidazol-1-yl)fluorobenzene (3.45 g, 18.1 mmol) gave the title product (3.35 g), after trituration of the crude with a mixture of diethyl ether / *isohexane* (1:1). MS (ESP): 326 (MH⁺) for C₁₈H₁₆FN₃O₂

NMR (DMSO-d₆) δ: 2.00 (s, 3H); 5.17 (s, 2H); 6.78 (s, 1H); 7.37 (overlapping m, 7H);

5 7.61 (dd, 1H); 7.63 (s, 1H); 10.21 (br s, 1H).

3-(3-Fluoro-4-(4-methyl-imidazol-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one

5-Benzyloxycarbonylamino-2-(4-methyl-imidazol-1-yl)fluorobenzene (54 g, 0.166 M) was dissolved in a mixture of dry tetrahydrofuran (600 ml) and 1,3-dimethyl-2,4,5,6-tetrahydro-
10 2(1H)-pyrimidinone (100 ml) under nitrogen, cooled to -70°, and treated with a solution of *n*-butyllithium (1.6 M in *isohexane*, 114 ml), over 30 minutes. After stirring for 30 minutes at -70°, a solution of (*R*)-glycidylbutyrate (26.35 g, 0.183 M) in dry tetrahydrofuran (50 ml) was added over 15 minutes. Stirring was continued for 16 hours allowing the temperature to rise to ambient. The mixture was treated with aqueous sodium bicarbonate (5%, 500 ml) and
15 EtOAc (800 ml), and undissolved solid was removed and washed well with diethyl ether to give title product (16.3 g).

The aqueous layer was further extracted with EtOAc (2 x 750 ml), the combined extracts dried (magnesium sulfate) and evaporated, and the residue trituated with diethyl ether. The resulting solid was recrystallised from ethanol to give more product (10.9 g). MS (ESP): 292
20 (MH⁺) for C₁₄H₁₄FN₃O₃

NMR (DMSO-d₆) δ: 2.13 (s, 3H); 3.56 (dd, 1H); 3.68 (dd, 1H); 3.86 (dd, 1H); 4.11 (t, 1H); 4.73 (m, 1H); 5.21 (br, 1H); 7.18 (s, 1H); 7.45 (dd, 1H); 7.60 (t, 1H); 7.73 (dd, 1H); 7.83 (s, 1H).

25 3-(3-Fluoro-4-(5-methyl-imidazol-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one

5-Benzyloxycarbonylamino-2-(5-methyl-imidazol-1-yl)fluorobenzene (3.2 g, 9.85 mmol) was dissolved in dry tetrahydrofuran (40 ml) under nitrogen, cooled to -70°, and treated with a solution of *n*-butyllithium (1.6 M in *isohexane*, 6.81 ml). After stirring for 20 minutes at -70°, (*R*)-glycidylbutyrate (1.57 g, 10.09 mmol) was added at -70°. Stirring was continued for 16
30 hours allowing the temperature to rise to ambient. The mixture was treated MeOH (10 ml), stirred 15 minutes, then poured into aqueous sodium bicarbonate (5%, 100 ml) and extracted

- with EtOAc (3 x 40 ml). The combined extracts were washed with brine (20 ml), dried (magnesium sulfate) and evaporated, and the residue purified by chromatography on a 20 g silica Mega Bond Elut® column, eluting with a gradient increasing in polarity from 5 to 10% MeOH in dichloromethane. Relevant fractions were combined and evaporated, to give the
- 5 desired product (0.86 g). MS (ESP): 292 (MH⁺) for C₁₄H₁₄FN₃O₃,
NMR (DMSO-d₆) δ: 2.03 (s, 3H); 3.57 (dt, 1H); 3.69 (dt, 1H); 3.87 (dd, 1H); 4.14 (t, 1H); 4.74 (m, 1H); 5.22 (t, 1H); 6.81 (s, 1H); 7.50 (overlapping m, 2H); 7.66 (s, 1H); 7.75 (t, 1H).
- 10 3-(3-fluoro-4-(4-methyl-imidazol-1-yl)phenyl)-5(R)-methanesulfonyloxymethyloxazolidin-2-one
3-(3-Fluoro-4-(4-methyl-imidazol-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one (11.8 g, 40.5 mmol) was stirred in a mixture of pyridine (200 ml) and triethylamine (4.86 g, 48.2 mmol) under nitrogen in an ice-bath. Methanesulfonyl chloride (5.16 g, 45 mmol) was added
- 15 dropwise, and the mixture stirred for 2 hours, allowing the temperature to rise to ambient. Solvent was evaporated, and the residue stirred vigorously with a mixture of aqueous sodium bicarbonate (5%, 200 ml) and *isohexane* (200 ml). The precipitate was filtered, washed with water then *isohexane*, and dried. The residue was recrystallised from hot acetone (200 ml) by dilution with *isohexane* (300 ml) to give the title product (11.7 g), mp 151-153°. MS (EI): 369
- 20 (M⁺) for C₁₅H₁₆FN₃O₅S
NMR (DMSO-d₆) δ: 2.16 (s, 3H); 3.27 (s, 3H); 3.88 (dd, 1H); 4.24 (t, 1H); 4.47 (dd, 1H); 4.54 (dd, 1H); 5.04 (m, 1H); 7.20 (d, 1H); 7.45 (dd, 1H); 7.63 (t, 1H); 7.73 (dd, 1H); 7.85 (t, 1H).
- 25 3-(3-fluoro-4-(5-methyl-imidazol-1-yl)phenyl)-5(R)-methanesulfonyloxymethyloxazolidin-2-one
3-(3-Fluoro-4-(5-methyl-imidazol-1-yl)phenyl)-5(R)-hydroxymethyloxazolidin-2-one (0.86 g, 2.96 mmol) was stirred in a mixture of pyridine (30 ml) and triethylamine (0.36 g, 3.55 mmol) under nitrogen in an ice-bath. Methanesulfonyl chloride (0.37 g, 3.26 mmol) was added
- 30 dropwise, and the mixture stirred for 18 hours, allowing the temperature to rise to ambient. Solvent was evaporated, and the residue dissolved in dichloromethane (50 ml), and washed

with aqueous sodium bicarbonate (5%, 25 ml), water (2 x 25 ml), brine (20 ml), and dried (magnesium sulfate). The residue after evaporation was triturated with diethyl ether to give the title product (0.68 g).

MS (ESP): 370 (MH⁺) for C₁₅H₁₆FN₃O₅S

5

Example 142 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-[3,6-dihydro-(2H)-pyran-4-yl]-3-fluorophenyl)oxazolidin-2-one

Diisopropylazodicarboxylate (0.22g, 1.1mmol) was added dropwise at ambient temperature to a stirred solution of 5(R)-hydroxymethyl-3-(4-[3,6-dihydro-(2H)-pyran-4-yl]-3-

- 10 fluorophenyl)oxazolidin-2-one (WO97/09328; 0.275g, 0.93mmol), 3-hydroxy-1,2,5-thiadiazole (Weinstock *et al.* Journal of Organic Chemistry 32, 2823 [1967]; 0.112g, 1.1mmol) and triphenylphosphine (0.288g, 1.1mmol) in dry THF (7ml). The solution was kept for 1.5 hours. Solvent was evaporated and the residue was purified by flash column chromatography, eluting with EtOAc/isohexane (1:1)
- 15 to give the title product (0.256g, 73%) as a solid (mp 146-148 °C). MS: 378 (MH⁺); NMR: 2.4 (1H, bs); 3.78 (3H, t); 3.96 (1H, m); 4.2 (3H, m); 4.66 (2H, m); 5.1 (1H, m); 6.05 (1H, s); 7.27-7.5 (3H, m); 8.41 (1H, s).

Example 143 : 5(R)-(3-Methyl-1,2,5-oxadiazol-5-oxide-4-yl)oxymethyl-3-(4-[3,6-dihydro-(2H)-pyran-4-yl]-3-fluorophenyl)oxazolidin-2-one

- 20 Sodium hydride (28mg of a 60% suspension in mineral oil, 0.69mmol) was added portionwise to a solution of 5(R)-hydroxymethyl-3-(4-[3,6-dihydro-(2H)-pyran-4-yl]-3-fluorophenyl)oxazolidin-2-one (0.2g, 0.69mmol) in dry dimethoxyethane (3ml) and the mixture was stirred for 40 minutes. 3-Methyl-4-nitro-1,2,5-oxadiazole-5-oxide [Nikolaeva *et*
- 25 *al.* Izv. Akad. Nauk SSSR, Ser. Khim. 965 (1972)] (0.1g, 0.69mmol) was added portionwise over 5 minutes and the cloudy solution stirred for 40 minutes. Water (20ml) was added and the mixture extracted three times with EtOAc. The combined extracts were dried by filtration through phase separation paper (Whatman 1PS) and evaporated. The residue was purified by flash column chromatography, eluting with EtOAc/isohexane (7:3) to give the title product
- 30 (0.112g, 41%) as a solid mp 138-140°C. NMR(CDCl₃): 2.07 (3H, s); 2.5 (2H, bs); 3.91 (3H, t); 4.2 (1H, t); 4.31 (2H, m); 4.62 (2H, m); 5.06 (1H, m); 6.05 (1H, s); 7.2-7.42 (3H, m).

Example 144 : 5(R)-(2-Methyl-1,3,4-oxadiazol-5-yl)oxymethyl-3-(4-[3,6-dihydro-(2H)-pyran-4-yl]-3-fluorophenyl)oxazolidin-2-one

Sodium hydride (28mg of a 60% suspension in mineral oil, 0.69mmol) was added to a solution of 5(R)-hydroxymethyl-3-(4-[3,6-dihydro-(2H)-pyran-4-yl]-3-fluorophenyl)oxazolidin-2-one (0.2g, 0.69mmol) in DMSO (5ml) and the mixture was stirred for 1 hour. 2-Methyl-5-sulfonylmethyl-1,3,4-oxadiazole (RB Woodward *et al*, (Journal of the American Chemical Society 105, 904 [1983]) (0.11g, 0.69mmol) was added and the solution heated at 110°C for 9 hours. Water (40ml) was added and the mixture extracted three times with EtOAc. The combined extracts were dried by filtration through phase separation paper (Whatman 1PS) and evaporated. The residue was purified by flash column chromatography, eluting first with EtOAc and then with EtOAc/MeOH (20:1) to give the title product (23mg, 9%) as a solid (mp 146-147°C). MS: 376 (MH⁺). NMR(CDCl₃): 2.41 (3H, s); 2.49 (2H, bs); 3.91 (3H, t); 4.18 (1H, t); 4.31 (2H, m); 4.7 (2H, m); 5.05 (1H, m); 6.04 (1H, s); 7.23 (2H, m); 7.4 (1H, d).

Example 145 : 5(R)-(5-Methoxycarbonylisoxazol-3-yl)oxymethyl-3-(4-[3,6-dihydro-(2H)-pyran-4-yl]-3-fluorophenyl)oxazolidin-2-one

Using the method of Example 142 but starting from 5-methoxycarbonyl-3-hydroxyisoxazole, the title compound was obtained in 65% yield as a solid (mp 145-147°C). MS: 419 (MH⁺). NMR(CDCl₃): 2.5 (2H, bs); 3.93 (3H, s + 3H, m); 4.18 (1H, t); 4.32 (2H, s); 4.59 (2H, m); 5.04 (1H, m); 6.06 (1H, s); 6.58 (1H, s) 7.24 (2H, m); 7.4 (1H, d).

Example 146 : 5(R)-1,2,5-Thiadiazol-3-ylloxymethyl-3-(4-iodophenyl)oxazolidin-2-one

Iodine (0.67g, 2.64mmol) was added portionwise to a stirred solution of 5(R)-1,2,5-thiadiazol-3-ylloxymethyl-3-phenyloxazolidin-2-one (0.7g, 2.53mmol) and silver trifluoroacetate (0.727g, 3.29mmol) in acetonitrile (4ml) and chloroform (6ml). The mixture was stirred for 24 hours in the dark. The mixture was filtered and the filtrate evaporated. The residue was extracted with EtOAc and the extract washed with water, dilute ammonia (0.1ml of 0.88SG ammonia in 25ml water), water and brine, dried (Na₂SO₄) and evaporated to give the title product as a solid (0.749g, 73%)

- 153 -

MS: 404 (MH⁺); NMR: 3.94 (1H, m); 4.18 (1H, t); 4.67 (2H, m); 5.1 (1H, m); 7.38 (2H, d); 7.7 (2H, d); 8.41 (1H, s).

The necessary starting material, 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-phenyloxazolidin-2-one, was made by the method of Example 142, but starting from

- 5 5(R)-hydroxymethyl-3-phenyloxazolidin-2-one (Gregory, WA. *et al*, J. Med. Chem. (1989), 32, 1673-81), the title product being obtained as a solid in 83% yield. MS: 278 (MH⁺); NMR(CDCl₃): 4.0 (1H, m); 4.2 (1H, t); 4.68 (2H, m); 5.04 (1H, m); 7.18 (1H, t); 7.4 (2H, t); 7.55 (2H, d); 8.0 (1H, s).

10 **Example 147 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-[2,5-dihydrothiophen-1,1-dioxo-3-yl]phenyl)oxazolidin-2-one**

- A mixture of 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(4-iodophenyl)oxazolidin-2-one (Example 146) (0.6g, 1.49mmol), 2,5-dihydrothiophen-1,1-dioxide (0.185g, 1.57mmol), triethylamine (0.26ml, 0.187mmol), tetrabutylammonium bromide (0.48g, 1.49mmol) and
15 palladium acetate (17mg, 0.0759mmol) in DMF (4ml) was heated at 60°C for 19 hours under nitrogen. After cooling, the mixture was partitioned between water and EtOAc and the aqueous layer was twice further extracted with EtOAc. The combined extracts were washed with water and brine, dried (Na₂SO₄) and evaporated. The residue was triturated with acetonitrile to give the title product (71mg, 12%) as a solid. MS: 394 (MH⁺);
20 NMR(400MHz): 4.0 (1H, m); 4.1 (2H, m); 4.25 (1H, t); 4.4 (2H, s); 4.7 (2H, m); 5.15 (1H, m); 6.57 (1H, s); 7.6 (4H, m); 8.45 (1H, s).

Example 148 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(3-fluoro-4-(1-(2(S),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one

- 25 1N aqueous HCl (1ml) was added to a solution of 5(R)-(1,2,5-thiadiazol-3-yloxymethyl)-3-(3-fluoro-4-(1-(2,2-dimethyl-1,3-dioxolan-4(S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one (0.154g, 0.32mmol) in THF (3ml) and the solution kept for two days. The solution was evaporated and the residue azeotroped twice with ethanol. The residue was purified by chromatography on a BondElut silica column, eluting first with
30 dichloromethane and then 2% MeOH/ dichloromethane to give the title product (37mg, 26%) as a solid. MS: 465 (MH⁺); NMR(400MHz): 2.5 (2H+DMSO); 3.3 (1H, s) 3.4 (1H, m); 3.5

- 154 -

(1H, m); 3.76 (1H, m); 4.0 (1H, t); 4.15 (1H, s); 4.26 (1H, t); 4.4 (1H, m); 4.8 (3H, m); 4.97 (1H, m); 5.18 (1H, m); 6.03 (1H, s); 7.32-7.46 (2H, m); 7.53 (1H, d); 8.47 (1H, s).

The necessary starting material was made by the method of Example 142, but starting from 5(R)-hydroxymethyl-3-(3-fluoro-4-(1-(2,2-dimethyl-1,3-dioxolan-4(S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one (prepared by analogy to Example 11) to give the title product in 56% yield. MS: 505 (MH⁺); NMR; 1.32 (6H, s); 2.41 (2H+DMSO); 3.58 (1H, m); 3.66 (2H, m); 3.82 (1H, t); 4.02- 4.27 (5H, m); 4.69 (1H, m); 4.9 (1H, m); 5.19 (1H, t); 6.0 (1H, s); 7.32 (2H, m); 7.5 (1H, d); 8.47.

10 **Example 149 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-(1-(2(R),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one**

Using the method described for Example 148, but starting from 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(R)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one, the title product was obtained in 50% as a solid. MS: 15 465 (MH⁺); NMR(400MHz): 2.42 (2H+DMSO); 3.5 (1H, m); 3.58 (1H, m); 3.71 (1H, m); 3.98 (1H, t); 4.1 (1H, s); 4.2 (1H, t); 4.35 (1H, m); 4.77 (3H, m); 4.93 (1H, m); 5.12 (1H, m); 6.02 (1H, s); 7.3-7.42 (2H, m); 7.5 (1H, d); 8.42 (1H, s).

The necessary starting material, 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(R)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluoro phenyl)oxazolidin-2-one, was made as follows:-

- i) 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(3-fluoro-4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one was made by the method of Example 142, but starting from 5(R)-hydroxymethyl-3-(4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one (WO97/30995 & by analogy to reference Example 4) in 25 58% yield. MS: 467 (MH⁺); NMR; 2.4 (2H+DMSO); 2.6 (2H, m); 3.02 (2H, m); 3.57 (2H, s); 3.92 (1H, m); 4.2 (1H, t); 4.62 (2H, m); 5.1 (1H, m); 5.91 (1H, s); 7.2-7.4 (7H, m); 7.48 (1H, d); 8.4 (1H, s).
- ii) Diisopropylethylamine (0.39ml, 2.24mmol) was added dropwise to a stirred solution at 5°C under nitrogen of 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one (3.48g, 7.47mmol) in 30 dichloromethane (60ml), followed by 1-chloroethyl chloroformate (1.05ml, 9.73mmol).

- The mixture was stirred at 5°C for 2 hours and the intermediate carbamate was freed from benzyl chloride by flash-column chromatography (silica gel, Merck 7736), eluting with a gradient of 10-30% EtOAc in isohexane. The carbamate was heated in refluxing MeOH (40ml) for 1 hour. Solvent was evaporated and the residue triturated with ether to give
- 5 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(3-fluoro-4-(1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one hydrochloride as a solid in 82% yield MS: 376 (MH⁺)(free base); NMR: 2.67 (2H, s); 3.3 (2H+DMSO); 3.75 (2H, s); 4.0 (1H, m); 4.25 (1H, t); 4.7 (2H, m); 5.14 (1H, m); 6.05 (1H, s); 7.4 (2H, m); 7.55 (1H, d); 8.42 (1H, s); 9.35 (1H, bs).
- 10 iii) A solution of (R)-2,2-dimethyl-1,3-dioxolan-4-ylcarbonyl chloride (S Handa *et al*, Synth. Commun. (1995), 25, 2837) [0.597g, 3.63mmol] in dichloromethane (5ml) was added dropwise to a stirred mixture of 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(3-fluoro-4-(1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one hydrochloride (1g, 2.42mmol) and pyridine (0.49ml, 6.06mmol) in dichloromethane (30ml) under nitrogen at -10°C. After
- 15 10 minutes the cooling bath was removed and the mixture stirred for a further hour. Water (30ml) was added and the organic layer washed with brine, dried (Na₂SO₄) and evaporated. The residue was triturated with ether and filtered to give 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(R)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one as a solid (1.13g, 93%) MS: 504
- 20 (MH⁺); NMR: 1.32 (6H, s); 2.42 (2H+DMSO); 3.7 (2H, m); 4.0 (1H, m); 4.11 (2H, m); 4.25 (2H, m); 4.8 (2H, m); 4.91 (1H, m); 5.12 (1H, m); 6.02 (1H, s); 7.29-7.43 (2H, m); 7.5 (1H, d); 8.42 (1H, s).

Example 150 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(3,5-difluoro-4-(1-(2(S),3-

25 **dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one**

- Using the method described for Example 148, but starting from 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(3,5-difluoro-4-(1-(2,2-dimethyl-1,3-dioxolan-4(S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one, the title compound was obtained in 51% yield as a solid. MS: 483 (MH⁺); NMR: 2.48 (2H+DMSO); 3.48 (1H, m); 3.54 (1H, m); 3.97. (1H,
- 30 t); 4.1 (1H, s); 4.17 (1H, t); 4.34 (1H, m); 4.67 (3H, m); 4.95 (1H, m); 5.12 (1H, m); 5.88 (1H, s); 7.33 (1H, s); 7.36 (1H, s); 8.42 (1H, s).

The necessary starting material was made as follows:-

- i) Using the method described for Example 149 step i), but starting from 5(R)-hydroxymethyl-3-(4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one, there was obtained in 58% yield, 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one as a solid. MS: 485 (MH⁺); NMR; 2.3 (2H, bs); 2.6 (2H, t); 3.03 (2H, s); 3.39 (2H, s); 3.95 (1H, m); 4.2 (1H, t); 4.65 (2H, m); 5.12 (1H, s); 5.77 (1H, s); 7.2-7.38 (7H, m); 8.41 (1H, s).
- ii) Using the method described for Example 149 step ii), but starting from 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one, there was obtained in 84% yield, 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(3,5-difluoro-4-(1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one hydrochloride as a solid. MS: 395 (MH⁺)(free base); NMR; 2.51 (2H, s); 3.28 (2H+DMSO); 3.71 (2H, s); 3.98 (1H, m); 4.2 (1H, t); 4.65 (2H, m); 5.1 (1H, m); 5.88 (1H, s); 7.33 (1H, s); 7.39 (1H, s); 8.41 (1H, s); 9.32 (1H, bs).
- iii) Using the method described for Example 149 step iii), but starting from, 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(3,5-difluoro-4-(1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one hydrochloride and the appropriate (S)-dioxolan there was obtained in 86% yield, 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(4-(1-(2,2-dimethyl-1,3-dioxolan-4(S)-ylcarbonyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one as a solid. MS: 523 (MH⁺); NMR: 1.31 (6H, 2s); 2.4 (2H+DMSO); 3.6-3.8 (2H, m); 4.08-4.2 (5H, m); 4.9 (1H, m); 5.12 (1H, m); 5.89 (1H, s); 7.32-7.37 (2H, 2s); 8.41 (1H, s).

Example 151 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-(1-hydroxyacetyl-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one

A saturated solution of ammonia in MeOH (8ml) was added to a stirred solution of 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(4-(1-acetoxyacetyl-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one (0.275g, 0.576mmol) in MeOH (8ml) and the solution kept for 20 hours. A small amount of insoluble material was filtered off and the filtrate concentrated. On keeping at 5°C, a solid was obtained which was filtered and washed with a little cold

MeOH and then cold ether to give the title compound (0.161g, 64%) as a solid. MS: 435 (MH⁺); NMR: 2.42 (2H+DMSO); 3.52 (1H, m); 3.67 (1H, m); 3.94. (1H, m); 4.0-4.17 (4H, m); 4.2 (1H, t); 4.5-4.73 (3H, m); 5.12 (1H, m); 6.0 (1H, m); 7.28-7.42 (2H, m); 7.5 (1H, dd); 8.42 (1H, s).

5 The necessary starting material, was made as follows:-

Acetoxyacetyl chloride (0.21ml, 1.95mmol) was added to a stirred mixture of 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(3-fluoro-4-(1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one hydrochloride (product of step ii, Example 149) [0.412g, 1mmol] and sodium bicarbonate (0.42g, 5mmol) in acetone/water (15ml, 2:1) at 5°C. The mixture was allowed to warm up to
10 room temperature after 10 minutes and stirred for 18 hours. More acetoxyacetyl chloride (0.3ml) and sodium bicarbonate (0.42g,) were added and after a further 6 hours, water was added and the mixture extracted three times with EtOAc. The combined extracts were washed successively with water, 1N HCl and brine, dried (Na₂SO₄) and evaporated. The residue was triturated with ether and the solid filtered to give 5(R)-1,2,5-thiadiazol-3-
15 yloxymethyl-3-(4-(1-acetoxyacetyl-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one (0.3g, 63% yield). MS: 477 (MH⁺); NMR: 2.08 (3H, s); 2.42 (2H+DMSO); 3.4 (2H, m); 3.98 (1H, m); 4.08 (2H, bs); 4.21 (1H, t); 4..65 (2H, m); 4.8 (2H, m); 5.12 (1H, m); 6.0 (1H, m); 7.31 (2H, m); 7.5 (1H, d); 8.4 (1H, s).

20 **Example 152 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-{1-hydroxyacetyl-1,2,5,6-tetrahydropyrid-4-yl}-3,5-difluorophenyl)oxazolidin-2-one**

Using the method described for Example 151, but starting from 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(4-(1-acetoxyacetyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one, the title compound was obtained in 80% yield as a solid.
25 MS: 453 (MH⁺); NMR: 2.34 (2H, m); 3.54 (1H, m); 3.71 (1H, m); 4.1 (1H, m); 4.05-4.28 (5H, m); 4.2 (1H, t); 4.54-4.72 (3H, m); 5.15 (1H, m); 5.89 (1H, m); 7.39 (2H, d); 8.45 (1H, s).

The necessary starting material was made by the method used to make the starting material for Example 151, but starting from 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(3,5-difluoro-4-
30 (1,2,5,6-tetrahydropyrid-4-yl)phenyl)oxazolidin-2-one hydrochloride (see Example 150 product (ii)) to give the product in 78% yield. MS: 477 (MH⁺); NMR: 2.08 (3H, s); 2.42


(2H+DMSO); 3.4 (2H, m); 3.98 (1H, m); 4.08 (2H, bs); 4.21 (1H, t); 4.65 (2H, m); 4.8 (2H, m); 5.12 (1H, m); 6.0 (1H, m); 7.31 (2H, m); 7.5 (1H, d); 8.4 (1H, s).

Example 153 : 5(R)-Imidazol-2-ylthiomethyl-3-(4-[3,6-dihydro-(2H)-pyran-4-yl]-3-

5 fluorophenyl)oxazolidin-2-one

1,8-Diazabicyclo[5,4,0]undec-7-ene (0.1ml, 0.674mmol) was added to a stirred suspension of 5(R)-methanesulfonyloxymethyl 3-(4-[3,6-dihydro-(2H)-pyran-4-yl]-3-fluorophenyl)oxazolidin-2-one (prepared from the 5(R)-hydroxymethyl compound (WO97/09328) by reaction with methylsulfonyl chloride) (0.25g, 0.674mmol) and 2-mercaptoimidazole (0.067g, 0.674mmol) in dioxan (2ml) under nitrogen. The mixture was heated at 60°C for 4 hours and evaporated. The residue was purified by column chromatography, eluting first with 2% MeOH/EtOAc and then with 4% MeOH/EtOAc to give the title product as a solid (0.077g, 30%); mp 178-179°C (dec.) MS: 476 (MH⁺); NMR: 2.39 (2H, bs); 3.42 (2H, m); 3.79 (2H, t); 3.86 (1H, m); 4.19 (3H, m); 4.89 (1H, m); 6.07 (1H, s); 7.04 (2H, s); 7.26 (1H, dd); 7.38 (1H, t); 7.46 (1H, d).

Example 154 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-((1S)(4S)-2-benzyl-2,5-diazabicyclo{2.2.1}heptan-5-yl)-3-fluorophenyl)oxazolidin-2-one



A mixture of 1-amino-4-[(1S)(4S)-2-benzyl-2,5-diazabicyclo{2.2.1}heptan-5-yl]-3-fluorobenzene (0.13g, 0.438mmol) and 3(S)-oxiranylmethoxy-1,2,5-thiadiazole (0.069g, 0.483mmol) in MeOH (2ml) was stirred and heated at 60°C for 20 hours. Solvent was evaporated and the residue partially purified by flash column chromatography, eluting with 4/96/0.8 MeOH/dichloromethane/0.88SG ammonia. The resulting crude ethanolamine (0.144g), with diethyl carbonate (0.2 ml), sodium methoxide (9mg) and MeOH (0.05ml) was stirred and heated at 110°C for 5 hours. The reaction mixture was purified by flash column chromatography, eluting with EtOAc/0.1% 0.88SG ammonia to give an oil which was triturated with ether to give the title product as a solid (mp 97-98°C) (0.049g, 23% over two stages). MS: 482 (MH⁺); NMR(CDCI₃); 1.83-2.0 (2H, dd); 2.72-2.96 (2H, dd); 3.41 (1H, m);

- 159 -

3.5 (2H, s); 3.91 (1H, m); 4.13 (1H, t); 4.3 (1H, s); 4.67 (2H, m); 5.0 (1H, m); 6.6 (1H, t); 7.05 (1H, dd); 7.2-7.38 (6H, m); 8.02 (1H, s).

The necessary starting materials were made as follows:-


1-Amino-4-[(1S)(4S)-2-benzyl-2,5-diazabicyclo{2.2.1}heptan-5-yl]-3-fluorobenzene :

- 5 i) A mixture of (1S)(4S)-2-benzyl-2,5-diazabicyclo{2.2.1}heptane dihydrobromide [Henry *et al.* J. Med. Chem. (1974), 17, 481] (1.05g, 3mmol), 3,4-difluoronitrobenzene (0.48g, 3mmol) and 1,8-diazabicyclo[5,4,0]undec-7-ene (1.38g, 9mmol) in acetonitrile (10ml) was stirred and heated at reflux for 2 hours. Solvent was evaporated and the residue was partitioned between EtOAc and water. The organic layer was filtered (1PS paper) and the
- 10 filtrate evaporated to give 4-[(1S)(4S)-2-benzyl-2,5-diazabicyclo{2.2.1}heptan-5-yl]-3-fluoro-1-nitrobenzene (0.95g, 97%) as a solid. MS: 328 (MH⁺); NMR(CDCl₃); 1.82-2.07 (2H, dd); 2.77-2.98 (2H, dd); 3.59 (2H+1H, s); 3.72 (2H, s); 3.91 (1H, m); 4.58 (1H, s); 6.6 (1H, t); 7.2-7.34 (5H+ CHCl₃);
- ii) Hydrazine hydrate (0.57 ml) was added to a suspension of 4-[(1S)(4S)-2-benzyl-2,5-
- 15 diazabicyclo{2.2.1}heptan-5-yl]-3-fluoro-1-nitrobenzene (1.63g, 5mmol) in ethanol (35ml) with stirring, followed by Raney nickel (~1g). The mixture was heated at 60°C for 1.5 hours. More hydrazine hydrate (0.2 ml) and Raney nickel (~0.5g) were added and heating continued for a further 3 hours. The mixture was cooled and stirred with charcoal (0.5g) for 1 hour and filtered. The filtrate was evaporated to give 1-amino-4-[(1S)(4S)-2-benzyl-2,5-
- 20 diazabicyclo{2.2.1}heptan-5-yl]-3-fluorobenzene (1.28g, 86%) as an oil. MS: 287 (MH⁺); NMR(CDCl₃); 1.8-1.95 (2H, dd); 2.73-2.9 (2H, dd); 3.17-3.5 (5H, m); 3.71 (2H, s); 4.12 (1H, s); 6.32-6.52 (3H, m); 7.18-7.35 (5H+ CHCl₃).

3(S)-oxiranymethoxy-1,2,5-thiadiazole :


- Diisopropylazodicarboxylate (4.2g, mmol) was added dropwise at ambient temperature to a
- 25 stirred solution of (S)-glycidol (1.54g), 3-hydroxy-1,2,5-thiadiazole (2.12g, 20.8mmol) and triphenylphosphine (5.45g, 20.8mmol) in dry THF (25ml). The solution was kept for 21 hours. Solvent was evaporated and the residue was extracted twice with isohexane (2x 50ml). The combined extracts were evaporated and the residue purified by flash column chromatography, eluting with EtOAc/isohexane (1:3) to give the title product (0.41g) as an
 - 30 oil NMR(CDCl₃); 2.75 (1H, m); 2.9 (1H, m); 3.38 (1H, m); 4.28 (1H, m); 4.7 (1H, m); 8.0 (1H, s).

Example 155 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-[(1S)(4S)-2,5-diazabicyclo{2.2.1}heptan-5-yl]-3-fluorophenyl)oxazolidin-2-one hydrochloride




- 5 Diisopropylethylamine (52mg, 0.4mmol) was added dropwise to a stirred solution at 5°C under nitrogen of 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-[(1S)(4S)-2-benzyl-2,5-diazabicyclo{2.2.1}heptan-5-yl]-3-fluorophenyl)oxazolidin-2-one (0.65g, 1.35mmol) in dichloromethane (10ml), followed by 1-chloroethyl chloroformate (0.19ml, 1.76mmol). The mixture was stirred at 5°C for 2 hours and the intermediate carbamate was freed from benzyl chloride by trituration with three portions of isohexane (3x15ml). The carbamate was heated
10 in refluxing MeOH (10ml) for 1 hour. Solvent was evaporated and the residue triturated with acetone to give the title product as a solid (0.366g, 63% yield). MS: 391 (MH⁺); NMR(CDCl₃); 2.0 (2H, dd); 3.2-3.34 (2H+DMSO); 3.56 (2H, dd); 3.9 (1H, m); 4.18 (1H, t); 4.34 (1H, s); 4.5 (1H, s); 5.07 (1H, m); 6.86 (1H, t); 7.15 (1H, d); 7.45 (1H, d); 8.42 (1H, s);
15 9.04 (1H, bs); 9.57 (1H, bs).

Example 156 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-[(1S)(4S)-2-acetoxvacetyl-2,5-diazabicyclo{2.2.1}heptan-5-yl]-3-fluorophenyl)oxazolidin-2-one




- 20 Using the method to make the starting material for Example 151 but starting from the title product of Example 155, the title product was obtained as an amorphous solid in 46% yield. MS: 491 (MH⁺); NMR(CDCl₃); 1.85-2.02 (2H, dd); 2.03 (3H, s); 3.28 (1H, d); 3.57 (1H, s); 3.63-3.83 (2H, m); 3.91 (1H, m); 4.1 (1H, t); 4.42-4.73 (5H, m); 5.0 (2H, m); 6.6 (1H, m); 7.07 (1H, m); 7.4 (1H, d); 8.01 (1H, s).
25 **Example 157 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-[(1S)(4S)-2-hydroxyv acetyl-2,5-diazabicyclo{2.2.1}heptan-5-yl]-3-fluorophenyl)oxazolidin-2-one**

- 161 -



A solution of the title product of Example 156 (91mg, 0.185mmol) in MeOH saturated with ammonia (2.5ml) was kept for 22 hours. Solvent was evaporated and the residue was redissolved in dichloromethane (5ml) and the solution washed with water. The organic layer was dried by filtration through phase separation paper (Whatman 1PS) and evaporated to give the title product as a foam (57mg, 69%). MS; 450 (MH⁺); NMR(CDCl₃); 1.85-2.17 (2H, m); 3.14-3.84 (5H, m); 3.88-4.29 (4H, m); 4.6-4.74 (3H, m); 5.0 (2H, m); 6.6 (1H, m); 7.08 (1H, m); 7.38 (1H, d); 8.02 (1H, s).

10 **Example 158 : 5(R)-1,2,5-Thiadiazol-3-yloxymethyl-3-(4-[(1S)(4S)-2-(2(S),3-dihydroxypropanoyl)-2,5-diazabicyclo{2.2.1}heptan-5-yl]-3-fluorophenyl) oxazolidin-2-one**




Using the method to make the starting material for Example 148 but starting from 5(R)-1,2,5-thiadiazol-3-yloxymethyl-3-(3-fluoro-4-(2-(2,2-dimethyl-1,3-dioxolan-4(S)-ylcarbonyl)-2,5-diazabicyclo{2.2.1}heptan-5-yl)phenyl)oxazolidin-2-one, the title product was obtained as an amorphous solid in 79% yield MS: 480 (MH⁺); NMR(400MHz, DMSO-d₆+acetic acid-d₄); 1.87-2.0 (2H, m); 3.12 (1H, m); 3.31 (1H, d); 3.48 (2H, m); 3.65 (2H, m); 3.86 (1H, m); 4.11 (1H, m); 4.45 (1H, m); 4.62 (1H, m); 4.78 (1H, m); 5.02 (1H, m); 6.78 (1H, m); 7.12 (1H, m); 7.4 (1H, dd); 8.33 (1H, s).

The necessary starting material was made as a solid in 63% yield (MS: 520 (MH⁺)) by the method used to make the starting material for Example 149 step iii), but starting from the title product of Example 155 and the appropriate (S)-dioxolan.

25 **Example 159 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-{8-acetoxycetyl-8-azabicyclo[3.2.1]oct-2-ene-3-yl}-3-fluorophenyl)oxazolidin-2-one**

- 162 -



- Acetoxycetyl chloride (0.3ml, 2.72mmol) was added dropwise to a stirred mixture of 5(R)-isoxazol-3-ylloxymethyl-3-(4-{8-azabicyclo[3.2.1]oct-2-enc-3-yl}-3-fluorophenyl)oxazolidin-2-one (0.35g, 0.91mmol), acetone (7ml), sodium bicarbonate (0.35g, 4.17mmol) and water (3.5ml) and the mixture was stirred for 2hours. More sodium bicarbonate (0.7g) and acetoxycetyl chloride (0.15ml) were added and after 2.5 hours a further portion of sodium bicarbonate (0.7g) was added and the mixture stirred for 20 hours. Solvent was evaporated and the residue partitioned between water and EtOAc. The organic layer was washed with sodium bicarbonate solution, dried (Na_2SO_4) and evaporated. The residue was purified by chromatography on a MegaBondElut column, eluting with a gradient of dichloromethane-6% MeOH/dichloromethane to give the title product as an oil (0.16g, 36%). MS: 486 (MH^+); NMR(400MHz): 1.79 (2H, m); 1.88-2.1 (5H, s+m); 2.25 (2H, d); 3.56 (1H, t); 3.62 (1H, m); 3.9 (1H, m); 4.19 (1H, t); 4.48 (3H, m); 4.62 (1H, m); 4.78 (2H, m); 5.06 (1H, m); 6.32 (1H, t); 6.35 (1H, s); 7.3 (2H, m); 7.48 (1H, dd); 8.66 (1H, s).
- The necessary starting material was made as follows:-
- Tris(dibenzylideneacetone) dipalladium(0) (0.19g, 0.208mmol), triphenylarsine (0.13g, 0.425mmol) and lithium chloride (0.265g, 6.31mmol) were added to a stirred solution of 5(R)-isoxazol-3-ylloxymethyl-3-(3-fluoro-4-iodophenyl)oxazolidin-2-one (prepared by analogy to reference Example 28) (0.85g, 2.1mmol) in degassed DMF (35ml) under nitrogen. After 5 minutes, a solution of 8-tert-butyloxycarbonyl-3-trimethylstannyl-8-azabicyclo[3.2.1]oct-2-ene (GB 2298647 ; 0.78g, 2.1mmol) in DMF (4ml) was added and the mixture was heated at 60°C for 18 hours. A solution of 2M potassium fluoride (30ml) was added and the mixture stirred for 40 minutes. Solvent was evaporated and the residue partitioned between water and EtOAc. The aqueous layer was extracted twice with EtOAc and the combined extracts dried (Na_2SO_4) and evaporated. The residue was purified by column chromatography, eluting with a gradient of dichloromethane-5% MeOH/dichloromethane to give 5(R)-isoxazol-3-ylloxymethyl-3-(4-{8-tert-


- 163 -

butyloxycarbonyl-8-azabicyclo[3.2.1]oct-2-ene-3-yl}-3-fluorophenyl)oxazolidin-2-one as an oil of 85% purity [hplc](0.97g, 81%). MS: 486 (MH⁺).

- ii) Saturated methanolic HCl (1ml) was added to a solution of the product of step i) (0.07g, 0.144mmol) in MeOH (1ml) and the mixture kept for 20 hours. Solvent was evaporated and the residue partitioned between water and EtOAc. The organic layer was washed with brine, dried (Na₂SO₄) and evaporated to give 5(R)-isoxazol-3-yloxymethyl-3-(3-fluoro-4-iodophenyl)oxazolidin-2-one as an oil (0.03g, 54% yield). MS: 386 (MH⁺).

Example 160 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-{8-hydroxyacetyl-8-azabicyclo

10 [3.2.1]oct-2-ene-3-yl}-3-fluorophenyl)oxazolidin-2-one



- Saturated methanolic ammonia (2ml) was added to a solution of the title product of Example 159 (0.21g) in MeOH/dichloromethane (1/1, 1ml) and the mixture kept for 44 hours. Solvent was evaporated and the residue purified by chromatography on a MegaBondElut column, eluting with a gradient of 10% EtOAc/ dichloromethane-50% EtOAc/dichloromethane-5% MeOH/dichloromethane -10% MeOH/dichloromethane to give the title product as an oil (0.03g, 27%). MS: 444 (MH⁺); NMR 1.75 (2H, m); 1.98 (2H, m); 2.24 (2H, m); 2.82 (1H, bd); 3.9 (1H, m); 4.10 (1H, t); 4.19 (1H, t); 4.46 (3H, m); 4.66 (1H, t); 5.08 (1H, m); 6.32 (1H, d); 6.36 (1H, s); 7.29 (1H, m); 7.34 (1H, m) 7.48 (1H, dd); 8.68 (1H, s).

20

N.B : The stereochemistry of the azabicyclo rings in Examples 159 and 160 is a mixture of (1S),(5R) and (1R),(5S), with the numbering ordered to give the lowest number to the double bond.

25 Example 161 : 3-(4-methylthio)phenyl-5(R)-(2-thiazovloxymethyl)oxazolidin-2-one

Sodium hydride (60% w/w in oil, 387 mg, 10 mmol) was washed with isohexane and suspended in DMF (2 ml) under nitrogen. 5(R)-hydroxymethyl-3-(4-methylthiophenyl)oxazolidin-2-one (1.39 g, 5.8 mmol) was dissolved in DMF and added

dropwise to the hydride suspension. Gas was evolved and stirring at ambient temperature was continued for 2 hours. 2-Bromothiazole (0.52 ml, 5.8 mmol) in DMF (10 ml) was added slowly, an exotherm from 22 to 29°C was observed. The reaction mixture was then stirred at ambient temperature for 4 hours and poured into water. The product was extracted into

5 dichloromethane, dried (MgSO_4) and concentrated to leave a dark brown gum. The residue was purified by flash chromatography on silica gel, eluting with EtOAc: isohexane, 2:1. The relevant fractions were combined and evaporated to give the product as a white powder (740 mg, mp 83-86°C).

MS: 322 (M^+), 323(MH^+) for $\text{C}_{14}\text{H}_{14}\text{N}_2\text{O}_3\text{S}_2$

10 NMR (CDCl_3) 7.5 (m, 2H); 7.3 (m, 2H); 7.11 (d, 1H); 6.75 (d, 1H); 5.05 (M, 1H); 4.7 (dd, 2H); 4.15 (t, 1H); 4.00 (dd, 1H); 2.5 (s, 3H).

Example 162 : 3-(4-methylsulfonylphenyl)-5(R)-(2-thiazoyloxymethyl)-oxazolidin-2-one

3-(4-methylthiophenyl)-5(R)-(2-thiazoyloxymethyl)oxazolidin-2-one (600 mg, 2.0 mmol) was

15 dissolved in dichloromethane (20 ml). 3-Chloroperoxybenzoic acid (50% w/w, 1.42 g, 4.13mmol) was added portionwise maintaining the temperature at < 20°C with external cooling. A white suspension formed and this was stirred at ambient temperature for 2 hours. The reaction mixture was concentrated under reduced pressure yielding a white solid. This was triturated twice, initially using diethyl ether and then using dichloromethane leaving the

20 oxidised product as a white powder (285mg, mp 136°C). MS: 354 (M^+), 355(MH^+) for $\text{C}_{14}\text{H}_{14}\text{N}_2\text{O}_5\text{S}_2$

NMR ($\text{DMSO}-d_6$) 7.95 (m, 2H); 7.82 (m, 2H); 7.12 (d, 1H); 6.82 (d, 1H); 5.15 (M, 1H); 4.74 (m, 2H); 4.32 (t, 1H); 4.08 (dd, 1H); 3.09 (s, 3H).

25 **Example 163 : 3-(4-Methylsulfonylphenyl)-5(R)-(isoxazol-3-yloxymethyl)oxazolidin-2-one**

5(R)-hydroxymethyl-3-(4-methylthiophenyl)oxazolidin-2-one (see Example 42; 1.0 g, 4.18 mmol), 3-hydroxyisoxazole (0.43 g, 5.05 mmol) and tributylphosphine (1.4 g, 5.34 mmol) were suspended in tetrahydrofuran (10 ml) under nitrogen. Diethylazodicarboxylate (0.79 ml,

30 5.02 mmol) was added dropwise, an exotherm from 19 to 33°C was observed. The resulting yellow solution was stirred at ambient temperature for 2 hours. The complete reaction mixture

was then passed down a flash chromatography column using silica gel, eluting with EtOAc: isohexane, 7:3. The relevant fractions were combined and evaporated to give impure product as a white powder (1.4 g). A portion of this crude material (388 mg,) was dissolved in dichloromethane (20 ml). 3-Chloroperoxybenzoic acid (50% w/w, 0.872 g, 2.5 mmol) was added portionwise, maintaining the temperature at < 20°C with external cooling, the reaction was then stirred at ambient temperature for 4 hours. The reaction mixture was concentrated under reduced pressure yielding a white solid. This was triturated with diethyl ether and filtered leaving the oxidised product as a white powder (300 mg, mp 180°C). MS (ESP): 339 (MH⁺) for C₁₄H₁₄N₂O₆S

10 NMR (CDCl₃) 8.18 (d, 1H); 7.98 (m, 2H); 7.8 (m, 2H); 6.0 (d, 1H); 5.1 (M, 1H); 4.5 (m, 2H); 4.25 (t, 1H); 4.08 (dd, 1H); 3.09 (s, 3H).

Example 164 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-bromo-pyrid-2-yl)-oxazolidin-2-one

To a stirred solution of 5(R)-hydroxymethyl-3-(4-bromo-pyrid-2-yl)oxazolidin-2-one (EP 694543; 3.75g, 13.7mmol), 3-hydroxyisoxazole (1.28g, 15.1mmol) and triphenylphosphine (4.31g, 16.4mmol) in anhydrous THF (83ml), was added dropwise diisopropyl azodicarboxylate (3.20g, 3.11ml, 15.8mmol) and stirred at room temperature for 5h. The solvent was then removed by rotary evaporation and purification by MPLC (Merck 9385 silica, eluting with CH₂Cl₂) and trituration with diethyl ether gave the title compound as

15 a white solid (2.93g, 63%)

NMR (300MHz DMSO-d₆) δ/ppm: 3.98(dd, 1H), 4.28(t, 1H), 4.50(m, 2H), 5.08(m, 1H), 6.38(d, 1H), 8.07(br s, 2H), 8.50(d, 1H), 8.69(d, 1H).

MS: (M+H)⁺ = 340 - Br isotopes.

25 **Example 165 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-tert-butoxycarbonyl-1,2,5,6-tetrahydropyrid-4-yl)pyrid-2-yl)oxazolidin-2-one**

To a stirred solution of Example 164 (340mg, 1.0mmol) in anhydrous deoxygenated DMF (8ml), under N₂, was added lithium chloride (113.6mg, 3.0mmol), bis(dibenzylideneacetone)palladium (91.6mg, 0.10mmol), triphenylarsine (124mg, 0.40mmol)

30 and the vinyl stannane (CAS[162046-38-0]; 502mg, 1.5mmol) and the reaction mixture heated to 55°C and stirred for 64 hours. The solvent was removed by high-vac. rotary evaporation

- 166 -

giving an oil which was taken into CH_2Cl_2 , filtered and purified by MPLC (Merck 9385 silica, eluted with 40% EtOAc/isohehexane), to give the title compound as a white powder (202mg, 46%) upon trituration with diethyl ether. MS: $(\text{M}+\text{H})^+ = 443$.

NMR (300MHz DMSO- d_6) δ /ppm: 1.35(s, 9H), 2.40(m, partially obscured, 2H), 3.51(t, 2H), 3.95(m, 3H), 4.27(t, 1H), 4.44(m, 2H), 5.03(m, 1H), 6.13(br s, 1H), 6.28 (d, 1H), 7.85(dd, 1H), 8.02(dd, 1H), 8.38(d, 1H), 8.54(d, 1H).

Reference Example 38 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1,2,5,6-tetrahydropyrid-4-yl)pyrid-2-yl)oxazolidin-2-one

10 To Example 165 (185mg, 0.42mmol) was added TFA (0.45ml), with stirring and heating in a water bath at 60°C, for 1 minute, to produce an orange / yellow solution which was triturated with diethyl ether to give the title compound as a yellow powder (180mg, 94%). MS: $(\text{M}+\text{H})^+ = 343$.

15 **Example 166 : 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-formyl-1,2,5,6-tetrahydropyrid-4-yl)pyrid-2-yl)oxazolidin-2-one**

Reference Example 38 (58mg, 0.13mmol) and triethylamine (71 μl , 0.51mmol) were dissolved in ethyl formate (1.0ml) and heated to reflux for 5 days, followed by removal of the solvent by high-vac rotary evaporation to give a gum which was redissolved in CH_2Cl_2 , washed with

20 water, concentrated and triturated with diethyl ether to give the title compound as a pale yellow powder (38mg, 81%). MS: $(\text{M}+\text{H})^+ = 371$.

NMR (300MHz DMSO- d_6) δ /ppm: 2.55(m, partially obscured, 2H), 3.59(m, 2H), 4.02(m, 3H), 4.27(m, 1H), 4.47(m, 2H), 5.05(m, 1H), 6.18(br s, 1H), 6.31 (d, 1H), 7.86(dd, 1H), 8.02(m, 1H), 8.09(m, 1H), 8.40(d, 1H), 8.61(d, 1H).

25

Example 167 : 5(R)-(3-methyl-1,2,4-oxadiazol-5-yloxymethyl)-3-(4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one

30

Prepared by the general method of Example 1 using Reference Example 4 (3.57g, 8.93mmol), 3-methyl-1,2,4-oxadiazol-5-one (1.00g, 0.01M), diisopropylazodicarboxylate (2.02g, 0.01M) and triphenylphosphine (2.81g, 0.011M) in dry THF (70ml). The resultant product was purified by MPLC (Merck 9385 silica, 20-30% EtOAc in tert-butyl methyl ether plus 0.5% MeOH) to give the title compound as a yellow oil (0.340g, 8%). MS: $\text{ESP}^+ (\text{M}+\text{H})^+ = 483$. $^1\text{H-NMR}$ (300MHz, CDCl_3): $\delta = 2.27$ (s, 3H), 2.44 (m, 2H), 2.60 (t, 2H), 3.17 (m, 2H), 3.64 (s, 2H), 3.89 (dd, 1H), 4.12 (m, 1H), 4.62 (m, 2H), 5.02 (m, 1H), 5.83 (s, 1H), 7.12 (m, 2H), 7.23- 7.41 (m, 5H).

10 **Reference Example 39 : 5(R)-(3-methyl-1,2,4-oxadiazol-5-yloxymethyl)-3-(4-(1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**

Prepared by the general method of Reference Example 6, using Example 167 (0.33g, 0.68mmol), diisopropylamine (0.03g, 0.21mmol) and 1-chloroethyl chloroformate (0.13g, 0.89mmol) in dichloromethane (8ml), to give the title compound as a yellow solid (0.21g, 15 72%). MS: $\text{ESP}^+ (\text{M}+\text{H})^+ = 393$. $^1\text{H-NMR}$ (300MHz, DMSO-d_6): $\delta = 2.22$ (s, 3H), 2.54 (partially obscured by DMSO, 2H), 3.25 (partially obscured by water, 2H), 3.74 (m, 2H), 3.95, 4.20 (dd x2, 2H), 4.66 (m, 2H), 5.14 (m, 1H), 5.88 (broad s, 1H), 7.35 (m, 2H), 9.25 (broad s, 2H).

20 **Example 168 : 5(R)-(3-methyl-1,2,4-oxadiazol-5-yloxymethyl)-3-(4-(1-acetoxyacetyl-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one**

Reference Example 39 (198mg, 0.46mmol), and sodium hydrogen carbonate (0.39g, 4.62mmol) were stirred in acetone/ water (2:1, 9ml) at 0°C. Acetoxyacetyl chloride (0.13g, 0.92mmol) was added dropwise and the reaction mixture was stirred at 0°C for 30min. 25 Additional acetoxyacetyl chloride (0.03g, 0.23mmol), was added and the mixture was stirred for a further 30min. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with saturated sodium chloride solution, dried (MgSO_4) and the solvent evaporated to give the title compound as a yellow solid after trituration with diethyl ether (170mg, 75%).

- 168 -

¹H-NMR (300MHz, DMSO-d₆): δ = 2.09 (s, 3H), 2.23 (s, 3H), 2.31, 2.43 (2xm, 2H), 3.57, 3.66 (2xt, 2H), 3.97, 4.22 (2x dd, 2H), 4.10 (broad d, 2H), 4.78 (m, 2H), 4.86 (d, 2H), 5.14 (m, 1H), 5.88 (m, 1H), 7.34 (m, 2H). MS: ESP⁺ (M+H)⁺ = 493.

5 Example 169

The following illustrate representative pharmaceutical dosage forms containing a compound of the formula (I), an in-vivo hydrolysable ester or a pharmaceutically-acceptable salt thereof, including a pharmaceutically-acceptable salt of an in-vivo hydrolysable ester, (hereafter compound X), for therapeutic or prophylactic use in humans:

10

(a)	<u>Tablet I</u>	<u>mg/tablet</u>
	Compound X.....	500
	Lactose Ph.Eur.....	430
	Croscarmellose sodium.....	40
15	Polyvinylpyrrolidone.....	20
	Magnesium stearate.....	10

(b)	<u>Tablet II</u>	<u>mg/tablet</u>
	Compound X.....	100
	Lactose Ph.Eur.....	179
20	Croscarmellose sodium.....	12
	Polyvinylpyrrolidone.....	6
	Magnesium stearate.....	3

(c)	<u>Tablet III</u>	<u>mg/tablet</u>
	Compound X.....	50
25	Lactose Ph.Eur.....	229
	Croscarmellose sodium.....	12
	Polyvinylpyrrolidone.....	6
	Magnesium stearate.....	3

(d)	<u>Tablet IV</u>	<u>mg/tablet</u>
30	Compound X.....	1
	Lactose Ph.Eur.....	92

- 169 -

	Croscarmellose sodium.....	4
	Polyvinylpyrrolidone.....	2
	Magnesium stearate.....	1
(e)	<u>Capsule</u>	<u>mg/capsule</u>
5	Compound X.....	10
	Lactose Ph.Eur	389
	Croscarmellose sodium.....	100
	Magnesium stearate	1
(f)	<u>Injection I</u>	
10	Compound X	50% w/v
	Isotonic aqueous solution	to 100%
(g)	<u>Injection II (e.g. bolus)</u>	
	Compound X	10% w/v
	Isotonic aqueous solution	to 100%
15 (h)	<u>Injection III</u>	
	Compound X	5% w/v
	Isotonic aqueous solution	to 100%
(i)	<u>Injection IV (e.g. infusion)</u>	
	Compound X	1% w/v
20	Isotonic aqueous solution	to 100%

Buffers, pharmaceutically-acceptable surfactants, oils or cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol, glidants (such as silicon dioxide) or complexing agents such as a cyclodextrin (for example, hydroxy-propyl β -cyclodextrin or sulfo-butyl-ether β -cyclodextrin) may be used to aid formulation. Also, improvements in aqueous solubility, if desired, may be achieved, for example, by conjugation of a compound of formula (I) with a phospholipid (such as a (phospho)choline derivative) to form a micellar emulsion.

Note : The above formulations may be obtained by conventional procedures well known in the pharmaceutical art, for example as described in "Remington : The Science & Practice of Pharmacy" Vols. I & II (Ed. A.R.Gennaro (Chairman) et al; Publisher : Mack Publishing

Company, Easton, Pennsylvania; 19th Edition - 1995) and "Pharmaceutics - The Science of Dosage Form Design" (Ed. M.E.Aulton; Publisher : Churchill Livingstone; first published 1988). The tablets (a)-(d) may be (polymer) coated by conventional means, for example to provide an enteric coating of cellulose acetate phthalate.


- 171 -

CLAIMS :

What is claimed is :

1. A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof,

5







wherein X is -O-, -S-, -SO- or -SO₂-;

HET is a C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently

- 10 selected from N, O and S, which ring is optionally substituted on an available carbon atom by 1 or 2 substituents independently selected from (1-4C)alkyl, amino, (1-4C)alkylamino, (1-4C)alkoxy, (1-4C)alkoxycarbonyl and halogen, and/or on an available nitrogen atom (provided that the ring is not thereby quaternised) by (1-4C)alkyl;


Q is selected from Q1 to Q9 :-

15


**Q1****Q2****Q3****Q4****Q5****Q6**

20


- 172 -



Q7



Q8



Q9

- 5 wherein R^2 and R^3 are independently hydrogen or fluoro;
 wherein A_1 is carbon or nitrogen; B_1 is O or S (or, in Q9 only, NH); X_q is O, S or N- R^1
 (wherein R^1 is hydrogen, (1-4C)alkyl or hydroxy-(1-4C)alkyl); and wherein
 in Q7 each A_1 is independently selected from carbon or nitrogen, with a maximum of 2
 nitrogen heteroatoms in the 6-membered ring, and Q7 is linked to T via any of the A_1 atoms
 10 (when A_1 is carbon), and linked in the 5-membered ring via the specified carbon atom, or via
 A_1 when A_1 is carbon; Q8 is linked to T via either of the specified carbon atoms in the 5-
 membered ring, and linked in the benzo-ring via either of the two specified carbon atoms on
 either side of the linking bond shown; and Q9 is linked via either of the two specified carbon
 atoms on either side of the linking bond shown;
- 15 wherein T is selected from the groups in (TA) to (TD) below (wherein AR1, AR2, AR2a,
 AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1 and CY2 are defined hereinbelow);
- (TA) T is selected from the following groups :-
- (TAa) AR1, AR1-(1-4C)alkyl-, AR2 (carbon linked), AR3;
- (Tab) AR1-CH(OH)-, AR2-CH(OH)-, AR3-CH(OH)-;
- 20 (TAc) AR1-CO-, AR2-CO-, AR3-CO-, AR4-CO-;
- (TAd) AR1-O-, AR2-O-, AR3-O-;
- (TAe) AR1-S(O) q -, AR2-S(O) q -, AR3-S(O) q - (q is 0, 1 or 2);
- (Taf) an optionally substituted N-linked (fully unsaturated) 5-membered heteroaryl ring
 system containing 1, 2 or 3 nitrogen atoms;
- 25 (TAg) a carbon linked tropol-3-one or tropol-4-one, optionally substituted in a position not
 adjacent to the linking position; or
- (TB) T is selected from the following groups :-
- (TBa) halo or (1-4C)alkyl

{optionally substituted by one or more groups each independently selected from hydroxy, (1-4C)alkoxy, (1-4C)alkanoyl, cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, -NR^vR^w, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), CY1, CY2 or AR1};

5 (TBb) -NR^v¹R^w¹;

(TBc) ethenyl, 2-(1-4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-nitroethenyl, 2-nitro-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl;

(TBd) R¹⁰CO-, R¹⁰S(O)_q- (q is 0, 1 or 2) or R¹⁰CS-

10 wherein R¹⁰ is selected from the following groups :-

(TBda) CY1 or CY2;

(TBdb) hydrogen, (1-4C)alkoxycarbonyl, trifluoromethyl, -NR^vR^w, ethenyl, 2-(1-4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-nitroethenyl, 2-nitro-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-

15 4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl or 2-(AR2)ethenyl; or

(TBdc) (1-4C)alkyl {optionally substituted as defined in (TBa) above, or by (1-4C)alkylS(O)_pNH- or (1-4C)alkylS(O)_p-((1-4C)alkyl)N- (p is 1 or 2)};

wherein R^v is hydrogen or (1-4C)alkyl; R^w is hydrogen or (1-4C)alkyl; R^v¹ is hydrogen, (1-4C)alkyl or (3-8C)cycloalkyl; R^w¹ is hydrogen, (1-4C)alkyl, (3-8C)cycloalkyl, (1-4C)alkyl-

20 CO- or (1-4C)alkylS(O)_q- (q is 1 or 2); or

(TC) T is selected from the following groups :-

(TCa) an optionally substituted, fully saturated 4-membered monocyclic ring containing 1 heteroatom selected from O, N and S (optionally oxidised), and linked via a ring nitrogen or
25 sp³ carbon atom;

(TCb) an optionally substituted 5-membered monocyclic ring containing 1 heteroatom selected from O, N and S (optionally oxidised), and linked via a ring nitrogen atom or a ring sp³ or sp² carbon atom, which monocyclic ring is fully saturated other than (where appropriate) at a linking sp² carbon atom;

30 (TCc) an optionally substituted 6- or 7-membered monocyclic ring containing 1 or 2 heteroatoms independently selected from O, N and S (optionally oxidised), and linked via a

ring nitrogen atom or a ring sp^3 or sp^2 carbon atom, which monocyclic ring is fully saturated other than (where appropriate) at a linking sp^2 carbon atom; or

(TD) T is selected from the following groups :-

- 5 (TDa) a bicyclic spiro-ring system containing 0, 1 or 2 ring nitrogen atoms as the only ring heteroatoms, the structure consisting of a 5- or 6-membered ring system (linked via a ring nitrogen atom or a ring sp^3 or sp^2 carbon atom) substituted (but not adjacent to the linking position) by a 3-, 4- or 5-membered spiro-carbon-linked ring; which bicyclic ring system is
 - (i) fully saturated other than (where appropriate) at a linking sp^2 carbon atom;
 - 10 (ii) contains one -N(Rc)- group in the ring system (at least two carbon atoms away from the linking position when the link is via a nitrogen atom or an sp^2 carbon atom) or one -N(Rc)- group in an optional substituent (not adjacent to the linking position) and is
 - (iii) optionally further substituted on an available ring carbon atom; or
- (TDb) a 7-, 8- or 9-membered bicyclic ring system (linked via a ring nitrogen atom or a ring sp^3 or sp^2 carbon atom) containing 0, 1 or 2 ring nitrogen atoms (and optionally a further O or S ring heteroatom), the structure containing a bridge of 1, 2 or 3 carbon atoms; which bicyclic ring system is
 - (i) fully saturated other than (where appropriate) at a linking sp^2 carbon atom;
 - (ii) contains one O or S heteroatom, or one -N(Rc)- group in the ring (at least two carbon
 - 20 atoms away from the linking position when the link is via a nitrogen atom or an sp^2 carbon atom) or one -N(Rc)- group in an optional substituent (not adjacent to the linking position) and is
 - (iii) optionally further substituted on an available ring carbon atom;
- 25 wherein Rc is selected from groups (Rc1) to (Rc5) :-

(Rc1) (1-6C)alkyl {optionally substituted by one or more (1-4C)alkanoyl groups (including geminal disubstitution) and/or optionally monosubstituted by cyano, (1-4C)alkoxy, trifluoromethyl, (1-4C)alkoxycarbonyl, phenyl (optionally substituted as for AR1 defined hereinafter), (1-4C)alkylS(O)_q- (q is 0, 1 or 2); or, on any but the first carbon atom of the (1-

30 6C)alkyl chain, optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy and fluoro, and/or optionally

- 175 -

monosubstituted by oxo, -NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl], (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylS(O)_pNH- or (1-4C)alkylS(O)_p-((1-4C)alkyl)N- (p is 1 or 2));
(Rc2) R¹³CO-, R¹³SO₂- or R¹³CS-

5 wherein R¹³ is selected from (Rc2a) to (Rc2e) :-

(Rc2a) AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1, CY2;

(Rc2b) hydrogen, (1-4C)alkoxycarbonyl, trifluoromethyl, -NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl], ethenyl, 2-(1-4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-nitroethenyl, 2-nitro-2-((1-4C)alkyl)ethenyl,

10 2-((1-4C)alkylaminocarbonyl)ethenyl,

2-((1-4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, 2-(AR2a)ethenyl;

(Rc2c) (1-10C)alkyl

{optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-

15 4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkanoyl, phosphoryl [-O-P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinyl [-O-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group selected from carboxy, phosphonate [phosphono, -P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinate [-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-

4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)_pNH-, (1-4C)alkylS(O)_p-((1-4C)alkyl)N-, fluoro(1-4C)alkylS(O)_pNH-,

25 fluoro(1-4C)alkylS(O)_p-((1-4C)alkyl)N-, (1-4C)alkylS(O)_q-, CY1, CY2, AR1, AR2, AR3, AR1-O-, AR2-O-, AR3-O-, AR1-S(O)_q-, AR2-S(O)_q-, AR3-S(O)_q-, AR1-NH-, AR2-NH-, AR3-NH- (p is 1 or 2 and q is 0, 1 or 2), and also AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing groups};

(Rc2d) R¹⁴C(O)O(1-6C)alkyl wherein R¹⁴ is AR1, AR2, (1-4C)alkylamino, benzyloxy-


30 (1-4C)alkyl or (1-10C)alkyl {optionally substituted as defined for (Rc2c)};

(Rc2e) R¹⁵O- wherein R¹⁵ is benzyl, (1-6C)alkyl {optionally substituted as defined for

- 176 -

(Rc2c)}, CY1, CY2 or AR2b;

(Rc3) hydrogen, cyano, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-4C)alkoxycarbonyl)ethenyl, 2-nitroethenyl, 2-nitro-2-((1-4C)alkyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, or of the formula (Rc3a)



5

(Rc3a)

wherein X^{00} is $-\text{OR}^{17}$, $-\text{SR}^{17}$, $-\text{NHR}^{17}$ and $-\text{N}(\text{R}^{17})_2$;

wherein R^{17} is hydrogen (when X^{00} is $-\text{NHR}^{17}$ and $-\text{N}(\text{R}^{17})_2$), and R^{17} is (1-4C)alkyl, phenyl or
 10 AR2 (when X^{00} is $-\text{OR}^{17}$, $-\text{SR}^{17}$ and $-\text{NHR}^{17}$); and R^{16} is cyano, nitro, (1-4C)alkylsulfonyl, (4-7C)cycloalkylsulfonyl, phenylsulfonyl, (1-4C)alkanoyl and (1-4C)alkoxycarbonyl;

(Rc4) trityl, AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b;

(Rc5) RdOC(Re)=CH(C=O)- , RfC(=O)C(=O)- , RgN=C(Rh)C(=O)- or

$\text{RiNHC(Rj)=CHC(=O)-}$ wherein Rd is (1-6C)alkyl; Re is hydrogen or (1-6C)alkyl, or Rd and
 15 Re together form a (3-4C)alkylene chain; Rf is hydrogen, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxy(1-6C)alkyl, $-\text{NRvRw}$ [wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen or (1-4C)alkyl], (1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy, hydroxy(2-6C)alkoxy, (1-4C)alkylamino(2-6C)alkoxy, di-(1-4C)alkylamino(2-6C)alkoxy; Rg is (1-6C)alkyl, hydroxy or (1-6C)alkoxy; Rh is hydrogen or (1-6C)alkyl; Ri is hydrogen, (1-6C)alkyl, AR1, AR2,
 20 AR2a, AR2b and Rj is hydrogen or (1-6C)alkyl;

wherein

AR1 is an optionally substituted phenyl or optionally substituted naphthyl;

AR2 is an optionally substituted 5- or 6-membered, fully unsaturated (i.e. with the maximum degree of unsaturation) monocyclic heteroaryl ring containing up to four heteroatoms

25 independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom, or a ring nitrogen atom if the ring is not thereby quaternised;
 AR2a is a partially hydrogenated version of AR2 (i.e. AR2 systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom or linked via a ring nitrogen atom if the ring is not thereby quaternised;

- 177 -

AR2b is a fully hydrogenated version of AR2 (i.e. AR2 systems having no unsaturation), linked via a ring carbon atom or linked via a ring nitrogen atom;

AR3 is an optionally substituted 8-, 9- or 10-membered, fully unsaturated (i.e. with the maximum degree of unsaturation) bicyclic heteroaryl ring containing up to four heteroatoms
5 independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom in either of the rings comprising the bicyclic system;

AR3a is a partially hydrogenated version of AR3 (i.e. AR3 systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen atom if the ring is not thereby quaternised, in either of the rings comprising the bicyclic
10 system;

AR3b is a fully hydrogenated version of AR3 (i.e. AR3 systems having no unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen atom, in either of the rings comprising the bicyclic system;

AR4 is an optionally substituted 13- or 14-membered, fully unsaturated (i.e. with the
15 maximum degree of unsaturation) tricyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom in any of the rings comprising the tricyclic system;


AR4a is a partially hydrogenated version of AR4 (i.e. AR4 systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen
20 atom if the ring is not thereby quaternised, in any of the rings comprising the tricyclic system;

CY1 is an optionally substituted cyclobutyl, cyclopentyl or cyclohexyl ring;


CY2 is an optionally substituted cyclopentenyl or cyclohexenyl ring.

2. A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-
25 hydrolysable ester thereof, as claimed in claim 1 wherein the optionally substituted N-linked (fully unsaturated) 5-membered heteroaryl ring system containing 1, 2 or 3 nitrogen atoms (group (TAf)) is selected from a group of formula (TAf1) to (TAf6) :-


- 178 -




(TAf1)




(TAf2)




(TAf3)



(TAf4)



(TAf5)



(TAf6)

5

wherein :


R⁶ is selected (independently where appropriate) from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, (1-4C)alkanoyl, carbamoyl and cyano;

- 10 R⁴ and R⁵ are independently selected from hydrogen, halo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), (1-4C)alkanoyl, (1-4C)alkoxycarbonyl, (2-4C)alkanoyloxy-(1-4C)alkyl, benzoxy-(1-4C)alkyl, (2-4C)alkanoylamino, -CONR^vR^w, -NR^vR^w and (1-4C)alkyl {optionally substituted by hydroxy, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), (1-4C)alkoxycarbonyl, (1-4C)alkanoylamino,
- 15 -CONR^vR^w, -NR^vR^w; wherein R^vR^w is hydrogen or (1-4C)alkyl; R^w is hydrogen or (1-4C)alkyl};

or R⁴ is selected from one of the groups in (TAfa) to (TAfc) below, or (where appropriate) one of R⁴ and R⁵ is selected from the above list of R⁴ and R⁵ values, and the other is selected from one of the groups in (TAfa) to (TAfc) below :-

- 20 (TAfa) a group of the formula (TAfa1)

- 179 -



(TAfa1)

wherein Z^0 is hydrogen or (1-4C)alkyl;

X^0 and Y^0 are independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl,

- 5 halo, cyano, nitro, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), RvRwNSO₂-, trifluoromethyl, pentafluoroethyl, (1-4C)alkanoyl and -CONRvRw [wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen or (1-4C)alkyl]; or

one of X^0 and Y^0 is selected from the above list of X^0 and Y^0 values, and the other is selected from phenyl, phenylcarbonyl, -S(O)_q-phenyl (q is 0, 1 or 2), N-

- 10 (phenyl)carbamoyl, phenylaminosulfonyl, AR2, (AR2)-CO-, (AR2)-S(O)_q- (q is 0, 1 or 2), N-(AR2)carbamoyl and (AR2)aminosulfonyl; wherein any phenyl group in (TAfa) may be optionally substituted by up to three substituents independently selected from (1-4C)alkyl, cyano, trifluoromethyl, nitro, halo and (1-4C)alkylsulfonyl;

(TAfb) an acetylene of the formula \equiv -H or \equiv -(1-4C)alkyl;

- 15 (TAfc) -X¹-Y¹-AR2, -X¹-Y¹-AR2a, -X¹-Y¹-AR2b, -X¹-Y¹-AR3, -X¹-Y¹-AR3a or -X¹-Y¹-AR3b;

wherein X¹ is a direct bond or -CH(OH)- and

Y¹ is -(CH₂)_m-, -(CH₂)_n-NH-(CH₂)_m-, -CO-(CH₂)_m-, -CONH-(CH₂)_m-, -C(=S)NH-(CH₂)_m- or -C(=O)O-(CH₂)_m-;

- 20 or wherein X¹ is -(CH₂)_n- or -CH(Me)-(CH₂)_m- and

Y¹ is -(CH₂)_m-NH-(CH₂)_m-, -CO-(CH₂)_m-, -CONH-(CH₂)_m-, -C(=S)NH-(CH₂)_m-, -C(=O)O-(CH₂)_m- or -S(O)_q-(CH₂)_m-;

or wherein X¹ is -CH₂O-, -CH₂NH- or -CH₂N((1-4C)alkyl)- and


Y¹ is -CO-(CH₂)_m-, -CONH-(CH₂)_m- or -C(=S)NH-(CH₂)_m-; and additionally Y¹ is

- 25 -SO₂- when X¹ is -CH₂NH- or -CH₂N((1-4C)alkyl)-, and Y¹ is -(CH₂)_m- when X¹ is -CH₂O- or -CH₂N((1-4C)alkyl)-; wherein n is 1, 2 or 3; m is 0, 1, 2 or 3 and q is 0, 1 or 2; and when Y¹ is -(CH₂)_m-NH-(CH₂)_m- each m is independently selected from 0, 1, 2 or 3.

3. A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-

hydrolysable ester thereof, as claimed in claim 1 wherein the 7-, 8- or 9-membered bicyclic ring system containing a bridge of 1, 2 or 3 carbon atoms (group (TDb)) is selected from a group defined by the ring skeletons shown in formulae (TDb1) to (TDb14) :-

7-membered ring skeletons




[4,1,0]

(TDb1)




[3,2,0]

(TDb2)



[3,1,1]


(TDb3)



[2,2,1]


(TDb4)

8-membered ring skeletons



[3,3,0]

(TDb5)



[4,2,0]

(TDb6)




[4,1,1]

(TDb7)



[3,2,1]


(TDb8)



[2,2,2]


(TDb9)

9-membered ring skeletons



[4,3,0]

(TDb10)




[5,2,0]

(TDb11)



[4,2,1]

(TDb12)



[3,3,1]

(TDb13)



[3,2,2]

(TDb14)

5


wherein;

- (i) the ring system contains 0, 1 or 2 ring nitrogen atoms (and optionally a further O or S ring heteroatom), and when present the ring nitrogen, O or S heteroatom/s are at any position other than as part of the 3-membered ring in (TDb1);
- (ii) the ring system is linked via a ring nitrogen atom or a ring sp^3 or sp^2 carbon atom (with the double bond, where appropriate, orientated in either direction) from any position in either ring [other than from a bridgehead position or from an sp^2 carbon atom in the 4-membered ring in (TDb2), (TDb6) and (TDb11)];
- (iii) one of the ring carbon atoms at a position not adjacent to the linking position, is replaced (other than when the ring contains an O or S heteroatom) by one of the following

- groups -NRc- [not at a bridgehead position], $>\text{C}(\text{H})\text{-NHRc}$, $>\text{C}(\text{H})\text{-NRc-(1-4C)alkyl}$, $>\text{C}(\text{H})\text{-CH}_2\text{-NHRc}$, $>\text{C}(\text{H})\text{-CH}_2\text{-NRc-(1-4C)alkyl}$ [wherein the hydrogen atom shown in brackets is not present when the replacement is made at a bridgehead position and wherein a central -CH₂- chain link is optionally mono- or di-substituted by (1-4C)alkyl]; with the proviso that
- 5 when the ring system is linked via a ring nitrogen atom or an sp² carbon atom any replacement of a ring carbon atom by -NRc-, O or S is at least two carbon atoms away from the linking position; and
- (iv) the ring system is optionally (further) substituted on an available ring carbon atom as for the bicyclic spiro-ring systems described in (TDa); wherein Rc is as defined in claim 1.

10

4. A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, as claimed in claim 1 wherein the groups defined in (TCa) to (TCc) are defined by formulae (TC1) to (TC4) :-



15

(TC1)

(TC2)

(TC3)

(TC4)

wherein in (TC1) : $>\text{A}_3\text{-B}_3\text{-}$ is $>\text{C}(\text{Rq})\text{-CH}(\text{Rr})\text{-}$ and G is -O-, -S-, -SO-, -SO₂- or $>\text{N}(\text{Rc})$;

wherein in (TC2) : m1 is 0, 1 or 2; $>\text{A}_3\text{-B}_3\text{-}$ is $>\text{C}=\text{C}(\text{Rr})\text{-}$ or $>\text{C}(\text{Rq})\text{-CH}(\text{Rr})\text{-}$ and G is -O-, -S-, -SO-, -SO₂- or $>\text{N}(\text{Rc})$;

- 20 wherein in (TC3) : m1 is 0, 1 or 2; $>\text{A}_3\text{-B}_3\text{-}$ is $>\text{C}(\text{Rq})\text{-CH}(\text{Rr})\text{-}$ (other than when Rq and Rr are both together hydrogen) and G is -O-, -S-, -SO-, -SO₂- or $>\text{N}(\text{Rc})$;

wherein in (TC4) : n1 is 1 or 2; o1 is 1 or 2 and $n1 + o1 = 2$ or 3; $>\text{A}_3\text{-B}_3\text{-}$ is $>\text{C}=\text{C}(\text{Rr})\text{-}$ or $>\text{C}(\text{Rq})\text{-CH}(\text{Rr})\text{-}$ or $>\text{N-CH}_2\text{-}$ and G is -O-, -S-, -SO-, -SO₂- or $>\text{N}(\text{Rc})$; Rp is hydrogen, (1-4C)alkyl (other than when such substitution is defined by $>\text{A}_3\text{-B}_3\text{-}$), hydroxy, (1-4C)alkoxy or

- 25 (1-4C)alkanoyloxy;


wherein in (TC1), (TC2) and (TC4); m1, n1 and o1 are as defined hereinbefore :

$>\text{A}_3\text{-B}_3\text{-}$ is $>\text{N-CH}_2\text{-}$ and G is $>\text{C}(\text{R}^{11})(\text{R}^{12})$, $>\text{C=O}$, $>\text{C-OH}$, $>\text{C-(1-4C)alkoxy}$, $>\text{C=N-OH}$, $>\text{C=N-(1-4C)alkoxy}$, $>\text{C=N-NH-(1-4C)alkyl}$, $>\text{C=N-N}((1-4C)alkyl)_2$ (the last two (1-


- 182 -

- 4C)alkyl groups above in G being optionally substituted by hydroxy) or $>C=N-N-CO-(1-4C)alkoxy$; wherein $>$ represents two single bonds;
- Rq is hydrogen, hydroxy, halo, (1-4C)alkyl or (1-4C)alkanoyloxy;
- Rr is (independently where appropriate) hydrogen or (1-4C)alkyl;
- 5 R¹¹ is hydrogen, (1-4C)alkyl, fluoro(1-4C)alkyl, (1-4C)alkyl-thio-(1-4C)alkyl or hydroxy-(1-4C)alkyl and R¹² is $-[C(Rr)(Rr)]_{m2}-N(Rr)(Rc)$ wherein m2 is 0, 1 or 2;
- and, other than the ring substitution defined by G, $>A_3-B_3-$ and Rp, each ring system may be optionally further substituted on a carbon atom not adjacent to the link at $>A_3-$ by up to two substituents independently selected from (1-4C)alkyl, fluoro(1-4C)alkyl (including
- 10 trifluoromethyl), (1-4C)alkyl-thio-(1-4C)alkyl, hydroxy-(1-4C)alkyl, amino, amino-(1-4C)alkyl, (1-4C)alkanoylamino, (1-4C)alkanoylamino-(1-4C)alkyl, carboxy, (1-4C)alkoxycarbonyl, AR-oxymethyl, AR-thiomethyl, oxo (=O) (other than when G is $>N-Rc$ and Rc is group (Rc2) defined in claim 1) or independently selected from Rc; and also hydroxy or halo (the last two optional substituents only when G is -O- or -S-);
- 15 wherein AR is optionally substituted phenyl, optionally substituted phenyl(1-4C)alkyl, optionally substituted naphthyl, optionally substituted 5- or 6-membered heteroaryl; optionally substituted 5/6 or 6/6 bicyclic heteroaryl ring system, in which the bicyclic heteroaryl ring systems may be linked via an atom in either of the rings comprising the bicyclic system, and wherein both the mono- and bicyclic heteroaryl ring systems are linked
- 20 via a ring carbon atom and may be (partially) hydrogenated; and wherein Rc is as defined in claim 1.


5. A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, as claimed in claims 1 and 4 wherein the groups in (TCa) to (TCc)
- 25 are defined by formulae (TC5) to (TC11) :-



(TC5)




(TC6)



(TC7)


- 183 -



wherein Rc is as defined in claim 1.

5

6. A compound of the formula (I) as claimed in claim 1, being a compound of the formula (IC), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof




(IC)

10

wherein HET is isoxazol-3-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl or 1,2,5-thiadiazol-3-yl; R^2 and R^3 are independently hydrogen or fluoro; R_{p1} and R_{p2} are independently hydrogen, AR-oxymethyl or AR-thiomethyl (wherein AR is phenyl, phenyl-(1-4C)alkyl, naphthyl, furan, pyrrole, pyrazole, imidazole, triazole, pyrimidine, pyridazine, pyridine, isoxazole, oxazole, isothiazole, thiazole or thiophene), (1-4C)alkyl, carboxy, (1-4C)alkoxycarbonyl, hydroxymethyl, (1-4C)alkoxymethyl or carbamoyl and R_{cp} is cyano, pyrimidin-2-yl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl or R_{cp} is of the formula $R^{13p}CO-$, $R^{13p}SO_2-$ or $R^{13p}CS-$ (wherein R^{13p} is hydrogen, (1-5C)alkyl [optionally substituted by one or more groups each independently selected from hydroxy and amino, or optionally monosubstituted by (1-4C)alkoxy, (1-4C)alkylS(O)_q-, (1-4C)alkylamino, (1-4C)alkanoyl, naphthoxy, (2-6C)alkanoylamino or (1-4C)alkylS(O)_pNH- wherein p is 1 or 2 and q is 0, 1 or 2], imidazole, triazole, pyrimidine, pyridazine, pyridine, isoxazole, oxazole, isothiazole, thiazole, pyridoimidazole, pyrimidoimidazole, quinoxaline, quinazoline, phthalazine, cinnoline or naphthyridine, or R^{13p} is of the formula $R^{14p}C(O)O(1-6C)alkyl$ wherein R^{14p} is (1-6C)alkyl), or R_{cp} is of the formula $R_fC(=O)C(=O)-$ wherein R_f is (1-6C)alkoxy.

25

7. A compound as claimed in claims 1, 4, 5 or 6 being
 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)-oxazolidin-2-one; or
- 5 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-dihydroxypropanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)-oxazolidin-2-one or pharmaceutically-acceptable salts or *in-vivo* hydrolysable esters thereof.
8. A compound as claimed in claims 1, 4, 5, 6 or 7 being
- 10 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-phosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one;
 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S)-hydroxy-3-phosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one;
 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-diphosphoryl-propanoyl)-1,2,5,6-
 15 tetrahydropyrid-4-yl)-3-fluorophenyl)oxazolidin-2-one;
 5(R)-Isoxazol-3-yloxymethyl-3-(4-(1-(2(S),3-diphosphoryl-propanoyl)-1,2,5,6-tetrahydropyrid-4-yl)-3,5-difluorophenyl)oxazolidin-2-one; or pharmaceutically-acceptable salts thereof.
- 20 9. A process for the preparation of a compound of the formula (I) as claimed in claim 1 or pharmaceutically-acceptable salts or *in vivo* hydrolysable esters thereof, which process comprises of (a) to (i):-
- (a) modifying a substituent in or introducing a substituent into another compound of formula (I);
- 25 (b) reacting a compound of formula (II)




(II)

wherein Yp is hydroxy with a compound of the formula (b1) HET-OH or (b2) HET-Lg,


- 185 -

wherein Lg is a suitable leaving group;

- (c) reacting a compound of formula (II) wherein Yp is a leaving group with a metal alkoxide compound of the formula HET-OM where M is an alkali metal, or another metal known to promote O-alkylation;
- 5 (d) reacting a compound of the formula Q-Zp wherein Zp is an isocyanate or amine group with an epoxide of the formula $\text{CH}_2(\text{O})\text{CH}-\text{CH}_2\text{O}-\text{HET}$;
- (e) when X is -S- using a process analogous to process (c) using (e1) a metal thioxide compound of the formula HET-SM where M is an alkali metal, or another metal known to promote S-alkylation; or using (e2) HET-SH and a compound of formula (II) in which Yp is a
- 10 suitable leaving group;
- (f) when X is -SO- or -SO₂- oxidising a compound of formula (I) wherein X is -S-;
- (g) converting of a compound of formula (I) in which the ring HET bears a quarternary nitrogen to a non-quarternary compound;
- (h) when HET is an isoxazole ring by reacting a compound of the formula (II) in which
- 15 Yp is -O-CH=N-OH with an acetylene;
- (i) reacting a urethane compound of formula (III) with a compound of formula (IV)



(III)



(IV)





- 20 wherein R²¹ is (1-6C)alkyl or benzyl; and thereafter if necessary :
 - (i) removing any protecting groups; (ii) forming a pharmaceutically-acceptable salt; (iii) forming an *in vivo* hydrolysable ester.
- 10. A method for producing an antibacterial effect in a warm blooded animal which
- 25 comprises administering to said animal an effective amount of a compound of the formula (I) as claimed in claims 1 to 8, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof.

- 186 -

11. A compound of the formula (I) as claimed in claims 1 to 8, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, for use as a medicament.
12. The use of a compound of the formula (I) as claimed in claims 1 to 8, or a
5 pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, in the manufacture of a medicament for use in the production of an antibacterial effect in a warm blooded animal.
13. A pharmaceutical composition which comprises a compound of the formula (I) as
claimed in claims 1 to 8, or a pharmaceutically-acceptable salt or an in-vivo hydrolysable
10 ester thereof, and a pharmaceutically-acceptable diluent or carrier.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 413/14, 417/14, C07F 9/6558, C07D 413/12, 487/08, 451/02, 417/12, A61K 31/42, 31/44 // (C07D 487/08, 209:00, 209:00)</p>	A3	<p>(11) International Publication Number: WO 99/64417</p> <p>(43) International Publication Date: 16 December 1999 (16.12.99)</p>											
<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/GB99/01753</p> <p>(22) International Filing Date: 3 June 1999 (03.06.99)</p> <p>(30) Priority Data:</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 33%;">9812021.5</td> <td style="width: 33%;">5 June 1998 (05.06.98)</td> <td style="width: 33%;">GB</td> </tr> <tr> <td>9820164.3</td> <td>17 September 1998 (17.09.98)</td> <td>GB</td> </tr> <tr> <td>9826066.4</td> <td>28 November 1998 (28.11.98)</td> <td>GB</td> </tr> </table> <p>(71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (for US only): GRAVESTOCK, Michael, Barry [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).</p> <p>(74) Agent: BRYANT, Tracey; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 3 February 2000 (03.02.00)</p> </td> </tr> </table>			<p>(21) International Application Number: PCT/GB99/01753</p> <p>(22) International Filing Date: 3 June 1999 (03.06.99)</p> <p>(30) Priority Data:</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 33%;">9812021.5</td> <td style="width: 33%;">5 June 1998 (05.06.98)</td> <td style="width: 33%;">GB</td> </tr> <tr> <td>9820164.3</td> <td>17 September 1998 (17.09.98)</td> <td>GB</td> </tr> <tr> <td>9826066.4</td> <td>28 November 1998 (28.11.98)</td> <td>GB</td> </tr> </table> <p>(71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (for US only): GRAVESTOCK, Michael, Barry [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).</p> <p>(74) Agent: BRYANT, Tracey; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).</p>	9812021.5	5 June 1998 (05.06.98)	GB	9820164.3	17 September 1998 (17.09.98)	GB	9826066.4	28 November 1998 (28.11.98)	GB	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 3 February 2000 (03.02.00)</p>
<p>(21) International Application Number: PCT/GB99/01753</p> <p>(22) International Filing Date: 3 June 1999 (03.06.99)</p> <p>(30) Priority Data:</p> <table border="0" style="width: 100%;"> <tr> <td style="width: 33%;">9812021.5</td> <td style="width: 33%;">5 June 1998 (05.06.98)</td> <td style="width: 33%;">GB</td> </tr> <tr> <td>9820164.3</td> <td>17 September 1998 (17.09.98)</td> <td>GB</td> </tr> <tr> <td>9826066.4</td> <td>28 November 1998 (28.11.98)</td> <td>GB</td> </tr> </table> <p>(71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (for US only): GRAVESTOCK, Michael, Barry [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).</p> <p>(74) Agent: BRYANT, Tracey; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).</p>	9812021.5	5 June 1998 (05.06.98)	GB	9820164.3	17 September 1998 (17.09.98)	GB	9826066.4	28 November 1998 (28.11.98)	GB	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 3 February 2000 (03.02.00)</p>			
9812021.5	5 June 1998 (05.06.98)	GB											
9820164.3	17 September 1998 (17.09.98)	GB											
9826066.4	28 November 1998 (28.11.98)	GB											
<p>(54) Title: OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM</p> <div style="display: flex; justify-content: space-around; align-items: flex-start; margin-top: 20px;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(Q1)</p> </div> </div> <div style="display: flex; justify-content: space-around; align-items: flex-start; margin-top: 20px;"> <div style="text-align: center;">  <p>(Q2)</p> </div> <div style="text-align: center;">  <p>(TC5)</p> </div> </div>													
<p>(57) Abstract</p> <p>Compounds of formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, X is -O- or -S-; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, formulae (Q1) and (Q2); R² and R³ are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5) wherein Rc is, for example, R¹³CO-, R¹³SO₂- or R¹³CS-; wherein R¹³ is, for example, optionally substituted (1-10C)alkyl or R¹⁴C(O)O(1-6C)alkyl wherein R¹⁴ is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.</p>													

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01753

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D413/14 C07D417/14 C07F9/6558 C07D413/12 C07D487/08
 C07D451/02 C07D417/12 A61K31/42 A61K31/44
 //(C07D487/08,209:00,209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 23384 A (THE UPJOHN CO.) 25 November 1993 (1993-11-25) cited in the application page 7, line 3 - line 21; claim 1 ---	1-6, 11-13
A	WO 97 09328 A (PHARMACIA & UPJOHN CO.) 13 March 1997 (1997-03-13) cited in the application page 16, line 15 - line 31; claim 1 --- -/--	1-6, 11-13



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 November 1999

Date of mailing of the international search report

07/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01753

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CHUNG-HO PARK ET AL: "ANTIBACTERIALS. SYNTHESIS AND STRUCTURE-ACTIVITY STUDIES OF 3-ARYL-2-OXOOXAZOLIDINES. 4 MULTIPLY-SUBSTITUTED ARYL DERIVATIVES" JOURNAL OF MEDICINAL CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 35, no. 6, 1992, page 1156-1165 XP000567006 ISSN: 0022-2623 cited in the application tables I, II</p>	1-6, 11, 12
A	<p>W A GREGORY ET AL: "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 2. The A Group" JOURNAL OF MEDICINAL CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 33, 1990, page 2569-2578 XP002082548 ISSN: 0022-2623 cited in the application tables I-VII</p>	1-6, 11, 12
A	<p>EP 0 645 376 A (MERCK PATENT GMBH) 29 March 1995 (1995-03-29) claim 1</p>	1-6, 11
A	<p>EP 0 710 657 A (MERCK PATENT GMBH) 8 May 1996 (1996-05-08) claims 1, 5-7</p>	1-6, 11
A	<p>WO 93 22298 A (TAIHO PHARMACEUTICAL CO LTD.) 11 November 1993 (1993-11-11) abstract</p>	1-6, 11
A	<p>WO 94 22857 A (TAIHO PHARMACEUTICAL CO LTD.) 13 October 1994 (1994-10-13) abstract</p>	1-6, 11
A	<p>WO 97 06791 A (SCRIPPS RESEARCH INST.) 27 February 1997 (1997-02-27) page 84, compound 15; page 87, compound 16; page 91, compound 17; page 94, compound 18</p>	1

INTERNATIONAL SEARCH REPORT

national application No.

PCT/GB 99/01753

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 10 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition (Rule 39.1 (IV) PCT-Method for treatment of the human or animal body by therapy).
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-5,9,11-13

Present claims 1-5, 9, 11-13 relate to an extremely large number of possible compounds and their preparation processes. The use of the term "optionally substituted" several times, without any further definition, in the claims makes the claims still more broad. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds of claims 6 to 8, the examples disclosed in the description, and their processes of preparation.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 99/01753

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9323384 A	25-11-1993	AU 668733 B	16-05-1996
		AU 4287793 A	13-12-1993
		CA 2133079 A	25-11-1993
		CN 1079964 A,B	29-12-1993
		CZ 9402505 A	16-08-1995
		EP 0640077 A	01-03-1995
		FI 945246 A	08-11-1994
		HU 72296 A	29-04-1996
		HU 9500659 A	28-11-1995
		IL 105555 A	15-07-1998
		JP 7506829 T	27-07-1995
		MX 9302665 A	01-11-1993
		NO 944237 A	04-01-1995
		PL 174909 B	30-10-1998
		PL 174850 B	30-09-1998
		SK 133794 A	07-06-1995
		US 5547950 A	20-08-1996
		US 5700799 A	23-12-1997
		ZA 9302855 A	24-10-1994
WO 9709328 A	13-03-1997	AU 6718196 A	27-03-1997
		BR 9610474 A	02-03-1999
		CA 2228647 A	13-03-1997
		CN 1197457 A	28-10-1998
		CZ 9800493 A	12-08-1998
		EP 0856002 A	05-08-1998
		FI 980452 A	27-02-1998
		NO 980855 A	30-04-1998
		PL 325152 A	06-07-1998
		SK 19598 A	04-11-1998
EP 645376 A	29-03-1995	DE 4332384 A	30-03-1995
		AT 178599 T	15-04-1999
		AU 682050 B	18-09-1997
		AU 7305094 A	06-04-1995
		CA 2132579 A	24-03-1995
		CN 1106806 A	16-08-1995
		CZ 9402247 A	12-07-1995
		DE 59408068 D	12-05-1999
		ES 2132295 T	16-08-1999
		HU 71233 A	28-11-1995
		JP 7179441 A	18-07-1995
		NO 943523 A	24-03-1995
		PL 305144 A	03-04-1995
		SK 112194 A	10-05-1995
		US 5561148 A	01-10-1996
		US 5723480 A	03-03-1998
		ZA 9407405 A	15-05-1995
EP 710657 A	08-05-1996	DE 19509093 A	09-05-1996
		AT 170179 T	15-09-1998
		AU 698987 B	12-11-1998
		AU 3452395 A	09-05-1996
		BR 9505039 A	21-10-1997
		CA 2161857 A	03-05-1996
		CN 1130626 A	11-09-1996
		CZ 9502858 A	15-05-1996
		DE 59503324 D	01-10-1998

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 99/01753

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 710657 A		ES 2123889 T FI 955223 A HU 74093 A JP 8225550 A NO 954366 A PL 311194 A SK 135895 A TR 960383 A ZA 9509212 A	16-01-1999 03-05-1996 28-11-1996 03-09-1996 03-05-1996 13-05-1996 05-06-1996 21-06-1996 24-07-1996
WO 9322298 A	11-11-1993	AU 653896 B AU 4271093 A CA 2112129 A,C EP 0605729 A FI 935920 A HU 70423 A HU 9500726 A KR 146931 B NO 934829 A US 5480899 A	13-10-1994 29-11-1993 11-11-1993 13-07-1994 29-12-1993 30-10-1995 28-11-1995 17-08-1998 11-02-1994 02-01-1996
WO 9422857 A	13-10-1994	AU 668818 B AU 6437394 A CA 2135474 A,C EP 0645387 A FI 945731 A HU 72308 A US 5521202 A	16-05-1996 24-10-1994 13-10-1994 29-03-1995 05-12-1994 29-04-1996 28-05-1996
WO 9706791 A	27-02-1997	AU 6846696 A CN 1198667 A CZ 9800409 A EP 0844874 A HU 9802675 A JP 11511171 T NO 980622 A SK 18898 A	12-03-1997 11-11-1998 16-09-1998 03-06-1998 29-03-1999 28-09-1999 07-04-1998 08-07-1998